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CHAPTER 1 
Scope of Dissertation 
 
 Glioblastoma is a rapidly fatal brain tumor. Despite the recognizable need for novel treatments, the only 
major update in standard clinical care over the past decade was the incorporation of a non-targeted, highly toxic, 
chemotherapeutic agent, temozolomide (1). The major efforts to dissect the underlying mechanistic aberrancies 
of adult glioblastomas have relied on genomic and transcriptomic profiling (2-5). Even though these approaches 
have revealed the inter-tumor and intra-tumor diversity of glioblastoma, they have neither successfully stratified 
patient outcome nor determined specific, individualized therapeutic strategies. 
 The dissection of glioblastoma pathogenesis must go beyond the understanding of genomic and 
transcriptomic alterations. Although many functional hallmarks that enable cellular malignant properties can be 
affected by genomic changes, additional components, including epigenetic and extracellular influences, can also 
shift the properties of cancer cells (6-8). Cancer cell signaling profiles provide a quantitative outlook on the effects 
secondary to cell-intrinsic changes, as well as the mechanisms by which cancer cells respond to the external 
environment (9, 10). Clinical stratification based on activated signaling profiles has proven successful in blood 
malignancies and has pinpointed the signaling bottlenecks that correlated with adverse patient outcome (10-15). 
The goal of this dissertation is to establish a novel stratification approach for adult glioblastoma, which couples 
signaling quantification and delineation of cellular diversity. This will be accomplished by using advanced and 
automated technical approaches, to dissect the molecular features of single cells in an unbiased fashion. The 
overarching goal of this work is to identify cellular characteristics that can be immediately investigated as targets 
for innovative and individualized therapies based on the unique cellular composition within each tumor. 
Chapter 2, entitled “The diversity of human malignancies”, describes the different levels of tumor diversity, 
including the heterogeneity between tumors from different individuals, between tumors that are spatially distinct, 
as well as intra-tumor single-cell diversity. Additionally, this chapter explains the different biological components 
that contribute to the diversity between individual cancer cells. Overall, this chapter builds the rationale for 
dissecting the alterations of signaling activity in single cancer cells, which is the central goal of this dissertation.  
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Chapter 3, entitled “Adult glioblastoma”, covers the current glioblastoma clinical diagnostics, standard 
therapeutics, and previous attempts to dissect and target its molecular alterations. This chapter continues to 
elaborate on the concept of tumor diversity, explained in Chapter 2, in the context of adult glioblastoma. A 
significant portion of this chapter describes the signaling network alterations in glioblastoma and why they should 
be considered hallmarks of glioblastoma pathogenesis. Most importantly, this chapter explores the reasons 
glioblastoma remains incurable and proposes some of the potential research and therapeutic approaches to 
tackle this deadly disease, including single-cell signaling quantification using flow cytometry-based approaches 
and computational analysis tools.   
Chapter 4, entitled “Characterizing phenotypes and signaling networks of single human cells by mass 
cytometry”, describes the application of single-cell mass cytometry analysis to human peripheral blood 
mononuclear cells. Specifically, it describes a step-by-step workflow that includes sample preparation, 
immunostaining, mass cytometry data collection and analysis. Multiple computational tools, including biaxial 
analysis, t-distributed stochastic neighbor embedding (t-SNE), and spanning-tree progression analysis of 
density-normalized events (SPADE), were used for the analysis and data display for various purposes. 
Moreover, the methods for performing and characterizing potentiated signaling in single cells are also described 
in detail. This chapter provides a basic analytical workflow for single-cell analysis that can be further applied in 
more complex and less well-characterized tissue types, such as glioblastoma, as described in subsequent 
chapters. 
 Chapter 5, entitled “Single-cell analysis of human tissues and solid tumors with mass cytometry”, 
describes the development of a combined mechanical and enzymatic dissociation protocol that allows derivation 
of viable single cells from human tissues and solid tumors for cytomic analysis, including fluorescence and mass 
cytometry. The impact of enzyme combinations and dissociation duration on cell viability and diversity were 
systematically tested, leading to a development of a universal cell preparation protocol that is applicable across 
multiple human tissue types. Fluorescence and mass cytometry analyses were performed in parallel on the 
obtained single cells. Immunohistochemistry stains were used to identify cell types within the original tissue, to 
confirm that the dissociation protocol effectively preserved the cellular diversity. Finally, computational tools, 
introduced in Chapter 4, were used to characterize the phenotype and cellular diversity of human tissues and 
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tumors. This work lay a crucial foundation for the discovery of novel glioblastoma cells that stratified patient 
survival, as described in Chapter 6, and enables the use of fluorescence and mass flow cytometry for the 
characterization of cellular diversity in other human tissues and tumors. 
 Chapter 6, entitled “Single-cell signaling profiles reveal clinically and biologically distinct glioblastoma 
cells”, describes the discovery of novel cell subsets, defined by unique signaling phenotypes and lineage 
aberrancies that stratified clinical survival of adult glioblastoma patients. Single-cell mass cytometry was used to 
characterize the signaling profile of individua; glioblastoma cells and was coupled with an automated risk-
stratification approach to uncover clinically significant cell subsets. Two novel glioblastoma cell subsets, 
“Glioblastoma Negative Prognostic” (GNP) cells, and “Glioblastoma Positive Prognostic” (GPP) cells, were 
discovered and showed contrasting association with patient clinical outcomes. Feature enrichment quantification 
of the outcome stratifying cell subsets, using Marker Enrichment Modeling, was then used to quantify the novel 
biological characteristics of the cells, and revealed that the stratifying cell subsets were defined by contrasting 
signaling profiles. Furthermore, connections between the clinically distinct glioblastoma cells, tumor infiltrating 
immune cells, and microglial activation phenotype were discovered. The contrasting signaling and protein identity 
phenotype of GNP cells and GPP cells, as well as the connectedness of glioblastoma cells and the immune cells 
in the tumor, is a significant advancement towards an establishment of clinical stratification that may dictate 
individualized therapy, which is discussed in Chapter 7. 
 Chapter 7 summarizes the tools, analysis approaches, and biological discoveries described in Chapters 
4-6, and elaborates on the future directions of this dissertation. Specifically, this chapter emphasizes the 
evaluation of signaling states as novel targets for therapy. It also explores the idea of using single-cell 
quantification to dissect the signaling kinetics, as well as the resistance mechanisms of innovative treatments. It 
also details how single-cell signaling profiles can aid clinical diagnostics and the development of novel surgical 
approaches in patients with glioblastoma. Moreover, this chapter discusses possible mechanistic relationships 
between cancer and immune cells in the tumor microenvironment, as well as the benefit of dissecting this 
connection as an alternative therapeutic approach. 
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 Appendix A describes a step-by-step tissue dissociation protocol for obtaining viable single cells for 
fluorescence and mass cytometry analysis from human solid tissues and tumors. This protocol is complementary 
to the technical development described in Chapter 5.  
 Appendix B describes fluorescence cell barcoding, a method that enhances throughput and maximizes 
the efficacy of inter-sample comparison by fluorescence flow cytometry. Key considerations for barcode 
optimization and data analysis are discussed in detail. A step-by-step fluorescence cell barcoding protocol is 
also provided. 
 Appendix C describes the use of fluorescence flow cytometry to tracking cell type-specific uptake of novel 
therapeutic compounds. This work resulted from a collaboration with a previous graduate student, Dr. Katherine 
Chong, from Dr. Gary Sulikowski’s group at Vanderbilt University. Different human cancer cell lines and healthy 
peripheral blood mononuclear cells were used to compare their differential uptake of fluorescence-tagged 
apoptolidin, a compound previously shown to preferentially target transformed cells compared to healthy cells. 
Additionally, immunofluorescence imaging was used in parallel with fluorescence flow cytometry to visualize and 
confirm the differential drug uptake. 
 Appendix D describes the application of fluorescence cell barcoding, explained in Appendix B, for a high-
throughput drug response assay. This work is a collaboration with a previous graduate student, Dr. David Earl, 
from Dr. Brian Bachmann’s group at Vanderbilt University, and Dr. P. Brent Ferrell Jr., a previous member from 
Dr. Jonathan Irish’s group, now a faculty member at Vanderbilt University. Acute myeloid leukemia patient 
samples were treated ex vivo with crude biological extracts. Samples were then fluorescently barcoded, 
simultaneously analyzed, leading to the identification of cell type-specific biological impact of the compounds. 
 Appendix E describes Marker Enrichment Modeling (MEM), a quantitative measure for feature 
enrichment used for the characterization of novel glioblastoma cells described in Chapter 6. This work was 
developed by Dr. Kirsten Diggins, a previous graduate student and now a postdoctoral fellow in Dr. Jonathan 
Irish’s lab at Vanderbilt University. This collaboration led to the application of MEM in a glioblastoma mass 
cytometry dataset, which successfully distinguished tumor infiltrating immune cells from glioblastoma cells using 
only non-canonical cell identity markers. 
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CHAPTER 2 
The Diversity of Human Malignancies 
 
Introduction 
 Cellular diversity is a phenomenon that exists in both normal and cancerous tissues (16). Eukaryotic 
organisms are created from single cells that differentiate into cells and organs that carry diverse functions, while 
remain connected via genetic lineages. A single organ is composed of different cell types that make up the 
complex architecture, including the vasculature, epithelium, immune cells and connective tissues. The 
phenotypic differences of genetically identical cells, which are influenced by non-genetic traits, contribute to the 
intra-organ cellular diversity (16). When the programs that control cellular homeostasis are disrupted, cellular 
imbalance and dysregulated cell growth can occur, and can lead to tumor formation. 
 Human malignancies exhibit multiple layers of diversity (17, 18). Differences in clinical progression and 
distinct morphological features of cells observed by pathologists has led to the standard categorizations of 
cancers. Even though the diversity of human malignancies had long been recognized, such as variations in 
clinical outcomes of patients who had been diagnosed with the same type of cancer, recent advanced 
technologies have further revealed its extent to be beyond what was previously comprehended. Generally, tumor 
diversity can be divided into two main categories: inter-tumor diversity and intra-tumor diversity. However, these 
categories are still relatively broad. The diversity of human malignancies can be further observed spatially and 
temporally, and even at the single-cell level. Therefore, a thorough understanding of the scope of tumor diversity, 
as well as its contributing biological features, is essential for the development of clinical diagnostics, as well as 
for the discovery of novel therapeutics. 
 
The scope of tumor diversity 
Diversity between individuals  
Diversity of tumor progression and patient survival has been noted in many types of human cancers that, 
historically, influenced establishment of diagnostic guidelines (19-21). The distinct underlying biology of 
individual tumor cells as well as other patient-specific factors are plausible explanations of the diversity in 
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therapeutic responses and patient outcomes. Histopathological criteria are historically and routinely used to 
classify human malignancies into categories that generally, although not perfectly, reflect diverse outcomes and 
occasionally predict benefits from specific therapies. These distinctions are usually based on microscopic 
observations of cellular morphology, the architectural arrangements of cells, as well as other unique histological 
features. Often, immunohistochemistry stains of specific cellular targets are also incorporated into routine 
diagnostic regimens and disease classifications, which are usually semi-quantitatively assessed by experts. 
Although clinically informative, many disease categories are distinguished based on arbitrary cut-off values or 
qualitative histopathologic descriptions. Advanced technologies have enabled large-scale quantitative 
characterization of human malignancies at genomic, transcriptomic, and proteomic levels, which has revealed 
extensive diversity between tumors, even among those that were classified as the same disease based on 
histopathological and immunohistochemical criteria alone (Figure 2-1A) (2, 3, 22-25).  
 
Figure 2-1 The scope of tumor diversity. (A) Tumors from different patients that are categorized as the same disease, 
based on traditional histopathological criteria, often have molecular differences that result in a diversity between individuals. 
(B) After treatment, or even as the tumor progress through its natural course of progression, the underlying molecular 
characteristics of the tumor can change over time. (C) For tumors that can metastasize to distant locations, or tumors that 
can occupy different sites at the initial diagnosis, the molecular features and cellular composition of tumors from different 
organs often differ. (D) Even at a single disease site, various cancer cell subsets can occupy different regions of the tumor. 
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Due to the increasing insights of the molecular alterations that confer diversity between tumors, inter-
tumor molecular heterogeneity is now part of the more recent classifications of many types of cancer (19, 21, 
26). Importantly, many of these classifications direct how patient care should be tailored to be most clinically 
beneficial based on the tumors’ molecular profiles. An example of this is the classification of breast cancer, which 
is based on the expression hormonal receptors (estrogen and progesterone receptors) and a cell surface 
receptor (ERBB2, also known as HER2) (27, 28). This classification reflects distinct biological mechanisms and 
predicts clinical responses to different targeted therapies. In general, the goal of cancer classification is to group 
patients into discrete, well-defined, disease categories. However, quantitative assessments of the molecular 
lesions in many types of malignancies have revealed that the differences between patients are usually subtle 
and often display continuous spectra of abnormalities rather than sharply distinct anomalies (23, 29). Therefore, 
approaches that can integrate objective and accurate quantification of features that drive even the subtle 
differences between different patients are needed to improve cancer stratifications. 
 
Temporal diversity 
 Despite aggressive therapies, human malignancies occasionally resist treatment and eventually recur 
(Figure 2-1B). Often, some cancer cells are more susceptible to certain treatment than others and are more likely 
to be eradicated during the initial course of therapy (30). Clinical treatment is a form of external selective pressure 
that can enrich for cells that are inherently resistant to such therapy. These resistant cells, which can be present 
at low abundance prior to therapy, can eventually expand and take over the tumor mass (31). This process of 
clonal selection can, therefore, significantly alter the homeostasis within the tumor microenvironment, resulting 
in a tumor that no longer responds to the initial primary treatment (32).  
Additionally, exposure to chemotherapeutics and targeted therapies can alter the intrinsic properties of 
cancer cells. For example, blockade of specific signaling molecules can force the cells to evolve and to re-route 
their functional network in order to maintain their malignant capacity (33). Moreover, cancer cells can acquire 
new molecular alterations, such as new genetic mutations, that lead to a resistance to the initial therapy (such 
as the acquisition of T790M mutation in lung adenocarcinoma secondary to inhibition of epidermal growth factor 
receptor, EGFR) (34). Therefore, the mechanisms essential for cancer cell survival can continuously evolve over 
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time, resulting in a temporal diversity even in an individual patient. Notably, this can occur despite the primary 
and recurrent tumors being categorized as the same disease based on the standard histopathological criteria. 
Even without treatment, the cellular makeup within a tumor can evolve as a result of the natural disease 
progression. An example of this process is the progression of pre-cancerous lesions (such as colonic polyps or 
pulmonary nodules) to full-blown malignancies (such as colonic adenocarcinoma or lung cancer) (35). 
 
Spatial diversity 
 Tumors that occupy different disease sites or organs can contain uneven distribution of cancer cells 
(Figure 2-1C, left) (36, 37). Most of the previous studies have reported discrepancies between the molecular 
features of primary tumors and tumors from different metastatic sites (38-41). Even in tumors that rarely 
metastasize beyond the organ of origin, such as malignant brain tumors, tumor samples obtained from different 
regions within the same tumor mass can have distinct molecular profiles (Figure 2-1C, right) (42-44). 
Hypothetically, the spatial diversity within a single tumor site can be due to cell-intrinsic factors, leading to 
preferential cell localization, or even extrinsic factors, such as region-specific growth factors, that inevitably 
impact or alter cellular characteristics and functions. A critical concern that arose from this observation is whether 
the primary tumor alone, especially a small sample obtained from a single tumor site, can sufficiently serve as a 
representation for clinical diagnostics and disease monitoring. 
Understanding the disparity of the cellular composition of tumors at different sites, as well as those from 
different regions within the same tumor, is critical for cancer diagnostics, for disease monitoring, as well as for 
designing treatments that can prevent or overcome disease progression. However, most of the current diagnostic 
and therapeutic approaches are usually based on the characterization of only the primary tumors and frequently 
on a small number of cells obtained via biopsy (17). Ultimately, studies that are based on matched primary-
metastasis samples from the same patients and samples from different regions within the same tumors are key 
to understanding the spatial diversity of human malignancies.  
 
Single-cell diversity 
Multiple subsets of cancer cells can co-exist within individual tumors, even at a single disease site (Figure 
2-1C, right) (5, 14, 15, 44). These cells are often functionally distinct (45, 46), carry contrasting molecular profiles 
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(5, 44, 47), and can respond distinctly to both non-specific and targeted treatments (30, 48, 49), leading to 
therapy resistance or even disease recurrence. In part, the unique combinations of these cancer cells contribute 
to the inter-tumor diversity described above, as observed via sample-level analyses (i.e. the degree or the 
average level of a specific molecular alteration changes with the presence, as well as the different proportions, 
of cancer cell subsets) (11, 50). 
The presence of single-cell diversity is a challenge for tumor characterization and can significantly 
interfere with clinical disease stratification that is based on bulk sample evaluation or a small representation of 
single cells (such as biopsies or needle aspirations). Without high-throughput sensitive single-cell assessments, 
rare cancer cell subsets can easily be overlooked. This is especially challenging with the current standard use 
of histopathological diagnosis, especially in solid tumors, which are often semi-quantitative and are expert-
dependent. Even though individual cancer cells can be evaluated via morphological and immunohistochemical 
observations, tissue imaging only captures a small fraction of cells from the tumor. Considering the spatial 
diversity that can be present within a tumor, assessments of a few hundred or a few thousand cells by 
histopathological approaches may not adequately capture the clinically-relevant cancer cells, or the significant 
features in small cell subsets, that may immensely impact patient clinical outcomes.  
In addition to cancer cell subsets, tumors are also composed of other non-cancer stromal cells, including 
normal cells that are specific to the organ of origin (such as neurons in the brain or hepatocytes in the liver), a 
variety of tumor-infiltrating immune cells, as well as cells forming the vascular structure including endothelial 
cells and pericytes. Single cell characterization is, therefore, essential to enable accurate distinction between 
stromal features and cancer-specific traits, which is critical for the identification of novel therapeutic targets. 
 
Factors that contribute to the diversity between individual cancer cells 
Genomic diversity 
 Genomic instability is one of the hallmarks of human malignancies (8, 51, 52). Genetic mutations initiate 
tumor formation by 1) activating oncogenic pathways, and/or 2) inhibiting tumor suppressing mechanisms (53). 
This is followed by subsequent acquisitions of additional genetic alterations secondary to genomic instability. 
Advanced technological approaches and analyses have revealed that cancers contain cells that differ in their 
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genomic makeup (Figure 2-2A) (17, 54). Since these aberrancies are inherently transmissible, the temporal 
developmental phylogeny of a given cancer cell can be systematically traced and reconstructed based on its 
genomic fingerprint (42, 54).  
 
Figure 2-2 Factors that contribute to the diversity between individual cancer cells. Different cellular components 
contribute to the diversity between individual cancer cells. (A) Genetic changes indicate alterations that occur specifically at 
the DNA nucleotide level. (B) Epigenetic changes indicate alterations secondary to enzymatic reactions that modify gene 
expression not resulting from changes of the DNA sequence. Specifically, epigenetic changes include other forms of DNA 
modifications, as well as histone and chromatin alterations. (C) Gene expression is a multi-step process that eventually 
leads to a specific cellular phenotype. Here, gene expression is broadly divided into transcription (DNA to RNA), and 
translation (RNA to protein). (D) Signal transduction indicate interactions between molecules that lead to their biochemical 
modifications, which can alter their subsequent activity and functions. Signal transduction can be a response to external 
stimulation, internal cues, and can even occur autonomously in some circumstances such as in the presence of an abnormal 
protein. 
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The genomic diversity within an individual tumor variably accumulates with every round of cell 
proliferation, resulting in the presence of different subsets of cancer cells that can vary at any given time in 
disease progression. For the last few decades, the characterization of cancer diversity largely focused on 
dissecting genomic alterations, as well as identifying and targeting the driver mutations (3, 55-57). This has 
proven to be successful in some, but not all types of cancer. Accumulation of additional passenger mutations 
can possibly impact cellular phenotypes and confer malignant capabilities, which may contribute to therapy 
resistance (17, 58). Moreover, the balance of cellular genetic diversity of human malignancies can also fluctuate 
throughout the course of treatment secondary to genomic instability and environmental selection. 
Cellular diversity is, however, not simply a result of genetic mutation alone. In a normal physiologic 
environment, the distinction of the different types of cells in a human body is based on non-genomic components 
since all cells are genetically identical (except for some immune cells). The only way to distinguish the different 
cell types is to characterize their cellular phenotype (such as protein expression) and functions, which are results 
of non-genetic influences. Critically, not all genomic changes lead to phenotypic differences, let alone clinically 
relevant features. Non-genomic alterations in cancer cells, such as epigenetic regulations and influences from 
the tumor microenvironment, can significantly impact gene expression, phenotype, and subsequent cellular 
functions. Thus, deciphering the diversity of human malignancies should not only be limited to the understanding 
of the diverse genetic component of the tumor, but should also encompass other cellular components that dictate 
clinical outcome and therapy resistance. 
 
Epigenetics 
One of the explanations of why genomic information is insufficient to fully capture the degree of cancer 
diversity is the variation of gene expression that confer subsequent cellular phenotype and function. Epigenetic 
modifications of DNA, chromatin structures, and histones, are results of reversible enzymatic reactions, which 
control the process of gene expression (Figure 2-2B). This mechanism is tightly regulated in normal physiologic 
conditions (59). Epigenetic changes can lead to an increase or decrease in gene expression, depending on the 
types (i.e. methylation, acetylation, etc.) and the targets (i.e. DNA, histones, etc.) of alterations. Mutations of 
genes encoding epigenomic regulatory enzymes can alter the epigenomic landscape of the cancer cells. Thus, 
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genetics and epigenetics can be closely connected. Critically, epigenetic regulation of a given gene is not strictly 
equivalent its genetic mutation (18). Disruptions of cancer cell epigenetics can also be secondary to the abnormal 
communications between cancer cells and other cells, as well as factors in the tumor microenvironment (17, 59, 
60).  
Overall, epigenetics is commonly altered in human malignancies. DNA hypo- and hyper-methylation have 
both been observed in different types of human malignancies (61-64). Alterations of the cancer cell epigenetics 
can be a consequence of oncogenic transformation. For example, the induction of mutated IDH (isocitrate 
dehydrogenase) enzyme in human gliomas, a prognostic mutation that is believed to occur very early during 
oncogenesis, leads to a global hypermethylation phenotype in the cancer cells (65). The connection between 
the mutant IDH and DNA hypermethylation is also observed in glioma patients (22). In contrast, epigenetic 
alterations can be the initiator of oncogenesis as the induction of genome-wide hypomethylation in mice was 
sufficient for the formation of aggressive T cell lymphomas (66). Moreover, DNA methylation profiles are tied to 
the clinical outcomes of patients with different types of cancer (22, 67). Drugs that enzymatically reverse the 
epigenomic landscape have also been approved for cancer treatments (68, 69). Epigenetics, however, can only 
partially explain gene expression, transcriptional changes, and subsequent cellular functions (8, 17, 51). 
 
Gene expression: Transcriptomics and proteomics 
A parallel sequencing of genomic DNA (gDNA) and mRNA from the same single cells revealed that a 
given genetic alteration can lead to variable transcript abundance between individual cells (70). This observation 
had reinforced the notion that genomic information alone cannot sufficiently predict the level of gene expression, 
and therefore, should not be used as a sole predictor of therapy responsiveness in cancer. Recently, the effort 
to dissect single-cell diversity in human tissues and cancers has shifted towards the characterization of 
transcripts, one of the cellular components that reflect gene expression. Particularly, the appealing single-cell 
RNA-sequencing approach enables a global, unbiased view of the entire transcriptome, without the need to 
select for specific cellular targets for quantification. As a result, single-cell RNA-sequencing has been used to 
quantify transcript abundance. Additionally, the abundance of specific transcripts has been used to infer the 
identity of single cells (Figure 2-2C) (5, 71-74). 
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Proteins are products of the translation of mRNA and are the components of cells that execute many of 
the key cellular functions (Figure 2-2C). Proteins are traditionally used as the defining features of cell identity. 
The complex regulatory mechanisms that govern translation result in an imperfect correlation between per-cell 
level of a given transcript and its protein product. Even in non-disease states, the rates of mRNA and protein 
turnover substantially impact their levels and, therefore, significantly contribute to their discrepancy (75, 76). The 
rate of translation is another contributing factor to the abundance of a given protein and is tightly regulated 
throughout development (75). However, the rate of translation can be significantly altered in disease states, 
including in human malignancies, secondary to intrinsic changes (such as genetic mutations) as well as to 
signaling transduction that responds to internal and external cues (77). The common discrepancies between the 
transcripts and proteins suggest that neither should be used as the sole representative of the other, let alone a 
representative of the eventual cellular mechanisms and functions. Even though proteins are considered the 
functioning component of cells, it is important to note that although quantification of total protein expression may 
indicate the cell’s “potential” mechanism, it still does not indicate the actual function of the protein at any given 
state. 
 
Post-translational modification of proteins: The signal transduction 
 Signal transduction is a mechanism by which the molecules in the cell biochemically interact, either 
autonomously or in response to external and internal cues, to execute cellular functions (9, 78). The connections 
between these effector molecules are often mapped as signaling cascades or pathways, showing their potential 
interactions, which are inter-connected to form a complex signaling network (Figure 2-2D). A variety of genetic 
mutations can subsequently lead to alterations of a similar set of signaling effectors. Therefore, core signaling 
molecules can be viewed as the nexus or the functional regulators of the cells (79). 
 The complex signaling network enables the cells to adapt under various pressure or stimulating 
conditions (33). Quantification of post-translational modifications (i.e. phosphorylation, acetylation, etc.) of 
signaling effectors provides a “snapshot” of the ongoing activity within a cell, under specific circumstances (10, 
12-15, 80-83). A parallel evaluation of total protein expression and signaling activity in acute myeloid leukemia 
revealed that signaling profiles in hematopoietic, leukemic, progenitors remained consistent despite the 
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irregularity of the cell phenotypes determined by conventional surface protein molecules (12). Moreover, 
potentiated signaling states strongly correlated with patient outcome as well as other clinically relevant biological 
traits (12, 15, 80). Even the unstimulated, basal, signaling states alone effectively stratified the clinical outcome 
of patients with hematologic malignancies (13). 
 Post-translational modifications of signaling molecules, both surface receptors and intracellular signaling 
effectors, can be easily detected by antibody-based techniques (i.e. using an antibody that can detect 
phosphorylation at a specific amino acid residue on a protein) (80, 84, 85). By coupling this detection with high-
throughput, flow cytometry, the signaling states can be mapped at the single-cell level, reflecting the mechanistic 
information of millions of cells at a given point in time (50). Importantly, the integration of protein identity 
assessments can also distinguish between cancer and stromal features. This enables simultaneous dissection 
of the cellular activity and relevant functions, and to monitor the targetable features that are specific to cancer 
cells. This approach would immensely aid the selection of drugs and compounds that can interfere with the 
activation states of the cancer cells, which significantly impact patient outcomes. 
  
Towards quantitative single-cell analysis in solid tumors 
Cellular diversity is a critical challenge towards successful cancer diagnostics and treatment. Previous 
studies have indicated that individual cells can distinctly respond to therapies and, therefore, can differentially 
confer to clinical resistance (30, 32). Critically, the detection of clinically unfavorable cancer cells can facilitate 
disease monitoring and clinical stratification of hematologic malignancies (86). Considering the degree of cellular 
diversity that is appreciated in the different types of cancer, the benefit of single-cell quantification and monitoring 
in other types of human malignancies should be thoroughly investigated. 
With the exception of hematologic malignancies, quantification and tracking of single cells are often not 
part of the current routine clinical diagnosis and stratification of cancers due to two main challenges. First, sample 
preparation protocols and quantitative analytical procedures for the characterization of single cells from non-
hematologic (i.e. solid) cancers are not widely available and/or are not standardized. Second, expert consensus 
on the cellular parameters that can couple clinical outcome prediction and identification of molecular lesions that 
can be targeted to improve patient prognosis is often lacking. Thus, the immediate task is to develop a 
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standardized, quantitative, single-cell analysis approach that 1) can be easily adopted in many types of solid 
tumors, and 2) enables automated discovery of clinical stratifiers that can be tested as therapeutic targets.  
Ideally, a high-throughput approach that would enable characterization of a large number of cancer cells 
should be used, to maximize sample representation. Flow cytometry can quantify features of millions of cells in 
a very short period of time (Chapter 4). In addition, fluorescence flow cytometry is already routinely implemented 
for the analysis of blood and bone marrow samples, making it an ideal platform to be immediately tested for 
clinical solid tumor analysis. The key challenge is to identify a standard protocol that can derive single cells from 
patient sample that would preserve the cellular diversity present in the original tissue, enabling the identification 
of clinically meaningful cell types (Chapter 5). 
Signaling quantification of single cancer cells would introduce a novel approach to define cellular identity 
based on functional characteristics. Risk-stratification analysis can further reveal the connections between the 
functionally distinct cancer cells and clinical outcomes (tumor progression and patient survival; Chapter 6). 
Notably, the association of a given signaling state with patient outcomes would indicate its role as a prognostic 
biomarker; whether it should be used as a target for therapy must be further elucidated via experimentations and 
clinical trials (Chapter 7). Importantly, using single-cell signaling profiles as surrogates for identifying novel 
therapeutic targets is highly advantageous. First, different layers of cellular alterations (i.e. genetic mutations, 
epigenetic changes, etc.) often converge through signaling effector modifications, the critical mechanistic 
converging point within a cell that leads to the execution of many cellular functions (79, 87); it would be more 
efficient to target one or few signaling effectors as opposed to attempting to modify thousands of redundant 
upstream features. Second, since most drugs and small molecules act against proteins, signaling effectors can 
be easily tested as direct targets for novel therapeutics. Taken together, the characterization of signaling states 
in single cancer cells would potentially reveal the key regulators or the mechanistic bottleneck that govern the 
cancer hallmark-promoting cellular functions (8, 51), which can potentially be targeted to improve patient 
outcomes. 
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CHAPTER 3 
Adult Glioblastoma 
 
Introduction 
 Glioblastoma is a grade IV and the most aggressive form of human gliomas (21). Glioblastoma comprises 
46.6% of all the adult malignant brain tumors that arise primarily within the brain parenchyma. The incidence of 
glioblastoma increases with age, with the median age at initial diagnosis being 64 years (88). Glioblastoma has 
a slightly higher incidence in males compared to females (3.2 vs 2.5 cases per 100,000 populations), in the 
United States (88). The median overall survival of glioblastoma patients is slightly less than 15 months after initial 
diagnosis, despite a very aggressive standard therapeutic regimen that includes maximal, safe surgical 
resection, radiation therapy, and administration of a highly toxic chemotherapeutic agent, temozolomide (1). The 
exact etiology of glioblastoma remains unknown and most cases occur sporadically. However, certain familial 
cancer syndromes that carry genetic alterations of signaling-related genes are associated with an increased 
incidence of glioblastoma (89). Examples of these syndromes include Li-Fraumeni syndrome (germline TP53 
mutation) (90), neurofibromatosis types 1 and 2 (germline NF1 and NF2 mutation, respectively) (91, 92), and 
Turcot’s syndrome (germline APC mutation) (93). However, these hereditary cases are relatively rare compared 
to glioblastomas that arise de novo. 
 Patients with glioblastoma often present with various neurological symptoms (94). These can either be 
1) generalized neurological deficits secondary to an increase in intracranial pressure (resulting from mass 
occupying lesions and/or an obstruction of the ventricular system), or 2) localized neurological symptoms, which 
depend largely on the anatomical location of the tumor within the brain. Adult glioblastomas often arise in the 
cerebral cortex, in contrast to gliomas in the pediatric population which tend to occur in midline locations, such 
as the pons (25). Gadolinium-enhanced magnetic resonance imaging (MRI) is the common imaging modality 
that is initially used when a brain space-occupying lesion is suspected clinically. This is to pinpoint the anatomical 
location of the mass or tumor and to gauge its extensiveness for planning a surgical approach (95, 96). Although 
not sufficient to establish a final diagnosis, the radiologic appearances of the mass can often suggest a 
differential diagnosis, or a tentative diagnosis, which is immensely crucial for pre-operative evaluation. 
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Figure 3-1 Histopathological findings of glioblastomas. (A) Abnormal vascular proliferation is one of the 
histopathological features of glioblastoma (arrowheads). (B) Palisading necrosis is occasionally observed in glioblastoma 
and is defined an area of necrosis (dashed outline) surrounded by abnormal tumor cells with nuclei that are organized 
perpendicularly to the necrotic region (black arrows). Images were taken by Dr. Bret C. Mobley, Vanderbilt University 
Medical Center. 
 
The standard diagnosis of glioblastoma is based on histopathological findings (21, 97). Tissue samples 
can be obtained via stereotactic biopsies, open biopsies, or surgical resections. The modality to obtain tissue is 
generally selected based on the patient’s clinical performance (whether the patient can withstand aggressive 
surgery), which is often assessed by the Karnofsky Performance Status (KPS) (98), as well as the anatomical 
location and the extent of the tumor itself (whether the tumor is located at a location that is safe for surgical 
removal). Glioblastomas are characteristically composed of poorly differentiated cells that can morphologically 
resemble brain resident glial cells. These cells demonstrate nuclear atypia, cellular pleomorphism, and mitotic 
activity (99). Importantly, the histological features that discern glioblastomas from lower-grade diffuse gliomas 
are the presence of necrosis and/or abnormal microvascular proliferation (Figure 3-1A). Although not always 
present, palisading necrosis is a pathognomonic feature of glioblastomas, and is characterized by a necrotic 
region surrounded by an accumulation of cancer cells whose nuclei are arranged perpendicularly to the necrotic 
border, in a parallel fashion (Figure 3-1B). These tumors were historically named “glioblastoma multiforme”, 
which reflected the diverse morphological appearances of cells within individual tumors; even by cell morphology 
alone, the cellular heterogeneity of glioblastomas can be greatly appreciated (100). Another fundamental feature 
of glioblastomas is their highly invasive and diffuse growth pattern. Unlike many other types of malignancies, the 
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tumor borders of glioblastomas are usually not well-defined radiologically or even microscopically. Based on 
histopathological findings, pleomorphic abnormal cells can be seen invading through the seemingly normal brain 
parenchyma, often along the white matter tracts. Not surprisingly, glioblastomas almost always cannot be 
completely surgically resected, and inevitably, eventually recur. 
 
2016 WHO classification of gliomas: Inclusion of inter-tumor molecular diversity in the diagnostic 
scheme 
The 2016 World Health Organization (WHO) classification of diffused gliomas requires that assessment 
of genetic and cytogenetic abnormalities be part of the routine clinical diagnosis and disease sub-classification 
(99). This is especially important for lower-grade diffused gliomas where the distinction between astrocytic and 
oligodendroglial tumors by histopathological appearances alone can be challenging. Previously, this distinction 
was based primarily on the morphological appearances of cells (101); astrocytic tumors contained cells with 
more “angular” nuclei, whereas oligodendroglial tumors contained cells with nuclei that appeared round (“fried 
egg” appearance) and often contained “chicken-wire” (angulated and branched) vascular structures. There was 
also an intermediate entity, oligoastrocytic tumors, that appeared to have mixed features between the two 
categories. This latter category, however, no longer exist in the latest standard classification scheme. These 
morphologic descriptions were found to be highly subjective and were highly variable even among experts (102). 
Presently, morphological information is not sufficient to distinguish between lower-grade astrocytic and 
oligodendroglial tumors.  
The molecular alterations that are part of the diagnostic protocol are molecules that are closely associated 
with the signaling network that enables the Cancer Hallmarks (8, 51). Loss or mutations of ATRX gene (alpha-
thalassemia X-linked intellectual disability), often accompanied by TP53 mutations, are characteristic of 
astrocytic tumors (although not required for the diagnosis), whereas 1p/19q co-deletion establishes the diagnosis 
of oligodendroglial tumors. Mechanistically, altered ATRX 1) impairs cellular DNA repair mechanisms and 2) 
lengthens telomeres via the ALT (alternative lengthening of telomeres) pathway, leading to an accumulation of 
genetic mutations in the immortal cancer cells (103-105). In contrast, patients with 1p/19q co-deleted 
oligodendroglial tumors have overall better clinical prognosis than those with astrocytic tumors (106). These 
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molecular alterations, however, are not as prevalent in glioblastomas compared to lower-grade diffused gliomas 
(104). 
The critical molecular component that is required for the diagnosis of all grades of diffuse gliomas, 
including glioblastomas, is the determination of the mutational status of IDH1/2 gene (encoding isocitrate 
dehydrogenase 1/2) (99). This distinguishes patients who have significantly better prognosis (IDH-mutant) from 
those with inherently worse outcome (IDH-wildtype). IDH-wildtype glioblastomas should only be defined after 
assessments of IDH1 codon 132 and IDH2 codon 172, the most common forms of IDH mutation (99). And since 
IDH1 R132H is significantly more common than mutations in IDH2, many institutions only rely on the assessment 
of the former, especially in older patients where IDH mutations are uncommon (21). 
 MGMT (O6-methylguanine-DNA-methyltransferase) promoter methylation is a predictive biomarker for 
response to alkylating chemotherapeutics (107). Currently, besides the assessment of MGMT promoter 
methylation, there are no other molecular biomarkers that can guide therapy decisions. However, it is important 
to note that 1) determination of MGMT promoter methylation status is not required to establish a diagnosis of 
gliomas or glioblastomas according to the most recent WHO guideline, and 2) its status only aids the decision to 
administer the non-targeted chemotherapeutic agent, temozolomide (TMZ), in patients who are more likely to be 
susceptible to its cytotoxic effects (e.g. elderly, clinically unstable patients). To date, there are no approved 
clinical biomarkers that can guide individualization of targeted therapies based on the underlying pathogenesis 
of individual tumors. Moreover, none of the current, clinically approved targeted therapies have consistently or 
significantly prolonged the progression or survival of patients with glioblastoma beyond a few months compared 
to baseline (108-110). 
 
Current states of glioblastoma therapy 
 Surgery, radiation, and chemotherapy are the current standard therapies for glioblastoma patients and 
are often used in combination. The standard glioblastoma treatment regimen that includes temozolomide, the 
chemotherapeutic agent that has shown the greatest survival benefit for glioblastoma patients to date, prolongs 
the median overall survival of glioblastoma patients by approximately 2.5 months (1). However, the median 
overall survival of glioblastoma patients is still only 14.6 months, and the two-year survival rate is only 26.5 
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percent (1). Moreover, patient 5-year survival rarely exceeds 5 percent (111). Although younger patients tend to 
have a better prognosis that older patients (112), this highly aggressive brain tumor is almost always fatal.  
 
Surgery and radiation 
For surgically assessible glioblastomas, the initial treatment is maximal, safe tumor resection. The tissue 
for histopathological diagnosis is also obtained at the time of surgery. Glioblastomas are locally invasive and 
tend to rapidly invade along the white matter tracts in the brain. However, the tumors can also involve cortical 
and deep gray structures. Although part of the tumors may be surgically resectable, these aggressive tumors 
usually have already infiltrated a large portion of the brain at the time of initial diagnosis. Data have shown that 
gross total resection of the tumor, based on post-operative MRI evaluation of imaging enhancement, significantly 
prolongs the overall survival of glioblastoma patients, compared to sub-total surgical resection (113, 114). 
However, post-operative neurological functions must be sufficiently preserved when planning the surgical 
approach; this can often significantly limit the extent of surgery. Intra-operative radiologic evaluations (computed 
tomography (CT) or MRI scanners) can aid the assessment of the anatomic location and the extent of safe 
surgical resection of tumors in real-time. However, it is important to note that microscopic invasions of cancer 
cells are often present despite the lack of radiologic enhancement as assessed either in real-time or post-
operatively, making surgery extremely challenging.  
Newer surgical approaches have enabled rapid or even real-time assessments and visualization of tumor 
margins. The administration of 5-aminolevulinic acid (5-ALA) to the patients pre-operatively results in a higher 
sensitivity in identifying malignant tissues at the invading margins of glioblastomas compared to conventional 
gadolinium-based MRI. Unlike gadolinium, 5-ALA is not dependent on the disruption of blood-brain barrier, but 
rather the intrinsically accelerated metabolic rate of cancer cells. The fluorescent porphyrin, a metabolite of 5-
ALA, is more rapidly accumulated in the glioblastoma cells compared to non-malignant cells and can be 
visualized intraoperatively using a fluorescence operating microscope (115). This method appears to improve 
the progression-free survival of glioblastoma patients (116). However, this technique can lead to false-positive 
detection of fluorescence signals in some non-malignant cells, such as reactive astrocytes, since it is dependent 
upon the differential cellular metabolic rate (117) Additionally, many factors can also attribute to false negative 
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signals, such as timing from 5-ALA administration to surgery, photobleaching, necrosis, as well as structural 
obstructions that prohibit fluorescence visualization (118). 
Mass spectrometric quantification of 2-HG (2-hydroxyglutarate, a by-product of mutant IDH enzyme) is 
an evaluation of a cancer-specific metabolite, which enables the distinction between infiltrative tumor cells and 
the invaded brain structures (119). This can be evaluated on either sampled tissue (performed within the 
operating room), or in real-time using a suctioning scalpel attached to a mass spectrometer (120). The latter 
approach is an appealing platform since it utilizes the vapor or byproduct of the surgery, which is normally 
discarded, eliminating the need for the collection of additional valuable tissue for pathological evaluation. 
Furthermore, it might have a role in the treatment of tumors that are inaccessible by conventional surgical 
approaches. However, mass spectrometric assessment heavily relies on quantification of metabolites that are 
known to be specifically present in malignant tissues and not in the normal adjacent brain. Since 2-HG is only 
produced in IDH-mutant cells, its detection is only beneficial in a small subset (less than 5-10%) of adult patients 
with glioblastomas (26). Notably, IDH-wildtype cancer cells that may co-exist within seemingly IDH-mutant 
tumors could potentially be overlooked. Therefore, for real-time mass spectrometry to be more widely applicable 
for the majority of glioblastoma patients, the identification of cancer-specific protein targets in IDH-wildtype 
glioblastomas, specifically in IDH-wildtype glioblastoma cancer cells, is critical.  
Following surgery, radiation is administered as an adjuvant therapy. Whole-brain radiation following 
surgery substantially improves patient overall survival (116, 121). Plan for radiation is often assessed after 
surgery and generally includes both the gadolinium-enhanced regions and the adjacent, radiographically non-
enhancing brain parenchyma. The goal of radiation is to prevent tumor recurrence, which most often occurs 
locally. Regular radiographic assessment is also needed after the initial treatment for early detection of tumor 
recurrence, should it occur. However, it is important to distinguish between true tumor recurrence and 
radiographic pseudo-progression (122). The latter is more likely if the new radiographic enhancement occurs 
during the first few months after completion of radiation treatment, especially if the patient also receives 
concurrent temozolomide (123). Other key distinguishing factors that would favor pseudo-progression include 
the lack of new symptomatic neurological deficits (124), and presence of MGMT promoter methylation (123).  
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More recently, the use of tumor-treating fields (TTFields) as an adjunct, maintenance therapy after the 
initial surgery and radiation was introduced (125, 126). TTFields are portable devices that deliver low-intensity, 
alternating electric fields via transducer arrays that are applied to the scalp. The alternating electric field inhibits 
the microtubules and disrupts the mitotic spindles, leading to abnormal chromosomal segregation and eventual 
death of cancer cells via caspase-dependent apoptosis (127, 128). Thus, the efficacy of TTFields is dependent 
on cell division rate with the more rapidly dividing cells being more susceptible to the treatment. The side effects 
of TTFields were shown to be very mild, the most common being local skin erythema and irritation (126, 129). 
Although TTFields are now approved for used as adjunct therapy in patients with glioblastoma, its estimated cost 
of $21,000 per month had raised concerns for its cost-effectiveness, especially without the proper price 
regulation (130). Moreover, it requires the patients to use the device on a shaved-scalp, and to continuously 
carry the device for at least 18 hours per day for up to 24 months, which can be somewhat inconvenient and can 
significantly affect their quality of life (126).  
 
Temozolomide 
Prior to the incorporation of TMZ into the standard clinical management of glioblastomas, the key 
therapeutic modality for the clinical management of glioblastomas involved maximal, safe, surgical resection, 
followed by radiation therapy and administration of nitrosourea-based chemotherapeutic agents. This had 
improved the survival of glioblastoma patients to some extent, at least compared to surgery alone. However, the 
median overall survival of patients was still less than a year after initial diagnosis (131, 132). 
TMZ has been the most important advancement in glioblastoma therapy during the past decade. After 
administration, TMZ is metabolized to an active compound, 5-(3-methyltriazen-1-yl) imidazole-4-carboxamide 
(MTIC), which enzymatically adds alkyl groups to either N7 or O6 positions of DNA guanine residues, leading to 
an induction of DNA damage and subsequent cell death (133). Post-surgical administration of TMZ plus radiation 
prolongs both the progression-free survival and overall survival of glioblastoma patients by 1.9 months and 2.5 
months, respectively, compared to radiation alone (1). Thus, TMZ is included in the standard treatment whenever 
patients are evaluated to be clinically stable enough to withstand some of the common side effects of the drug, 
which include thrombocytopenia and leukopenia (134). 
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The methylation status of MGMT promotor predicts clinical responsiveness of patients to TMZ therapy 
(107). Patients whose tumors harbor detectable methylated MGMT promotor (about 50% of patients of primary 
adult glioblastomas) respond slightly better to temozolomide therapy, compared to those with unmethylated 
MGMT promotor, regardless of whether the patients receive radiation. Mechanistically, methylation of MGMT 
promoter blocks its transcription, leading to a decreased level of MGMT enzyme. This leaves the alkylated DNA, 
produced by TMZ, to remain unperturbed, which subsequently induces cell death (135). Therefore, although it 
is not part of the standard WHO classification, MGMT promoter methylation status is often assessed clinically, 
specifically to determine if the benefit from TMZ would outweigh its potential adverse effects, especially in 
patients with poor clinical performances. However, this biomarker does not offer any other benefit beyond the 
decision to administer a non-targeted and highly toxic chemotherapy. Additionally, TMZ only prolongs the overall 
survival of patients with methylated MGMT promotor by only a few months (107).  
 
Signaling alterations in glioblastoma cells sustain cancer hallmarks 
Receptor tyrosine kinase signaling 
Glioblastomas harbor diverse alterations of signaling molecules that regulate and enable one or more 
Cancer Hallmarks (Figure 3-2) (3, 7, 8, 22). RTK (receptor tyrosine kinase), p53, and RB (retinoblastoma) 
pathways were demonstrated to be the most commonly altered signaling pathways in glioblastomas, based on 
studies by The Cancer Genome Atlas (TCGA) (3, 136). Bulk genomic and transcriptomic profiles of glioblastoma 
were used to classify this deadly brain tumor into four molecular subclasses, namely 1) Proneural, 2) Classical, 
3) Mesenchymal, and 4) Neural (2). Alterations of genes encoding RTKs and downstream signaling effectors 
were proposed to be definitional of the different subclasses (PDGFRA alterations = proneural; EGFR alterations 
= classical; NF1 loss or mutation = mesenchymal) (2). Even though these analyses revealed that the overall 
inter-tumor diversity of glioblastomas is due to alterations of signaling molecules, these subclasses are not 
predictive of clinically distinct patient outcomes. Moreover, subsequent single-cell transcript analysis revealed 
that the molecular subclass diversity is present even between individual cancer cells in a single tumor (5).  
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Figure 3-2 Glioblastoma is characterized by alterations of signaling molecules that regulate cancer hallmarks. 
Signaling network associated with the classic, enabling, and emerging cancer hallmarks (blue text) is portrayed in the 
context of glioblastoma, focusing on alterations in cancer cells. The incidence of genetic alterations of individual signaling 
molecules in adult glioblastomas, based on data from The Cancer Genome Atlas (TCGA), is specified (red text). 
Abbreviations: 2-HG, 2-hydroxyglutarate; αKG, α-ketoglutarate; ATM, ataxia-telangiectasia mutated; ATRX, Alpha-
thalassemia X-linked intellectual disability; CDK; cyclin-dependent kinase; CTLA-4, cytotoxic T-lymphocyte-associated 
protein 4; DSB, double stranded break; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; 
FGF, fibroblast growth factor; FGFR, FGF receptor; GLUT, glucose transporter; HIF-1α, Hypoxia-inducible factor 1-alpha; 
IDH, isocitrate dehydrogenase; IκB, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor; IKK, IκB 
kinase; JAK, Janus kinase; MDM2, mouse double minute 2 homolog; MEKK, mitogen-activated protein (MAP) kinase kinase 
kinase; MGMT, O6-methylguanine-DNA-methyltransferase; mIDH, mutant IDH; MKK, MAP kinase kinase; mTOR, 
mammalian target of rapamycin; NF1, neurofibromin; NF2, merlin; NFκB, nuclear factor kappa-light-chain-enhancer of 
activated B cells; NEHJ, non-homologous end-joining; PD1, programmed death 1; PDGF, platelet-derived growth factor; 
PDGFR, PDGF receptor; PDL1, PD-ligand 1; PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and tensin homolog; 
RB, retinoblastoma; RSK, ribosomal S6 kinase; STAT, signal transducer and activator of transcription; TERT, telomerase 
reverse transcriptase; TET, ten-eleven translocation; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor. 
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Even though they are often thought of as distinct cascades, these pathways are inter-connected by 
functionally versatile effector molecules that biochemically interact, leading to a formation of a highly complex 
network (9). Therefore, alteration of a single molecule can disrupt the functional output of multiple linked 
cascades. Alterations of EGFR (epidermal growth factor receptor) gene are found in approximately half of adult 
glioblastomas and are the most common oncogenic lesions in these aggressive tumors (Figure 3-2; Sustained 
proliferative signaling) (3). In most cases, amplification of EGFR is also accompanied by its genetic mutations, 
which can occur as point mutations, in-frame deletions, or fusions of EGFR with other genes (3). EGFRvIII, an 
EGFR mutation that involves an in-frame deletion of exons 2-7, which encode the extracellular domain of the 
receptor (the ligand binding site), is among its most prevalent mutations. EGFRvIII protein is constitutively active 
and can initiate autonomous activation of downstream signaling molecules in the absence of extracellular ligand 
binding and stimulation (sustained proliferative signaling) (137, 138). EGFRvIII is also present in approximately 
half of glioblastomas with amplified EGFR (139). Experiments in animal models suggested that the interaction 
and dimerization between EGFR and EGFRvIII induced nuclear translocation of EGFRvIII, as well as subsequent 
increase in STAT3 and STAT5 phosphorylation, which eventually led to an increased in malignant transformation 
capabilities (140).  
Mutations of other RTKs in adult glioblastomas, although present, are not as common as EGFR 
alterations. Among these are PDGFRA (platelet-derived growth factor receptor, alpha), MET, and FGFR 
(fibroblast growth factor receptor) alterations, which are most often accompanied by altered EGFR (3, 136). Only 
7% of adult glioblastomas have amplifications or mutations of one or more non-EGFR RTKs without EGFR 
aberrancies (3). Activation of different RTKs can lead to activations of similar signaling effectors due to the 
redundancy of signaling pathways, allowing the cells to maintain functions that sustain their malignant properties 
via multiple routes (141, 142). This has been shown in ex vivo experiments that blockade of multiple signaling 
nodes was required for inhibiting RTK activation (143). Moreover, about a third of glioblastoma patients do not 
have detectable genetic alterations of RTKs at all (3), suggesting that alternative oncogenic mechanisms must 
exist to maintain the malignant properties of glioblastoma cancer cells. 
 Many of the previously proposed innovative therapies in glioblastoma have focused on targeting the 
aberrant surface receptors, particularly RTKs, since they are among the most prevalent genetic alterations 
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observed in adult glioblastomas (108, 110, 144). Moreover, disruptions of signaling activities that are connected 
to RTK potentiation can lead to functional dysregulations, allowing maintenance of cellular malignant 
characteristics, such as sustained cell proliferation, tumor invasion, and evading growth suppression (3, 7, 8, 
136, 145). However, drugs that inhibit the enzymatic functions of these receptors, often tested as monotherapies, 
have shown very limited clinical success (109, 110, 146, 147). Several mechanisms have been hypothesized to 
be the cause of the failures of these seemingly logical innovative therapies, such as receptor co-activation, 
signaling network re-wiring, and selection of cancer cell subclones that are inherently resistant to such treatments 
(44, 48, 142). 
Although surface signaling receptors have been the focus for genetic and transcriptomic characterization, 
“downstream” signaling effectors are also commonly altered in adult glioblastomas. Mutations of PTEN and 
genes encoding PI3K (phosphoinositide 3-kinase), the components of the AKT signaling pathway downstream 
to RTK activation, are the most common altered signaling effectors in adult glioblastomas as their combined 
aberrancies were seen in approximately 50% of patients (3). PI3K/AKT activations are associated with regulation 
of cell proliferation and protein translation (148). Increased activation of PI3K/AKT pathway independent of the 
activation state of the surface receptors can be a result of defective signaling inhibition (such as PTEN mutation) 
or constitutive AKT activation (such as oncogenic PI3K alterations) (Figure 3-2). These changes eventually result 
in subsequent uncontrolled cell growth observed in glioblastomas.  
AKT signaling also plays a major role in cell metabolism, one of the Cancer Hallmarks that is commonly 
disrupted in human malignancies (51). For glioblastoma, dysregulated metabolism has been proposed to be one 
of its key pathogenesis since the presence of necrosis is one of its pathologic diagnostic criteria. Specifically, 
hypoxia can induce AKT phosphorylation, which then inactivates the pyruvate dehydrogenase complex leading 
to an increase in glycolytic metabolism (149) (Figure 3-2; Dysregulated energetics). Disruption of AKT signaling 
can diminish glucose uptake and the subsequent production of lactic acid in glioblastoma cells (150). Other 
mechanisms by which AKT activation increases glycolysis include localizing glucose transporters (GLUT) to the 
cell membrane to increase glucose uptake, increasing the activity of hexokinase (HK), as well as, activating the 
glycolytic rate-limiting enzyme phospho-fructokinase-1 (PFK-1) (151-156). Increased glycolysis is also 
associated with poor overall survival in patients with lower-grade gliomas and glioblastomas (149). Additionally, 
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adult glioblastoma is one the human malignancies with the highest level of AKT activation, suggesting that 
PI3K/AKT signaling has significant biological importance even though mutations of the gene encoding AKT itself 
are rarely observed in glioblastoma (157).  
PIK3/AKT signaling is connected to other pathways including MAPK/ERK pathway, as both can activate 
common signaling effectors, such as S6K (158). Inhibition of either pathway can re-wire the signaling network, 
leading to an induction of the activity of the other pathway (159). In contrast to PI3K/AKT signaling, alterations 
in the MAPK/ERK signaling pathway only occur in approximately 10-12% of adult glioblastoma patients (3). Most 
of the alterations occur in NF1 gene, which encodes neurofibromatosis 1 (NF1) protein, a negative regulator of 
RAS (160). Deletion of NF1 is one of the key molecular changes that were proposed to be characteristic for the 
mesenchymal molecular subclass of adult glioblastomas (2). Alterations of RAS and RAF (almost exclusively 
BRAF), however, were seen in only 1-2% of adult glioblastomas. BRAF V600E mutation occurs mainly in 
pediatric gliomas (161). MAPK/ERK signaling can also regulate cell metabolism by increasing the ATP 
production of the citric acid cycle (162).  
 
Dysregulation of cell cycle and cellular mortality 
The pathogenesis of glioblastomas is closely associated with disrupted cell cycle regulatory mechanism. 
Approximately 35% of adult glioblastomas harbor a mutation in TP53 gene (3, 136), leading to the impairment 
of the cellular DNA repair mechanisms (Figure 3-2; Resisting cell death, and genome instability and mutation). 
Together, this results in dysregulated proliferation of cells that bear genomic instability (163, 164). However, 
TP53 mutations are more prevalent in, and are characteristic of, lower-grade diffuse astrocytomas (although 
they are not required to establish a diagnosis) compared to glioblastomas (21). TP53 mutations are also found 
more commonly in secondary glioblastomas (those that have progressed from lower-grade tumors) compared 
to primary glioblastomas (165). This indicates a continued progression of cancer cells from pre-existing lesions. 
Genetic amplification of MDM2 (mouse double minute 2 homolog), a gene encoding the negative regulator of 
p53, can also lead to a loss of p53 function (163, 166). This is more commonly the case for primary glioblastomas, 
and often without the genetic mutation of TP53 itself (3). The resulting over expression of MDM2 enables the 
cancer cell to escape the tightly regulated cell cycle. 
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Other common mutations in the cell cycle pathways include changes in CDKN2A and CDKN2B genes, 
which encode p16 and p15, respectively (Figure 3-2; Evading growth suppression) (3, 136). The physiologic 
roles of these proteins are to control the transition from G1 to S phase and to halt the cell cycle in G1. p16 and 
p15 are traditionally considered to be part of the RB pathway, one of the major disrupted signaling pathway in 
glioblastomas. Mutations of CDKN2A and/or CDKN2B are present in approximately half of de novo tumors (3). 
CDK4 which encodes cyclin dependent kinase 4, a positive G1 regulator, is also commonly amplified resulting 
in accelerated cell cycle and proliferation (167). While these proteins mechanistically affect the function of RB 
protein, RB mutation itself is not as common in glioblastoma (168).  
In contrast, mutations in the promoter region of TERT gene are common in primary IDH-wildtype 
glioblastomas. However, they are less common in secondary tumors (169, 170) (Figure 3-2; Replicative 
immortality). TERT encodes telomere reverse transcriptase enzyme, the catalytic subunit of the telomerase 
complex (171). TERT catalyzes the addition of nucleotides to the ends of chromosomal telomeres, a process 
that prevents overt degradation of the ends of chromosomes that can occur due to repeated cell replications. 
TERT promoter mutations in glioblastomas are associated with increased TERT transcript levels, TERT protein 
levels, and its overall enzymatic activity. This results in telomere lengthening and cellular immortality (3). Not 
surprisingly, patients with glioblastomas or low-grade gliomas with TERT promoter mutations have significantly 
shortened overall survival (106). 
Lower-grade gliomas and secondary glioblastomas appeared to be more dependent on a pathway that 
is known as alternative lengthening of telomeres (ALT) (172, 173). Specifically, the lack of ATRX is linked to the 
ALT phenotype since ATRX normally represses ALT (174). ATRX is a DNA-dependent ATPase that is required 
for checkpoint activation and protection of genomic stability (175). As mentioned previously, ATRX loss is a 
hallmark that is often used to distinguish astrocytomas form oligodendrogliomas, by means of 
immunohistochemistry staining, although this is not absolutely required for diagnosis establishment (21). 
Interestingly, ATRX loss is mostly identified IDH-mutant gliomas and is mutually exclusive with 1p/19q co-
deletion, a diagnostic feature of oligodendroglial tumors (104). 
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Disruption of cellular energetics 
For cancers to progress, they must adapt their cellular metabolisms to keep up with the accelerated rate 
of cell proliferation, the disrupted tumor microenvironment, and the change in the availability of energy resources. 
The commonly observed metabolic switch from oxidative phosphorylation to aerobic glycolysis in cancer cells 
(the Warburg effect, (151, 153)) might be due to their need to thrive in low-oxygen environment, which could be 
secondary to rapid tumor growth. Alterations of cellular metabolism has long been thought to one of the key 
aberrancies in glioblastoma, partly due to the observation of tumor necrosis (Figure 3-1 and Figure 3-2; 
Dysregulated energetics) (21). Further studies revealed that many genetic changes that impact the signaling 
network alter the cellular energetics of glioblastomas and lower-grade gliomas, leading to upregulation of surface 
GLUT, or even biochemical alterations of glycolytic enzymes (151-156). For example, the presence of TP53 
mutation can endorse the Warburg effect by promoting anaerobic glycolysis and dysregulating cellular energetics 
(176, 177).  
The most important discovery of altered cellular metabolism in glioblastoma is the identification of IDH1/2 
mutations, which disrupt normal cellular metabolomics (26, 178). IDH enzyme has multiple isoforms: IDH1 
functions mainly in the cytoplasm, whereas IDH2 resides within the mitochondria (179). In a normal cell, IDH 
catalyzes isocitrate into α-ketoglutarate (α-KG), both of which are intermediates of the citric acid cycle. It had 
been postulated that IDH mutations might facilitate the Warburg effect by changing the metabolic pool and 
subsequently increasing the glycolytic influx (180). Alternatively, IDH mutations might confer a different metabolic 
alteration that either occur independently or even in parallel with the classical Warburg effect (181). The mutation 
produces a gain-of-function IDH enzyme that, in addition to its normal metabolic function, also produces an onco-
metabolite 2-hydroxyglutarate (2-HG) (182). 2-HG mechanistically alters cellular epigenetics and angiogenic 
signals. Interestingly, IDH1 and IDH2 mutations are mutually exclusive, with the majority in diffused gliomas and 
glioblastomas being IDH1 R132H (26). Importantly, these mutations are virtually always heterozygous (affecting 
only one allele), resulting in the production of mutant and wildtype enzymes within the same cell (183). The 
discovery of IDH mutations has reshaped the understanding of glioblastoma pathogenesis, at least in a subset 
of patients. IDH mutation is thought to be one of the earliest oncogenic drivers since it is sufficient to induce 
several malignant properties, and mosaic somatic IDH mutation is associated with many syndromes that carry 
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an increased risk for gliomas (65, 184-186). This is also supported by the much higher prevalence of IDH 
mutation in secondary glioblastomas (50%-80%) and in lower-grade diffuse gliomas (60%-80%), compared to 
primary glioblastomas (5%-10%) (187). These findings suggested that distinct oncogenic mechanisms may be 
required for the progression or even the initiation of these tumors. Importantly, patients with IDH mutant 
glioblastomas have significantly prolonged progression-free and overall survivals, compared to those that lack 
the mutations (26). This is potentially due to the ability of mutant IDH to alter the epigenomic landscape of cancer 
cells, enabling a resistance mechanism against treatment with DNA alkylating agents. 
 
Local invasion of glioblastoma cancer cells 
The diffuse invasion of glioblastoma cancer cells into the surrounding brain parenchyma at the time of 
initial diagnosis is a major hurdle for therapeutic interventions. Extensive surgical and radiotherapeutic 
approaches have been used to radically eradicate the affected brain. However, glioblastomas often recur locally 
or, not uncommonly, at a different region within the brain (188). Unlike many other types of solid tumors that 
metastasize beyond the organ of origin, glioblastomas rarely metastasize extracranially (189). Specifically, 
glioblastoma cancer cells tend to locally invade and migrate along the white matter tracts and vascular structures 
(190). These observations suggested that the cellular mechanisms that regulate glioblastoma cell migration is 
both aggressive, yet highly specific. A thorough understanding of this unique feature of glioblastoma can 
significantly aid the future development of therapeutic approaches that halt cancer cell migration at an early 
stage. 
Many signaling-related molecules that are differentially associated with glioblastoma molecular 
subclasses are also mechanistically involved in cell motility and cancer cell migration (Figure 3-2; Invasion) (2, 
191, 192). Hypoxia can also induce cellular migration via activation of HIF1α (193). Additionally, MET 
overexpression and NF1 mutation, which are definitional of mesenchymal glioblastomas, are both associated 
with increased cell migration (2, 194, 195). MET (the receptor of hepatocyte growth factor, HGF, which is highly 
expressed in glioblastoma) can activate key downstream signaling effectors, including PI3K/AKT and ERK 
pathways, by heterodimerizing with CD44 (196, 197), a marker of mesenchymal phenotype that is closely 
associated with the cytoskeleton actin (198). And since the extracellular matrix in the brain also contain a 
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significant portion of hyaluronic acid, the ligand of CD44, the interaction between CD44 and MET is thought to 
play a significant role in glioblastoma cancer cell migration (191, 199). Moreover, higher degree of resistance to 
radiation therapy was observed in an ex vivo model of gliomas that underwent mesenchymal differentiation via 
NFκB signaling activation (200). Although these mesenchymal features were thought to be related to an 
aggressive cancer phenotype that requires more intensive therapies (2), the association between CD44 
expression and cancer aggressiveness is not a straightforward, linear correlation (192). Intermediate expression 
of CD44 is associated with significantly more aggressive tumors compared to those with either very low or very 
high expression levels (192). Notably, a subset of patients with CD44hi mesenchymal gliomas showed longer 
survival times compared to patients with CD44int mesenchymal gliomas (192). Further characterization of cell 
subsets that may affect sample-level biphasic CD44 expression, as well as their associated signaling 
mechanisms, could reveal molecules that, once targeted, can suppress cancer cell migration and tumor 
progression.  
 
Epigenetic alterations 
 In addition to genetic alterations, epigenetic aberrancies are vastly diverse among glioblastoma tumors 
and are closely related to the genomic profiles and even the anatomic locations of the tumors (22, 25, 201). 
MGMT promoter methylation is present in approximately 45% of glioblastoma patients (Figure 3-2; Resisting cell 
death) (3, 202) and is often evaluated in routine clinical testing to predict benefit from TMZ administration (107, 
202, 203). The global DNA methylation landscape classifies glioblastomas into biologically distinct groups that 
are correlated with genetic alterations, clinical parameters, and patient outcomes (25). Tumor-level DNA 
methylation is also closely connected to transcriptional molecular subclasses (3, 22). Specifically, the glioma-
CpG island methylator phenotype (G-CIMP) group is more prevalent in proneural glioblastomas. Mechanistically, 
2-HG, the onco-metabolite of mutant IDH (more commonly present in proneural tumors), can inhibit many α-KG-
dependent dioxygenases, such as histone demethylases and the TET (ten-eleven translocation) protein family, 
by acting as their competitive inhibitor (Figure 3-2; Dysregulated energetics) (204). This results in a higher level 
of DNA methylation in IDH-mutant glioblastomas (65, 204). Moreover, the age of patients with G-CIMP tumors 
tends to be younger at the time of diagnosis (22). Interestingly, a subset of patients with IDH-mutant 
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glioblastomas that also carry demethylated MGMT promotor are associated with worse clinical outcome 
compared to those with IDH-mutant, MGMT promotor methylated tumors (205).  
 
Coordination between glioblastoma cells and the tumor microenvironment  
Abnormal angiogenesis 
Abnormal microvascular proliferation is a key diagnostic feature that distinguishes glioblastoma from 
lower-grade diffuse gliomas and correlates with disease aggressiveness and tumor recurrence (206). 
Microvascular proliferation in glioblastoma is defined by 1) endothelial cell proliferation and 2) loss of vascular 
integrity (207). VEGF (vascular endothelial growth factor) is one of the key angiogenic factors that is 
overexpressed in gliomas and glioblastomas compared to normal brain tissues (Figure 3-2; angiogenesis) (208). 
Both VEGF and its receptor, VEGFR, are highly upregulated in vivo and correspond to tumor grade (209). In 
part, the upregulation of VEGF was thought to be secondary to tumor necrosis, since HIF-1α induces 
transcription of VEGF in a hypoxic environment (210). 2-HG in IDH-mutant tumors can also suppress the 
degradation of HIF-1α by inhibiting its ubiquitination enzyme, resulting in a blockade of HIF-1α proteasomal 
degradation (211, 212). Additionally, VEGF can induce vascular permeability, which leads to vasogenic edema 
that is frequently observed in glioblastoma both radiologically and histopathologically (213, 214). 
Bevacizumab (an anti-VEGF antibody) has been approved for clinical use in recurrent glioblastomas 
therapy (109, 110). However, the use of bevacizumab is not widely standardized since it only prolongs tumor 
progression by a few months and does not improve patient overall survival (109, 110, 146, 215). This could be 
due to an interplay between VEGF and other pro-angiogenic factors in glioblastoma, specifically their potential 
redundant and/or independent signaling pathways. Examples of these factors/receptors include FGF/FGFR and 
PDGF/PDGFR (216). Additionally, angiogenesis in glioblastoma can be enhanced through several mechanisms 
including direct and indirect activation of endothelial cells, as well as modulation of the extracellular matrix by 
production of proteolytic enzymes (217-219).  
Abnormal vasculatures in glioblastomas are also the niche of glioblastoma cancer stem cells, which 
appear to preferentially co-localize with endothelial cells (220). Active communication between endothelial cells 
and cancer stem cells cooperatively maintain the niche, particularly via NOTCH signaling (221, 222). Specifically, 
NOTCH ligands are produced by the endothelial cells and can stimulate the proliferation and maintain the self-
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renewal capability of cancer stem cells. Moreover, cancer stem cells may contribute to the formation of the 
vascular structure in the tumor by differentiating into either endothelial cells (223-226) or even pericytes that 
provide structural support for the vasculature (227). However, the ability of cancer stem cells to differentiate to 
both components of the vascular structure is still debatable (227, 228).  
 
Glioblastoma and the immune system  
 A critical advancement in cancer therapeutics in the past decade has been in success of immunotherapy 
as alternative treatment in many types of cancer (229, 230). Tumors of the central nervous system (CNS) 
including glioblastoma, however, were previously overlooked as candidates for immunotherapy due to the 
perceived notion of them being in an anatomic immune-privilege site and being poorly immunogenic. However, 
the discoveries of CNS and tumor immune cell infiltration as well as the CNS lymphatic system has reshaped 
the understanding of the potential role of the immune system in human brain diseases and malignancies (231-
234). Particularly, there are routes that facilitate CNS immune surveillance, which readily enables entry of 
immune cells into the brain parenchyma. Therefore, immunotherapy can and should be further evaluated as an 
alternative treatment strategy for patients with glioblastoma (Figure 3-2; Inflammation and avoid immune 
destruction). 
 Brain resident microglia (referred from now on as “microglia”) are the primary effector cells of the innate 
immune system in the CNS. Unlike other immune cells, microglia are intrinsic components of the brain and are 
maintained by local expansion of brain resident cells, rather than by postnatal hematopoietic progenitors (235-
237). The abundance of microglia has been shown to be inversely correlated with the grade of diffused glioma; 
lower-grade tumors had a higher microglial signature based on transcriptional analysis (73).  In contrast, the 
signature of monocyte-derived macrophage (referred from now on as “macrophage”) was increased in high-
grade diffuse gliomas, including glioblastomas, and was associated with a higher endothelial transcriptional 
signature (73). This was not surprising as microvascular proliferation is a pathognomonic feature of 
glioblastomas. Specifically, leaky microvascular proliferation and disruption of blood-brain barrier can contribute 
to the infiltration of macrophages and subsequent interaction between the tumor and the immune system (145). 
Glioblastoma cells can release chemoattractants to recruit microglia and macrophages, while these immune 
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cells can also release factors that regulate glioblastoma cell growth (237). Therefore, interference of the 
interaction between cancer cells and microglia/macrophages is a potential avenue for immunotherapy in 
glioblastoma. 
 Lymphocytes are the key immune cell types that can be found in the cerebrospinal fluid (CSF) of healthy 
individuals (238), suggesting that they have immediate access to the brain parenchyma and are involved in 
immune surveillance (239). The presence of CD8+ T cells in glioblastoma has been shown to be associated with 
prolonged patient survival (240, 241). Tumor-infiltrating lymphocytes (TILs) are present in varying abundance in 
primary glioblastomas, suggesting that there is a spectrum of immunogenicity that can vary between different 
tumors (242, 243). Suppression of the signal by which cancer cells prohibit T cell response is a key mechanism 
of many immunotherapies that have shown success in solid tumors (244-247). The expression of PD1 (program 
death 1) and presence of lymphocytes in glioblastomas suggested that these therapeutics can also benefit 
glioblastoma patients (145). Thorough characterization of tumor immunogenicity, as well as the presence and 
diversity of immune cell populations within the tumor microenvironment, can be informative for predicting clinical 
responses to immunotherapy. 
  
Targeting the aberrant signaling network in glioblastoma 
 Genetic alterations are key features that have been used for the selection of novel glioblastoma 
treatment. Most of the targeted therapies had been designed to directly inhibit the activity of RTKs, usually as 
single agents. Currently, there are only four drugs that are approved by the FDA for use in glioblastoma treatment 
and bevacizumab is the only approved targeted therapy (the other three being non-targeting alkylating agents 
temozolomide, carmustine, and lomustine).  
 
Inhibition of receptor tyrosine kinase signaling 
Since alterations of EGFR and activation of its downstream signaling effectors are commonly observed 
in glioblastomas, inhibition of EGFR function is thought to provide survival benefit. The hypothesis that genetic 
alterations can predict clinical responses to RTK targeted therapies is also based on the observations seen in 
other human malignancies, such as melanoma and lung adenocarcinoma (108, 248, 249). Many forms of EGFR 
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inhibition have been tested as innovative therapies in glioblastomas (Figure 3-3), including drugs that target the 
tyrosine kinase domain (i.e. erlotinib and gefitinib) (108, 249-251), block EGFR extracellular ligand binding 
domain (i.e. cetuximab) (144), or even target a commonly mutated form of EGFR, EGFRvIII (i.e. rindopepimut) 
(252, 253). EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, small molecules that were previously 
successful in the treatment of patients with lung adenocarcinoma with specific EGFR mutations (34, 248), were 
among the first drugs tested in clinical trials for glioblastoma patients. Although highly promising based on known 
genetic alterations, gefitinib and erlotinib provided very limited clinical benefit in a small group of patients (108). 
Additionally, neither gefitinib nor erlotinib significantly diminishes EGFR activity in vivo (147). Cetuximab also 
shows very limited activity in glioblastoma patients (144).  
 
Figure 3-3 Targeting the complex signaling network in glioblastoma cancer cells and the tumor microenvironment. 
Drugs that have been previously tested as innovative targeted therapies in glioblastoma are shown (yellow boxes). *Drugs 
that are currently FDA-approved for glioblastoma treatment. For acronyms, see Figure 3-2. 
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EGFR status alone is ineffective in predicting the clinical response of glioblastoma patients to EGFR 
inhibition. Further attempts have been made in trying to identify alternative biomarkers that would predict clinical 
responsiveness to EGFR TKIs. Intact PTEN was shown to be closely associated with clinical response to EGFR 
TKIs, especially those with detectable EGFRvIII (108). However, there were exceptions as some patients with 
PTEN loss responded to erlotinib or gefitinib, whereas others with intact PTEN did not. Disruption of downstream 
signaling of EGFR was also proposed as a mechanism that promoted tumor progression without EGFR activity 
(254).  Overall, these findings suggested that several signaling molecules are likely to be involved in the 
resistance to targeted therapies. It is also possible that these mechanisms can continuously adapt in response 
to external pressure, which can be unique kinetic features of individual tumors.  
 Inhibitions of non-EGFR RTKs, especially PDGFRα, were thought to be promising alternative therapeutic 
approaches. However, clinical trials of imatinib treatment in glioblastomas, either as monotherapy or in 
combination with other chemotherapeutics, did not significantly improve tumor progression or patient overall 
survival (255, 256). Evaluations of bulk tumor lysates have shown that multiple RTKs can be co-activated within 
the same tumor, enabling post-translational activations of several key effector bottlenecks (142). Moreover, 
cancer cell subsets containing diverse genetic amplification of many RTK-encoding genes can co-exist within 
the same tumor, and even within the same cells (44). This suggests that the diversity of single-cell signaling 
activation might be responsible for the failures of mono-therapies that specifically target individual RTKs. 
 Approaches to target molecules downstream to RTKs have also been explored since direct inhibition of 
surface RTKs showed minimal activity in clinical trials. PI3K and mTOR were some of the main candidates since 
they are highly activated in glioblastomas. Many of the compounds show very little promise, despite being well-
tolerated clinically (250, 257-259). Interestingly, cancer signaling activity was shown to be a predicting factor of 
clinical responsiveness to inhibition of downstream signaling effectors; a subset of patients with recurrent 
glioblastoma with high levels of ribosomal protein S6 kinase phosphorylation appeared to benefit from treatment 
with an mTOR inhibitor, temsirolimus (260). This further emphasizes that considerations to select innovative 
therapeutics in glioblastoma should go beyond genomic alterations. 
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Anti-angiogenic therapies 
 Based on the classic pathological finding of glioblastomas, anti-angiogenetic therapy was thought to be 
highly successful as a novel therapeutic approach (Figure 3-3). Bevacizumab is currently approved for use as 
adjunctive therapy for recurrent glioblastomas; this is based mainly on the radiographic response observed 
clinically (261). However, its use is largely dependent on experts’ opinion, on a case-by-case basis, rather than 
being a standard treatment protocol since bevacizumab shows very minor clinical improvement and has severe 
adverse effects. Moreover, clinical trials have surprisingly shown that bevacizumab only had minor benefits to 
progression free survival but not overall survival (110, 146). This discordance between tumor progression and 
patient survival could be attributed to the inefficiency of gadolinium-enhanced MRI to accurately detect early 
recurrence of the tumors due to the treatment with bevacizumab affecting vascular permeability (262).  
Other anti-angiogenic therapies such as aflibercept, a decoy receptor for VEGF-A, VEGF-B, and PDGF, 
also have poor clinical benefit and tolerability (263). Even combined inhibition of EGFR and VEGFR by 
vandertanib does not significantly improve patient overall survival (264). The mechanisms that explain why these 
seemingly logical treatments have failed have yet to be elucidated. Hypothetically, anti-angiogenic therapies may 
re-route the cancer cell metabolism towards a process that promote tumor progression and do not require nearby 
blood vessels as the source of oxygen (such as anaerobic glycolysis). Alternative mechanisms that should be 
further tested include the re-wiring of cancer cell signaling network, or alterations of the homeostasis of the 
perivascular niche and the resident cancer stem cells, secondary to anti-angiogenic therapy. 
  
Immunotherapy 
The multi-step interaction between cancer cells and the immune system involves presentation of antigens 
from cancer cells, by the antigen-presenting cells, to T cells which are primed against the specific antigen (265). 
T cells then circulate back to the tumor site, recognize the cancer cells expressing the antigen, and attack the 
cancer cells leading to cancer cell death (265). External interference or even augmentation of the immune-cancer 
interaction are potential mechanistic routes for immunotherapy. The discovery of TILs and antigen-presenting 
cells has suggested that glioblastoma could be a candidate for many immunotherapeutic strategies, including 
CAR (chimeric antigen receptor) T-cells (266, 267), immune checkpoint inhibitors (268-270), as well as dendritic 
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cell (DC) vaccine therapy (252, 253). One of the challenges is to accurately identify patients who would benefit 
from such therapy.  
 PDL1 (programmed death-ligand 1) was shown to be highly expressed in the majority of primary and 
secondary glioblastomas and appeared to be higher in cancer cells compared to the seemingly normal tissue 
surrounding the tumor (271). PDL1, which is expressed by cancer cells, interact with PD1 on tumor-infiltrating T 
cells to inhibit the anti-tumor immune response upon T cells’ recognition of cancer cells. A subset of 
glioblastomas was shown to have higher PDL1 expression than others, suggesting that there is a spectrum of 
glioblastoma immunogenicity and that some patients may respond more favorably to checkpoint inhibitors than 
others (242, 271). Blockade of PD1/PDL1 interaction had shown success in many types of cancer, most 
prominently melanoma, and many anti-PD1 agents are being tested as alternative therapy for glioblastomas. 
Although many other immune checkpoint inhibitors and vaccines have shown promising results in clinical trials 
(145), thorough characterization of the immune compartment in glioblastomas is needed to dissect the 
mechanistic connections between immune cells and cancer cells, as well as to explore potential biomarkers to 
establish standard selection criteria for enrolling patients for immunotherapy. 
 
Diversity of adult glioblastomas 
 Molecular studies of glioblastomas indicate that there are additional layers of biological complexity and 
diversity beyond the current standard WHO classification (3-5, 22, 205). Indeed, glioblastomas are among the 
types of human malignancies with the highest genetic mutational burden which were mostly associated with core 
signaling pathways (3, 272, 273). Detailed transcriptional analysis further elucidated the aberrancies of signaling-
related genes by classifying adult glioblastomas into four molecular subclasses based on the commonality of 
specific genetic and transcriptomic alterations: 1) proneural (PDGFRA alterations and IDH mutation), 2) classical 
(EGFR alterations), 3) mesenchymal (NF1 deletion), and 4) neural subclasses (predominantly containing 
features of neural tissues, although likely due to sampling at tumor edges and normal tissue contamination) (2, 
4, 29, 274). Interestingly, tumors of distinct molecular subclasses were not readily distinguishable by 
histopathological findings alone (2). These findings suggested that there are core biological features that are 
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significantly distinct between adult glioblastomas, and that regarding them as a unified disease entity might 
insufficiently capture their critical distinctive features that can guide novel therapeutic avenues. 
Although the discovery of inter-tumor molecular diversity of adult glioblastomas provided a significant 
progress towards individualized medicine, it has not sufficiently captured the outcome diversity in glioblastoma 
patients. Therefore, transcriptomic molecular profiling has not been clinically implemented despite it being highly 
informative in revealing the diversity of tumors between patients. It is important to note that the transcriptional 
molecular classification of glioblastoma was based on the average abnormality of bulk tumors (2, 4). Most 
importantly, bulk-tumor information does not adequately reflect the unique cellular composition within individual 
tumors. Features of non-cancerous component within a tumor, including tumor-infiltrating immune cells and 
vascular cells, can immensely mask the significant biological characteristics in cancer cells, especially in rare 
cell subsets, that drive poor outcome (29). Tracking of genetic alterations in individual glioblastomas also 
revealed the evolutionary dynamics within a tumor, enabling systematic tracing of the cancer cell developmental 
hierarchy and route of migration (42). Diversity of genetic aberrancies was demonstrated in individual cancer 
cells from adult glioblastomas (44, 47). Amplifications of genes encoding commonly altered RTKs in 
glioblastomas were seen in different cells, and not uncommonly within the same cells (44). Interestingly, the 
diversity of clinically used molecular markers IDH mutational status and MGMT promotor methylation was also 
evident within individual tumors (275). This latter finding also raised the hypothesis that there is cell-cell variation 
of IDH mutational status and MGMT promoter methylation status within an individual tumor. And if so, should 
the IDH-wildtype cells within a tumor that was tested IDH-mutant at sample level, or the unmethylated MGMT 
cells within a sample-level methylated tumor, be recognized and quantified as their own entity, since these 
molecular lesions are mechanistically related to unfavorable responses to standard chemotherapy? 
Transcriptional analysis of single cancer cells from adult glioblastomas revealed co-existence of cells that harbor 
features of distinct molecular subclasses within individual tumors, as well as cells that had combined features of 
multiple subclasses (5). Indeed, features of single cells were strongly associated with patient outcome in blood 
malignancies where clinical tracking of specific cell subsets can inform disease prognostication (15, 86).  
 The presence of multiple cancer cell subsets has been reported in glioblastomas and has been proposed 
to be a contributing factor towards therapy resistance. However, whether it is the degree of cellular diversity 
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within an individual glioblastoma, or the presence of a specific cell subsets that drive therapy resistance, has yet 
to be elucidated. Single-cell analysis revealed that clones derived from individual cells from a single tumor 
differentially responded to ex vivo drug treatments (30, 48), suggesting the presence of multiple cancer cell 
subsets that carry potential contrasting resistance mechanisms at the single cell level. Although there is ample 
evidence in other types of human cancer that genomic and/or transcriptomic alterations can strongly predict 
clinical responsiveness to therapies that specifically target the proteins encoded by the altered genes, the same 
logic does not seem to apply to glioblastoma, as mentioned previously. Taken together, the next critical steps 
are 1) to pinpoint the cancer cell subset(s) in glioblastoma that drive poor outcome, 2) to characterize the defining 
features of the unfavorable cell subsets, and 3) to identify novel therapeutic approaches that can eliminate the 
subsets and improve patient survival.  
  
Single-cell quantification of signaling and proteins: The future of glioblastoma clinical stratification 
and target discovery 
 Alterations in cancer cell signaling facilitate the maintenance of the functional hallmarks that sustain 
malignant capabilities. Signaling states are cumulative responses that are secondary to cell intrinsic aberrancies 
(i.e. genetic mutations, epigenetic alterations, etc.) or to the changes in the tumor microenvironment (i.e. 
availability of nutrient or oxygen, presence of growth factors or cytokines, interactions with immune or vascular 
cells, etc.). Moreover, signaling is a process by which cells integrate internal and external information to govern 
various cellular processes (9). This suggests that mapping of the signaling network in individual cells can 
illustrate the cellular functional capabilities as well as their global alterations, which make them unique. 
 Although genomic and transcriptomic data have suggested that signaling alterations are key 
pathogenesis in adult glioblastomas, very few studies focused on quantifying the actual signaling activity in 
primary patient samples. Critically, studies that characterize intracellular signaling of single cell from primary 
patient samples, without first undergoing ex vivo culture or subset selection, do not exist. Per-cell mapping of 
signaling at basal state (13), as well as after external potentiation (12, 14, 15, 80), have proven to be successful 
in stratifying the clinical outcome of patients with various hematologic malignancies. Additionally, signaling 
activity and proteins are actionable cellular targets that can be immediately tested for their therapeutic efficacy. 
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Therefore, by coupling single cell signaling quantification with clinical outcome assessment in adult glioblastoma, 
it is possible to pinpoint both the cancer cell subsets that dictate poor survival, and the subset-specific signaling 
hindrance that may be the mechanism of therapy resistance. 
 
 
Figure 3-4 Understanding the protein phenotype of cells in a normal brain is a critical for the characterization of 
single cells in glioblastoma. Many cell types comprise an adult human brain and have rather well-defined cellular protein 
expression. In adult glioblastomas, the tumor microenvironment is composed of cancer cells, brain resident cells, and 
peripherally-derived immune cells. Abbreviations: CD133, prominin 1; GFAP, glial fibrillary acidic protein; EGFR, epidermal 
growth factor receptor; ITGα6, integrin alpha 6; SSEA-1, stage-specific embryonic antigen 1; SOX2, SRY-BO2; PDGFRα, 
platelet-derived growth factor receptor alpha; OLIG2, oligodendrocyte transcription factor 2; DCX, doublecortin; MBP, myelin 
basic protein; TUJ1, neuron-specific class III beta-tubulin; NeuN, neuron nuclear antigen; S100B, S100 calcium binding 
protein B; CD24, heat stable antigen; CD45, protein tyrosine phosphatase, receptor type, C; HLA-DR, human leukocyte 
antigen – antigen D related; CD31, platelet endothelial cell adhesion molecule; CD34, CD34 antigen; αSMA, alpha smooth 
muscle actin; CD11b, integrin alpha M chain; CD64, Fc-gamma receptor 1; CD68, scavenger receptor class D member 1; 
CD3, T-cell co-receptor; CD45RO, a CD45 isoform; Iba1, ionized calcium-binding adapter molecule 1; TMEM119, 
transmembrane protein 119; CD44, hyaluronic acid receptor. Filled, lineage-defining proteins; Half, proteins that can be 
expressed in certain cell types). 
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Single-cell technologies enable accurate distinction between stromal and cancer-specific features (5, 13), 
which is crucial for subsequent selections of innovative therapies. Critically, analysis of adequate number of cells 
must be a priority to maximize sample representation. Multi-dimensional flow cytometry has long been the 
standard for the assessments of blood and bone marrow specimens, in both research and clinical settings (276, 
277). In the traditional, standard fluorescence flow cytometry, single cells are stained with a cocktail of antibodies 
(each detects a specific protein epitope), each are labeled with distinct fluorophores. Stained cells are then run 
through the micro-fluidics system of a flow cytometer, in a single-cell stream, and are then subjected to 
wavelength-specific light excitation. The fluorophores that are conjugated to the antibodies would emit light at 
different emission spectra, which allows 1) determination of the presence of specific proteins in individual cells, 
and 2) quantification of the abundance of each protein in each cell in comparison to the other cells in the sample.  
Flow cytometry, therefore, fits the requirements for the single-cell risk stratification approach. First, flow 
cytometry enables quantification of both surface and intracellular proteins, including post-translationally modified 
signaling effectors (80, 84, 278). Second, the quantification is achieved at the single cell level. And third, 
thousands to millions of single cells can be quantified in a single setting, resulting in a higher representation of 
cell subsets present in the primary tumor sample compared to other single-cell technologies such as single-cell 
RNA sequencing or quantitative imaging (5, 71-73, 279-281).  
The design of antibody panels for flow cytometry analyses requires knowledge of the cellular composition 
of the sample of interest, as well as either known (or hypotheses) of cellular targets that are to be quantified. For 
tissue types with long-standing history of single-cell analyses, such as blood and bone marrow, the cell subsets 
and their immunophenotypes are rather well-characterized (81, 282). The clinical single-cell analyses of 
hematologic malignancies are based on that knowledge, with additional quantification of cancer-specific features 
that are associated with patient clinical outcome (12, 15, 80). To adopt a similar approach for single-cell 
glioblastoma analysis, it is therefore crucial to understand the protein expression of cell types that are present in 
a healthy human brain, and to build the glioblastoma antibody panel on top of that for feature discovery (Figure 
3-4). With the ultimate goal of using single-cell signaling profile to stratify clinical outcome of glioblastoma 
patients, signaling effectors would also be included as targets for quantification (Figure 3-2) (12, 13, 15, 80).  
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With the growing knowledge cell phenotype and the continuously increasing targets that should be 
quantified to thoroughly capture the relevant biological features, the number of cellular targets (and, thus, the 
number of antibodies in the panel) poses a critical challenge for conventional fluorescence flow cytometry (Figure 
3-4). Once excited by light, a given fluorophore that is coupled to an antibody emits a spectrum of wavelengths 
that can overlap with the emitted light from other fluorophores, which can interfere with data analysis. To minimize 
spectral overlap and to maximize the accuracy of target quantification, the number of antibodies per panel is 
unavoidably limited. A standard fluorescence flow cytometry panel includes approximately 8-15 antibodies 
(occasionally over 20 parameters, at which signal compensation prior to data analysis can be challenging). The 
number antibodies per panel is even more conservative in clinical settings since accurate signal quantification is 
critical for patient care.   
 Mass cytometry had overcome the limitation of conventional fluorescence flow cytometry (50, 83). Similar 
to fluorescence flow cytometry, mass cytometry is a high-throughput, single-cell, antibody-based technology that 
enables per-cell quantification of protein targets, including assessment of intracellular signaling activity (83). 
However, the antibodies that are used in mass cytometry analysis are conjugated to rare metal isotopes instead 
of fluorophores. Cells are run through a mass cytometer in a single-cell stream and are then atomized into clouds 
of ions by an argon plasma. The mass of the ions in the clouds, which would correspond to specific antibodies 
and cellular targets, are then quantified by inductively-coupled mass spectrometry (ICP-MS) (83). The precise 
time-of-flight (TOF) quantification of the isotopic mass eliminates the spectral overlap which is a common 
challenge with the use of fluorophores. Therefore, mass cytometry enables accurate quantification of at least 35 
parameters at single cell level (50, 283). The significantly increased dimensionality of mass cytometry analysis 
had enabled simultaneous quantification of not only identity proteins (to distinguish stromal cells from cancer 
cells) (284, 285), but also cell viability (286), cell cycle (287), as well as signaling states in individual cells (12, 
83, 288). 
The increasing complexity of single-cell data demands systematic analysis algorithms. Conventionally, 
the analysis of single-cell fluorescence flow cytometry data involves sequential interpretations of biaxial plots 
(81, 83). With 35 dimensions of single-cell data, the number of pairwise plots would be close to 600. This 
traditional analysis is not only cumbersome and impractical, it is also ineffective to thoroughly capture and 
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potentially discovery the underlying biology of the dataset. Computational algorithms have enabled unbiased 
analyses and visualization of single-cell data in comprehensible and biologically meaningful ways. Examples for 
these tools include t-SNE (t-distributed stochastic neighbor embedding) (289, 290), SPADE (spanning-tree 
progression analysis of density-normalized events) (282), local linear embedding (LLE) (291), and ISOMAP 
(292). Additionally, some algorithms, such as SPADE (282), FlowSOM (293), DensVM (294), and ACCSENSE 
(295), can automatically assign cells into subsets or clusters, based on their phenotypic similarity. Overall, when 
these tools are used either independently or in combination, they can reveal novel biological findings (such as 
new biomarkers or rare cell subsets) that otherwise would have been overlooked by conventional analyses. 
 
Conclusion 
 To date, adult glioblastoma remains incurable. Despite the ample attempts to identify novel therapeutics, 
the approved treatment options that improves patient outcome are limited. Critically, signaling network alterations 
appeared to be the key mechanism of glioblastoma pathogenesis. However, there is no clinical stratification that 
effectively couples single-cell diversity with the identification of immediately targetable signaling activity.  
Single-cell protein analysis using fluorescence flow cytometry is already part of the routine clinical 
diagnostic workflow of blood and bone marrow specimens. Implementation of approaches that can accurately 
dissect higher data dimensions in individual cells would enable a comprehensive outlook of clinically relevant 
cell subsets, as well as their unique cytotypes. Mass cytometry is, therefore, an appealing platform since it can 
precisely and simultaneously quantify high dimensions of identity proteins as well as the clinically significant 
signaling activity and cellular functions in individual cells. This would reveal patient-specific, trackable, and 
potentially targetable, biomarkers that can shape the individualized therapeutic approaches. Subsequent 
disease monitoring could then be effectively tailored to encompass patient-specific features.  
Given the degree of cellular diversity and the pertinence of signaling alterations in glioblastoma, the next 
generation of clinical stratification and therapeutics should incorporate quantitative, single-cell, profiling of the 
signaling network. Ultimately, single-cell analyses could be integrated into routine clinical testing of glioblastoma 
for rapid assessment of clinically relevant cell subsets and biomarkers to guide individualized therapy. One of 
the critical roadblocks is the lack of a standardized, widely applicable, single-cell acquisition protocol that can be 
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easily implemented in the routine workflow. Additionally, the current clinical data analysis relies heavily on 
manual expert interpretation. As the increasing data dimensionality starts to become part of routine clinical care, 
automated computational tools can significantly expedite the lab turnaround time, while maximizing quantitation 
accuracy and minimizing analytical bias. The key to a successful clinical application is, therefore, the 
development of a robust automation strategy. 
The goal of this dissertation is to tackle the important hurdles towards a clinical stratification that captures 
the alterations of signaling activities in adult glioblastoma single cells. This dissertation describes the discovery 
of novel, clinically distinct glioblastoma cells defined by altered signaling and protein identity, while 
simultaneously providing a frame of work that can be readily implemented in other types of human malignancies. 
Moving forward, this body of work is a critical starting point for clinical diagnostics, stratification, and disease 
monitoring, that are continuously evolving towards automation, quantitation, and therapy individualization, based 
on the diversity of individual cancer cells. 
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Preface 
 Human tissues comprise of diverse cell populations that can be characterized and distinguished by 
unique expressions of cell identity proteins. Single-cell analysis approaches enable dissection and deconvolution 
of tissue cellular diversity. Flow cytometric tools are appealing platforms for in-depth cellular identity 
characterization since they directly assess per-cell protein expression. With the increasing biological knowledge 
on features that are associated with cell identity, a higher number of cellular features are needed to be 
simultaneously quantified to 1) capture the complex tissue microenvironment, and 2) enable discovery of novel 
cellular characteristics or cell types that may be associated with clinical features. Fluorescence flow cytometry, 
a single-cell analysis tool that is commonly used for characterizing blood and bone marrow in both research and 
clinical settings, can simultaneously quantify 8-10 features per cell in a standard setting, and up to 15-20 features 
per cell with newer instrumentations. Overlapping emission spectra of fluorophores, however, is the key limitation 
that restricts the number of cellular features that can be simultaneously measured in individual cells. Mass 
cytometry is a flow cytometry-based technique that utilizes isotope-labelled antibodies, paired with a time-of-
flight analysis. This approach significantly minimizes signal overlap, thus, enables simultaneous quantification of 
35 or more features per cell. This chapter describes the use of mass cytometry and subsequent computational 
analyses for the characterization of different cell types found in human peripheral blood mononuclear cells. 
Additionally, mass cytometry is used here as a tool to dissect the signaling kinetics in a human acute myeloid 
leukemia cell line. This was accomplished by quantifying the change of phosphorylation of signaling effector 
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molecules in response to short-term potentiation ex vivo. The work presented here describes the tools essential 
for the overall goal of this dissertation, which is to characterize the cellular phenotype and signaling profiles of 
cell subsets that are associated with favorable and unfavorable clinical outcomes of adult patients with 
glioblastoma. 
 
Abstract 
Single cell mass cytometry is revolutionizing our ability to quantitatively characterize cellular biomarkers 
and signaling networks. Mass cytometry experiments routinely measure 25-35 features of each cell in primary 
human tissue samples. The relative ease with which a novice user can generate a large amount of high quality 
data and the novelty of the approach have created a need for example protocols, analysis strategies, and 
datasets. In this chapter, we present detailed protocols for two mass cytometry experiments designed as training 
tools. The first protocol describes detection of 26 features on the surface of human peripheral blood mononuclear 
cells. In the second protocol, a mass cytometry signaling network profile measures 25 node states comprised of 
five key signaling effectors (AKT, ERK1/2, STAT1, STAT5, and p38) quantified under five conditions (Basal, 
FLT3L, SCF, IL-3, and IFNγ). This chapter compares manual and unsupervised data analysis approaches, 
including bivariate plots, heatmaps, histogram overlays, SPADE, and viSNE. Data fi les in this chapter have 
been shared online using Cytobank (http://www. cytobank.org/irishlab/). 
 
Introduction 
Computational tools and instrumentation advances have introduced a new era of single cell systems 
biology research where it is straightforward to comprehensively characterize all cell types, known and unknown, 
in primary tissues (296). Traditional aggregate analysis techniques, such as Western blotting, characterize 
cellular features with the assumption that the total signal reflects the sum of a homogeneous underlying 
population of cells. However, even among clonally derived cell lines, biologically meaningful cell-to-cell 
differences in protein expression and phosphorylation are the rule, not the exception (11). The presence of 
multiple cell subpopulations with distinct expression signatures is common in primary samples taken directly 
from the body, such as healthy tissue and tumor specimens (17, 297). In the case of blood cancers, cancer cell 
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subsets defined by abnormal signaling are associated with patient clinical outcomes, including overall survival 
(15, 80). Single cell tools such as flow cytometry enable high content single cell measurements of cellular identity 
and functional response (10, 84). Overlap in the emission spectra of conventional fluorescent probes can create 
experiment design and data analysis challenges that are particularly a drawback in quantitative single cell 
comparisons (283). Moreover, autofluorescence of some tissue types can overlap with fluorophore emission 
spectra and complicate quantitative analysis.  
Mass cytometry employs metal isotope reporters (mass tags) that are not normally found in biological 
specimens (83). Typically, mass tags are coupled to an antibody or other target-specific probe so that their 
abundance in a cell corresponds to the abundance of a target of interest. Intercalator reagents containing iridium 
or rhodium are routinely used to mark single cells (298). In addition to making cells detectable as an event to the 
instrument, comparison of event length and uptake of a cell marking intercalator helps distinguish single cells, 
cell doublets, and other particles (Figure 4-1). Intercalator reagents aim to provide a consistent, strong signal 
that is minimally variable with experimental conditions. Regular marking of events with an invariant signal helps 
to identify cell events when parsing mass cytometry data into flow cytometry standard (FCS) format, gating single 
cells (Figure 4-1), and analyzing cells with computational tools (Figures 2-2 and 2-3).  
While mass spectrometry avoids fluorescence associated problems, there are aspects of the technology 
that can be valuable to monitor and test. Mass cytometry issues include 1) impure isotopic mass tags, 2) spillover 
between closely spaced spectral channels when signal is very abundant (+1 and −1 spillover), 3) variable oxide 
formation (primarily +16 spillover), and 4) other less common confounding signals not originating from the cells 
(e.g., barium in buffers, gadolinium contrast agent from patient magnetic resonance imaging). This chapter will 
not specifically address these aspects of the technique except to say that they can be minimized by following 
best practices for instrument use, reagent quality control, and experiment design [(283, 296).  
A key advantage of mass cytometry is the multiplexed detection of many features of each cell. Typical 
experiments measure approximately 35 features of every cell (83, 288, 294, 299), with 42 being state of the art 
(288). The theoretical limit on the instrument has not been approached and is likely between 100 and 200 
features per cell using the current technology. Mass cytometry therefore, allows single-cell deep profiling of cell 
identity, phenotype, response, and functional outcome. Relative to microscopy, mass cytometry is high content 
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and high throughput at the single cell level: a typical experiment quantifies 35 features on each of ≥ 100,000 
cells from a sample in ~15–20 min. Mass cytometry has numerous applications for characterizing the cellular 
heterogeneity of healthy and diseased tissues and for tracking changes in populations over time in primary tissue 
samples (11). 
Here we present protocols for two mass cytometry experiments: 1) quantifying cell surface biomarkers 
expressed on healthy human peripheral blood mononuclear cells (PBMCs) and 2) quantifying intracellular 
signaling network responses in Kasumi-1 cells using phospho-flow (278, 300). Data from experiments provided 
in this chapter are available online (http://www.cytobank.org/irishlab). In addition, computational tools are an 
integral part of analyzing multidimensional datasets. In this chapter we provide examples of multidimensional 
data visualization. As data analysis can be daunting in 25-dimensional datasets, this chapter compares analysis 
of the human PBMC cell surface immunophenotyping dataset by three methods: 1) traditional bivariate gating, 
heatmaps, and histogram overlays (301), 2) Spanning-Tree Progression Analysis of Density-Normalized Events 
(SPADE (282)), and 3) visualization of t-Stochastic Neighbor Embedding (viSNE (290)).  
 
Materials 
1. Ficoll-Paque solution. 
2. 15 mL and 50 mL conical tubes. 
3. Cell culture medium: RPMI 1640 containing 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 
μg/mL streptomycin, stored at 4°C. Heat by immersing in 37°C water bath for 15-20 min. 
4. Freezing medium: 12% DMSO and 88% FBS, keep cold on ice. 
5. Cryopreservation tubes, 1.8 mL. 
6. 12 x 75 mm round-bottom polystyrene cytometry tubes. 
7. Water bath set at 37°C. 
8. Cell culture incubator set at 37°C with 5 % CO2. 
9. Absolute methanol stored at -20°C or lower. 
10. 1× phosphate buffered saline (PBS). 
11. Staining medium: 1% bovine serum albumin (BSA) in phosphate buffered saline (PBS). 
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12. Deionized water. 
13. Intercalator: 500 μM iridium. Prepare a 50X working solution (12.5 μM) by diluting with PBS. 
14. Cytometry tubes with 35-μm cell strainer caps. 
15. Trypan blue, prepared as recommended by manufacturer. 
16. Hemocytometer. 
17. 16% paraformaldehyde (PFA) aqueous solution. 
18. Antibodies: refer to Tables 2-1 and 2-2. 
19. Stimuli: refer to Table 4-3. 
20. 15-30 mL of human peripheral blood. 
21. Kasumi-1 cells (ATCC; CRL-2724). 
22. Mass cytometer (CyTOF) (Fluidigm). 
23. Data in this manuscript were analyzed using Cytobank (http://www.cytobank.org). 
Table 4-1 Antibody panel for cell identity 
# Target Tag Clone µL§ Catalog #* 
1 CD19 142Nd HIB19 1 3142001B  
2 CD117 143Nd 104D2 1 3143001B  
3 CD11b 144Nd ICRF44 1 3144001B  
4 CD4 145Nd RPA-T4 1 3145001B  
5 CD8a 146Nd RPA-T8 1 3162001B  
6 CD20 147Sm 2H7 1 3147001B  
7 CD34 148Nd 581 1 3148001B  
8 CD61 150Nd VI-PL2 1 3150001B  
9 CD123 151Eu 6H6 1 3151001B  
10 CD45RA 153Eu HI100 1 3153001B  
11 CD45 154Sm HI30 1 3154001B  
12 CD10 156Gd HI10a 1 3156001B  
13 CD33 158Gd WM53 1 3158001B  
14 CD11c 159Tb Bu15 1 3159001B  
15 CD14 160Gd M5E2 1 3160001B  
16 CD69 162Dy FN50 1 3162001B  
17 CD15 164Dy W6D3 1 3164001B  
18 CD16 165Ho 3G8 1 3165001B  
19 CD44 166Er BJ18 1 3166001B  
20 CD38 167Er HIT2 1 3167001B  
21 CD25 169Tm 2A3 1 3169003B  
22 CD3 170Er UCHT1 1 3170001B  
23 IgM 172Yb MHM-88 1 3172004B  
24 HLA-DR 174Yb L243 1 3174001B 
25 CD56 176Yb CMSSB 1 3176003B  
§µL of antibody per 100 µL total volume.   
*Source was Fluidigm for all antibodies. 
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Methods 
Immunophenotyping of surface markers of cell identity in human PBMCs 
 Human PBMCs are heterogeneous populations of cells that can be defined and categorized into distinct 
cell types by different surface marker expression levels. CyTOF allows simultaneous measurement of all the key 
surface markers of cell identity to enable deep profiling of cell subsets in human PBMCs. The protocol outlined 
below describes the method for live-cell surface staining of human PBMCs to characterize expression of 25 
different cell surface markers. 
 
Preparation and freezing of PBMCs 
1. Collect 15-30 mL of human peripheral blood from each donor in sterile tubes with heparin or EDTA 
anticoagulant. 
2. Transfer the blood to a 50 mL conical tube and add an equal amount of 1X PBS into the same tube and 
pipet to mix. 
3. Add Ficoll-Paque solution into two new 50 mL conical tubes at 12.5 mL per tube (see Note 1). 
4. Slowly overlay 20 mL of diluted blood sample onto the Ficoll-Paque solution in each tube (see Note 2).  
5. Slowly add PBS into each tube to increase the volume in each tube to 50 mL. 
6. Centrifuge at 400 x g for 30 min at room temperature. Set the deceleration on the centrifuge to the lowest 
speed to avoid mixing the PBMCs with the rest of the solution. 
7. Check for a white ring of PBMCs (buffy coat) right above the red blood cell pellet. Gently aspirate and 
discard the majority of the plasma above the ring. Avoid disturbing the buffy coat. 
8. Gently pipette the buffy coat using a wide bore pipet tip and transfer the buffy coat into a new 15 mL 
conical tube. Combine buffy coat from all the tubes of the same blood donor. 
9. Add PBS to the 15 mL conical tube to increase the volume in each tube to 15 mL. 
10. Centrifuge at 300 x g for 10 min at room temperature. Set the deceleration on the centrifuge to high brake 
speed. 
11. Aspirate to discard the supernatant. 
12. Resuspend cell pellet in 2 mL of PBS. Count cells with trypan blue (see Note 3). 
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Figure 4-1 Phenotyping human PBMC subsets with traditional bivariate gating and heatmap analysis. (A) 
Bivariate plots compare features measured on healthy human PBMCs by mass cytometry.  Heat corresponds to 
proportional cell abundance in a plot region for the population indicated above the plot.  Intact cells (grey gate) were 
defined using event length and an iridium-based cell marker (Ir-191 intercalator).  Among the intact cells, leukocytes 
were defined as CD45+ events. CD3 and CD19 were then used to identify T cells and B cells, respectively. Subsets of 
T cells and B cells were identified using additional markers (CD4, CD8, CD45RA, and IgM). The non-T non-B cells 
(CD45+ CD3- CD19-) were gated as monocytes, dendritic cells, and natural killer (NK) cell using CD14, CD11b, CD11c, 
HLA-DR, CD16, and CD56. (B) A heatmap compares expression of 27 measured features on the same cells populations 
shown in (A) using a log-like arcsinh15 scale.  The heat corresponds to the arcsinh15 fold difference in median expression 
for a given marker compared to the table minimum. 
 
13. Add 10 mL of PBS to each tube and centrifuge at 300 x g for 10 min at room temperature again. Repeat 
the wash as needed until the supernatant in relatively clear. 
14. Aspirate to discard the supernatant and avoid disturbing the cell pellet. 
15. Resuspend the cells in freezing medium to yield a concentration of 10-15 × 106 cells/mL. 
16. Aliquot cell suspension into cryopreservation tubes at 1 mL per tube. 
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17. Freeze the cells slowly at the rate of -1°C/min in -80°C freezer (see Note 4). Transfer the cryopreservation 
tubes into liquid nitrogen the next day for long-term storage. 
 
Live-cell surface staining of PBMCs 
1. Remove a cryopreservation tube with PBMCs from liquid nitrogen. Immediately immerse the 
cryopreservation tube in 37°C water bath. Remove the cryopreservation tube form the water bath once 
the cell suspension is completely thawed. This step should not take longer than 1-2 min. 
2. Add 10 mL of warm cell culture medium into a 15 mL conical tube. Transfer thawed PBMCs form the 
cryopreservation tube into the same 15 mL conical tube. Pipet to mix cells with the cell culture medium.  
3. Pellet the PBMCs at 300 x g for 5 min at room temperature. Aspirate to discard the supernatant. 
4. Add 5 mL of warm cell culture medium and pipet to mix the PBMCs with the medium. Count the cells 
using trypan blue (see Note 3) and adjust the volume to yield a concentration of 1-2 x 106 live cells/mL. 
Pipet the cells to get a single cell suspension. 
5. Label two cytometry tubes as “Intercalator only” and “Surface panel.” 
6. Aliquot the PBMC suspension into cytometry tubes at 1 mL per tube. Put the tubes with cell suspension 
into a 37°C incubator with 5% CO2. Rest cells for 15 min before staining. 
7. Take the cytometry tubes from the incubator. Pellet the cells at 300 x g for 5 min at room temperature.  
8. Check for cell pellets and discard supernatant by decanting (see Note 5). 
9. For the tube labeled “Intercalator only,” vigorously vortex the cell pellets in void volume and add 1 mL of 
ice-cold methanol (stored at -20°C or lower) to permeabilize the cells. Pipet or briefly vortex to mix (see 
Note 6) and store the tube at -20°C for at least 10 min (see Note 7). 
10. For the tube labeled “Surface panel,” resuspend the cell pellets with 75 μL of staining medium (see Note 
8). 
11. Transfer 75 μL of cell suspension from the tube labeled “Surface panel” to a new cytometry tube. Add 
antibodies from Surface Marker Panel (Table 4-1) to the tube to a final volume of 100 μL. Pipet or briefly 
vortex the cells with the antibodies to mix. Incubate the cells with the antibodies at room temperature for 
30 min. 
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12. Add 1 mL of 1X PBS and pipet or briefly vortex to mix. Pellet the cells at 300 x g for 5 min at room 
temperature. 
13. Check for cell pellets and discard supernatant by decanting (see Note 5). Repeat steps 12 and 13 once.  
14. Vigorously vortex the cell pellet in void volume and add 1 mL of ice-cold methanol (stored at -20°C or 
lower) to permeabilize the cells, pipet or briefly vortex to mix (see Note 6) and store the tube at -20°C 
with the tube labeled “Intercalator only” for at least 10 min. 
 
Figure 4-2 SPADE clusters PBMCs into populations based on similar marker expression. SPADE plots show 
clustered populations of healthy human PBMCs (circles) connected using a minimum spanning tree.  Each circle 
represents a population of cells with a similar phenotype for the 21 markers shown.  The size of each circle is 
proportional to the number of cells in that population.  The heat color for each circle corresponds to the median 
expression of the indicated marker on the cells within that circle.  Heat corresponds to the arcsinh15 fold difference in 
median expression for a given marker.  Note the scale min and max differ for each marker.  Black outlines termed 
“bubbles” and associated population labels derive from manual interpretation of cellular identity based on marker 
expression. 
 
Cell rehydration and DNA intercalation 
1. Take the tubes from -20°C. 
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2. Add 1 mL of staining media to each tube, pipet or briefly vortex to mix. Pellet the cells at 800 x g for 5 
min at room temperature. 
3. Check for cell pellets and discard supernatant by decanting (see Note 5). Repeat steps 2 and 3 once. 
4. Add 200 μL of 1X PBS to each cytometry tube, pipet or briefly vortex to mix. 
5. Add 4 μL of 50X Intercalator to each tube. Pipet or briefly vortex to mix the cells. Incubate cells with 
intercalator for 30 min at room temperature. 
6. Add 1 mL of 1X PBS to each tube, pipet or briefly vortex to mix. Pellet the cells at 800 x g for 5 min at 
room temperature.  
7. Check for cell pellets and discard supernatant by decanting (see Note 5). Repeat steps 6 and 7 once.  
8. Add 1 mL of deionized water to each tube, pipet or briefly vortex to mix.  
9. Strain the cells through cytometry tubes with 35-μm cell strainer cap. Cells are now ready for CyTOF. 
 
Phospho-flow signaling in Kasumi-1 Human AML Cell Line 
 A phospho-flow signaling experiment can characterize the cellular heterogeneity of intracellular signaling 
responses to various stimuli among cells within a given cell population. Here, we are using Kasumi-1, a human 
AML cell line, to demonstrate the concept. This experiment includes addition of various stimuli (Fms-related 
tyrosine kinase 3 ligand (FLT3L), stem cell factor (SCF), interleukin- 3 (IL-3), and interferon-γ (IFNγ)) to the cells 
to stimulate signaling, followed by fixation and immunostaining with antibodies specific for phosphorylated 
proteins (Figure 4-4). 
 
Cell culture 
1. Culture Kasumi-1 cells according to the manufacturer’s recommendation. 
2. The day before the experiment, passage cells and resuspend the cells at 0.5–1.0 x 106 cells/mL in the 
recommended cell culture media. Keep the cells in a 37°C incubator with 5% CO2. 
 
Stimulation of cells 
1. Label 6 cytometry tubes as “Intercalator only,” “Unstimulated,” “FLT3L,” “SCF,” “IL-3,” and “IFNγ.” 
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2. Take Kasumi-1 cells from the incubator and aliquot 1 mL of cell suspension into each cytometry tube.  
3. Prepare the stimuli while the cells are resting in the incubator. Make a 50X solutions of each stimulus by 
diluting them in PBS (Table 4-3).  
4. Add 20 μL of the corresponding 50X stimuli to each cytometry tubes. For tubes labeled “Intercalator only” 
and “Unstimulated,” do not add any stimulus. Place all the tubes back in the incubator and incubate for 
15 min (see Notes 9 and 10).  
 
Figure 4-3 viSNE arranges cells in a 2D map representing phenotypic similarity. viSNE maps show healthy human 
PBMCs arranged according to phenotypic similarity for the 21 displayed markers measured by mass cytometry.  The 
axes are unitless dimensions that reflect phenotypic differences. The distance between any two cells on the map 
corresponds to how similar or different the cells are from each other in high-dimensional space.  Heat corresponds to 
the arcsinh15 fold difference in median expression for a given marker.  This allows for a global single-cell view of every 
parameter in every cell.  Cell populations can then be identified through various techniques, including automated 
clustering or manual analysis of well-characterized markers. 
 
Fixation and permeabilization of cells 
1. At the end of the stimulation timepoint, add 100 μL of 16% PFA to each cytometry tube and vortex the 
tube to mix (see Note 11). Allow cells to fi x for at least 5 min at room temperature. 
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2. Wash the cells by adding 1 mL of PBS to each tube and pipet or vortex to mix. Pellet the cell suspension 
at 800 x g for 5 min at room temperature. Check for cell pellets and discard supernatant by decanting 
(see Note 5). 
3. Vigorously vortex the cell pellets in void volume to resuspend the cells. 
4. Add 1 mL of ice-cold methanol to each tube (stored at -20°C or lower) to permeabilize the cells. Pipet or 
briefly vortex to mix (see Note 6) and store the tube at -20°C for at least 10 min  
 
 
Figure 4-4 Mass cytometry phospho-flow analysis of AML cell signaling responses. (A) A heatmap compares 
phospho-protein abundance in Kasumi-1 AML cells following 15 minutes of stimulation by FLT3L, SCF, IL-3 or IFN.  
Each row in the heatmap or histogram overlay corresponds to a stimulation condition and each column corresponds to 
a phospho-protein (p-AKT, p-ERK1/2, p-STAT5, p-STAT1, or p-p38).  Heat corresponds to the arcsinh15 fold difference 
in median expression for a given marker compared to the unstimulated condition (Unstim).  (B) The same data as in (A) 
are shown in histogram overlay format.  Histogram overlays illustrate the distribution of marker expression within a 
population and highlight heterogeneity (e.g. p-STAT5 response to IL-3). 
 
Intracellular phospho-protein staining and DNA intercalation of cells 
1. Take the tubes from -20°C. 
2. Add 1 mL of staining media to each tube, pipet or briefly vortex to mix. Pellet the cells at 800 x g for 5 
min at room temperature.  
3. Check for cell pellets and discard supernatant by decanting (see Note 5). Repeat steps 2 and 3 once.  
4. Add 200 μL of 1X PBS to the tube labeled “Intercalator only.” Pipet or briefly vortex to mix and set the 
tube aside. 
5. For the remaining tubes, resuspend the cell pellets with 95 μL of staining media per tube (see Note 8).  
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6. Transfer 95 μL of cell suspension to new cytometry tubes. Add intracellular antibodies from the signaling 
panel (Table 4-2) to each tube. Pipet or briefly vortex the cells with the antibodies to mix. Incubate the 
cells with the antibodies at room temperature for 30 min.  
7. Add 1 mL of 1X PBS to each tube and pipet or briefly vortex to mix. Pellet the cells at 800 x g for 5 min 
at room temperature.  
8. Check for cell pellets and discard supernatant by decanting (see Note 5). Repeat steps 7 and 8 once.  
9. Add 200 μL of 1X PBS to all the tubes (except the tube labeled “Intercalator only”) and pipet or briefly 
vortex to mix.  
10. Add 4 μL of 50X intercalator to all the tubes including the tube labeled “Intercalator only.” Pipet or briefly 
vortex to mix. Incubate the cells with intercalator for 30 min at room temperature.  
11. Add 1 mL of 1X PBS to each tube, pipet or briefly vortex to mix. Pellet the cells at 800 x g for 5 min at 
room temperature. 
12. Check for cell pellets and discard supernatant by decanting (see Note 5). Repeat steps 11 and 12 once.  
13. Add 1 mL of deionized water to each tube, pipet or briefly vortex to mix. 
14. Strain the cells from each tube through a cytometry tube with 35-μm cell strainer cap. Cells are now ready 
for CyTOF. 
Table 4-2 Antibody panel for cell signaling 
# Target Tag Clone µL§ Catalog #* 
1 p-STAT5 150Nd 47 1 3150005A  
2 p-AKT 152Sm D9E 1 3152005A  
3 p-STAT1 153Eu 58D6 1 3153003A  
4 p-p38 156Gd D3F9 1 3156002A  
5 p-ERK1/2 167Er D13.14.4E 1 3167005A  
§µL of antibody per 100 µL total volume.   
*Source was Fluidigm for all antibodies. 
 
Table 4-3 Stimulation conditions 
Stimulus Time (min) 50X Dose § 
FLT3L 15 10 µg/mL 
SCF 15 25 µg/mL 
IL-3 15 10 µg/mL 
IFN 15 10 µg/mL 
§ Add 20 µL of 50X to 1 mL cells to yield 1X 
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High-dimensional data analysis 
CyTOF simultaneously measures 30+ features per cell, providing a global view of biological events in 
individual cells. However, such high dimensional data is difficult to analyze effectively with conventional bivariate 
data visualization and serial manual gating alone. Computational tools help users visualize relationships in high 
dimensional space and separate rare cells into populations based on distinct, multi-feature phenotypes. As data 
analysis can be daunting in 25-dimensional datasets, this chapter compares analysis of the human PBMC cell 
surface immunophenotyping dataset by three methods: 1) traditional bivariate gating (see Note 12), heatmaps, 
and histogram overlays (using Cytobank (301), Figure 4-1, see Note 13) Spanning-Tree Progression Analysis of 
Density- Normalized Events (SPADE (282), Figure 4-2, see Note 14) visualization of t-Stochastic Neighbor 
Embedding (viSNE (290), Figure 4-3, see Note 15). 
 
Notes 
1. Avoid spilling Ficoll-Paque solution on the side of the 50 mL conical tubes. 
2. Gently overlay blood and PBS mixture on top of the Ficoll-Paque solution. This can be done by adjusting 
the release speed of the serological pipet aid to minimum. Do not mix the Ficoll-Paque solution and the 
diluted blood sample since this would minimize PBMCs isolation. 
3. To count live cells, mix 10 μL of trypan blue working solution with 10 μL cell suspension and count cells 
under a microscope using a hemocytometer. 
4. To maximally preserve cell viability, cells should be frozen down at a slow rate close to −1°C/min. This 
can generally be achieved by placing cryopreservation vials in plastic containers that are immersed in 
isopropanol prior to transfer to -80°C. Commercially available products can also be used. Transfer viably 
cryopreserved cells from -80°C to liquid nitrogen within 48 h. 
5. To avoid losing the cell pellet, decant only once and try to discard as much supernatant as possible. 
Avoid re-decanting after inverting the cytometry tubes to an upright position since this can loosen the cell 
pellet or detach it from the bottom of the tube. 
6. Cell pellets may clump when methanol is added if they are not resuspended well. To prevent cell 
clumping, vigorously vortex the pellets in void volume prior to adding ice-cold methanol. 
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7. Following permeabilization ice cold methanol for 10 min, samples can be maintained long term at -20°C 
or -80°C for months without additional apparent changes to target epitopes. 
8. The goal of this step is to resuspend each cell pellet to yield the total volume indicated in the protocol 
and to avoid losing cells in the following steps. Therefore, less staining media than what is indicated in 
the protocol might be needed depending on the void volume in the tube. 
9. Stimuli should be added as soon as the cells are taken out of the incubator to avoid cooling the cells 
below 37°C. 
10. In general, 15-min stimulations work well for many signaling responses, including the cytokine 
stimulations used here. However, if this protocol should be adapted for other stimulations, it is crucial to 
find optimal time points and concentrations for each signaling response. 
11. Adding 100 μL of 16% PFA to each tube would yield a final concentration of approximately 1.6% PFA. 
Cells must be in single-cell suspension prior to adding PFA to avoid fixing cells in clumps. 
12. Bivariate analysis: employs pairwise comparisons of markers to select, or gate, cell populations. 
Identification of cell subsets has traditionally relied on sequential bivariate gating. Here, we use the PBMC 
surface immunophenotyping data to demonstrate the concept (Figure 4-1) before using the high 
dimensional population identification tools SPADE and viSNE. In this example, established cell surface 
markers were used for sequential manual gating of well-characterized human blood mononuclear cell 
populations, including B cells, T cells, monocytes, dendritic cells, and natural killer (NK) cells. 
13. Heatmaps and histogram overlays: are ways to visualize a statistic, such as median expression or fold 
change, across a large number of populations or experimental variables. Unlike bivariate analysis and 
viSNE, these tools do not provide a single- cell view of the data. Instead, these tools summarize a key 
population feature using color. Histogram overlays illustrate the distribution of a single marker for a 
population and shade the graphic based on the statistic, whereas heatmaps generally just show the color. 
To demonstrate these data visualization tools, we have used the Kasumi-1 phospho-flow dataset (Figure 
4-4). Kasumi-1 phospho-flow experiment data are available online (www.cytobank.org/irishlab).  
14. SPADE: With high content single cell experiments measuring more than 25 features per cell, sequential 
bivariate gating can overlook populations of cells with low or unexpected patterns of marker expression. 
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When applied to flow data, SPADE clusters cells based on phenotypic similarities in high-dimensional 
space. SPADE is a powerful complement to manual analysis approaches. After the initial clustering step, 
SPADE creates a minimum-spanning tree that illustrates the relationships between cell populations in 
two dimensions. Each node of the tree is a cluster of cells, and nodes can be colored to reflect the 
expression intensity of each marker (299). Here, we subjected the human PBMC immunophenotyping 
dataset to SPADE analysis to create a minimum-spanning tree (Figure 4-2). Known cell subsets in human 
PBMCs were identified as “bubbles” (Figure 4-2) through manual review of biomarker expression on 
different populations on the tree.  
15. viSNE: is a computational tool that projects cells onto a two dimensional map such that the distances 
between cells in 2D reflect the distance between them in high-dimensional space (294). Thus, cells that 
are close together on a viSNE map are phenotypically similar for the markers used to create the map. 
Users then identify and characterize populations of cells based on the groups formed in the viSNE map. 
We performed a viSNE analysis of the human PBMCs immunophenotyping dataset (Figure 4-3). As with 
SPADE, expression intensity of each parameter can be visualized as heat intensity on the viSNE map, 
enabling identification of known cell subsets in human PBMCs. Importantly, viSNE allowed a global 
single-cell view of the data. viSNE enabled identification of rare cell subsets and cell populations without 
supervision or prior knowledge of the expected population distribution. 
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Preface 
 Single-cell mass cytometry is a high-throughput analytical platform that enables simultaneous 
quantification of 35 or more features per individual cells, in hundreds of thousands of cells in a single setting. 
This technology was initially introduced as a new-generation flow cytometry that enhances the power for single-
cell feature characterization in human bone marrow and blood samples. The applications of mass cytometry, as 
well as fluorescence flow cytometry, in human solid tissues and tumors had been very limited since cell 
suspensions are required for the analyses. Prior to the development of the protocol described in this chapter, 
methods for obtaining single cells from solid tissues and tumors varied largely between different studies, even 
among similar tissue types. The goal of this development was to establish a tissue dissociation protocol that 1) 
maximizes cell viability, 2) preserves the cellular diversity of the original tissues, 3) obtains cells suitable for multi-
platform flow cytometry analyses, and 4) can be applied in multiple human solid tissue and tumor types. Human 
glioblastoma was among the key human tissue types that were tested here. Therefore, the final protocol is a 
fundamental building block of the overall goal of this dissertation. Experimental parameters that could impact the 
key objectives mentioned above were systematically tested on multiple tissue types; these included 1) the use 
of mechanical dissociation (fine mincing), 2) types and combinations of tissue digestion enzymes, 3) duration of 
enzymatic dissociation, and 4) preservation of cellular diversity as assessed by multiple analytical approaches 
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including fluorescence flow cytometry, mass cytometry, and immunohistochemical stains. This systematic 
comparison led to the development of a universal tissue dissociation protocol which is applicable for obtaining 
viable single cells from human glioblastoma, human melanoma, human tonsils, and small cell lung cancer 
patient-derived xenografts, while maintaining the cellular diversity of the original tissue. Additionally, the cells 
derived from this protocol are suitable for both fluorescence flow and mass cytometry analyses, and can be 
further evaluated for use in other single-cell analysis platforms such as single-cell RNA-sequencing. This protocol 
was subsequently applied for the collection of viable single cells from adult glioblastoma surgical resections for 
cellular profiling, which is further elaborated in Chapter 6. 
 
Abstract  
Background: Mass cytometry measures 36 or more markers per cell and is an appealing platform for 
comprehensive phenotyping of cells in human tissue and tumor biopsies.  While tissue disaggregation and 
fluorescence cytometry protocols were pioneered decades ago, it is not known whether established protocols 
will be effective for mass cytometry and maintain cancer and stromal cell diversity.   
Methods: Tissue preparation techniques were systematically compared for gliomas and melanomas, patient 
derived xenografts of small cell lung cancer, and tonsil tissue as a control. Enzymes assessed included DNase, 
HyQTase, TrypLE, collagenase (Col) II, Col IV, Col V, and Col XI. Fluorescence and mass cytometry were used 
to track cell subset abundance following different enzyme combinations and treatment times. 
Results: Mechanical disaggregation paired with enzymatic dissociation by Col II, Col IV, Col V, or Col XI plus 
DNase for 1 hour produced the highest yield of viable cells per gram of tissue.  Longer dissociation times led to 
increasing cell death and disproportionate loss of cell subsets.  Key markers for establishing cell identity included 
CD45, CD3, CD4, CD8, CD19, CD64, HLA-DR, CD11c, CD56, CD44, GFAP, S100B, SOX2, nestin, vimentin, 
cytokeratin, and CD31.  Mass and fluorescence cytometry identified comparable frequencies of cancer cell 
subsets, leukocytes, and endothelial cells in glioma (R = 0.97), and tonsil (R = 0.98). 
Conclusions: This investigation establishes standard procedures for preparing viable single cell suspensions 
that preserve the cellular diversity of human tissue microenvironments.   
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Introduction   
In preparing single cell suspensions of healthy and malignant tissue, a common goal is to preserve 
viability while maintaining cellular diversity and preserving rare subsets. Multidimensional cytometry is well suited 
to this challenge because it can simultaneously characterize known cell types and reveal novel cell subsets (11, 
296). Mass cytometry uses antibodies to quantify features of individual cells in primary tissues (81, 302) and has 
been applied to characterize cell subsets in human bone marrow, blood, and germinal center tissues as well as 
diverse murine tissues (12, 83, 290).  However, mass cytometry remains relatively untested in the context of 
solid tumors.  Fluorescence flow cytometry and fluorescence activated cell sorting (FACS) have been used to 
prospectively isolate functionally distinct cell subsets and suggest that mass cytometry analysis could help to 
further characterize solid tumors (11).  A key goal of this study was to evaluate the suitability of different cell 
preparation techniques for mass cytometry and to develop standard procedures and quality controls that do not 
require measuring light scatter.  An additional goal was to use the multidimensionality of mass cytometry to 
characterize preservation of cellular diversity under different solid tumor cell preparation techniques.   
In this study, mechanical and enzymatic dissociation protocols were systematically tested on multiple 
types of fresh human solid tumors and tissues to develop an efficient, reliable method for dissociation and single-
cell analysis by mass cytometry.  Human tonsils and lymphoma tumors reliably dissociate with mechanical force 
alone and we have previously established protocols for their study by fluorescence cytometry (15, 303) and mass 
cytometry (82).  Preparation techniques for tissue samples derived from intraoperative resections of gliomas 
(grades II-IV), melanomas, and patient derived xenografts (PDX) of small cell lung cancer (SCLC) were 
compared.  As a control, the same techniques were applied to human tonsillar tissue.  The abundance of different 
cell types, such as leukocytes, endothelial cells, epithelial cells, fibroblasts, and cancer cell subsets, was tested 
under these conditions.  Established protein markers for expected cell types in tissues tested in this study were 
used in fluorescence cytometry (Table S5-1) and mass cytometry (Table S5-2, Table S5-4).  The common 
markers were selected so that both rare and abundant cell types could be compared between mass and 
fluorescence cytometry.  The additional markers in the mass cytometry panel provided a more comprehensive 
analysis of cell diversity.   
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Six enzymes for cell separation were selected to compare in solid tumor preparation protocols for mass 
cytometry analysis: HyQTase, TrypLE, collagenase (Col) II, Col IV, Col V, and Col XI.  Enzyme choice was based 
in part on prior use in several solid tumor types and preparation of single cell suspensions containing cancer cell 
and immune subsets for FACS (304-309).  DNase was also tested to determine its ability to enhance live cell 
yield from dissociation. Dissociation kinetics for enzyme combinations in distinct tissue types were also 
characterized. Finally, specific enzymes and dissociation duration times were selected based on optimal viable 
cell yield and representation of expected cell populations. 
 
Materials and Methods 
Tissue Sample Collection – All samples were obtained with patient consent, with Vanderbilt institutional review 
board (IRB) approval, in accordance with the Declaration of Helsinki, and were de-identified.  Gliomas were 
intraoperative specimens from WHO grade II, III, or IV tumors (IRB #131870), collected in sterile normal saline. 
Melanomas were cutaneous and lymph node resections (IRB #030220), collected in MEM (Corning/Mediatech, 
Corning, NY) with 10% FBS + 1X Pen/Strep (GE Healthcare, Pittsburgh, PA). Small-cell lung cancer (SCLC) 
patient derived xenograft (PDX) samples were obtained as a gift from the Rudin laboratory (LX-22, (310)) and 
propagated solely as patient-derived xenografts in female athymic nude mice (HSD:Athymic Nude-Foxn1nu/nu) 
obtained from Envigo with Vanderbilt institutional animal care and use committee (IACUC) approval. SCLC PDX 
were collected in RPMI 1640 (Corning/Mediatech, Corning, NY) plus 10% FBS+ 1X Pen/Strep. Glioma, 
melanoma, and SCLC PDX samples were transported at room temperature without delay to the laboratory and 
processing began within 30 minutes of collection from patients. Human tonsillar tissue was obtained from routine 
tonsillectomies (IRB #121328), collected in RPMI 1640 (Corning/Mediatech, Corning, NY) plus 10% FBS + 1X 
Pen/Strep, transported on ice, and processed within 4 hours of collection. 
 
Mechanical and Enzymatic Dissociation – Sequential dissociation steps are described in detail in the main text. 
“Coarse mincing” indicates no additional mechanical dissociation of tissues (i.e. tissues were left as obtained 
intraoperatively). “Fine mincing” indicates additional mechanical dissociation using scalpels. Conventional 
mechanical dissociation of tonsils included fine mincing and immediate filtration of tissue through a 70 µm cell 
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strainer without additional enzymatic dissociation, as previously established (15, 82, 303). Dissociation enzymes 
were obtained from Sigma Aldrich (Darmstadt, Germany) (collagenase II, IV, V, and XI), ThermoFisher 
(Waltham, MA) (TrypLE-Express), and GE Healthcare (PA) (HyQTase). Collagenases were used at 1 mg/mL. 
HyQTase and TrypLE-Express were used at 1X according to the manufacturer’s recommendations. DNase I 
(Sigma Aldrich) was used at a final concentration of 0.25 mg/mL. For conditions involving collagenases and no 
enzyme, cells were resuspended in recommended media for specific tissue types prior to adding indicated 
enzymes (gliomas, DMEM/F12 + Glutamax, (Gibco/Life Technologies, MA) with a defined hormone and salt mix 
(311) and 50 µg/mL gentamicin; melanomas, MEM with 10% FBS + 1X Pen/Strep; Tonsils and SCLC PDXs, 
RPMI 1640 + 10% FBS + 1X Pen/Strep. For dissociation conditions with HyQTase or TrypLE, tissues were 
dissociated in working concentrations of enzymes (with or without DNase), without addition of cell culture media, 
according to the manufacturer’s recommendations. Enzymatic dissociations were performed in a 37C incubator 
with 5% CO2, with constant rocking on a nutating platform mixer at 18 rpm. Cells were then strained with 70 µm 
and 40 µm cell strainers prior to further analysis. 
 
Quantification of cell viability – Cell suspensions obtained from different dissociation protocols were resuspended 
in corresponding cell culture media at volumes proportional to initial tissue weight (1 mL per 100 mg of tissue). 
Viable cells were quantified using Trypan Blue staining, normalized to the initial tissue weight, and reported as 
millions of live cells per gram of tissue. 
 
Statistical testing – Enzyme conditions were compared as groups (horizontal lines) using a Student’s t-test. The 
relationship between cell subset abundance measured by fluorescence or mass cytometry was compared using 
Pearson’s correlation R and Spearman’s rank correlation ρ (rho). 
 
Cell line and cell culture – Jurkat cells were obtained from Utpal Dave at Vanderbilt, and were grown in RPMI 
1640 + 10% FBS + 1X Pen/Strep as recommended. MeWo cells were obtained from Kimberly Dahlman and 
Jeffery Sosman with permission of Antoni Ribas (UCLA) and were grown in MEM + 10% FBS + 1X Pen/Strep, 
as recommended. 
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Flow cytometry - Cell suspensions were evenly divided for parallel phenotyping with fluorescence and mass 
cytometry according to the protocols below.  Conditions were identical between mass and fluorescence 
cytometry with the exception of an additional staining step including saponin for mass cytometry analyses of 
glioma and melanoma that include SOX2.  This type of saponin step has been established to have no significant 
impact on subsequent mass cytometry staining (312). 
 
Fluorescence flow cytometry – For fluorescence cytometry, live surface staining was performed for surface 
marker detection (Supplemental Table S5-1). After washing with PBS and pelleting twice (at 200 x g for 5 min 
each time), cells were fixed with 1.6% paraformaldehyde (Electron Microscopy Services, Fort Washington, PA) 
for 10 min at room temperature, washed with PBS (HyClone Laboratories, Logan, UT), pelleted at 800 x g, and 
permeabilized with 100% ice-cold methanol (Fisher Scientific, Waltham, MA) at -20°C overnight following 
established protocols (15, 278). Cells were washed twice with cell staining media composed of PBS plus 1% 
BSA (Fisher Scientific, Waltham, MA) and pelleted at 800 x g. For each comparison, cells were stained in 100 
µL staining media for 30 minutes at room temperature. All antibodies are listed in Supplemental Tables. Note 
that some antibodies that detect cell surface antigens (CD45-BV786, CD44-PE, and CD31-PE-Cy7) were used 
after fixation and methanol permeabilization due to concerns for stabilization of fluorochromes after methanol 
exposure. After staining, cells were washed twice with PBS, pelleted at 800 x g, and resuspended in PBS for 
analysis on a 5-laser LSRII (BD Biosciences, San Jose, CA) at the Vanderbilt Flow Cytometry Shared Resource. 
 
Mass cytometry – Solid tissue cells obtained from the same dissociation conditions as those analyzed by 
fluorescence flow cytometry were stained live for cell surface markers, fixed, permeabilized, and washed as for 
fluorescence flow cytometry above and in concordance with established mass cytometry protocols (81). 
Permeabilization with 0.02% Saponin (Millipore, Darmstadt, Germany) in PBS was also included before 
methanol permeabilization of gliomas and melanomas as part of an optimized multi-step protocol that included 
detecting SOX2, which was not included in the fluorescence panel. Metal-tagged antibodies were used to stain 
cells in 100 µL cell staining media for 30 minutes at room temperature (Supplemental Table S5-4). After staining, 
cells were washed once with PBS, once with deionized water, pelleted at 800 x g, and resuspended in deionized 
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water containing normalization beads (Fluidigm). Standard bead-based normalization was used as previously 
described (313). Cells were collected on a CyTOF 1.0 at the Vanderbilt Flow Cytometry Shared Resource. 
Original data were normalized with MATLAB normalization software prior to further analysis using Cytobank 
(301) and established mass cytometry analysis methods (314). viSNE analysis was performed using 60,000 
cCasp3-HH3+ cells per sample. For glioma G-LC-15, the following markers were used for viSNE analysis: CD31, 
CD64, CD45RO, S100B, CD45, PDGFRα, SOX2, CD24, CD44, CD3, GFAP, αSMA, HLA-DR, and CD56. For 
tonsil T02-23, the following markers were used for viSNE analysis: CD4, IgD, CD16, CD45RO, CD45RA, CD45, 
CD27, CD86, CD33, CD11c, CD14, CD19, CD38, CD8, CD3, IgM, HLA-DR, and CD56. Samples of the same 
tissue type dissociated with different types of collagenase were analyzed simultaneously by viSNE. 
 
Histone H3 testing – Healthy peripheral blood mononuclear cells (PBMCs) were used as controls in testing 
histone H3 as a nucleated cell marker for multiple flow cytometry platforms. PBMCs were stained live for 
detection of cell surface markers (Supplemental Table S5-2).  After being washed twice with PBS, cells were 
then fixed with 1.6% paraformaldehyde and permeabilized with 100% ice-cold methanol for intracellular staining. 
Stained PBMCs were then evenly divided and half of the cells were stained with iridium at a final concentration 
of 0.25 µM in PBS for 15 minutes at room temperature. Cells were then washed once with PBS, once with 
deionized water, pelleted at 800 x g, and resuspended in deionized water containing normalization beads. Cells 
were collected as described above. 
 
Results 
Tissue dissociation with collagenase and DNase improved live cell yield 
A matrix of dissociation conditions was tested to identify optimal protocols for multiple solid tumor types 
and tonsil controls (Figure 5-1, Figure S5-1, and Figure S5-2).  The mechanical dissociation protocol (see 
Materials and Methods) was first compared to fine mincing of tonsil tissue followed by a 2-hour enzymatic 
dissociation with combinations of collagenase and DNase.  For tonsils, a combination of fine mincing, 
collagenase, and DNase resulted in superior live cell yield per gram of tissue compared to conventional 
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dissociation methods (Figure S5-1, p < 0.05). Additionally, fine mincing of tonsils did not adversely affect cell 
viability (Figure S5-2) when compared to coarse mincing (left as obtained intraoperatively). 
 
Figure 5-1 Collagenase plus DNase treatment provides better yield of live cells from three human tissues than no 
enzyme, TrypLE, HyQTase, or collagenase treatment alone.  Graphs show millions of viable cells per gram yielded by 
different tissue preparation conditions following fine mincing for (A) gliomas, (B) melanomas, and (C) tonsil tissue.  In 
addition to DNase (closed symbols), preparation enzymes tested included no additional enzyme (No enz), recombinant 
trypsin TrypLE (Tryp), HyQTase (HyQ), and collagenase (Col) II, IV, V, or XI.  Average live cell yield is indicated for each 
condition by the thick horizontal line. Individual tissues or tumors are represented by different symbols.  Representative 
trypan blue stained images are depicted under each condition.  Scale bars = 100 μm.  Symbols denote not significant (n.s.), 
p < 0.05 (♦ ), or p < 0.01 (♦ ♦ ).  N indicates number of separate individual sample donors tested under each condition for 
each tissue type.  
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Since freshly resected tissues and tumors frequently differ in size, fine mincing was selected as an initial 
mechanical dissociation step for all tissue types.  To determine the optimal enzymes for disaggregation of human 
gliomas, seven different enzymatic conditions were tested for their ability to yield live, single cells (Figure 5-1A, 
N = 3).  Intraoperative samples of gliomas were finely minced and incubated with a cocktail of DNase plus one 
enzyme (either HyQTase, TrypLE, Col II, Col IV, Col V, or Col XI) or DNase alone for 2 hours at 37C, with 
continuous rocking. Increased live cell yield per gram of tissue was seen in conditions containing collagenase 
and DNase as compared to other conditions (p < 0.01). Additionally, DNase plus collagenase improved live cell 
yield for glioma compared to collagenase alone (p < 0.01).  No significant differences were observed in live cell 
yield per gram of glioma tissue between conditions using different types of collagenases plus DNase. High-
resolution images of trypan blue stains are shown in Figure S5-3. 
The same matrix of conditions was tested on intraoperative samples of human melanomas (Figure 5-1B, 
N = 3). As with glioma, no significant difference in live cell yield was observed between different types of 
collagenases, and viable cell yields were highest in conditions containing collagenases and DNase (p < 0.01). 
In freshly resected tonsils (Figure 5-1C, N = 4), collagenases with DNase gave a higher live cell yield than either 
DNase alone (p < 0.05) or TrypLE plus DNase (p < 0.01). However, collagenases with DNase did not significantly 
differ from HyQTase with DNase, and addition of DNase did not result in higher or lower live cell yield, in tonsil 
dissociation. 
 
Enzymatic dissociation with collagenase and DNase for 1-2 hours provided superior live cell yields 
While incubation in enzyme solutions enhanced tissue disaggregation (Figure 5-1 and Figure S5-1), 
excessive incubation might adversely affect cell viability.  A dissociation time course was performed on 
intraoperative glioma specimens to determine the optimal time point for highest live single cell yield (Figure 5-
2A).  Gliomas were finely minced and incubated in collagenases plus DNase for 30 minutes, 1 hour, 2 hours, 4 
hours, or 6 hours (Figure 5-2A, N = 3). Live cell yield per gram of glioma tissue significantly decreased after 4 
hours of enzymatic dissociation with Col II, Col V, or Col XI plus DNase compared to earlier time points (Col II 
and Col XI, p < 0.001; Col V, p < 0.05), whereas it significantly decreased after 6 hours of dissociation with Col 
IV plus DNase (Figure 5-2A, p < 0.001).  
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Figure 5-2 Collagenase and DNase treatment for 1 or 2 hours provided better overall live cell yield than other times. 
(A) Gliomas (N = 3) were finely minced and treated for varying times with DNase and either Col II, Col IV, Col V, or Col XI.  
Yield of live single cells (x106) per gram was quantified from Trypan blue images after 30 minutes (’), 1 hour (h), 2h, 4h, and 
6h (filled symbols). Individual tissues or tumors are represented by different symbols. Grey circles mark average yield and 
are connected with dashed lines to indicate dissociation kinetics. Dissociation kinetics were similarly assessed for (B) 
melanomas (N = 3), (C) tonsil tissue (N = 4, except for 10h, 16h, 24h where N = 2), and (D) SCLC PDX tumors (N = 3) (D). 
Symbols denote not significant (n.s.), p < 0.05 (♦), p < 0.01 (♦♦), or p < 0.001 (♦♦♦). 
 
Dissociation kinetics of tonsils were also characterized for time points ranging from 15 minutes to 24 
hours (Figure 5-2C). Finely minced tonsils dissociated with Col II plus DNase for 1-2 hours gave higher live cell 
yield when compared to earlier time points (p < 0.05) as well as later time points (p < 0.001). Similarly, viable 
cell yield decreased significantly after 1-2 hours when tonsils were dissociated with either Col IV or Col XI plus 
DNase (IV, p < 0.05; IX, p < 0.01). Live cell yield from the combination of Col V and DNase also decreased after 
6 hours (p < 0.01). Live cell yield from intraoperative melanoma specimens and SCLC patient-derived xenografts 
(PDXs) did not significantly decrease after 6 hours of dissociation, regardless of the type of collagenase (Figure 
5-2B and 3-2D).  
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Figure 5-3 Frequency of cell types in glioma, and tonsil tissue quantified by fluorescence and mass cytometry.  
Biaxial plots show gating for established cell types in human tumors and tissues prepared using Col II plus DNase for 1 
hour. Nucleated cells (HH3+) were identified. Immune cells (CD45+), T cells (CD45+ CD3+), APCs (CD45+ CD3- HLA-DR+), 
endothelial cells (CD31+ CD45-), and non-immune non-endothelial cells (CD45- CD31-) were also found. (A) In fluorescence 
cytometry analysis of glioma from an individual patient (G-RT-06), CD56 (NCAM) and GFAP expression are shown for 
CD45- CD31- cells. (B) A similar gating scheme was applied to mass cytometry data from G-RT-06.  In tonsil tissue from 
donor T02-23, CD44 and HLA-DR are shown for CD45+ CD3- HLA-DR+ cells, for both fluorescence (C) and mass cytometry 
analysis (D). Frequency of terminal populations (dashed gates) was compared between fluorescence and mass cytometry 
in Table 5-1.   
 
Testing histone H3 as a nucleated cell marker compatible with mass and fluorescence cytometry  
An anti-Histone H3 (HH3) monoclonal antibody was next tested as a potential marker of nucleated cells 
that would function equivalently in fluorescence and mass cytometry. Jurkat T leukemia cells gated as intact 
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cells were 98.9% positive for HH3 in fluorescence cytometry (Figure S5-4A).  Similarly, when Jurkat cells were 
gated first as HH3+, they were observed to be >99.8% intact cells when gated using light scatter in fluorescence 
cytometry (Figure S5-4B).  Peripheral blood mononuclear cells (PBMCs) were used to further test HH3 because 
PBMC have well-studied cell subsets that have been extensively characterized by both fluorescence and mass 
cytometry (81, 300, 315). PBMCs from a healthy donor were stained with a panel of 16 mass-tagged antibodies 
(Table S5-2). Frequencies of known cell subsets identified by biaxial gating were closely correlated in the same 
mass cytometry dataset gated using HH3 or established iridium-based gating (Figure S5-5, Pearson correlation 
R = 1.00, Spearman rank of subset abundance rho (ρ) = 1.00, Table S5-3), supporting the use of HH3 as 
nucleated cell marker across multiple flow cytometry platforms.  
 
Assessment of cell subset diversity in solid tumor following collagenase and DNase treatment 
Two- to seven-dimensional fluorescence flow cytometry has been used extensively to characterize 
presence and abundance of cell subsets in patient-derived tissues. Glioma cell subsets consistent with those 
documented in prior studies were present after a 1-hour dissociation with DNase plus Col II using fluorescence 
flow cytometry (Figure 5-3A, Col II). In glioma sample G-RT-06, 55.4% of all events were identifiable as intact 
nucleated cells based on HH3 staining. CD45+ immune cells comprised 59.7% of live intact cells, which included 
CD3+ T cells (26.7%) as well as other immune cell types (71.8%). Presence of immune cell subsets was 
confirmed with immunohistochemistry (IHC) staining of formalin-fixed paraffin-embedded (FFPE) sections of the 
same sample (Figure S5-6). Additionally, CD31+ endothelial cells were detected (5.1% of non-immune cells), as 
were cell subsets that differentially expressed CD56 (NCAM) and GFAP. The abundance of nucleated cells and 
other known cell subsets was similar between different collagenase types (Figure S5-7).  
To determine if cells derived from dissociations using collagenase and DNase were suitable for mass 
cytometry analysis, cells obtained from intraoperative glioma resections (G-RT-06) were stained with 16 isotope-
labelled antibodies (Table S5-4). Histone H3 was used to identify intact nucleated cells. A biaxial analysis 
sequence similar to that used for fluorescence flow cytometry analysis was used for comparison of subset 
abundance identified by these two cytometry platforms (Figure 5-3B). A strong correlation of cell subset 
abundance between the two methods was observed and quantified (Table 5-1; Pearson’s R = 0.97, Spearman’s 
74 
  
rank ρ = 0.93). Similar comparisons were performed in tonsils (Figure 5-3D). Strong correlations of subset 
abundance between the two different cytometry platforms was also observed in tonsil (Table 5-1; Pearson’s R = 
0.98, Spearman’s rank ρ = 0.90). 
Subsets of immune cells in tonsils were also identified by fluorescence flow cytometry, including CD3+ T 
cells, CD44+ antigen-presenting cells (APCs), CD44- APCs, and additional immune and non-immune cell types, 
as expected (Figure 5-3C, Col II). Abundance of tonsil cell subsets was similar between dissociations using 
different collagenase types (Figure S5-8). Single cells obtained from resected melanomas (MP-04) and a 
melanoma cell line, MeWo, were analyzed by fluorescence flow cytometry and were observed to have intrinsic 
auto-fluorescence on some channels, whereas glioma and tonsil samples studied here showed no auto-
fluorescence (Figure S5-9).  Mass cytometry was next used to study melanoma tumors (Figure S5-10). CD45+ 
immune subsets, including CD45+HLA-DR+ antigen-presenting cells, CD45+CD3+ T cells (CD8+ and CD8-, and 
CD45RO+ memory and CD45RO- non-memory), as well as CD31+ endothelial cells were identified in melanoma. 
Additionally, among the non-immune, non-endothelial cells, other cell subsets were identifiable by nestin, SOX2, 
CD44, HLA-ABC, vimentin, and cytokeratin.  
 
Table 5-1 Mass and fluorescence cytometry detect comparable frequencies of cell types in glioma, melanoma, 
and tonsil tissue 
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Figure 5-4 Treatment of a glioma with different collagenases yielded comparable cell subset frequencies. viSNE 
plots show non-apoptotic nucleated cells (cCasp3-HH3+) from glioma G-LC-15 obtained following 1-hour treatment with 
DNase plus either Col II, VI, V, or XI. Heat plots indicate cell density (first column) or expression of 8 proteins indicating cell 
type (CD45, CD3, CD64, CD31, GFAP, CD56, S100B, and SOX2). viSNE mapping was run together. Color-coded inserts 
next to the complete map highlight cell subsets (grey = CD45+CD3+ T cell, 0.9 ± 0.1%; red = CD45+CD64+ microglia, 3.9 ± 
1.0%; green = CD45-CD31+ endothelial cells, 0.7 ± 0.2%; fuchsia = SOX2+ stem-like cells, 1.2 ± 0.5%). 
 
To characterize the effects of different types of collagenase on the presence of cell subsets, mass 
cytometry analysis of cells derived from glioma dissociation at one hour with DNase plus either Col II, Col IV, 
Col V, or Col XI was performed (Figure 5-4). This time point was selected based on its highest live cell yield 
across multiple tissue types, shown above. viSNE analysis (290) was used to compare cell subsets in the 
different dissociation conditions. Known cell subsets in gliomas were present in all conditions, including CD45+ 
immune cells (CD3+ T cells, and CD64+ microglia), CD45-CD31+ endothelial cells, GFAP+ glial cells, S100B+ 
astrocyte-like cells, and SOX2+ stem-like cells. Established cell subsets were also observed in tonsil specimens 
dissociated for one hour in all types of collagenase (Figure S5-11). As expected, the majority of cells were CD45+ 
immune cells. Additionally, known immune subsets, including CD3+CD4+ helper T cells, CD3+CD8+ cytotoxic T 
cells, CD19+IgD+ naïve B cells, and CD19+CD27+ memory B cells, were identified. These findings suggest that 
both mass cytometry and fluorescence cytometry identify key cell subsets in glioma and tonsil dissociated with 
collagenase plus DNase.   
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Figure 5-5 Enzymatic treatment times longer than one hour differentially impact glioma tumor cell subsets. Biaxial 
plots and bar graphs quantify cell subsets measured in mass cytometry analysis of glioma G-LC-15 after varying treatment 
times with collagenase II and DNase.  (A) Gating for apoptotic cells (cCasp3+) and live immune cells (cCasp3-CD45+), 
endothelial cells (cCasp3-CD31+), and non-immune, non-endothelial cells (cCasp3-CD45-CD31-). (B) Subsets of glioma 
tumor-infiltrating immune cells were identified, including microglia (HLA-DR+CD64+), CD45RO+ and CD45RO- subsets of 
CD3+ T cells, and other immune cells. (C) Pericytes (CD45-CD31-αSMA+), ependymal cells (CD45-CD31-CD24+), SOX2+ 
stem-like cells (CD45-CD31-SOX2+), GFAP+ cells (CD45-CD31-GFAP+), and astrocyte-like cells (CD45-CD31-S100B+) were 
quantified as subsets of G-LC-15. (D) Gating for cell types as in (A-C) was applied to mass cytometry analysis of cells from 
G-LC-15 treated with collagenase II plus DNase for 1, 2, 4, 6, 10, 16, or 24 hours. (E) Percentage of apoptotic cells as in 
(A) was measured for each dissociation time, as in (D). 
 
Longer dissociation times led to disproportionate cell death and loss of cellular diversity 
To determine if the abundance of cell subsets changed over time with enzymatic dissociation, time course 
dissociations of glioma sample, G-LC-15 (Figure 5-5), and tonsil sample, T02-23 (Figure S5-13), with DNase 
plus Col II were performed. Cell subsets were identified using sequential biaxial analysis and given the indicated 
labels following expert review. Apoptotic cells, defined by high cCasp3 signal, were excluded from subsequent 
cell subset quantification (Figure 5-5A). Within the population of HH3+ nucleated cells, marker analysis identified 
CD45+ immune cells and CD31+ endothelial cells. Known subsets of immune cells were present within the CD45+ 
population, including microglia (HLA-DR+CD64+), memory T cells (CD3+CD45RO+), and non-memory T cells 
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(CD3+CD45RO-) (Figure 5-5B). Within the CD45-CD31- population, pericytes (αSMA+) and ependymal cells 
(CD24+) were seen, as well as rare SOX2+ stem-like cells, GFAP+ glial cells, PDGFRα+ cells, and S100B+ 
astrocyte-like cells (Figure 5-5C). Quantification of these cell subsets was performed in samples obtained from 
different dissociation durations to characterize maintenance and enrichment of cell subsets over time (Figure 5-
5D). Among immune cells, a decrease in microglia (after 1 hour) and memory T cells (after 4 hours) was noted, 
whereas the proportion of non-memory T cells appeared to remain constant over the full range of times tested. 
SOX2+ stem-like cells were most abundant after 1 hour of dissociation and decreased thereafter. Even though 
the proportion of SOX2+ stem-like cells increased at 24 hours after dissociation, the overall decrease in viable 
cells after 4-6 hours of glioma dissociation (Figure 5-2A) suggested an overall loss in total viable stem-like cells 
at later time points. Additionally, the abundance of GFAP+ glial-like cells (known to be present in most gliomas, 
Figure S5-12) remained constant during the initial 10 hours of dissociation and showed a decrease after 16 
hours. This suggested that longer dissociation depletes key cell subsets in glioma. Most of the nucleated, non-
apoptotic cells that remained after 24 hours of dissociation lacked expression of the key cell identity markers 
used in this study. Moreover, the abundance of cCasp3+ apoptotic events also increased over time (Figure 5-
5E). 
A similar time course strategy was applied to tonsil specimen dissociation (Figure S5-13A). A decrease 
in the abundance of most immune cell subsets was observed at all time points greater than 1 hour of dissociation 
with Col II plus DNase (Figure S5-13B). This decrease affected all T cell subsets, plasma cells/blasts, germinal 
center B cells, class-switched memory B cells, and unswitched memory B cells. Notably, abundance of naïve B 
cells remained constant during the initial 6 hours of dissociation and only decreased after 10 hours. CD27-IgD- 
B cells increased in abundance at time points extending to 6 hours, followed by a decrease at 10 hours. Dendritic 
cells were the only immune cell subsets that continued to increase in abundance at 24 hours of dissociation. As 
expected, longer dissociation times likewise led to an increase in apoptotic cells (Figure S5-13C).  
 
Discussion 
A common protocol of collagenase II plus DNase for 1 hour was identified as effective for preparing viable 
and mass cytometry compatible single cell suspensions of all tested human solid tumors and healthy tissues. 
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Multiple types and combinations of enzymes and dissociation kinetics were compared in freshly resected patient-
derived tissues and patient-derived xenografts.  Unexpectedly, collagenase also resulted in greater viable cell 
yield from tonsils when compared to the conventional dissociation method (Figure 5-1 and Figure S5-1), 
indicating that the protocol for preparation of tonsil and lymphoma tumors could be further refined.  DNase clearly 
improved live cell yield from gliomas and melanomas and is strongly recommended for tissues where there may 
be ongoing cell death. Even though DNase was not observed to improve tonsil dissociation, DNase also did not 
adversely affect tonsil cell viability. Live cell yield from glioma dissociation began to decrease after 4-6 hours. 
However, live cell yields from melanoma and SCLC PDX were constant throughout the dissociation duration 
tested (6 hours) for all types of collagenase. In contrast, live cell yield from tonsils was maximal during the initial 
2 hours of dissociation, except for collagenase V, which significantly decreased only after 6 hours.   
Critically, dissociation of tissue using combined collagenase and DNase preserved cellular diversity, as 
seen by mass cytometry and standard fluorescence flow cytometry (Figure 5-3 and Figure 5-4). At one hour after 
dissociation, known cell subsets were present as expected in each of the tested tissue types. These included 
immune cells in tonsil, infiltrating immune cells in glioma and melanoma, and tissue-specific cell subsets, such 
as cancer cell subsets, endothelial cells, glial cells, pericytes, and stem-like cells in gliomas. A difference in 
abundance of T cells observed between fluorescence and mass cytometry was determined to be due to use of 
different anti-CD3 antibody clones, as has been previously reported (315, 316).  While immune cells and GFAP+ 
cells in glioma were confirmed with IHC stains and observed to be in relatively close agreement between IHC 
and flow cytometry, small tissue sections and sections that do not sample all tumor regions may over- or under-
represent cell subsets or overlook rare cells. The quantitative analysis of a large number of whole cells by 
multidimensional flow cytometry (105 to 107) provides a strong complement to the location information provided 
by imaging cytometry (50).  
Longer dissociation times led to increased cell death and disproportionate depletion of cell subsets in 
both gliomas and healthy tonsil.  Additionally, the abundance of glial/astrocyte-like cells, as well as rare stem-
like cells in glioma, decreased over time. Even though the proportions of some cell subsets increased at later 
time points (endothelial cells, pericytes, SOX2+ stem-like cells in gliomas, and dendritic cells and CD27-IgD- B 
cells in tonsils), the significant increase in cell death over a long period of dissociation would result in an overall 
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decrease in total yield of those cell types. Comparison of the results from gliomas, melanomas, SCLC xenografts, 
and tonsil tissue indicates that different tissues may be sensitive to prolonged enzymatic digestion. Dissociation 
conditions should be evaluated closely and carefully matched to tissue type and study goals. However, based 
on the results here, no more than 1 hour of dissociation is recommended unless the protocol is being optimized 
for a specific purpose. In future single-cell-level studies of other complex solid tissues, it will be critical to identify 
conditions that efficiently generate single-cell suspensions while preserving rare subpopulations of interest. 
Additionally, cell viability stains such as Cisplatin can be included in future mass cytometry experiments that aim 
to test cell functions like signaling, proliferation, viability, or cytokine production (286). 
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Supplemental data 
 
 
Figure S5-1 Tonsil dissociation with fine mincing and enzymes gave higher live cell yield compared to conventional 
dissociation method. Enzymatic dissociations of tonsils by fine mincing and incubation with collagenases and DNase (2 
hours) were compared to traditional mechanical dissociation (see Materials and Methods). Viable cells (x106) per gram of 
tissue were quantified. Average live cell yield of each condition are shown as horizontal lines. Scale bars = 100 μm. (n.s. = 
not significant; Col = collagenase; no enz = no enzyme; HyQ = HyQTase; Tryp = TrypLE). (Cell straining, N = 3; Col, N = 
4). (▲ p < 0.05) 
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Figure S5-2 Fine mincing did not adversely affect live cell yield from tonsil dissociation. Live cell yield (x106) per 
gram of tonsils obtained by coarse (open circles) and fine (filled circles) mincing of tonsils were compared after a 2-hour 
incubation in different enzyme combinations. All conditions contained DNase. Average live cell yield of each condition are 
shown as horizontal lines. Representative Trypan Blue stained images of each conditions are shown. Scale bars = 100 μm. 
(n.s. = not significant; Col = collagenase; no enz = no enzyme; HyQ = HyQTase; Tryp = TrypLE).
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Figure S5-3 Trypan Blue staining allowed quantification of live cell yield. Higher resolution of Trypan Blue stains shown in Figure 1. No enz = no enzyme; 
HyQ = HyQTase; Tryp = TrypLE; Col = collagenase. Scale bars = 100 µm.
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Figure S5-4 Histone H3 effectively identifies intact Jurkat cells via fluorescence flow cytometry. (A) Intact Jurkat T 
cells (98.4%) were identified by conventional biaxial analysis using SSC-A (x-axis) and FSC-A (y-axis). 98.9% of intact 
Jurkat cells were HH3+ (nucleated). (B) Sequential gating starting with HH3 identified 97.3% nucleated events, 99.8% of 
which were defined as intact cells based on FSC-A and SSC-A biaxial analysis. 
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Figure S5-5 Histone H3 is an antibody-based nucleated cell marker for mass cytometry. Live surface stained healthy 
human PBMCs were stained intracellularly with HH3 antibody and iridium. Either HH3 (A) or iridium (Ir) (B) was used for the 
initial intact cell gates. CD45+ events were identified. Sequential biaxial gating was used to identify known cell subsets from 
either HH3+CD45+ or Ir+CD45+ events. Gating subsets of CD45+ immune cells is the same for both HH3+ nucleated cells 
and Ir+ intact cells. Pearson analysis and Spearman rank comparing abundance of terminal cell subsets (fuchsia) gated 
using either HH3 or iridium as intact cell marker are shown in Table S5. 
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Figure S5-6 Glioma infiltrating immune cells were identified by immunohistochemistry. Hematoxylin and eosin (H&E) 
stains of FFPE sections of glioma, G-RT-06, are shown. IHC stains with CD45 and CD3 antibodies of the same sample are 
also depicted. Scale bars = 50 μm 
  
86 
  
 
Figure S5-7 Known cell subsets in glioma were identified by fluorescence flow cytometry after dissociation with 
either collagenase IV, V, or XI. Sequential biaxial gating of glioma G-RT-06 after 1-hour dissociation with DNase plus 
either (A) Col IV, (B) Col V, or (C) Col XI is shown. The gates shown are the same used in DNase plus Col II dissociation 
of the same glioma shown in Figure 5A. Abundance of subsets are shown as percentages. 
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Figure S5-8 Known cell subsets in tonsil were identified by fluorescence flow cytometry after dissociation with 
either collagenase IV, V, or XI. Biaxial gating of patient-derived tonsil after 1-hour dissociation with DNase plus either (A) 
Col IV, (B) Col V, or (C) Col XI, is shown. Gating scheme is similar to that used to identify cell subsets of the same tonsil 
sample after DNase plus Col II dissociation shown in Figure 5C. Abundance of cell subsets are shown as percentages. 
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Figure S5-9 Unstained melanoma cells showed variable auto-fluorescence signal. (A) Unstained intact cells from 
primary (P) and metastatic (M) sites of melanoma MP-04, as well as MeWo melanoma cell line, and (B) two patient-derived 
glioma samples (G-LC-15, and G-RT-06) and one tonsil (T02-23), were measured for their auto-fluorescence signal on 
Ax488, PE, and PE-Cy7 channels. Histograms display transformed ratio of medians of signal intensity compared with the 
minimal signal of each column (channel). 
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Figure S5-10 Cell subsets in melanoma can be characterized by mass cytometry. HH3+ nucleated cells from 
melanoma sample MP-026, identified by mass cytometry, were characterized for cell subsets by biaxial analysis. Immune 
cell subsets, endothelial cells, and non-immune, non-endothelial cell subsets were identified using 12 cell identity markers 
(CD45, CD31, HLA-DR, CD3, CD8a, CD45RO, Nestin, SOX2, HLA-ABC, Cytokeratin, and Vimentin). 
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Figure S5-11 Presence and abundance of tonsil cell subsets were comparable after 1-hour dissociation with 
different types of collagenases plus DNase. Patient-derived tonsils were dissociated for 1 hour with DNase plus either 
Col II, IV, V, or XI. Nucleated (HH3+) cCasp3- events were mapped simultaneously by viSNE. Contour plots of different 
dissociation conditions are shown to illustrate cell density (first column, top row). Heat plots show expression of 15 cell 
identity markers (CD45, CD3, CD4, CD8, CD27, CD45RA, CD45RO, CD19, IgM, IgD, HLA-DR, CD38, CD11c, CD86, and 
CD14). 
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Figure S5-12 GFAP+ cell subsets are present in gliomas. Hematoxylin and eosin (H&E) stains of 4 gliomas are shown 
(top row). Green arrowheads depict blood vessels or vascular proliferation, and dashed borders show area of necrosis. 
GFAP staining (bottom row) of the same tumors illustrates GFAP+ (red arrowheads) and GFAP- (blue arrowheads) cells. 
Scale bars = 50 μm. 
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Figure S5-13 Disproportionate depletion and selection of immune cell subsets was observed in tonsil samples with 
collagenase II dissociation over time. (A) Biaxial gating was used to identify apoptotic (cCasp3+) events, as well as intact 
nucleated immune cell subsets, in tonsils after 1-hour dissociation with Col II plus DNase. Terminal gates are outlined as 
dashed gates. (B) A similar gating scheme as in (A) was applied to cells obtained from different duration after dissociation 
with Col II plus DNase (x-axis) of the same tonsil sample. Abundance of terminal cell subsets were quantified as percentages 
compared to non-apoptotic nucleated (cCasp3-HH3+) cells (y-axis). (C) Abundance of apoptotic cells from different time 
points after dissociation is shown as percentage compared to all events.  
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Table S5-1 Fluorescence antibodies 
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Table S5-2 Mass cytometry antibody panel for healthy PBMCs 
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Table S5-3 Pearson analysis and Spearman rank comparing histone H3 and Iridium as intact cell markers 
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Table S5-4 Mass cytometry antibody panels for dissociated solid tissues and tumors 
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Preface 
 Despite the immense effort to identify meaningful clinical stratifications and therapeutics based on 
molecular alterations, adult glioblastomas still carry a high fatality rate. Previous glioblastoma studies had two 
critical limitations. First, although there was ample evidence that signaling alterations were the hallmarks of 
glioblastoma pathogenesis, most of the studies used genomics and transcriptomics information to infer signaling 
rather than directly quantifying the ongoing signaling activity. Second, the studies that quantified signaling activity 
either did not dissect the signaling in single cells, despite the increasing awareness of cellular diversity in 
glioblastoma, or presumed that the data observed in animal models would reflect signaling in patient tumors. 
The work presented in this chapter aims to tackle both limitations. By coupling single-cell mass cytometry 
signaling quantification with a risk stratification approach, two novel glioblastoma cell subsets were uncovered. 
These cells were defined by unique signaling enrichments, abnormal developmental phenotype, and a significant 
capacity to stratify patient clinical outcomes. Additionally, a relationship between brain resident microglia, tumor 
infiltrating immune cells, and the clinically distinct glioblastoma cells was discovered, indicating a tight 
association between cancer cells and the tumor microenvironment. Single-cell mass cytometry was critical to 
revealing these findings since the discovery relied on the ability to pinpoint specific signaling mechanism in rare 
cell subsets (occasionally 1 in 10,000). This explains why the findings here have not been identified in previous 
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studies that utilized other technical platforms. Importantly, the proteomic profiles of the stratifying cell subsets 
suggest immediately testable cellular targets for innovative therapeutics. 
 
Abstract:  While genomic and transcriptomic profiles have revealed extensive cellular diversity in adult 
glioblastoma, such approaches have not yet stratified patient outcomes.  Single cell mass cytometry was used 
here to systematically reveal glioblastoma cells based on per-cell measurements of 42 proteins and phospho-
proteins that govern neural and immune cell development and function.  Risk stratification analysis pinpointed 
two distinct glioblastoma populations that were closely associated with better or worse clinical outcomes. The 
defining biological features of glioblastoma negative prognostic cells included potentiation of essential survival 
signaling effectors, and inflammatory signaling was observed within positive prognostic cells.  Prognostic 
signaling in glioblastoma cells was closely related to microglial activation phenotype and leukocyte infiltration.  
Once revealed, seven cellular features were sufficient to identify prognostic glioblastoma cells in a clinically-
compatible workflow.  
 
Main Text 
Glioblastoma is the most common primary malignant brain tumor in adults (317). These aggressive 
tumors are composed of vascular cells, immune cells, neural-lineage cells, and cancer cells with diverse 
transcriptional, genomic, and protein expression profiles (5, 48, 284). As in other cancers, altered signaling in 
the biochemical networks that govern growth, survival, and interaction with the microenvironment is thought to 
confer hallmark capabilities to glioblastoma cells, including survival, proliferation, invasion, and immune evasion 
(7). However, the extreme diversity of cell types and molecular lesions within and between glioblastomas has 
obscured the identity of biological events that drive poor outcomes. There remains an urgent need to better 
understand how the cellular composition of glioblastomas and per-cell signaling in different tumor cell types 
relate to tumor progression and patient survival. 
Genomic and transcriptomic profiles have shown that the inter- and intra-tumor cellular diversity in 
glioblastoma is largely driven by alterations in receptor tyrosine kinases (RTKs) (2, 3). Previous studies have 
either measured signaling states in bulk primary tumors (140, 142, 318-320) or characterized genomic and 
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transcriptomic profiles in small numbers of single cells (5, 30, 44, 47, 48). However, stratification of patient clinical 
outcomes has not resulted from these approaches. Very little is known about the activation states of signaling 
effector proteins in primary glioblastoma cells.  Mass cytometry simultaneously measures key phospho-protein 
signaling nodes while also tracking proteins controlling cell lineage and identity (83), and we recently reported 
proof-of-concept studies of human glioblastoma using mass cytometry (285, 321, 322).  Mass cytometry studies 
also leverage single cell analysis tools like viSNE (290), FlowSOM (323), and MEM (321) to reveal and 
characterize phenotypically distinct cells. Prior studies with phospho-specific flow cytometry have revealed cell 
subsets defined by signaling that are closely linked to clinical outcomes (10, 12, 13, 15, 80).  This study 
investigated associations between patient outcomes, intracellular signaling, and aberrant expression of 
developmental programs in glioblastoma cells.  
 
Results 
Distinguishing glioblastoma, immune, and vascular cells in tumors 
Millions of single cells from freshly dissociated, surgically resected IDH-wildtype glioblastomas were 
comprehensively analyzed by single-cell mass cytometry. Cells from 28 patient samples were analyzed using a 
32-dimensional antibody panel (Figure 6-1A, Table S6-1, and Table S6-2, signaling & proteins). For this cohort, 
the median progression-free survival (PFS) and the median overall survival (OS) after diagnosis were 6.3 and 
13 months, respectively (Figure S6-1). These survival times were similar to those observed in larger population 
of patients undergoing standard therapy (26, 178). A comprehensive cytomic view of each tumor was generated 
using viSNE analysis (290). As a representative, patient LC26 is shown (Figure 6-1B and Figure 6-1C). This 
analysis confirmed the presence of multiple cell types within a tumor (5, 48, 284). Expression of canonical identity 
proteins was used to characterize non-glioblastoma cells, including CD45+HLA-DR+ antigen-presenting cells 
(APCs), CD45+HLA-DR- non-APC immune cells, and CD45-CD31+ endothelial cells (Figure 6-1B and Figure 6-
1C). Differential expression of surface and intracellular proteins was observed between the key cell types. In 
addition to the canonical proteins, other proteins were also highly expressed in non-glioblastoma cells, in 
accordance to previous reports, including CD34, PDGFRα, and ITGα6 in endothelial cells (324-326), and CD44 
in immune cells (327, 328). 
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Figure 6-1 Single-cell quantification of phospho-protein signaling and identity proteins in glioblastoma. (A) A 
diagram of the study depicts isolation of viable cells from glioblastoma tumors, pathological confirmation of IDH-wildtype 
status, immunostaining for mass cytometry analysis, viSNE dimensionality reduction, and expert identification of four main 
cell types, as in Figure 6-1B.  Next, glioblastoma cells from each patient were computationally isolated and combined for 
new analyses using FlowSOM, MEM, statistical tests for clinical associations, as in Figure 6-2. (B) viSNE plots from one 
patient’s glioblastoma tumor (LC26) show individual cells colored according to expression of 20 identity proteins and 8 
phosphorylated signaling effectors.  Heat indicates protein or phospho-protein expression per cell and position indicates 
phenotypic similarity. (C) Plots show cell density and cell identity for the same cells from tumor LC26 showing in Figure 6-
1B.  Protein features including CD45, CD31, HLA-DR, and others shown in (B) were used to identify cells as antigen 
presenting cells (APC, blue), other immune cells (non-APC, orange), endothelial cells (Endo, red), and glioblastoma cells 
(green).  
 
Biologically distinct glioblastoma cells within an individual tumor 
Intra-tumor single-cell diversity among CD45-CD31- glioblastoma cells was apparent in the t-SNE plot as 
multiple, well-separated islands (Figure 6-1B and Figure 6-1C).  In addition, identity-protein expression ranged 
across multiple orders of magnitude and contrasted between the cell-type islands, indicating glioblastoma cell 
subsets were distinguishable by differences in per-cell protein expression. This analysis also revealed 
unexpected diversity of developmental phenotypes in subsets of glioblastoma cells, including lineage aberrancy 
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(such as co-expression of astrocytic S100B and stem-like CD133, or neuronal TUJ1 and stem-like SOX2) as 
well as co-expression of molecular subclass markers (such as mesenchymal CD44 and classical EGFR) (2).  
Moreover, the phosphorylation states of eight key signaling effectors were quantified, revealing intra-tumor 
signaling diversity of glioblastoma single cells (Figure 6-1B, p-STAT5-Y694, p-AKT-S473, p-STAT3-Y705, p-S6-
S235/S236, p-STAT1-Y701, p-NFĸB(p65)-S529, p-ERK1/2-T202/Y204, and p-p38-T180/Y182). For example, 
simultaneous phosphorylation of S6, STAT5, and STAT3 was observed in a subset of glioblastoma cells that 
expressed S100B, but not in cells that expressed EGFR, GFAP, or CD44 (Figure 6-1B). Thus, the per-patient 
approach revealed unexpected combinations of cellular identity proteins and unique signaling features within 
cells from an individual glioblastoma tumor.   
 
Systematic analysis of glioblastoma cells across tumors 
By focusing initially on each patient, the analysis was able to best isolate the major cell lineages within 
the tumor and discern immune and endothelial populations. This optimally identified each patient’s glioblastoma 
cells in a context-specific manner. From each patient, at least 4,710 glioblastoma cells were identified and then 
pooled for a new comparison across the patient cohort. This is to determine whether cell subsets were common 
or unique to individual tumors.  A total of 131,880 glioblastoma cells were identified from 28 patients and 
combined for simultaneous, in-depth profiling based on cellular identity and signaling features (Figure 6-2A). 
Automated clustering by FlowSOM (293) revealed 43 phenotypically distinct glioblastoma cell subsets (Figure 
S6-2), the majority of which were observed in multiple patients’ tumors Figure S6-3).   
 
Clinically distinct glioblastoma cells 
It may be the case that phenotypically distinct cell subsets are associated with differential clinical 
outcomes, as has been observed in blood cancers (15).  To assess risks associated with newly revealed 
glioblastoma cell subsets, a computational workflow was designed to compare associations between cell subset 
abundance and patient overall survival (Figure 6-2B and Figure S6-2, see Supplementary Methods). Using this 
automated pipeline, glioblastoma cell subsets with contrasting and statistically significant associations with 
patient survival were revealed and characterized (Figure 6-2B). Glioblastoma Negative Prognostic (GNP) cells 
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(red; subsets 29, 32, 33, and 37) were defined as cell subsets with associated hazard ratios (HR) of death >1 
(p<0.05) (Figure 6-2C), whereas Glioblastoma Positive Prognostic (GPP) cells (green; subsets 1, 2, 13, and 22) 
were defined as cell subsets with associated HR of death <1 (p<0.05) (Figure 6-2D). The remaining cell subsets 
were not significantly deterministic of patient survival. Assessment of the presence and abundance of GNP and 
GPP cells in the entire patient cohort illustrate the extensive variation in abundance of clinically significant 
glioblastoma cell subsets across patients (Figure 6-2E, Figure S6-4A, and Figure S6-4B). Interestingly, there 
was no linear correlation between GNP and GPP cell abundance despite their contrasting connections with 
patient survival (Figure S6-4C).  
To determine if the cumulative abundance of the multiple individual cell subsets comprising the GNP or 
GPP populations was predictive of clinical outcome, cumulative GNP and GPP cells were tested with Kaplan-
Meier survival analysis using the Wilcoxon test (Figure S6-5). Patients whose tumors had over 5% GNP cells (in 
the glioblastoma cell fraction) had significantly shortened OS (Figure S6-5A, p=0.0022) and PFS (Figure S6-5B, 
p=0.02). In contrast, presence of GPP cells over 5% was associated with a significantly greater OS (Figure S6-
5C, p=0.0063) and PFS (Figure S6-5D, p=0.015). The preliminary statistical analysis indicated that the 
abundance of GNP and GPP glioblastoma cell subsets was closely associated with patient survival. To 
determine if the effect of cell subset abundance was a) continuous, and b) independent of other widely 
recognized predictors of survival (age (112, 329), MGMT promoter methylation status (107, 330), and treatment 
including extent of surgical resection (113, 114), therapy with temozolomide (1), and radiation (331, 332)), a 
multivariate Cox proportional-hazard model was developed by incorporating the above-listed survival predictors 
with GNP or GPP cell abundance.  Multivariate examination of GNP cell abundance as a continuous variable, 
keeping the other predictors constant, indicated that each additional 1% increase of GNP cells was associated 
with an approximately 8% increase in the mortality rate compared to baseline (HR 1.08 [95% CI 1.02-1.14]; 
p=0.008). In a similar analysis of GPP cells, each additional increase in 1% of GPP cells was associated with an 
approximately 19% decrease in the mortality rate (HR 0.81 [0.67-0.98]; p=0.03) and approximately 5% decrease 
in time to tumor progression or recurrence compared to baseline (HR 0.95 [0.91-0.99]; p=0.03). Strikingly, when 
GNP and GPP were assessed simultaneously, abundance of GNP cells was the primary predictor of OS (HR 
1.06 [1.00-1.12]; p=0.05), while abundance of GPP cells was the primary predictor of PFS (HR 0.94 [0.90-0.99]; 
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p=0.024).  Thus, the abundance of GNP and GPP cell subsets were each associated with distinct patient 
outcomes, independent of the standard prognosticators of glioblastoma patient survival, and each other.   
 
Figure 6-2 Risk stratification reveals clinically distinct Glioblastoma Negative Prognostic cells and Glioblastoma 
Positive Prognostic cells. (A) A diagram depicting the automated identification of glioblastoma cell subsets that linked to 
clinical outcome. Glioblastoma cells identified from 28 patients were computationally pooled for a new combined viSNE 
analysis. FlowSOM was used to automatically reveal glioblastoma cell subsets which were systematically assessed for their 
association with patient overall survival. (B) Forty-three glioblastoma cell subsets were identified across 28 patients. For 
each subset, overall survival was compared between patients with high vs low cell abundance (see Supplementary 
Methods). Cell subsets are color-coded based on hazard ratio (HR) of death (HR>1, red; HR<1, green) and p-values. (C) 
Overall survival analyses of abundance of Glioblastoma Negative Prognostic (GNP) cells (subsets 29, 32, 33, and 37) and 
(D) Glioblastoma Positive Prognostic (GPP) cells (subsets 1, 13, 22, and 2) are shown. (E) Abundance of GNP (red) and 
GPP (green) cells in 5 patients (W11, RT14, LC08, LC10, and LC02) are displayed. The non-prognostic cell subsets are 
shown in gray. The underlying contour depicts all glioblastoma cells from 28 tumors. 
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Figure 6-3 Clinically distinct glioblastoma cells are identified by abnormal developmental phenotype and altered 
signaling profiles. (A) Histogram plots of GNP (red), GPP (green), and other glioblastoma cells (gray) are shown to 
illustrate the differential expression of developmental proteins and phosphorylated signaling effectors. (B) Individual cell 
subsets that comprised GNP cells and GPP cells were mapped over biaxial plots to illustrate their shared and distinctive 
features. The underlying contours include glioblastoma, immune, and endothelial cells from 28 tumors. (C) MEM quantified 
the enrichment of identity proteins (P) and phosphorylated signaling effectors (S) in cell subsets comprising GNP population. 
(D) MEM analysis was also performed in cell subsets comprising GPP population. 
 
Exceptional biological features of clinically distinct glioblastoma cells 
To identify the signature of each prognostic glioblastoma cell subset, a systematic manual comparison 
between GNP, GPP, and other glioblastoma cells was performed (Figure 6-3A and Figure S6-6). GNP cells 
aberrantly co-expressed mature neural-lineage proteins (astrocytic S100B, and neuronal TUJ1) and stem-like 
SOX2. Additionally, GNP cells showed abnormal proliferative activity (M-phase marker, cyclin B1) as well as 
phosphorylation of RTK signaling effectors promoting cell survival, growth, and replicative capacity (p-STAT5, 
p-S6, p-STAT3). In contrast, GPP cells co-expressed higher levels of both EGFR and CD44, had lower signaling 
effector phosphorylation levels, and were less proliferative as measured by cyclin B1. To exclude the possibility 
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that GNP or GPP subsets contained immune or endothelial cells, these populations were compared on biaxial 
plots for the respective definitional markers CD45 and CD31 and were shown to exclusively contain non-immune, 
non-endothelial cells (Figure 6-3B, first column). Additional biaxial analyses of defining and distinguishing 
features of GNP and GPP cells were performed (Figure 6-3B).  
Marker Enrichment Modeling (MEM) was used to objectively quantify the signature of GNP and GPP 
cells (Figure S6-7 and Figure S6-8) (321).  MEM automatically derives a label for cell types based on the 
magnitude and variance of the features in a given subset relative to a reference population, which was used here 
to calculate enrichment of total proteins (P) and phospho-protein signaling effectors (S) in GNP cells (Figure 6-
3C) and GPP cells (Figure 6-3D).  The reference point for the MEM quantification of a given subset was all other 
glioblastoma cells (Figure S6-7; see Supplementary Methods for MEM interpretation). MEM provided an 
unbiased assessment of signature features and confirmed aberrant enrichment of lineage proteins 
(▲S100B+5±1.6, SOX2+3.5±1.3) and phosphorylated STAT5 (▲p-STAT5+4±2.6) in GNP cells. Specifically lacking from 
clinically unfavorable GNP cells was EGFR, GFAP, and CD44 (▼EGFR-2±0, GFAP-2±0, CD44-2±0). In contrast, 
total EGFR and CD44 were positively enriched in GPP cells (▲EGFR+5.5±1, CD44+2±1) and proliferation (▼cyclin 
B1-4.5±3.8) and pro-survival phospho-proteins (▼p-S6-9±4.7, p-STAT5-4.5±1, p-STAT3-3±3) were consistently lacking 
in GPP cells (Figure 6-3C and Figure 6-3D).  
 
Towards tracking clinically distinct glioblastoma cells in the clinic 
For clinical application of the high-dimensional analysis that was used to discover GNP and GPP cells, it 
would be useful if these distinct populations could be estimated or identified using traditional, lower-dimensional 
approaches. Traditional biaxial cytometry gating was previously shown to closely match findings by mass 
cytometry in glioblastoma (284) and could be implemented using the widely-available fluorescence flow 
cytometry platforms. A conventional biaxial gating scheme, using only the top 7 cellular features identified by 
MEM scoring, successfully re-discovered GNP and GPP cells without the use of high-dimensional tools such as 
t-SNE/viSNE (Figure S6-9A).  Populations of GNP and GPP cells identified by traditional gating were then 
mapped back onto the t-SNE analysis to determine whether they comprised distinct islands or were mixed.  Cells 
gated using the traditional biaxial approach occupied the same, distinct t-SNE phenotypic islands as those 
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identified by computational tools Figure S6-9B and Figure 6-2B). MEM analysis showed that the cells identified 
by traditional gating were statistically similar in identity, protein expression, and phosphorylation as those cells 
identified by the automated cell subset discovery approach (Figure S6-9C, Figure 6-3C, and Figure 6-3D).  The 
similarity of the manually and computationally identified cells was also apparent in histogram plots (Figure S6-
9D). It was crucial to couple high-dimensional single-cell mass cytometry with an automated, risk-stratification 
approach, to discover and quantify the features of clinically significant glioblastoma cell subsets, in an unbiased 
manner. However, once revealed, GNP and GPP cells could be reliably identified by traditional analysis 
approach compatible with clinical flow cytometric profiling. 
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Figure 6-4 Clinically distinct glioblastoma cells were closely related to immune infiltration and microglial activation 
phenotype. (A) Histogram plots showing abundance of CD45+ immune cells in GNP-high, immune-low tumors (top row: 
LC11, LC12, RT07), and GNP-low, immune-high tumors (bottom row: RT01, W11, LC22). (B) An analysis of S100B+ cells 
of the same tumors is shown. (C) CD45+ cells from 23 tumors were combined for a viSNE analysis. Protein features shown 
in Fig. S11 were used to identify 13 immune cell subsets. Each subset was colored based on its correlation with GPP cell 
abundance, as determined by Pearson correlation coefficient R (R > +0.5, orange; R = 0, white; and R < -0.5, teal). The 
correlation between subset “k” and GPP cells is shown (x-axis, GPP abundance; y-axis, subset “k” abundance) (D) A similar 
correlation analysis was performed between immune cell subsets and GNP cells. The correlation between abundance of 
subset “k” and GNP cells is also depicted. (E) Histogram plots show the expression of key immune markers in subsets “a” 
(memory T cells), “c” (non-memory T cells), “i” (monocyte-derived macrophages), and “j” (resident microglia), and “k” 
(phenotypically activated resident microglia). 
 
Immune microenvironment associations with clinically relevant glioblastoma cells 
Infiltrating immune cells comprise a large proportion of non-cancer cells in glioblastomas. Recent studies 
have revealed a high degree of variation in total immune abundance and relative proportions of immune cell 
subsets across different glioblastoma tumors (73). In this dataset, the abundance of tumor-infiltrating CD45+ cells 
(Figure 6-4A) and S100B+ cells (Figure 6-4B) was quantified and compared between tumors, revealing an 
inverse correlation between the abundance of immune cells and clinically unfavorable GNP cells (Figure S6-
10A). This correlation was not observed, however, with the clinically favorable GPP cells (Figure S6-10B).  
To further dissect the abundance and phenotype of immune cell subsets, single cells from 23 patients 
were characterized with antibodies against immune-cell surface proteins and t-SNE analysis on the CD45+ cells 
(Figure 6-4C and Table S6-2). Nine immune-related surface features were used to generate the immune-specific 
viSNE map (Figure S6-11). Consistent with previous reports, the intratumor heterogeneity among CD45+ cells 
suggested the presence of diverse immune cell subsets. Using both the cellular distribution on the viSNE map 
and per-cell protein expression profiles, 13 subsets of CD45+ cell were identified by expert gating on t-SNE axes 
(Figure 6-4C and Figure 6-4D, left). The abundance of each CD45+ cell subset was compared to abundance of 
GPP (Fig.4C, right) and GNP cells (Figure 6-4D, right), using Pearson correlation coefficient R. Of the 13 subsets, 
subset “k” was the only CD45+ cell subset that showed a contrasting correlation with GPP cells (Figure 6-4C, 
right; R = +0.55) and GNP cells (Figure 6-4D, right; R = -0.5). Based on histogram analysis, the cellular 
phenotype of subset “k” was CD45intCD11bintHLA-DRint, which resembled resident microglia (Figure 6-4E, bottom 
row) (333, 334). Additionally, subset “k” also expressed CD44, a feature that was previously shown to indicate 
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microglial activation (Figure 6-4E, right-most column) (335, 336). This analysis also confirmed the phenotype of 
other immune cell subsets present in glioblastomas, including memory T cells (“a” CD3+CD45RO+), non-memory 
T cells (“c” CD3+CD45RO-), monocyte-derived macrophages (“i” CD45hiCD11bhiHLA-DRhi), and non-activated 
resident microglia (“j” CD45intCD11bintHLA-DRintCD44-) (Figure 6-4E).  
 
Discussion 
Value of single-cell signaling profiles  
By coupling single-cell quantification of identity proteins and phosphorylated signaling effectors, this study 
uncovered novel glioblastoma cells that differentially predicted clinical survival with robust statistical significance. 
Single-cell mass cytometry was critical to revealing this signature in two ways. First, assessment of a large 
number of cells per tumor enabled this study to pursue statistically powerful approaches towards the identification 
of rare and novel cell subsets. Second, per-cell quantification of phosphorylation-specific signaling effectors was 
key to the discovery of novel cell subsets, which revealed potential mechanisms of tumor progression as well as 
interactions between distinct cell types in the tumor microenvironment. The GNP signature was defined by 
abnormal neural-lineage features and simultaneous high basal phosphorylation of many signaling effectors 
downstream of RTKs, in particular STAT5, which is known to be associated with cell growth and survival. In 
contrast, the GPP signature was defined by EGFR and CD44 enrichment, lack of proliferation, and specific lack 
of STAT5 phosphorylation. This result agrees with single-cell transcript analysis that revealed CD44 expression 
is widespread and heterogeneous within tumors (5).  Thus, tracking signaling in subpopulations of tumor cells 
and aligning this information with developmental markers proved critical to identifying prognostic populations.   
 
Cellular heterogeneity and homogeneity in glioblastoma 
Previous studies of blood cancers have reported contrasting results regarding the role of intra-tumor 
signaling heterogeneity. Studies of leukemia have clearly demonstrated that signaling heterogeneity is 
associated with stem-ness and poor clinical outcomes (12, 80).  In contrast, in lymphoma, emergence and 
dominance of the tumor by a subset with abnormal suppression of signaling revealed signaling homogeneity in 
the worst outcome cases (15).  Here, homogeneity in either GNP or GPP cells was associated with the most 
extreme ends of good and bad clinical outcome and heterogeneity was of intermediate outcome. For example, 
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GNP cells comprised more than 70% of poor outcome samples LC02 and RT07 and GPP cells comprised more 
than 90% of LC06, a good outcome case (Figure 6-2, Figure 6-S4, and Table S6-1). This difference is likely a 
result of the analysis strategy that focused on defining a cell population based on degree of risk stratification. 
Yet, it remains striking that GNP and GPP cells are consistent in phenotype across tumors and were found at 
greater than 1% abundance in >50% of the glioblastomas studied here (Figure S6-3). The abundance of GNP 
cells in post-therapy glioblastomas should now be measured to determine whether these cells further increase 
in abundance following treatment resistance.  
 
Immune cells, microglia, and immunotherapy implications 
Identification of negative prognostic signaling events and their associated cell types resulted in a clinically 
applicable detection method for characterizing human tumors (Figure S6-9) and revealed a close relationship 
between signaling in cancerous cells and microenvironmental changes.  Prior studies of low-grade, IDH-mutant 
glioma suggested that vascularity of higher-grade tumors is accompanied by an increase in cells with a 
monocyte-derived macrophage transcriptional signature (73).  The results here confirm that glioblastomas can 
contain a significant population of macrophages.  In particular, tumors composed of GPP cells were also more 
likely to contain CD45+ hematopoietic cells, including CD45hiCD11bhiCD64+HLA-DR+ macrophages (Figure 6-4).  
Separately, the abundance of CD44hi microglia (CD45intCD11bintCD64+HLA-DR+) was directly associated with 
GPP cell abundance and inversely associated with GNP cell abundance.  Microglial CD44 expression denotes 
activation (335, 336).  These results are consistent with the idea that prevalence and activation of tissue-resident 
microglia may be critical in eliciting anti-tumor immunity.  It is not clear from these studies whether an altered 
immune microenvironment precedes development of an aggressive glioblastoma or whether the more 
aggressive tumors suppress anti-tumor immunity. 
Further supporting the importance of the glioblastoma immune microenvironment is that clinically 
favorable glioblastoma cells showed enrichment of p-STAT1 and p-NFĸB (Figure 6-3), transcription factors that 
activate antigen presentation, inflammation, and anti-tumor immunity (337-342). In melanoma, STAT-driven 
expression of HLA-DR, an MHC class II molecule, is associated with improved responses to checkpoint inhibitor 
immunotherapy (343).  Here, unfavorable GNP cells were associated with diminished tumor-infiltrating immune 
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cell abundance (Figure 6-4 and Figure S6-8). While active proliferation marked by cyclin B expression was a 
hallmark of GNP cells (Figure 6-4), it is unlikely that the GNP cell can out-proliferate the cytotoxic immune cells 
and dominate the tumor microenvironment without some mechanism for suppression of the cytotoxic CD8+ T 
cells observed within most tumors (Figure 6-3 and Figure 6-4).  GPP cells with inflammatory STAT1 and NFĸB 
signaling were not correlated with recruitment of total CD45+ leukocytes (Figure S6-10) or a blood-derived 
immune cell subset (Figure 6-4 and Figure S6-11), but GPP were associated with activated, resident CD44+ 
microglia (Figure 6-4 and Figure S6-11).  These findings suggest that immunotherapy is likely to be most 
productive in tumors containing GPP cells and that additional research is needed to understand whether GNP 
cells directly suppress microglia or immigrant leukocytes.  
 
Relationship between glioblastoma cell signaling and outcome 
GNP cells were closely associated with the unfavorable clinical outcome, while presence of GPP cells 
primarily predicted delayed time to progression or recurrence. Although the divergent connections of GNP and 
GPP cells with patient outcome were apparent, correlation between these two novel cell subsets was not 
observed (Figure S6-4C). These findings indicated that GPP and GNP cells might have a complex mechanistic 
relationship, which would be valuable to explore in future studies. The discovery of GNP cells, abnormal both in 
neural-lineage phenotype and basal signaling activity, has the potential to lead to new therapeutic approaches 
for glioblastoma. The negatively prognostic STAT5 phosphorylation in GNP cells, for example, should be 
explored as a potential therapeutic target and a biomarker of therapy response. Critically, the identification of 
signaling features that were specifically enriched in clinically distinct glioblastoma cells led to a development of 
a lower-dimensional pipeline which can be immediately adopted for clinical stratification.  
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Supplemental Material 
Materials and Methods 
Patient samples 
 Surgical resection specimens of 28 IDH-wildtype glioblastomas collected from the Vanderbilt University 
Medical Center between 2014 and 2016 were processed into single cell suspensions following an established 
protocol (Table S6-1) (285). Only samples that were confirmed to be IDH-wildtype glioblastomas by standard 
pathological diagnosis were used. All samples were collected with patient informed consent in compliance with 
Vanderbilt Institutional Review Board (IRB #131870), and in accordance with the declaration of Helsinki. 
 
Patient characteristics and collection of clinical data 
 All patients were adults ( 18 years of age) at the time of their maximal safe surgical resection of their 
cerebral (supratentorial) glioblastomas. Extent of surgical resection was classified as either gross total or subtotal 
resection by both a neurosurgeon and a neuroradiologist independently. Gross total resection was defined as 
consensual agreement of no significant residual tumor enhancement on patients’ gadolinium-enhanced 
magnetic resonance imaging (MRI) of the brain obtained within 24 hours after surgery. All patients were 
considered for treatment with postoperative chemotherapy (temozolomide) and radiation according to the 
standard of care (1), after determination of MGMT promoter methylation status by pyrosequencing (Cancer 
Genetics, Inc., Los Angeles, CA, USA). Multiplex polymerase chain reaction (PCR) was used to determine 
IDH1/2 mutational status. Patients’ postoperative course was followed until October 2017, noting time to first, 
definitive radiographic progression or recurrence of glioblastoma consensually agreed upon by the treating 
neuro-oncologist and neuroradiologist, and the time to patients’ death. All deaths were deemed to be due to the 
natural course of patients’ glioblastoma. 
 
Mass cytometry analysis 
 Cells derived from patient samples were prepared as previously described (285, 312). Rhodium viability 
stain and cleaved caspase 3 antibody were included to exclude non-viable and apoptotic cells, respectively. A 
multi-step staining protocol was used, which included 1) live surface stain, 2) 0.02% saponin permeabilization 
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intracellular stain, and 3) intracellular stain after harsh permeabilization with ice-cold methanol (Table S6-2) 
(285). Detection of total histone H3 was used to identify intact, nucleated cells (284). Cells were resuspended in 
deionized water containing standard normalization beads (Fluidigm) (313), and collected on a CyTOF 1.0 at 
Vanderbilt University. A 32-dimensional mass cytometry antibody panel was used to analyze over 2 million viable 
cells from 28 tumors (ranging from 4,860 to 336,284 cells per tumor). Data were normalized with MATLAB-based 
normalization software (313), and were arcsinh transformed (cofactor 5), prior to analysis on a web-based 
Cytobank software (301). Mass cytometry data are publicly available at http://vanderbilt.cytobank.org/. 
 
Cell subset identification by FlowSOM 
 Cell subset identification was performed in R, using the previously published FlowSOM R package (293). 
t-SNE values (t-SNE1_glioblastoma and t-SNE2_glioblastoma; Fig. 2B) from viSNE analysis of CD45-CD31- 
glioblastoma cells from 28 patients were used as parameters for cell subset clustering. The number of cell 
subsets assigned to the algorithm ranged from 5 to 45. The optimal number of clusters was defined as 43, since 
it was the fewest number of clusters that effectively predicted patient clinical outcome while minimizing intra-
cluster signal variance (Figure S6-2). 
 
MEM quantification 
 MEM analysis was performed in R, using the previously published R package (321). In short, MEM 
captured and quantified cell subset-specific feature enrichment by scaling the magnitude (median) differences 
between samples, depending on the spread (interquartile variance, IQR) of the data. These values were then 
computed in comparison to the remaining cells in a given dataset. MEM values can be interpreted as either being 
positively enriched (▲, positive values) or negatively enriched (▼, negative values). The variation of a given 
cellular feature across GNP or GPP cell subsets were quantified as ± standard deviations (SD). 
 
Survival and statistical analysis 
 Time from surgical resection to death (overall survival, OS) and time from surgical resection to the initial 
radiographic progression/recurrence or death before radiographic assessment (progression free survival, PFS) 
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were plotted and analyzed using GraphPad Prism version 7.00 for Windows (GraphPad Software, San Diego, 
CA, USA) using right-censored Kaplan-Meier curves. Survival time points were censored if, at last follow up, the 
patient was known to be alive or had not had radiographic progression. Differences in the survival curves were 
compared using the Gehan-Breslow-Wilcoxon method (i.e. Wilcoxon test), reporting a hazard ratio between the 
survival curves.  
 The abundance of glioblastoma cell subsets and their clinical significance was assessed using outcome-
guided analysis (Figure 6-2 and Figure S6-2). Patients were divided into Low and High groups, based on the 
distribution (interquartile variance) of the abundance of a given cell subset across the cohort. A Wilconxon test 
was then used to assess the p-value and the hazard ratio (HR) of death. Glioblastoma cell subsets that were 
significantly (p < 0.05) associated with early death (HR > 1) were termed Glioblastoma Negative Prognostic 
(GNP) cells, whereas the subsets that were significantly (p < 0.05) associated with prolonged survival (HR < 1)) 
were termed Glioblastoma Positive Prognostic (GPP) cells. Abundance of GNP and GPP cells is each tumor 
was quantified as percentages per total glioblastoma cells. 
 A Cox proportional hazards regression model was created to assess the influence of GNP and GPP cells 
on OS and PFS as continuous variables while accounting for other factors known to affect survival, including 
age at diagnosis, glioblastoma MGMT promoter methylation status, extent of surgical resection (EOR), treatment 
with temozolomide (TMZ), and radiation (XRT). The hazard model can be written as: 
 
ܪܴ =
ℎ(ݐ)
ℎ଴(ݐ)
= ݁(௕ಸಿುீே௉ା௕ೌ೒೐஺௚௘ା௕ಾಸಾ೅ெீெ்ା௕ಶೀೃாைோା௕೉ೃ೅௑ோ்ା௕೅ಾೋ்ெ௓) 
where ௛(௧)
௛బ(௧)
 represents the ratio of hazard comparing the risk of death at time t to the baseline hazard (obtained 
when all variables are equal to zero) and ݁௕ೣ represents the hazard ratio of variable ݔ. The data were fit using R 
software, version 3.4 (R foundation for Statistical Computing, Vienna, Austria), utilizing the rms library (version 
4.5). The proportional-hazards assumption was tested in all multivariate models and supported by a non-
significant relationship between Schoenfeld residuals and time for each covariate included in the model (p > 
0.38; degree of freedom = 1) and the overall model (p = 0.96; degrees of freedom = 6 and 7). Statistical 
significance α was set at 0.05 for all statistical analyses.  
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Table S6-1 – Patient characteristics 
Sample 
ID Gender Age TMZ RT EOR 
MGMT 
meth 
PFS 
(days) 
OS 
(days) Status 
K01 Female 59 Yes Yes STR No 176 364 Dead 
LC02 Male 67 No No STR No 53 53 Dead 
LC03 Male 60 No No STR No 57 57 Dead 
LC04 Male 65 Yes Yes GTR No 263 918 Dead 
LC06 Male 41 Yes Yes GTR No 958 1136 Alive 
LC08 Female 55 Yes Yes STR No 210 441 Dead 
LC09 Male 68 Yes Yes STR Yes 66 110 Dead 
LC10 Male 78 No Yes STR No 117 178 Dead 
LC11 Female 76 Yes Yes STR Yes 111 411 Dead 
LC12 Male 40 Yes Yes GTR Yes 606 724 Alive 
LC18 Male 69 Yes Yes STR No 133 240 Dead 
LC21 Female 69 Yes Yes GTR Yes 267 267 Dead 
LC22 Male 64 Yes Yes STR No 263 366 Dead 
LC25 Female 60 Yes Yes GTR No 185 391 Alive 
LC26 Male 71 Yes Yes STR Yes 363 386 Alive 
LC27 Male 62 Yes Yes STR No 79 252 Dead 
RT01 Female 69 Yes Yes STR No 162 198 Dead 
RT07 Female 70 Yes Yes STR No 49 57 Dead 
RT10 Male 56 No No STR Yes 22 113 Dead 
RT14 Female 55 Yes Yes GTR Yes 472 483 Alive 
RT15 Female 80 No Yes STR No 98 353 Dead 
W02 Male 75 Yes Yes STR Yes 446 507 Dead 
W04 Male 60 Yes Yes STR No 220 456 Dead 
W05 Male 60 Yes Yes STR No 241 282 Dead 
W11 Male 69 Yes Yes GTR No 491 504 Alive 
W12 Male 50 Yes Yes STR Yes 190 505 Alive 
W14 Male 47 Yes Yes STR Yes 125 452 Alive 
W15 Male 50 Yes Yes STR Yes 400 441 Alive 
 
TMZ = temozolomide 
RT = radiation 
EOR = extent of resection 
STR = subtotal resection 
GTR = gross total resection 
MGMT meth = MGMT promotor methylation 
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Table S6-2 – Mass cytometry antibody panels 
Target Mass Clone 
Signaling & 
proteins Immune Stain 
Panel viSNE Panel Live Sap MeOH 
Rhodium 103 - ●  ●    
Cyclin B1 139 GNS-1 ●      
TUJ1 141 TUJ1 ●      
cCasp3 142 5A1E ●      
CD117 143 104D2 ●      
S100B 144 19/S100B ●      
CD64 144 10.1   ●    
CD31 145 WM59 ● *     
CD34 148 581 ●      
CD45RO 149 UCHL1   ●    
p-STAT5 (Y694) 150 47 ●      
BMX 151 40/BMX ●      
p-AKT (S473) 152 D9E ●      
p-STAT1 (Y701) 153 58D6 ●      
CD45 154 HI30 ● * ●    
NCAM/CD56 155 HCD56 ●      
p-p38 (T180/Y182) 156 D3F9 ●      
p-STAT3 (Y705) 158 4/P-STAT3 ●      
ITGα6 159 GoH3 ●      
CD133 160 AC133 ●      
PDGFRα 161 16A1 ●      
SOX2 163 O30-678 ●      
SSEA-1 164 W6D3 ●      
EGFR 165 AY13 ●      
p-NFκB p65 (S529) 166 K10-895.12.50 ●      
L1CAM 167 5G3 ●      
Nestin 168 10C2 ●      
CD44 169 BJ18 ●  ●    
GFAP 170 1B4 ●      
p-ERK1/2 (T202/Y204) 171 D13.14.4E ●      
p-S6 (S235/S236) 172 N7-548 ●      
SOX10 173 A-2 ●      
HLA-DR 174 L243 ●  ●    
NCAM/CD56 175 HCD56   ●    
Histone H3 176 D1H2 ●  ●    
 
● = included in the panel 
 = included for generation of viSNE map 
* Excluded from viSNE analysis of only glioblastoma cells 
Live = live surface stain 
Sap = 0.02% saponin stain 
MeOH = stain after ice-cold methanol permeabilization 
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Figure S6-1 Survival of 28 adults with IDH-wildtype glioblastomas. (A) Progression-free survival (PFS) and (B) overall 
survival (OS) of 28 patients with IDH-wildtype glioblastomas are depicted in Kaplan-Meier survival plots. Censored values 
are indicated by tick marks on the curves. The median PFS was 190 days (6.3 months), and the median OS was 388.5 
days (13 months). 
  
118 
  
 
Figure S6-2 Identification of glioblastoma cell subsets that significantly stratify patient overall survival. 
Glioblastoma cells from 28 tumors were combined for a new viSNE analysis. The top-left map shows cell density.  
Automated FlowSOM clustering was used to identify glioblastoma cell subsets, ranging from 5 to 45 subsets. The overall 
survival of patients with high vs low abundance of each cell subset was assessed using the Wilcoxon test. Cell subsets 
were are color-coded based on hazard ratio (HR) of death (HR>1, red; HR<1, green) and p-values. The optimal cell subset 
number, 43, is marked with thick borders (see Figure 6-2). For cell FlowSOM and survival analyses, see Supplementary 
Methods. 
  
119 
  
 
Figure S6-3 Glioblastoma cell subsets were present across patients at varying abundance. (A) Percent of tumors (y-
axis) whose tumors were composed of at least 0.1% of a given glioblastoma cell subset (x-axis) is depicted. Glioblastoma 
cell subsets are arranged from being present in 100% of tumors (left) to being present in fewest tumors (right). (B) 
Abundance of glioblastoma cell subsets (%, y-axis) per tumor is shown. Each data point (open circle) represents one tumor. 
Horizontal lines depict the median abundance of cell subsets across all tumors. Boxes and error bars represent the 25th to 
75th percentile and the standard deviation, respectively. Cell subsets that constitute GNP cells are labeled in red, and those 
that constitute GPP cells are labeled in green.   
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Figure S6-4 Abundance of GNP and GPP cells were not significantly correlated to each other. (A) Glioblastoma cells 
in each tumor are displayed over a cell density contour of the viSNE analysis of all the glioblastoma cells from 28 tumors. 
Abundance of GPP (green) and GNP (red) cells in each tumor is shown as percentages. Tumors are arranged from that 
with the lowest abundance of GNP cells (LC06; 0.0%) to the tumor with the most abundant GNP cells (LC02; 85.7%). 
Glioblastoma cells that were non-predictive of clinical outcome are shown in gray. (B) Stacked bar graph illustrates the 
abundance of GPP cells (green), GNP cells (red), and other glioblastoma cells (gray) per total glioblastoma cells (y-axis) in 
each patient (x-axis). (C) Correlation between the abundance of GNP (x-axis) and GPP cells (y-axis) was assessed by 
Pearson’s correlation coefficient (R = -0.24) and Spearman’s rank ( = +0.54) tests. Each data point represents one tumor. 
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Figure S6-5 Glioblastoma Negative Prognostic cells and Glioblastoma Positive Prognostic cells contrastingly 
linked to patient clinical outcomes. The associations of GNP cell abundance with overall survival (A) and progression 
free survival (B) was assessed using Wilcoxon tests. The p-values and hazard ratios are depicted in the corresponding 
Kaplan-Meier plots. Similar analyses of GPP cell abundance were performed for their associations with overall survival (C) 
and progression free survival (D). 
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Figure S6-6 Expression of identity proteins and phosphorylation-specific signaling effectors in individual 
glioblastoma cells. viSNE analysis was performed on glioblastoma cells combined from 28 tumors. (A) Per-cell expression 
levels of 18 identity proteins, (B) 8 phosphorylated signaling effectors and proliferation marker cyclin B1 are depicted. 
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Figure S6-7 Glioblastoma cell subsets showed differential enrichment of identity proteins and phosphorylated 
signaling effectors. (A) Forty-three glioblastoma cell subsets that were automatically identified by FlowSOM are arranged 
according to their associations with overall survival (HR>1, red, left; HR<1, green right) and statistical significance (p-
values). (B) Heatmap represents the identity-protein MEM values of glioblastoma cell subsets (columns). GNP cells are 
labeled in red, which GPP cells are labeled in green. Hierarchical clustering of identity proteins was performed based on 
their MEM values and is depicted on the left of the heatmap. (C) MEM values and hierarchical clustering of phosphorylation-
specific signaling effectors of each glioblastoma cell subset were also analyzed. HR = hazard ratio of death. 
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Figure S6-8 Quantitative MEM labels of the enriched identity proteins and signaling features of glioblastoma cell 
subsets. Enrichment of identity proteins (P) and phosphorylated signaling effectors (S) of glioblastoma cell subsets was 
quantified using MEM. GNP and GPP cells are labeled in red and green, respectively. See also Figure 6-3 and Figure S6-
7.  
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Figure S6-9 A standard low-dimensional biaxial analysis workflow effectively identifies clinically distinct 
glioblastoma cell subsets. (A) Biaxial plots demonstrating a sequential gating scheme compatible to standard clinical flow 
cytometry workflow. Biaxial GNP and biaxial GPP cells were identified using red and green gates, respectively. (B) Biaxial 
GNP (red) and biaxial GPP (green) cells are overlaid over a contour of glioblastoma cells from 28 tumors subjected to a 
common viSNE analysis as shown in Figure 6-2. (C) MEM analysis was used to quantify enriched identity proteins (P) and 
phosphorylated signaling effectors (S) of biaxial GNP and biaxial GPP cells. (D) Histogram analysis depicts the expression 
of key identity proteins and phosphorylated signaling effectors of biaxial GNP (red) and biaxial GPP cells (green). This was 
compared to all glioblastoma cells (black, bottom row). The transformed ratio of medians compared to all glioblastoma cells 
are also specified.  
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Figure S6-10 Abundance of CD45+ immune cells inversely correlated with GNP cells but was not associated with 
GPP cells. (A) The correlation between the abundance of total CD45+ immune cells (x-axis, % per total cell in tumor) and 
GNP cells (y-axis, % per glioblastoma cells) was assessed using Pearson’s correction coefficient (R) and Spearman’s rank 
(). (B) A similar correlation between GPP cells and immune cells was also evaluated as depicted. 
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Figure S6-11 viSNE analysis revealed cellular diversity among CD45+ immune cells. (A) CD45+ cells from 23 
glioblastomas were subjected to an immune-specific viSNE analysis. Cell density is depicted. (B) Per-cell expression of 9 
surface immune identity proteins that were used to generate the viSNE map are shown. 
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CHAPTER 7 
Summary and Future Directions 
 
Summary of dissertation 
 Cellular diversity is a core component of human malignancies. A thorough understanding of the cell 
subsets and their mechanistic hindrance that drives tumor progression, therapy resistance, and eventual 
recurrence, is essential for disease stratification and the development of novel therapeutics. Advanced 
technological approaches and computational tools have made systematic, unbiased, single-cell analyses 
attainable. Integration of single-cell assessments with pertinent automated analytical approaches, which are 
tailored for specific systems and objectives, is critical for the discovery of features that drive poor outcome.  
This dissertation presents a modular workflow that combines single-cell proteomics quantification with 
outcome-guided feature discovery of human adult glioblastoma, a rapidly fatal brain tumor (Chapter 6). This 
automated workflow was systematically built upon tools that were successfully established for quantitative single-
cell analysis of hematologic malignancies (Chapter 4). This pipeline also couples a new technological 
development that enables derivation of viable single cells while preserving cellular diversity, a critical hurdle in 
solid tumor single-cell analysis (Chapter 5 and Appendix A), with an advanced automated feature quantification 
(Appendix E). This has led to the discovery of novel glioblastoma cancer cell subsets, and their subset-specific 
signaling bottlenecks, that strongly and quantitatively predicted tumor progression and patient survival. The novel 
signaling hallmarks in the stratifying glioblastoma cell subsets can be used as predictive biomarkers and should 
be immediately tested as targets for innovative therapies. Moreover, this automated pipeline can be readily 
evaluated and modified for applications in other solid malignancies.  
 
Measurements and displays of single-cell proteomic features 
Chapter 4 presents the basic single-cell mass cytometry protocol and the key analytical tools. Using a 
well-characterized, cytometry-ready human PBMCs as an example, this study demonstrated the power of mass 
cytometry for per-cell quantification of proteomics features that reflect cell identity. Dimensionality-reduction 
tools, such as SPADE (282) and viSNE (290), efficiently displayed the global phenotypic connectivity of single 
cells in PBMCs. The eventual subset delineation still heavily relied on manual identification by means of gating. 
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This step can be difficult in tissues that are less well-characterized or those that display erratic phenotypic 
aberrancies, such as cancers. Although there have been many developments of automated cell subset 
identification algorithms, identifying the approach that can efficiently and automatically derive clinically 
meaningful cell subsets is especially challenging.  
The critical obstacle is to pinpoint the definitions of the cell subsets. Cells in human PBMCs carry distinct 
protein phenotypes that correlate well with their physiologic functions. For example, CD38+ plasma cells produce 
antibodies, whereas CD8+ T cells execute cytotoxic functions. In human malignancies, however, the significance 
of cell subset definition is generally shifted towards the identification of cells that govern therapy resistance or 
tumor recurrence (14, 15, 86).  
Previous work in hematologic malignancies demonstrated that single-cell signaling activities that occur 
in response to external potentiation were closely associated to patient outcome (14, 15, 80). Even though surface 
protein identity and signaling activation showed strong correlations in healthy blood cells, signaling profiles better 
defined leukemic cells that predicted poor survival (12, 14, 15). These studies are examples of alternative 
approaches to define cell subsets beyond identity protein expression. A single-cell ex vivo signaling potentiation 
protocol, which was the basis for these stratifications, is also described in detail in Chapter 4. Using a human 
leukemia cell line as an example, post-translational modifications of key signaling effectors were quantified. This 
protocol efficiently revealed distinct cellular mechanistic adaptations to various environmental cues.  
 
Solid tissue and tumor dissociation: Overcoming the roadblock towards single-cell analysis 
 Single-cell characterization in healthy blood and hematologic malignancies have made significant 
advancement during the past few decades. As samples are readily in suspension, they require minimal 
preparation for various single-cell analytical platforms, including all flow cytometry. To broadly apply these 
valuable single-cell tools to enable similar in-depth analyses in solid tissues and tumors, a combined mechanical 
and enzymatic dissociation protocol was developed, as described in Chapter 5 (see Appendix A for a 
complementary step-by-step protocol).  
 This protocol is a major advancement for solid tumor single-cell biology. Not only can it be applied in 
many types of solid tissues and tumors (including glioblastomas), viable cells that are derived using this 
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standardized universal protocol are suitable for quantitative analysis on multiple flow cytometry platforms 
(fluorescence and mass). Moreover, the protocol maximizes cell viability and preserves the diversity of cells 
within the original tissues and tumors, making it ideal for the discovery of features even in a rare cell population.  
 This advancement had bridged the critical gap in the characterization of cell subsets and the degree of 
cellular diversity within individual glioblastomas. Even though cellular diversity has been observed in previous 
glioblastoma studies, the conclusions were usually drawn from a small number of single cells and were rarely 
based on samples that were directly derived from patients without prior ex vivo cell expansion or xenograft 
generation (5, 44, 48, 73). In contrast, the development described here enabled 1) high-dimensional single-cell 
characterization in a large number of cells (millions of cells per sample), and 2) quantification of cellular 
proteomics features, which can also include post-translational modifications that infer signaling activities 
(Chapter 6).  
 
Outcome stratification and the discovery of therapeutic target candidates in adult primary glioblastomas 
 The discovery of novel glioblastoma cell subsets presented in Chapter 6 resulted from an analysis that 
was built upon 1) single-cell protein quantification (Chapter 4), 2) the development of a universal tumor 
dissociation workflow (Chapter 5), and 3) a system-tailored risk stratification approach. In contrast to the 
molecular alterations in glioblastomas that were identified using bulk-tumor analyses (2, 3, 22), the single-cell 
approach precisely distinguished stromal features (immune and vascular) from glioblastoma-specific 
characteristics. Importantly, a clustering algorithm, resulting in automated cell subset identification, was 
incorporated into the workflow enabling an unbiased discovery of features that may be the mechanisms of poor 
outcomes (293).  
 Critically, the overall objective was to identify glioblastoma cells that were closely associated with extreme 
patient outcomes (either favorable or unfavorable), as well as their biological defining features. The novel clinical 
stratifying glioblastoma cell subsets were characterized by two core features. First, single cells in each subset 
had minimal variations of protein identity expression and signaling effector phosphorylation, indicating that the 
glioblastoma cell subsets were relatively uniform and that the biological characteristics were distinct between 
subsets. Second, these cell subsets significantly predicted tumor progression and patient overall survival. 
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 Comprehensive analysis further revealed that GPP cells were the main predictor of prolonged time to 
tumor progression, while GNP cells were closely associated with shorter overall survival. This is the first 
discovery in glioblastoma that there are cancer cells with contrasting clinical influences co-existing within 
individual tumors. Interestingly, the abundance of these two populations did not appear to be strongly inversely 
correlated. This suggested that although it is possible that the GPP and GNP cells may mechanistically interact 
and oppose each other, there are other factors that independently influence the presence and the balance of 
these cells, such as presence of immune cell subsets and their differential activation. 
 Importantly, the association of the cell subsets and patient outcome was the critical defining feature of 
glioblastoma cell subsets and led to the discovery of clinically distinct populations. Moreover, single-cell mass 
cytometry quantified simultaneous activation states of multiple signaling effectors, which are considered to be 
core converging points of multiple pathways that are commonly activated in glioblastoma. Therefore, these 
signaling effectors are representations of the global signaling activity that could be secondary to activation of 
different surface receptors. Furthermore, the signaling states that define the glioblastoma prognostic cells should 
be tested as biomarkers that predict responsiveness to targeted therapies (260), and should be evaluated as 
indicators of specific, individualized combinatorial therapy.  
 Evidence of lower-grade gliomas suggested a tight connection between tumor grades and the component 
of the tumor-infiltrating immune cells, indicating a close relationship between cancer cells and the cell in the 
tumor microenvironment (73). The work presented in Chapter 6 demonstrates that the abundance of total 
immune cells in glioblastoma varied significantly between tumors, ranging from less than 0.1% to more than 50% 
of total cells. Further investigation revealed that the abundance of the brain resident microglia that were 
phenotypically activated significantly contributed to the differences observed. Specifically, unfavorable tumors 
lacked the phenotypically activated resident microglia, which were highly abundant in the more clinically 
favorable glioblastomas. The signaling profile of a subset of GPP cells suggested that glioblastoma-infiltrating 
immune cells might be directly interacting with cancer cells to elicit an anti-tumor response. This discovery is 
especially valuable for future studies that aim to characterize the efficacy of immunotherapy, or even how 
targeting cancer cells impact the homeostasis within the tumor microenvironment. 
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Future directions 
Bridging cutting-edge single-cell discoveries and clinical applications 
 The modular workflow and biological discovery described in this dissertation has significant potential for 
clinical applications. With the increasing knowledge of biological features that predict outcome and suggest 
targeted therapies, high-dimensional analyses of single cells can become the future of standard clinical 
laboratory practice. Considering the extent of cancer cell diversity even within a single tumor, the use of high-
dimensional single-cell technologies, such as mass cytometry, as an initial laboratory approach could become a 
routine. The goal would be to map the cytomic characteristics and to profile the signaling regulators of individual 
cancer cells, in order to identify key features to track throughout the course of therapy, which may potentially 
indicate cellular targets for individualized treatment.  
 As demonstrated in Chapter 6, high-dimensional single-cell mass cytometry and risk stratification were 
critical to the identification of GPP and GNP cells in an unbiased fashion. Furthermore, MEM accurately 
quantified and revealed the most critical characteristics of the stratifying cell subsets. By using clinical 
significance as the defining feature of cell subsets, the clinically stratifying glioblastoma cells were revealed. This 
demonstrates that cancer cell subsets can, and probably should, be defined beyond the expression of proteins 
or other cellular features. Critically, signaling profiles of cancer cells should strongly be considered part of the 
routine clinical quantification since they were consistently associated with clinical outcome across many types of 
human malignancies. Here, signaling profiles showed very promising implications for clinical diagnostics, as well 
as for the development of stratification approaches that also suggest immediately testable therapeutic targets. 
Moving forward, assessments for GNP and GPP cells should also be evaluated as part of future clinical trials to 
evaluate the randomization of different therapeutic arms.  
 
Novel surgical approaches to assist surgery in real-time  
 The highly infiltrative nature of glioblastomas is a major hurdle for surgical treatments which aim to 
physically remove the bulk of the tumor. Grossly, it is extremely challenging to distinguish the tumor from the 
surrounding brain that is often infiltrated by cancer cells. This almost always lead to an incomplete resection that 
can only be identified microscopically, despite the lack of signal enhancement per post-operative radiological 
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evaluations. Many advanced surgical approaches have been tested to maximize the extent of safe surgical 
resection of glioblastomas to maximally remove cancer cells, while preserving critical brain functions. Gamma 
knife has been shown to successfully identify the infiltrative “margins” of IDH-mutant tumors (119). This approach 
is based upon real-time mass spectrometry analysis of vaporized surgical waste to identify 2-HG, a cancer-
specific biomarker in IDH-mutant tumors. However, its benefit so far had been limited to 5-10% of adult 
glioblastoma patients whose tumors can produce 2-HG. 
 The discovery of proteomic features of GNP cells described in this dissertation has the potential to 
broaden the clinical applicability of Gamma knife to benefit patients with IDH-wildtype glioblastomas. The key 
proteomics defining characteristics of GNP cells can be readily tested for mass spectrometry analysis, which will 
aid the surgical removal of grossly undisguisable, clinically unfavorable, glioblastoma cells. The next step is to 
determine if maximal removal of GNP features would improve patient outcome, which might be dependent upon 
whether these cells are responsible for tumor recurrence and/or patient death (see below under single-cell 
characterization of recurrent glioblastomas).  
 
A practical approach towards individualized disease monitoring 
 The overarching goal of the work in this dissertation is to create a diagnostic platform towards 
individualized clinical care for glioblastoma patients. It is possible that, in the near future, disease monitoring and 
therapeutic regimens would be tailored based on the unique profiles of single cells that comprise individual 
glioblastomas. High-dimensional quantitative feature discovery based on studies of specific patient cohorts can 
suggest “disease-specific” features to be initially evaluated. For example, the high-dimensional characterization 
of GNP and GPP cells in Chapter 6 suggests that there are key molecules (i.e. p-STAT5, p-STAT1, p-NFĸB, 
S100B, SOX2, EGFR, CD44, and cyclin B1) that should be quantified for the clinical stratification of adult 
glioblastoma patients. Importantly, the clinically distinct GNP and GPP cells were composed of different cell 
subsets that have very similar, but not identical, signaling and protein characteristics. For example, p-STAT3 
and p-S6 were enriched in 3 of the 4 cell subsets that constitute the GNP population, while p-NFĸB is enriched 
in only 2 of the 4 subsets that make up the GPP population. The components of GNP and GPP populations also 
can differ slightly between tumors. Yet, all of these subsets significantly dictate distinct clinical outcomes. Thus, 
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the assessments of the subset-defining features may need to be tailored in a patient-specific manner to enable 
effective disease monitoring over the course of therapy.  
 
Targeting the signaling regulators that drive poor outcome 
 A key consideration towards using signaling profiles as surrogates for individualized therapy is whether 
they could be used as targets for therapy. For over a decade, signaling profiles have been successfully shown 
to stratify outcome in many types of hematologic malignancies (12-15, 80). However, profiles of downstream 
signaling effectors have not been used to create unique therapeutic approaches for individual patients. 
 One of the critical missing links between the discovery of the stratifying signaling characteristics and 
successful clinical implementation is the confirmation that the signaling profiles of unfavorable cancer cells are 
also present in vivo, which would validate that the signaling states are viable therapeutic targets. Imaging 
technologies might not be able to quantify features of millions of cells like flow cytometry. However, they can 
partially address this concern. Especially with the invention of techniques such as imaging mass cytometry (IMC) 
(279) and multiplexed ion beam imaging (MIBI) (280), the per-cell dimensionality that can be obtained and 
quantified from imaging approaches has significantly increased from conventional immunohistochemistry (IHC) 
and immunofluorescence (IF) analyses. These approaches can assist with the identification of unfavorable 
cancer cells, defined by unique high-dimensional intracellular signaling activity, in intact (i.e. undissociated) 
patient samples. Alternatively, a simplified low-dimensional imaging workflow, using IHC or IF stains, can be 
immediately derived and tested using the critical cellular features discovered by mass cytometry. This would 
generate a clinically applicable platform that utilizes samples that are readily available in clinical laboratories.  
   Single-cell high-throughput drug screening can aid the identification of compounds, or combinations of 
compounds, that can effectively eliminate the unfavorably signaling states or the cells that harbor such states 
(344, 345). Specifically, cell barcoding technologies (either fluorescence (Appendix B and D, (344, 345)) or metal 
(346)) are promising approaches for rapid identification of individualized treatment regimens. These techniques 
enable simultaneous and accurate comparison of hundreds of therapeutic conditions. Patient samples that 
contain diverse populations of cancer cells can be treated with different therapeutic compounds ex vivo to track 
the loss of the unfavorable cancer cells, or the loss of specific adverse signaling events. Importantly, single-cell 
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approaches can determine the specificity of treatments on cancer cells compared to other stromal cells in the 
tumor microenvironment (347). Additionally, the unfavorable cancer cells can be physically isolated from the 
sample (i.e. by cell sorting, based on their unique phenotype) to be treated with compounds ex vivo; the cell 
subset-specific changes in phenotype and signaling states can then be tracked overtime. These approaches 
distinguish between the change in the intrinsic cellular features (such as signaling network re-wiring) from the 
loss or death of cell subsets. Eventually, the drug combinations that show the most promising results can be 
further evaluated in in vivo models, as well as in clinical trials. 
 Traditionally, clinical trials are designed to test two or more arms of treatments on specific patient 
populations. The extensive inter-tumor diversity, however, must be taken into consideration for the selection of 
therapeutic compounds for the development of clinical trials in this new era. The idea of “N-of-1” trials and 
experimentations have been introduced based on the notion that no two tumors are alike and, therefore, an 
exploratory approach for drug selection should be adopted (348). This is because different drugs or combinations 
of drugs might be needed to achieve a similar end goal in different patients, due to the differential sensitivity of 
cancer cells to treatments. Critically, specific desirable outcomes, such as a decrease in a signaling state, need 
to be clearly defined. Using the unfavorable signaling state in GNP cells as an example, the end goal for the N-
of-1 compound evaluation could be a decrease in glioblastoma cell STAT5 phosphorylation level. Notably, the 
N-of-1 screening process could include not only drugs that are known to directly target STAT5 or its immediate 
upstream molecule, such as JAK, but also other novel compounds to initially identify drugs that exhibit STAT5 
inhibitory effect regardless of their specific mechanisms (i.e. using STAT5 phosphorylation as a surrogate for 
drug efficacy as oppose to only targeting STAT5). 
While eventually the promising therapeutic compounds must be tested in patients, the initial step is to 
evaluate the efficacy and specificity of the drugs in an ex vivo setting. At least in the field of glioblastoma, 
neurosphere culture assay is commonly used as a mean to maintain viable cancer cells ex vivo for functional 
characterization or for therapy evaluation (Figure 7-1A) (30, 45, 349). Brain- or glioblastoma-derived cells are 
maintained as 3-dimensional spheres in a non-adherent serum-free culture condition that is supplemented with 
specific growth factors (EGF and basic FGF (bFGF)) (349, 350). However, neurosphere culture selects for 
specific cell populations and cannot maintain the cellular diversity seen in vivo (Figure 7-1B). Particularly, the 
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standard neurosphere culture enriches for stem-like cells while depleting immune cells and cells with mature 
neural phenotype (Figure 7-1B). Ideally, the platform for N-of-1 compound screening (either the cell culture 
conditions or animal models) should mimic the tumor microenvironment to enable accurate prediction of the drug 
efficacy in vivo in order to make this individualized screening approach applicable in clinical settings. 
 
 
Figure 7-1 Neurosphere culture sustains the viability of some cell types derived from adult glioblastoma but does 
not maintain cellular diversity. (A) Cells from a freshly dissociated glioblastoma were subjected to a standard neurosphere 
culture protocol (serum-free, with EGF and bFGF supplement) (350). Representative images of the cells and formed 
neurospheres from days 0, 4, 8, 15, 22, 25, and 29 are shown. Images were taken at 40X (scale bars = 100 μm). (B) Cells 
from days 0, 1, and 2 (rows) were collected and stained with a panel of fluorescently tagged antibodies (columns, showing 
5 proteins quantified) and analyzed with a fluorescence flow cytometer. SPADE analysis (282) was performed on live, intact 
cells. Each node represents a cell subset with similar protein expression. Heat represents the degree of expression of the 
indicated surface proteins. Filled arrow heads illustrate CD45+ immune cells. Arrows illustrate CD45-NCAM+ neural-like 
cells. And open arrow heads illustrate CD45-CD133+ stem-like cells. Acronyms: EGF, epidermal growth factor; bFGF = 
basic fibroblast growth factor; NCAM, neural cell adhesion molecule. 
 
137 
  
Elucidating the cancer cell signaling mechanisms with signaling potentiation 
Co-activation of surface receptors and their convergence via downstream molecules suggested that 
quantification of post-translational modifications of signaling effectors better recapitulates the signaling activity 
than the assessment of the presence of receptors alone (142). However, the “static” signaling characteristics of 
clinically distinct glioblastoma cells described in Chapter 6 of this dissertation only reflect the baseline activity of 
the cells. Further experimentations are needed to elucidate their actual signaling mechanisms, specifically to 
understand their potential adaptive mechanisms under different environmental stimulations. Previous work in 
healthy blood and hematologic malignancies revealed that signaling potentiation of cells ex vivo further 
elaborated the understanding of the disease by two folds. First, combination of baseline and potentiated signaling 
better correlated with significant clinical features, including responses to chemotherapy as well as clinically-
relevant cytogenetics, compared to basal signaling alone (80). Second, tracking of signaling responses overtime 
revealed mechanistic interactions between different cell types that would have been overlooked by static analysis 
(83). It would be especially valuable to map the glioblastoma cell subset-specific signaling network, especially of 
the GNP cells, by dissecting the “potential” signaling routes and how they communicate with other cells in the 
tumor microenvironment under specific circumstances.  
Signaling potentiation of human glioblastoma cell lines illustrated how signaling kinetics of different cell 
types can be elucidated using a high-throughput flow cytometry assay (Figure 7-2). Mass cytometry was used 
to profile the expression of several identity proteins, which revealed distinct phenotypes between four different 
human glioblastoma cell lines (Figures 7-2A and S7-1). MET and PDGFRα expressions were shown as 
examples (Figure 7-2B). Notably, LN-229 and LN-18 cells both showed expression of MET on the cell surface 
(the antibody used in the assay is specific to the extracellular domain of MET). When both cell lines were 
stimulated with HGF, the sole ligand of MET, LN-229 showed a much higher level of AKT phosphorylation 
compared to basal, unstimulated state (Figure 7-2C). Here, the level of phosphorylation of a signaling effector, 
under a specific potentiation condition, is defined as a signaling node state. When coupled with fluorescence cell 
barcoding to enhance the analysis throughput (see Appendix B), a total of 1,845 signaling node states could be 
simultaneously compared across four different glioblastoma cell lines (Figure 7-2D).  
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Figure 7-2 Ex vivo potentiation revealed diverse signaling responses between human glioblastoma cell lines. (A) 
viSNE analysis of four human glioblastoma cell lines (blue, LN-229; orange, T98G; green, LN-18; red, U118). The 
expression of identity proteins used to generate the viSNE map is depicted in Figure S7-1. (B) Here, per-cell expression of 
MET and PDGFRα is shown. (C) Histogram analysis of p-AKT and p-STAT1 (x-axes) of LN-229 (2 left columns) and LN-18 
(2 right columns) under different stimulation conditions. Color of histograms reflect the median values of transformed ratio 
compared to their corresponding unstimulated condition (unstim, first rows). (D) Heatmap illustrating 465 signaling node 
states of LN-229, LN-18, and U118 cells, and 450 signaling node states of T98G cells. Color reflects the median values of 
transformed ratio compared to the unstimulated state. Note: TNFα stimulation data was not available for T98G cells. 
 
The kinetics of signaling secondary to external potentiation can be similarly dissected in different cancer 
cell subsets in patient samples. Signaling potentiation can also be coupled with signaling inhibition or drug 
treatment to map how the signal re-wires if a certain point in the network is impeded. This is especially valuable 
for identifying potential drug resistance mechanisms. The selection of growth factors and ligands for signal 
potentiation should also be based on those that are known, or are hypothesized, to be present in the tumor 
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microenvironment of human glioblastomas. This should include factors in the cerebrospinal fluid (CSF) and the 
neural stem cell niche. These experimentations may reveal how a given cancer cell subset might differentially 
behave if it were present in a different anatomic location within the brain. 
 
Dissecting the mechanism of glioblastoma recurrence with single-cell biology 
 The identification of GNP and GPP cells described in Chapter 6 is the first time single-cell analysis has 
been successfully used to stratify clinical outcomes of adults with IDH-wildtype glioblastoma. This discovery has 
significant roles for clinical implementation as disease stratification and for selection of novel therapeutic 
compounds. Evidence for the significance of the signaling states of GNP cells as targets for therapy is the 
demonstration that GNP cells are present in recurrent tumors, especially at higher abundance. This would 
indicate that GNP cells could be the mechanism underlying therapy resistance. Most of the studies in adult 
glioblastomas, including previous single-cell genomic and transcriptomic studies as well as the work presented 
in this dissertation, were conducted in primary tumors that were collected prior to therapy (5, 73). Given what 
little is known about the cellular diversity of glioblastomas at recurrence, single-cell analysis of cell subsets and 
their signaling profiles of paired primary-recurrent tumors is now needed.  
 Since the analysis of millions of single cells using flow cytometry-based approaches gives a better 
representation of the cellular diversity within the tumor, a method to collect patient samples that would enable 
subsequent derivation of viable single cells is key. As demonstrated throughout this dissertation, primary tumors 
can be easily collected intra-operatively for single-cell preparation (Chapters 5 and 6). This is not always 
available in the case of recurrent glioblastomas where tumor resection is not routinely performed, due to the 
extent of the tumors and the patients’ quality of life. A large resource of recurrent glioblastomas could potentially 
be collected after death, during autopsy. However, since the tissues and cells can rapidly deteriorate, a rapid 
autopsy protocol could be especially valuable for studies that would largely benefit from high-quality viable cells 
(351). Rapid autopsy is generally performed within 1-3 hours of after death to minimize post-mortem demise and 
enables collection of large quantity of samples from different sites for systematic comparison of their cellular 
constituents (351). This process has shown significant benefits in many studies and could be readily adopted for 
studying the signaling profiles of individual cancer cells in recurrent glioblastomas. 
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Cancer-immune interaction 
 The relationship between the abundance of the novel glioblastoma stratifying cell subsets and the brain 
resident microglia that were phenotypically activated suggested a mechanistic relationship between the two cell 
components. The abundant GNP cells in the clinically unfavorably tumors were actively proliferating, which could 
inevitably prevent the infiltration of immune cells within the tumor microenvironment, although it is unlikely the 
only explanation without mechanistic evidence of immune cell suppression. Alternatively, GNP cells could 
potentially be less immunogenic than GPP cells, leading to overall inactive and scarce immune cells within the 
tumor microenvironment. Animal models can be used to compare the immunogenicity between GNP and GPP 
cells (352-354). Subsequently, certain immunogenic chemotherapies can be tested to determine if the 
immunogenicity of GNP cells can be enhanced to elicit a proper anti-tumor immune response (355). 
Additionally, the presence of activated microglia may directly alter the signaling activity in GPP cells 
and/or induce an anti-tumor signaling phenotype. It has been previously demonstrated that different resident 
brain cells, including microglia, can secrete microvesicles that contain factors and cytokines, enabling them to 
interact with neighboring cells (356). IL-1β, a known activator of the canonical NFκB signaling pathway (Figure 
7-2D), is one of the many factors that can be secreted by microglia (357, 358). Notably, enrichment of p-NFκB 
is one of the defining features of some GPP cells described in Chapter 6. Whether or not activated microglia can 
directly suppress the unfavorable signaling effector STAT5 needs to be evaluated. Overall, these observations 
suggest that there could be an ongoing, variable, immune surveillance and activation in adult glioblastomas. 
Further dissection of the mechanisms can provide alternative therapeutic avenues in addition to directly targeting 
the cancer cells. 
 
Conclusion 
 A thorough characterization of signaling alterations in individual cancer cells is key to tackle the fatality 
of adult glioblastomas. This dissertation provides a novel modular workflow that dissects the diversity of the 
critical hallmarks of glioblastoma pathogenesis. This was accomplished by 1) the development of a protocol for 
the derivation of viable single cells from glioblastoma patient samples, 2) the use of a system-tailored single-cell 
mass cytometry analysis of proteins and signaling alterations, and 3) the coupling of a patient outcome 
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assessment with cell subset characterization for the discovery of clinically distinct glioblastoma cells. Overall, 
this workflow has the potential to become a prototype towards the individualization of glioblastoma patient care 
(Figure 7-3). 
 
Figure 7-3 Towards individualized disease monitoring and clinical care in adult glioblastomas. In addition to the 
standard pathological diagnosis (green), single-cell isolation (orange) and quantification of protein identity and signaling 
profiles in individual glioblastoma cells (pink) has the potential to be part of the standard clinical care. The rapid turn-around 
time of standard flow cytometry and the quantitative clinical prediction of GNP and GPP cells enable immediate disease 
stratification. High-dimensional single-cell mass cytometry can be standardized for additional in-depth feature quantification, 
which can benefit subsequent selection of therapeutic compounds to be tested by high-throughput drug screening 
approaches. With a drug screening platform that accurately predicts responsiveness in vivo, this immediately leads to a 
development of an individualized treatment strategy. In cases of tumor progression (purple), the same analytical pipeline 
can be repeated to identify a new optimal therapeutic approach. 
 
The discovery of clinically distinct glioblastoma cells, their protein and signaling phenotypes, as well as 
their correlation with the tumor microenvironment, suggests numerous diagnostic and therapeutic avenues that 
should be promptly investigated. The single-cell stratification scheme can be immediately tested for clinical utility 
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since the abundance of both GNP and GPP cells can significantly predict patient outcome and tumor progression 
with a large effect size, independent of other known clinical predictors. Importantly, a lower-dimensional 
diagnostic approach that mimics the standard analytical workflow of hematologic specimens can easily be 
adopted for clinical use. Critically, signaling activity that is definitional of the GNP cells should be tested as novel 
therapeutic targets, or as surrogates for drug activity. Moreover, the single-cell signaling platform described here 
can serve as the foundation for dissecting potential drug resistance mechanisms, such as signaling network 
rewiring, as novel compounds are being investigated. Additionally, the mechanisms underlying the cancer-
immune interaction should also be comprehensively explored as an alternative approach to targeting 
glioblastoma via modifications of the tumor microenvironment. Technical approaches that are valuable for high-
throughput drug discovery are also described in the Appendices of this dissertation. 
 A critical limitation of single-cell mass cytometry is the lack of intra-tumor spatial information. Quantitative 
imaging to dissect the regional preference of the prognostic glioblastoma cells can further reveal the mechanisms 
responsible for therapy resistance, such as contact with the ventricular subventricular zone or the perivascular 
niche. Additionally, identification of physical contact between GPP cells and microglia may further advocate that 
the anti-tumor signaling profile of GPP cells is a response to immune cell activation. Moreover, it would be 
valuable to determine if GNP and GPP cells often co-localize within the same region of the tumor or if they exist 
in distinct regions, which could indicate the presence of specialized tumor microenvironment that may be primed 
by different cancer cell types. Regardless, single-cell snapshot proteomics described in this dissertation presents 
an immediate approach for clinical stratification that simultaneously identify future therapeutic targets. 
 As high-throughput single-cell feature quantification becomes a routine in research and clinical settings, 
experimental and analytical automation are mandatory. This is to maximize the efficiency and accuracy of the 
system and to eliminate bias. The discovery of GNP and GPP cells relied on a systematic and automated feature 
discovery pipeline which was tailored to fit a specific system, to address a specific question. Importantly, this 
workflow can be a valuable addition to the characterization and clinical stratification of other types of solid 
malignancies. Signaling features and the clinical significance of cancer cells should now be included as cell 
subset defining features, incorporated as part of routine disease stratification, and used as evidence for the 
selection of individualized therapeutic regimens.  
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Supplement data 
 
Figure S7-1 Protein expression in human glioblastoma cell lines. (A) Single-cell mass cytometry data of four human 
glioblastoma cell lines were subjected to a viSNE analysis (LN-299, blue; T98G, orange; LN-18, green; U118, red). (B) 
Twenty-two surface and intracellular identify proteins that were quantified and were used to generate the viSNE map are 
shown. 
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Preface 
 One of the major challenges in understanding the complex relationship of cells in solid tissues and tumors 
is the lack of a standard protocol that enables quantification of multiple cellular features of numerous single cells 
that are representative of the original tissues. As described in previous chapters, mass cytometry is an appealing 
platform for characterizing single cells in solid tumors. However, viable single-cell suspension is required for this 
approach. This chapter describes a step-by-step protocol for solid tissue and tumor dissociation to derive single 
cells for mass cytometry analysis. Its development and optimization are described in detail in Chapter 5. 
Description of high-dimensional data analysis algorithm and display of data are presented here. Moreover, a 
practical approach for troubleshooting when implementing the protocol in a new tissue type is discussed.  
 
Abstract 
 Mass cytometry is a single-cell biology technique that samples > 500 cells per second, measures > 35 
features per cell, and is sensitive across a dynamic range of > 104 relative intensity units per feature. This 
combination of technical assets has powered a series of recent cytomic studies where investigators used mass 
cytometry to measure protein and phospho-protein expression in millions of cells, characterize rare cell types in 
healthy and diseased tissues, and reveal novel, unexpected cells. However, these advances largely occurred in 
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studies of blood, lymphoid tissues, and bone marrow, since the cells in these tissues are readily obtained in 
single-cell suspensions. This unit establishes a primer for single-cell analysis of solid tumors and tissues, and 
has been tested with mass cytometry. The cells obtained from these protocols can be fixed for study, 
cryopreserved for long-term storage, or perturbed ex vivo to dissect responses to stimuli and inhibitors. 
 
Introduction 
One key method for understanding a tissue or organ is to dissect and identify the diverse cells that 
comprise it. Flow cytometry excels at quantifying the abundance and protein expression signatures of hundreds 
to thousands of cells per second (359) and holds great promise for understanding diseases like cancer, where 
altered protein expression and signaling activity in rare cell subsets can contribute to oncogenesis and drive 
treatment resistance (10, 11). The ability of flow cytometry to quantify proteins on each of millions of cells and 
reveal signaling in rare, 1-in-10,000, cells has made it indispensable to modern immunology and clinical 
hematopathology, where cells in suspension are readily obtained. Mass cytometry is a newly developed form of 
flow cytometry with the ability to measure 35 or more features at a rate of 500 or more cells per second (83, 296, 
359-361). This expanded detection capacity is ideal for characterizing the diverse cells present in human tumors, 
which typically include endothelial cells, epithelial cells, fibroblasts, immune cells, and malignant cells (284). 
Flow cytometry provides outstanding statistical power to detect rare cells and to quantify the cellular 
identity of millions of cells, compared to other techniques that are limited to hundreds or thousands of cells (11, 
359, 360). Our group and others have implemented this technology in studies of donor and patient cells that are 
obtained as a suspension, such as blood and bone marrow (81, 83, 282, 315, 362-365) or that can be 
disaggregated from lymphoid structures by mechanical force alone (13, 15, 82, 303, 366). Clinical diagnoses of 
blood malignancies use fluorescence flow cytometry characterization of cell surface marker expression, as well 
as cell subset quantification (19, 367-369). Additionally, flow cytometry has been used clinically to identify 
minimal residual disease and to detect disease progression in leukemia (290, 370, 371). Fluorescence flow 
cytometry has also been applied to studies of solid tissues and tumors for research purposes (45, 305-309). 
In addition to their ability to characterize cell surface markers, flow cytometry technologies allow 
simultaneous detection and quantification of intracellular targets in individual cells (10, 80, 84). Commercially 
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available fluorescence flow cytometers generally measure 8 to 12 targets per cell using target-specific antibodies 
conjugated to individual fluorophores (283). The number of targets is limited due to the overlap of emission 
spectra of different fluorophores. Mass cytometry is a newer flow cytometry–based technology that allows 
detection of more than 35 targets in individual cells. Instead of conjugation to fluorescent dyes, mass cytometry 
antibodies are conjugated to isotopically pure heavy metals. Specifically, fundamental elements of mass 
cytometry include 1) the staining of individual cells with isotope-tagged antibodies to detect specific cellular 
targets; and 2) quantification of the isotopic signal via time-of flight, as in other forms of mass spectrometry, 
which indicates specific antibody binding (50, 83, 302). Therefore, the abundance of a specific metal isotope in 
each cell corresponds to the abundance of a specific cellular target detected by the antibody. The use of metal 
isotopes and time-of-flight quantification in mass cytometry results in relatively little spectral overlap between the 
channels distinguished by isotopes (315, 372, 373). Additionally, multiple cellular targets of interest can be 
measured simultaneously, and the numbers are greater than those routinely measured in current fluorescence-
based cytometry (50, 359-361). Mass cytometry has the potential to track evolving cell subsets and to measure 
features typically associated with one cell type (e.g., mature immune cell or stem cell associated proteins) on all 
the cells in a sample (294, 296, 374). This type of single-cell systems biology has the potential to reveal 
unexpected, clinically relevant cell types and measure a wealth of features on cells without the need to return to 
a sample for repeat measurements (374) (12, 360, 375, 376).  
Mass cytometry–based characterization of human bone marrow (83), blood (299), and tonsil (82) cell 
subsets has been accomplished in prior studies and described in protocols (81). However, mass cytometry has 
just recently been developed and applied in solid tissues and organs (321). One of the major limitations for flow 
cytometry is the need to generate a suspension of viable single cells derived from the tissue of interest. Although 
fluorescence flow cytometry has been used to study some solid tissues and cancers, the protocols used to derive 
viable single cells, even from the same organs, can vary significantly between studies (377-379). Basic Protocol 
1 below has been optimized to yield viable cells and to preserve known cell subsets from a variety of human 
tissues, including lymph nodes, gliomas, melanomas, and small cell lung cancer (SCLC) patient-derived 
xenografts (PDXs) (284). It is thus suitable for preparing single cells for fluorescence cytometry, mass cytometry, 
and other applications requiring isolated single cells. We also provide a protocol detailing cellular immunostaining 
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for detection of cell-surface and intracellular epitopes in mass cytometry analysis of cells from human tonsils, 
gliomas, and melanomas (Basic Protocol 2), and a section in the Commentary describing computational analysis 
of multi-dimensional data obtained from mass cytometry based on established approaches (282, 290, 314). 
 
Caution: When working with human cells, appropriate biosafety practices must be followed. 
Note: All solutions and equipment coming into contact with living cells must be sterile, and aseptic technique 
should be used accordingly. 
 
Basic protocol 1: Preparation of viable single cells from human tissue and tumors 
This protocol describes preparation of single-cell suspensions from human tissues. It has been 
experimentally tested to preserve cell subsets detected using imaging platforms and maximize cell viability for 
cells from human tonsils, glioma tumors, melanoma tumors, and small cell lung cancer (SCLC) patient-derived 
xenografts (PDX) (284). Human tonsils, glioma tumors, and melanoma tumors were resected from patients and 
transported directly to the laboratory (within 1 hr after collection for human gliomas and melanomas, and within 
4 hr after collection for human tonsils). SCLC PDXs were flank xenografts in immunocompromised mice, 
generated from patient specimens. When grown as flank tumors, these xenografts form a solid tissue about 1 to 
2 cm in diameter. SCLC PDXs were transported to lab within 1 hr after collection. We expect that this protocol 
will work in other human tissue and cancer types, as well as solid tissues from other species. However, it is 
important to note that 1) choice of enzymes, and 2) total dissociation time need to be optimized before routine 
use of the protocol in tissues not indicated here. 
 
Materials 
1. Tissue sample 
2. Phosphate-buffered saline (PBS; Corning/Mediatech, cat. no. 21040CV,), room temperature 
3. Experimental media: 
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a. For glioma: DMEM/F12 + GlutaMax (Gibco/Life Technologies, cat. no. 10565018) with a defined 
hormone and salt mix (Reynolds, Tetzlaff, & Weiss, 1992) and 50 µg/ml gentamicin sulfate 
(Corning/Mediatech, cat. no. 30-005-CR) 
b. For melanoma: MEM (Corning/Mediatech, cat. no. 10010CV) with 10% FBS (Thermo Fisher 
Scientific, cat. no. 26140079) and 100 U/ml penicillin/100 µg/ml streptomycin (add from 100X 
penicillin-streptomycin solution, GE Healthcare, cat. no. SV30010) 
c. For tonsils: RPMI 1640 (Corning/Mediatech, cat. no. 10040CV) with 10% FBS (Thermo Fisher 
Scientific, cat. no. 26140079) and 100 U/ml penicillin/100 µg/ml streptomycin (add from 100X 
penicillin-streptomycin solution, GE Healthcare, cat. no. SV30010) 
4. 20X collagenase II: dilute collagenase from Clostridium histolyticum (Sigma, cat. no. C6885) to 2500 
CDU/ml (20 mg/ml) in PBS (store at –80C) 
5. 100X DNase I: dilute DNase I from bovine pancreas (Sigma-Aldrich, cat. no. DN25) to 10,000 Kunitz 
Units/ml in PBS (store at –80ºC) 
6. ACK lysing buffer (Lonza, cat. no. 10-548E) 
7. Trypan blue (Hyclone, cat. no. SV30084.01, prepared as recommended by manufacturer) 
8. DMSO (Catalog no. BP231-1, Fisher Scientific, MA) 
9. 15-ml (Corning Falcon, cat. no. 430055) and 50-ml (Corning Falcon, cat. no. 430829) conical tubes  
10. Benchtop centrifuge with swing-out rotor (Sorvall model ST 16; Thermo Scientific) 
11. 60-mm petri dish (Fisher Scientific, cat. no. FB0875713) 
12. P1000 plastic pipet tips with narrow end cut to make a wide opening (diameter 2 to 3 mm) 
13. Scalpels with blade no.10 (Fisher Scientific, cat. no. 12-460-451) 
14. Incubator set at 37°C, 5% CO2 
15. Nutating platform placed inside incubator, set to 18 rpm (Fisher Scientific, cat. no. 05-450-213) 
16. 70-µm (Corning Falcon, cat. no. 431751) and 40-µm (Corning Falcon, cat. no. 431750) cell strainers 
sized to fit 50-ml conical tubes 
17. Inverted phase contrast microscope for cell culture (use 10X objective magnification for quantifying cell 
viability) 
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18. 1.8-ml cryogenic tubes with cap (Thermo Fisher Scientific, cat. no. 377267) 
19. Additional reagents and equipment for counting viable cells by trypan blue exclusion  
 
 
Figure A-1 Step-by-step illustration of tissue dissociation protocol. Surgically resected patient samples were 
transported in PBS, normal saline, or experimental medium at room temperature. Mechanical dissociation was followed by 
1-hr enzymatic dissociation using collagenase II and DNase I (see text). ACK lysis was used to eliminate red blood cell 
contamination, prior to cell counting and cryopreservation or experiment. 
 
Perform mechanical dissociation 
This protocol is for preparation of single cells from human tissues from surgical resections. Samples should 
be placed in appropriate experimental medium (see below), phosphate-buffered saline (PBS), or normal saline 
(0.9% NaCl), immediately after surgical resection. The volume of medium or normal saline should be enough to 
immerse the entire sample (Figure A-1). Ideally, samples should be transported directly to lab for preparation at 
room temperature (23°C). 
1. Transfer pieces of human tissue from surgery to a cell preparation laboratory while keeping the sample 
submerged in room temperature PBS (see Time Considerations). 
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2. Once in lab, transfer tissue pieces and PBS to one or more 50-ml conical tubes using cut P1000 tips, 
ensure tubes are well balanced, and centrifuge 5 min at 100 x g, room temperature, to pellet cells and 
tissue pieces. 
3. Carefully discard supernatant by pipetting and resuspend tissue in 5 ml or more of warm (37°C) 
experimental medium, as needed to cover tissue.  
a. For larger pieces of tissue (larger than 1 cm3), use multiple rounds of mincing as in steps 4 and 
5.  
b. Dead cells will not pellet effectively at 100 x g and will be present in the supernatant with other, 
non-cellular tissue components and secreted factors.  
c. Experimental medium may vary by cell type, as different cell types may have distinct nutrient and 
supplement requirements. For this protocol, media were selected based on established cell 
culture protocols for each cell type. Furthermore, if additional assays, such as a signaling 
response assay using phospho-specific flow cytometry (278, 380), are to be performed, it is 
important to test different types of medium for those specific assays. For example, to preserve 
lymphocyte signaling capability for subsequent detection by phospho-specific flow cytometry, 
medium containing FBS is superior to serum-free medium (15, 82, 303). Conversely, multiple 
growth factor supplements are added to the neurosphere culture medium to ensure growth of 
human glioma cells (381, 382). 
4. Transfer tissue and experimental medium into a 60-mm petri dish using cut P1000 tips. 
5. Mince tissue in experimental medium with scalpel to obtain 1 to 3 mm3 pieces. 
6. Transfer minced tissue and cells in experimental medium into 15- or 50-ml conical tubes, as dictated by 
the total volume of the cell and medium suspension, using cut P1000 tips. 
7. Centrifuge tissue and cells in experimental medium 5 min at 100 x g, room temperature. 
8. Discard supernatant by pipetting and add 4.7 ml of warm experimental medium. 
a. This volume of experimental medium leaves room for 300 µl of enzyme solutions in the next step, 
and is recommended for tissue that was originally 1 cm3 in size. For larger pieces of tissue, the 
volumes in steps 8 and 9 should be increased proportionately to match tissue size. For example, 
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9.4 ml of warm experimental medium would be used in step 8 for tissue that was originally 2 cm3 
in size. 
 
Perform enzymatic dissociation 
9. Add 250 µl of 20X collagenase II and 50 µl of 100X DNase I, and mix with serological pipet. 
a. The final concentrations of collagenase II and DNase I should be 1 mg/ml and 100 Kunitz Units/ml, 
respectively. 
b. Collagenases II, IV, V, and XI displayed equivalent activity on tumor and tissue types tested (284). 
10. Incubate the tube on a nutating platform (18 rpm) in an incubator (37°C, 5% CO2) for 60 min.  
11. Remove tubes from the incubator and carefully triturate the cell suspension by pipetting up and down 25 
to 50 times using a 10-ml plastic serological pipet. When complete, the cell suspension should look 
homogeneous and have no visible tissue pieces. 
12. Strain with a 70-µm cell strainer into a new 50-ml conical tube. 
13. Strain flow-through from step 12 with a 40-µm cell strainer into a new 50-ml conical tube. 
14. Wash by passing 10 ml of warm (37°C) experimental medium through the 40-µm strainer into the same 
tube. 
15. Centrifuge the collected strained cell suspension 10 min at 100 x g, room temperature, and discard 
supernatant by pipetting. 
Remove RBC and quantify viable cells 
1. If pellet contains red blood cells or platelets, add 5 ml or more of ACK lysis buffer according to the 
manufacturer’s protocols, mix with a serological pipet, and leave at room temperature for 60 sec to allow 
for hypotonic lysis.  
2. Add 5 ml or more of warm experimental medium (the same volume used in step 16 for ACK lysis buffer, 
for a final 1:1 ratio), centrifuge 10 min at 100 x g, room temperature, and discard supernatant. 
3. Resuspend cells in warm experimental medium and count viable cells using trypan blue exclusion (Figure 
A-2). 
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a. Cells are now ready to be prepared for mass cytometry analysis. If mass cytometry analysis is to 
be performed on a different day, or if the cells need to be preserved for long-term storage, 
cryopreservation is required. This can be performed per a previously established protocol 
(Leelatian et al., 2015). In brief, pelleted cells should be resuspended in freezing medium 
(experimental medium with 10% DMSO) at a concentration of 10−15 x 106 cells/ml, aliquotted into 
cryopreservation tubes at 1 ml per tube, and frozen slowly at the rate of −1°C/min in a −80°C 
freezer before transfer into liquid nitrogen the following day. 
 
Figure A-2 Trypan blue stain for viable cell quantification. Trypan blue stain was used to quantify cell viability after 
mechanical and enzymatic dissociation. Representative images of dissociated human tissues including tonsil, glioma, and 
melanoma are shown. Red boxes show higher resolution of live (trypan blue–negative, white) and dead cells (trypan blue–
positive, black) of each tissue type. Note that some pigmented cell types, such as melanocytes or neurons of the substantia 
nigra, can be brown or red and therefore appear dark in monochrome phase-contrast images. These cells should be 
distinguished from dead cells in counting. Scale bars = 100 µm. 
 
Basic protocol 2: Preparation of cells for mass cytometry 
This section describes a protocol for immunostaining of single-cell suspensions derived from human 
tissues and tumors. Tonsils, glioma tumors, and melanoma tumors are used as examples. Using antibodies 
listed in Table A-1, this protocol allows characterization of immune cell subsets (CD45+) in tonsils, as well as 
infiltrating immune cells in glioma tumors and melanoma tumors. These antibodies allow characterization of 
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immune cells into distinct groups: myeloid lineage (CD11b, CD11c, CD14, CD16, CD64, CD68, HLA-DR), B cell 
and plasma cell lineage (CD19, CD38, CD27, IgM, IgD, HLA-DR), and T cell lineage (CD3, CD4, CD8, CD8a, 
CD45RA, CD45RO). Additionally, antibodies that were specifically selected for identifying non-immune cell 
subsets in glioma (CD31, TUJ1, S100B, PDGFRα, c-MET, SOX2, CD24, Nestin, CD44, GFAP, αSMA, and 
CD56) and melanoma (CD31, β-catenin, S100B, vimentin, CD49F, cytokeratin, SOX2, Nestin, CD44, αSMA, 
and CD56) tumors were included. The antibodies described here are isotope-tagged antibodies for mass 
cytometry analysis. This protocol was adapted from previously established fluorescence flow cytometry protocols 
(81, 84, 276, 383). 
All new antibodies should be titrated prior to use with appropriate positive control cells that express the 
target of interest and negative control cells that are known to not express the target of interest. The goal of an 
antibody titration is to determine the optimal concentration of an antibody that separates the true signal of the 
positive control cells from any background or nonspecific signal observed in the negative control cells. Antibody 
titration is required for every combination of antibody clone, tissue preparation technique, and antibody 
conjugation. This extensive validation is necessary because clones can perform differently under different 
antigen-exposure conditions, such as permeabilization of cells by detergent or alcohol, and protocols to 
conjugate fluorochrome or metal reporter tags to antibodies can change their binding properties. Examples of 
appropriate validation and titration have been published (278, 380, 383, 384). For each cellular target that the 
user aims to detect, it must first be determined if the target is exposed on the cell-surface (i.e., extracellular) or 
present within the cell (i.e., intracellular). Most extracellular targets are detected with live cell staining (see “Stain 
viable cells to detect extracellular targets” below). However, if the target of interest is an intracellular target, it is 
especially important to optimize the permeabilization technique and reagents (278). Examples of 
permeabilization reagents include saponin (Perm 1), methanol (Perm 2), ethanol, and Triton X-100, among many 
others. For the protocol described here, saponin permeabilization (Perm 1; for SOX2 antibody staining) is used 
prior to methanol permeabilization (Perm 2; for staining of the remaining intracellular targets) in human glioma 
and melanoma. 
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Materials 
1. Perm 1: room-temperature 0.02% (w/v) saponin (Calbiochem, cat. no. 558255) in PBS 
2. Perm 2: ice-cold 100% methanol (Fisher Scientific, cat. no. A412-4) kept at −20°C until immediately prior 
to adding to cells 
3. Dissociated single cells (Basic protocol 1)  
4. Experimental media:  
a. For glioma: DMEM/F12 plus GlutaMax (Gibco/Life Technologies, cat. no. 10565018) with a 
defined hormone and salt mix (311) and 50 µg/ml gentamicin sulfate (Corning/Mediatech, cat. no. 
30-005-CR) 
b. For melanoma: MEM (Corning/Mediatech, cat. no. 10010CV) with 10% FBS (Thermo Fisher 
Scientific, cat. no. 26140079) and 100 U/ml penicillin/100 µg/ml streptomycin (add from 100X 
penicillin-streptomycin stock solution, GE Healthcare, cat. no. SV30010) 
c. For tonsils: RPMI 1640 (Corning/Mediatech, cat. no. 10040CV) with 10% FBS (Thermo Fisher 
Scientific, cat. no. 26140079) and 100 U/ml penicillin/100 µg/ml streptomycin (add from 100X 
penicillin-streptomycin stock solution; GE Healthcare, cat. no. SV30010) 
5. Optional: 100X DNase I: dilute DNase I from bovine pancreas (Sigma-Aldrich, cat. no. DN25) to 10,000 
Kunitz Units/ml in PBS (store at –80ºC) 
6. Staining medium: 1% (w/v) bovine serum albumin (BSA; Fisher Scientific, cat. no. BP9703100) in PBS 
7. Live Stain reagent mix: A combined solution of all relevant antibodies (antibody list in Table A-1)  
8. Phosphate-buffered saline (PBS; Corning/Mediatech, cat. no. 21040CV)  
9. 16% paraformaldehyde (PFA; Electron Microscopy Sciences, cat. no. 15710)  
10. Saponin Stain reagent mix: A combined solution of all relevant antibodies (antibody list in Table A-1)  
11. Methanol Stain reagent mix: A combined solution of all relevant antibodies (antibody list in Table A-1)  
12. 1X Four Elements Calibration Beads (Fluidigm, cat. no. 201078) 
13. 15-ml conical tubes (Corning Falcon, cat. no. 430055) 
14. Benchtop centrifuge with swing-out rotor (Sorvall model ST 16; Thermo Scientific)  
15. 5-ml round-bottom FACS tubes without cap (Corning Falcon, cat. no. 352052)  
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Table A-1 Tissue-specific antibody panels 
Metal Antibody Clone 
Working 
Dilution 
Volume to use Sample type Staining condition 
conc 
(µg/mL) in 100 µL stain (µL) Ton Glio Mel Surf Sap MeOH 
141Pr HLA-ABC W3-32 Fluidigm 1:200 0.5       
142Nd cCasp3 D3E9 Fluidigm 1:200 0.5       
144Nd CD11b ICRF44 Fluidigm 1:200 0.5       
145Nd CD4 RPA-T4 Fluidigm 1:200 0.5 
      
CD31 WM59 Fluidigm 1:200 0.5       
146Nd 
IgD IA6-2 Fluidigm 1:200 0.5       
CD64 10.1 Fluidigm 1:200 0.5       
CD8a RPA-T8 Fluidigm 1:200 0.5       
147Sm β-catenin D10A8 Fluidigm 1:200 0.5       
148Nd CD16 3G8 Fluidigm 1:200 0.5       
149Sm CD45RO UCHL1 Fluidigm 1:200 0.5       
152Sm TUJ1 TUBB3 50 1:100 1       
153Eu CD45RA HI100 Fluidigm 1:200 0.5 
      
S100B 19-S100B 100 1:100 1       
154Gd CD45 HI30 Fluidigm 1:400 0.25       
155Gd CD27 L128 Fluidigm 1:100 1       
156Dy Vimentin RV202 Fluidigm 1:200 0.5       
159Tb CD11c Bu15 Fluidigm 1:200 0.5 
      
CD49F GoH3 100 1:100 1       
160Gd CD14 M5E2 Fluidigm 1:200 0.5       
161Dy 
CD19 HIB19 100 1:100 1       
PDGFRα 16A1 200 1:100 1       
Cytokeratin C-11 Fluidigm 1:200 0.5       
162Dy c-MET L6E7 100 1:100 1       
163Dy SOX2 O30-678 100 1:100 1       
166Er CD24 ML5 Fluidigm 1:200 0.5       
167Er CD38 HIT2 Fluidigm 1:200 0.5       
168Er 
CD8 SK1 Fluidigm 1:200 0.5       
Nestin 10C2 100 1:100 1       
169Tm CD44 BJ18 100 1:100 1       
170Er CD3 SP Fluidigm 1:200 0.5       
171Yb CD68 Y1/82A Fluidigm 1:200 0.5 
      
GFAP 1B4 25 1:100 1       
172Yb IgM MHM-88 Fluidigm 1:200 0.5       
173Yb αSMA Ab54723 50 1:100 1       
174Yb HLA-DR L243 Fluidigm 1:200 0.5       
175Lu CD56 HCD56 50 1:100 1       
176Yb Histone H3 D1H2 Fluidigm 1:200 0.5       
 
Conc = concentration; Ton = tonsil; Glio = glioma; Mel = melanoma; Surf = surface; Sap = saponin; MeOH = post-methanol 
Fluidigm = use antibodies provided by Fluidigm 
 
16. Rotor adapters with round buckets that accommodate 5 ml FACS tubes (Thermo Fisher Scientifc, cat. 
no. 75003680)  
17. 5-ml round-bottom FACS tubes with filter caps (Corning Falcon, cat. no. 352235) 
 
Prepare antibody 
1. Example reagent mixes for healthy human tonsil tissue, glioma tumors, and melanoma tumors are shown 
in Table A-1 and separated according to staining step. Prepare reagent mixes separately for each of 
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three example staining steps: live cell staining (Live), staining in 0.02% saponin (Saponin Stain), and 
staining after methanol treatment (Methanol Stain).  
a. Adaptation of this protocol for phospho-flow should detect cell surface proteins following fixation 
as described in “Live cell staining” even though the cells are no longer viable, as described by 
(81, 278, 380).  
b. This protocol does not use metal barcoding, but that technique can be useful in addressing 
potential batch effects from staining and collecting data at different times (312, 346). 
 
Stain viable cells to detect extracellular targets 
2. If preparing cells from cryopreservation, thaw cryovial in a 37ºC water bath for 1 to 2 min (until just 
completely thawed). If preparing cells that were freshly dissociated, skip to step 5. 
3. Transfer cells from cryopreservation tubes to a 15-ml conical tube. 
4. Resuspend cells in 10 ml of warm experimental medium. The goal is to dilute and remove DMSO as 
quickly as possible after thawing. Addition of DNase I may be helpful upon sample thawing to preserve 
viability. Use the same concentration of DNase as used during tissue dissociation (see Basic Protocol 1, 
step 9). Specifically, resuspend the cells in this step in 9.9 ml of warm experimental medium, add 100 µl 
of 100X DNase I to the cell suspension, and proceed to the next step. 
5. Pellet cell suspension 5 min at 100 x g, room temperature, and discard supernatant. 
6. Resuspend cells in 1 ml of staining medium and transfer cell suspension to a 5-ml FACS tube (without 
filter cap). 
7. Pellet cell suspension 5 min at 100 x g, room temperature, and discard supernatant by briskly decanting. 
a. For all centrifugation steps involving a cell pellet, invert and decant only once. After placing the 
tube upright again, cells typically enter suspension and the pellet can detach. Thus, additional 
decanting significantly lowers viable cell yield. 
8. Resuspend cell pellet in staining medium to achieve the transfer volume.  
a. The “transfer volume” is the volume transferred in step 9, below, and is calculated by subtracting 
the summed volume of staining antibodies (the “antibody volume”) from the total volume in which 
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staining will occur in step 10. For example, consider a protocol where approximately 10 µl of cells 
in staining medium from step 8 are to be stained with 1 µl each of 30 antibodies in a total volume 
of 100 µl in step 10. In this case, at step 8, at least 60 µl of staining medium should be added to 
the 10 µl of cells in staining medium to achieve a transfer volume of 70 µl for step 9. For steps 8 
to 10, the volume of antibodies varies and is specified in Table A-1 for tonsil, glioma, and 
melanoma. The total volume in step 10 is 100 µl (including cells in transfer volume and all 
antibodies).  
9. Transfer cell suspension in staining medium to a new FACS tube. 
10.  Add Live Stain reagent mix (Table A-1) to the same FACS tube. Briefly vortex to mix cells with antibodies. 
Total staining volume (cells in staining medium plus antibodies) should be exactly 100 µl. Live Stain 
reagents in Table A-1 can be combined in a 1.5-ml microcentrifuge tube prior to mixing with cells in FACS 
tubes.  
11. Leave cells at room temperature for 30 min. 
12. Add 1 ml of staining medium to the FACS tube and pellet cells 5 min at 100 x g, room temperature, then 
decant to discard supernatant (see step 7). 
13. Repeat step 12 once. 
14. Add 1 ml of PBS to FACS tube and resuspend the cells by gentle vortexing until there are no visible cell 
clumps. 
15. Add 100 µl of 16% PFA to FACS tube, for a final concentration of 1.6%, and vortex to mix. This step is 
for cell fixation prior to further intracellular staining steps. 
16. Leave cells at room temperature for 10 min. 
17. Pellet cells 5 min at 800 x g, room temperature, and decant to discard supernatant (see step 7). 
Cells are now ready for intracellular staining. 
 
Stain to detect intracellular targets 
18. Determine the optimal permeabilization conditions required for each intracellular target. If a subset of 
intracellular antigens requires permeabilization with saponin, as is the case with antibodies used to stain 
158 
  
glioma and melanoma, include steps 19 to 27. If all intracellular antibodies have been shown to effectively 
detect target antigens after permeabilization with ice-cold methanol (as is the case for the antibodies that 
were used to stain tonsils), skip to step 28.  
a. Antibodies for mass cytometry are pre-labeled with metal isotopes. Many of these antibodies are 
commercially available (see Table A-1). For antibodies that are not commercially available in 
isotope-tagged formats, they can be labeled with a metal isotope using a commercial conjugation 
kit (385). The isotope-labeled antibodies can then be used for immunostaining by following the 
protocol described below. 
19. Resuspend cells in 1 ml of Perm 1, pellet 5 min at 800 x g, room temperature, and decant to discard 
supernatant (see step 7). 
20. Repeat step 19 once. 
21. Resuspend cell pellet in appropriate volume of Perm 1 (see step 8). 
22. Transfer appropriate volume of cell suspension in Perm 1 to a new FACS tube (see step 8). 
23. Add Saponin Stain (Table A-1) reagent mix to the same FACS tube. Briefly vortex to mix cells with 
antibodies. 
a. Total staining volume (cells in Perm 1 plus antibodies) should be exactly 100 µl. Note that the 
Saponin Stain mix, in addition to the prior Perm 1, must also contain saponin. 
24. Leave cells at room temperature for 30 min. 
25. Add 1 ml of Perm 1 to the FACS tube, pellet cells 5 min at 800 x g, room temperature, and decant to 
discard supernatant (see step 7). 
26. Repeat step 25 once. 
27. Add 1 ml of PBS to the FACS tube, pellet cells 5 min at 800 x g, room temperature, and decant to discard 
supernatant (see step 7). 
28. Vigorously vortex cell pellet to resuspend cells in void volume. 
29. Add 1 ml of Perm 2 to FACS tube. Vortex to thoroughly resuspend cells with Perm 2. 
a. The final concentration of ice-cold methanol after the Perm 2 is added to cells should be > 95%. 
30. Keep cells at −20°C for at least 20 min.  
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a. Alternatively, cells can be stored in Perm 2 at −80°C for days or weeks before proceeding, if 
necessary. 
31. Remove FACS tubes from −20°C and add 1 ml of PBS to each tube. 
32. Pellet cells 5 min at 800 x g, room temperature, then decant to discard supernatant (see step 7).  
33. Add 1 ml of staining medium to FACS tubes. Pellet cells 5 min at 800 x g, room temperature, then decant 
to discard supernatant (see step 7). 
34. Repeat step 33. 
35. Resuspend cell pellet in appropriate volume of staining medium (see step 8). 
36. Transfer appropriate volume of cell suspension in staining medium to a new FACS tube (see step 8). 
37. Add Methanol Stain reagent mix to the same FACS tube. Briefly vortex to mix cells with antibodies. 
a. See step 8 and Table A-1. Total staining volume (cells in staining medium plus antibodies) should 
be exactly 100 µl. Note that Methanol Stain reagent mix does not contain methanol.  
b. Methanol Stain reagents in Table A-1 can be combined in a 1.5-ml microcentrifuge tube prior to 
mixing with cells in FACS tubes. 
38. Incubate cells at room temperature for 30 min. 
39. Add 1 ml of staining medium to the FACS tube and pellet cells 5 min at 800 x g, room temperature, then 
decant to discard supernatant (see step 7). 
40. Repeat step 39 once. 
41. Add 1 ml of PBS to the FACS tube and pellet cells 5 min at 800 x g, room temperature, then decant to 
discard supernatant (see step 7). 
42. Add 1 ml of deionized water to the FACS tube and pellet cells 5 min at 800 x g, room temperature, then 
decant to discard supernatant (see step 7). 
43. Resuspend cell pellets in 1X Four Elements Calibration Beads in deionized water prior to mass cytometry 
analysis. Use 1 ml for every 0.5 x 106 cells. 
44. Filter cells using FACS tubes with filter caps. 
Cells are now ready for mass cytometry analysis. 
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Figure A-3 Biaxial analysis of cells derived from human tissue and tumors. Biaxial plots of non-apoptotic (cCasp3−), 
nucleated (HH3+) cells from mass cytometry analysis of (A) tonsil, (B) glioma, and (C) melanoma are shown. Intermediate 
gates are shown in gray, and terminal gates are shown in blue. Cell types or protein identity of cells in each gate are 
indicated. The percentages of cells in gates are also specified.  
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Figure A-4 High-dimensional analysis of mass cytometry data using viSNE. Non-apoptotic (cCasp3−), nucleated 
(HH3+) cells from mass cytometry analysis of (A) tonsil (plots of 106,568 cells), (B) glioma (plots of 65,834 cells), and (C) 
melanoma (plots of 94,810 cells), are shown. The first plot of each tissue type depicts cell density of the viSNE map. The 
remaining plots display expression of indicated protein. viSNE maps of each tissue type were generated separately and the 
markers shown here for each tissue type were used to generate the maps. 
 
Commentary 
Background Information 
Flow cytometry technologies employing fluorescence- and mass-based reporters have been successfully 
applied to characterize protein phenotype and to quantify the abundance of diverse human cell types. Flow 
cytometry protocols commonly use reporter-conjugated antibodies to make relative quantitative measurements 
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for tens of features in each of hundreds of thousands of cells in minutes (298, 385-389). Mass cytometry, a 
newer form of flow cytometry based on mass spectrometry, has gained attention for the relative ease with which 
more than 35 cellular features can be measured (83, 302, 390). However, as flow cytometry requires individual 
cells in suspension, mass cytometry’s application to solid tumors and tissues has previously been modest 
compared to its rapid adoption in immunology and blood cancer research, where samples of viably 
cryopreserved cells have been collected and characterized for decades (288, 362, 364, 370, 374, 391, 392). The 
key limitation has been the perceived difficulty in making cells from solid tissues into single-cell suspensions that 
are viable and representative of different cell types present in the original tissue. Furthermore, mass cytometry 
antibody sets had not been designed and tested to effectively identify cells outside the immune system. It is only 
recently that mass cytometry has been tested and applied to solid tissues and tumors (284, 321). Key to this 
work was the development of a protocol that preserved the viability and diversity of the tissue cells in a way 
compatible with detection of cell surface and intracellular features by mass cytometry. 
 
Critical parameters and troubleshooting 
Table A-2 lists some possible problems that may arise in preparing cells for mass cytometry, along with 
their possible causes and solutions. 
 
Tissue quality and transportation 
The protocols in this unit are applicable to human tissues extracted by surgery or to animal tissues 
isolated after dissection. To preserve tissue viability, samples should be transported to the laboratory for 
further preparation as rapidly as possible. The dissociation protocol presented here was tested on 
samples that were processed between 30 min and 4 hr after surgical resection (284). Additionally, 
samples should be transported in sterile PBS, appropriate experimental medium, or other sterile transport 
medium that has been tested to preserve cell viability and representative cell subsets for specific tissue 
types. Samples should be entirely submerged in the transport medium in a closed container. Unless 
specifically optimized and validated using other conditions, samples should be immediately transported 
at room temperature (23°C) to the laboratory for further preparation.  
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Mechanical dissociation 
As described in Basic Protocol 1, tissue should be mechanically dissociated into fine (1 to 3 mm3) 
pieces to maximize surface contact with dissociation enzymes in subsequent steps. During mechanical 
dissociation in the petri dish, tissue pieces should be adequately covered in warm (37°C) experimental 
medium. For larger samples, the tissue should be divided into batches for mincing and combined prior to 
addition of the dissociation enzymes: collagenase II and DNase I. 
 
Selection of enzymes and duration of dissociation 
Dissociation enzymes are incorporated in the protocol to break down the extracellular matrix to 
yield a single-cell suspension. Many types of enzymes are available, such as collagenases, trypsin, 
papain, and HyQTase, among others. These enzymes can be used individually or in combination. The 
types of dissociation enzymes used can affect the viability of single cells derived from the starting tissue. 
As described above, a suitable dissociation protocol will maximize cell viability as well as preserve 
representative cell subsets in the original tissue. Variables to consider when testing the dissociation 
conditions include the use of a single enzyme or combinations of enzymes, and duration of dissociation 
(284). Additionally, inclusion of DNase I in the dissociation protocol described here significantly improves 
viable cell yield from multiple tissues (284). Therefore, it is highly recommended to include DNase I in 
the dissociation solution unless it is specifically demonstrated experimentally that DNase I is not required 
to improve cell viability. The protocol described here uses 1 hr of enzymatic dissociation, which has been 
shown to result in the highest viable cell yield for various human tissues and tumors (284). Specifically, 
for most tissues, shorter dissociation time led to release of fewer cells, whereas longer dissociation led 
to increased cell death. It is recommended that the type of dissociation enzyme and duration of enzymatic 
dissociation be tested and optimized for a new tissue type to achieve optimal viable cell yield. This can 
be quantified by using trypan blue staining (see Basic protocol 1). In addition to overall cell viability, it is 
crucial to determine preservation of known cell types and cells of interest as part of the optimization 
process. When testing the dissociation on a particular tissue, imaging techniques such as colorimetric 
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immunohistochemistry or immunofluorescent detection of known cellular targets can be used to 
characterize the presence of cell subsets in the original tissue. 
 
Immunostaining for mass cytometry 
It is highly recommended to optimize the immunostaining protocol for each antibody in a panel to 
ensure target-specific staining and to optimize signal-to-background levels (278). Parameters that need 
optimization (278) include 1) antibody specificity (which can be tested using positive and negative control 
cells that are known to express and lack the target of interest), 2) antibody concentration (to allow 
maximal distinction between positive and negative cells, and minimize nonspecific background staining), 
3) staining order (extracellular staining or intracellular staining), and 4) compatibility of permeabilization 
reagents for intracellular targets (saponin, ice-cold methanol, or other reagents). If multiple 
permeabilization reagents are required for different intracellular targets, specificity and sensitivity of the 
antibodies should be tested to ensure that the targets are still detectable after multiple permeabilization 
steps. For the glioma immunostaining presented here, saponin permeabilization was used for SOX2 
detection, prior to subsequent permeabilization by ice-cold methanol. It has been previously shown that 
saponin does not destroy intracellular targets normally detectable after methanol permeabilization, and 
therefore these reagents can be used in the same protocol, with the use of saponin preceding methanol 
(312). However, each antibody should be specifically tested and optimized prior to use. 
 
Treatment of cells with reagents for detection of intact cells via mass cytometry 
In flow cytometry analyses, an initial step is to identify intact cells and remove cellular debris or 
enucleated cells from further analyses. Conventional fluorescence flow cytometry relies on measurement 
of cell size (forward scatter, FSC) and cell granularity (side scatter, SSC) to identify cells. Additionally, 
cellular debris can be distinguished due to its smaller size (low FSC) and higher granularity (high SSC). 
In contrast to fluorescence flow cytometry, mass cytometry does not have direct parameters to distinguish 
intact cells from cellular debris. Therefore, mass cytometry analysis requires measurement of indirect 
parameters to identify intact cells. Iridium-conjugated DNA intercalator is commonly used to identify intact 
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cells by mass cytometry analysis (393). The per-cell quantity of DNA-intercalated iridium provides 
information about DNA content, which can be used to define intact cells. However, iridium-conjugated 
DNA intercalator cannot be detected using fluorescence flow cytometry. In this protocol, we used anti-
histone H3 antibody staining for detection of intact nucleated cells (284). The advantage of using an 
antibody-based technique is that it is readily applied across different flow cytometry platforms 
(fluorescence and mass cytometry). 
 
Anticipated results 
The protocols in this unit produce viable single-cell suspensions from solid tumors and tissues and are 
expected to identify most common cell types, including endothelial cells, immune cells, epithelial cells, neural 
cells, and fibroblasts. These protocols have been validated for human tonsil tissue, glioma tumors, melanoma 
tumors, and small cell lung cancer patient–derived xenografts. Maximum viable cell yield per gram of tissue from 
the dissociation of human tonsils, glioma, and melanoma using collagenase II plus DNase I should be achieved 
after 1 hr of incubation (284). Histone H3 staining should allow highly specific identification of nucleated, intact 
cells. Additionally, cells derived from Basic Protocol 1 are suitable for quantitative measurement of protein 
expression in individual cells and cell subset abundance using either fluorescence flow or mass cytometry, 
among other applications. For other tissue types not mentioned above, tissue-specific optimization of the 
dissociation protocol that takes into consideration the critical parameters described here is highly encouraged. 
Specifically, a systematic comparison of different dissociation durations, as well as different enzyme 
combinations, is required. For every condition, it is crucial to quantify cell viability using techniques such as 
trypan blue staining. Additionally, the relative abundance of known cell subsets after different dissociation 
conditions should be quantified, as has been done above using flow cytometry. These data should be compared 
to prior knowledge of cell types present in the tissue, and possibly with immunohistochemistry stains of the 
original intact tissue (for more details, see (284)).  
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Table A-2 Potential problems and troubleshooting  
Problems Potential causes Troubleshooting 
Few viable cells after 
dissociation 
 Poor sample quality  Use fresh surgically resected specimens (i.e. avoid using fixed samples). 
 Small tissue size  If possible, use tissue at least 0.5 cm3 in size. Smaller samples can be used but will yield 
fewer cells. 
 Transport medium  Use sterile PBS or appropriate experimental medium. Other isotonic solutions should be 
tested prior to routine use. 
 Transport temperature 
 
 Specimens should be transported at room temperature. If transportation at other 
temperature (i.e. on ice) is to be used, it should be compared to room temperature. 
 Duration of 
transportation 
 
 Duration of sample transportation should be noted. Ideally, samples should be dissociated 
immediately after surgical collection. Longer transportation times will decrease cell yield. 
 Dissociation enzyme 
 
 Dissociation enzymes should be tested for optimal viable cell yield prior to use in a new 
tissue type. 
 DNase I should be included in the dissociation protocol unless shown experimentally to 
be unnecessary. 
 Duration of enzymatic 
dissociation 
 Some tissue types may require shorter or longer dissociation duration. The dissociation 
kinetics should be tested for the specific types of enzyme used in the protocol. Testing of 
dissociation durations ranging from 15 minutes to  6 hours is recommended. 
Red blood cell or 
platelet contamination 
 ACK lysis is not 
included in the protocol 
 ACK lysis should be used when there is visible red blood cell contamination. This should 
be done prior to cryopreservation. 
Few viable cells after 
cryopreservation 
 Freezing medium 
 
 Freezing medium should contain 10-12% DMSO in appropriate medium (e.g. FBS, or 
experimental media), which should contain serum or BSA, depending on cell types. 
 Freezing temperature  Temperature of cell cryopreservation should be gradually decreased in a controlled 
environment at ~ 1C decrease/min in a -80C ultralow freezer. Within 1 week, cells should 
be transferred to liquid nitrogen for long term storage. 
 Thawing conditions  Cells from cryopreservation should be warmed in a 37C water bath for 1-2 minutes until 
completely thawed. Cell suspension should be immediately washed using warm 
experimental media to remove DMSO 
Cell subsets of 
interest were not 
detected 
 Inappropriate 
dissociation condition 
for tissue type 
 Antibodies with known specificity (and known optimal staining condition) should be used 
to test if the dissociation protocol preserves the cell subsets of interest. 
 Antibody specificity  Antibodies that have been shown to specifically detect targets with other techniques (such 
as western blot) might not always work for flow cytometry-based technologies. Therefore, 
new antibodies should always be tested for specificity prior to use. This should be done 
using a known positive control cell type, and a known negative control cell type (rather 
than relying on an isotype control antibody). 
 Antibody concentration  All new antibodies should be titrated to yield optimal concentration prior to use. The ideal 
concentration should allow maximal separation between the positive and the negative 
control cells, while minimizing signal of negative control cells (i.e. non-specific staining, 
background). 
 Immunostaining 
condition 
 Antibodies that detect surface antigens should be used during live surface 
immunostaining. Note that some antibodies that detect surface transmembrane antigens 
were created to detect the intracellular portion of the antigen (i.e. cytoplasmic domain) 
and, therefore, should be used during intracellular immunostaining. 
 Antibodies that detect intracellular antigens should be tested for appropriate 
permeabilization conditions. Different permeabilization reagents might be required for 
different antibodies. Additionally, steps of permeabilization with different reagents, if 
needed, should also be tested. 
Non-specific staining  Antibody specificity and concentration 
 Every antibody should be tested for their specificity and for the appropriate concentration 
prior to use for staining. 
 
Signal normalization using bead standards 
During each mass cytometry analysis, the detection sensitivity of the mass cytometer can vary 
between individual samples. Additionally, signal can vary between different mass cytometry experiments. 
Specifically, the signal intensity of a given cellular target, which is known to be consistent, can vary 
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between different samples for different mass cytometry analyses. To allow accurate comparison between 
samples, bead standards are used (313). Known metal isotopes with standard signal intensity are 
embedded within polystyrene beads. These beads are mixed and analyzed simultaneously with each 
sample to allow monitoring of signaling variation during data acquisition. The change of the isotope signal 
of the beads proportionately correlates with the variation of each sample due to detection variability. 
Therefore, the variation of signal between samples can be adjusted to allow direct comparison of the 
signal between samples. Normalization is performed using publicly available MATLAB normalization 
software prior to further data analysis. For more details, refer to (313). 
 
Quantification of single-cell protein expression by biaxial analysis 
Biaxial plots are a mainstay in cytometry and are typically used to compare the abundance of 
cells with differing relative intensity of two or more quantified cellular targets. A protocol to generate 
biaxial and other common plots of mass cytometry data was previously established (81). In a typical 
cytometry analysis workflow (314, 394), cells are filtered or assigned to populations based on expression 
profiles of cellular targets in a process called gating (Figure A-3). Gating can be repeated sequentially on 
increasingly refined cell subsets, resulting in a nested hierarchy of cell types that traditionally captures a 
developmental continuum or indicates an increasingly polarized and specific cell identity (83, 363, 394, 
395). Figure A-3 shows examples of sequential biaxial gating of cells derived from mass cytometry 
analysis of healthy tonsil (Figure A-3A), a patient glioma (Figure A-3B), and a patient melanoma (Figure 
A-3C; (81, 284)). For samples with known cell types, such as healthy peripheral blood mononuclear cells 
(PBMCs), established sets of identity markers can be used to distinguish cell types (316, 396). However, 
concepts of cell identity are still under active discussion in established single-cell fields like immunology 
(395). Furthermore, methods of defining and identifying cell populations are likely to be re- fined as the 
field of single-cell biology matures. Key areas of growth include measurement platforms like mass 
cytometry, analysis tools from machine learning (290, 295, 296, 397), reference knowledge bases of 
established cell identities (301, 398), annotated repositories of single-cell data, and quantitative labels of 
cell type (321). 
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Heat plots and viSNE analysis 
A new generation of flow cytometry and single-cell analysis tools compress multiple dimensions 
of information into rich two-dimensional views. Examples include mountain plots (15), viSNE and related 
views of t-SNE axes (290, 295), SPADE plots (282), and many other tools that have the potential for 
machine learning of cell identity (for more details, see (81, 314, 321, 394, 397). Here, we demonstrate 
two-dimensional viSNE plots (290). viSNE analysis places cells on a two-dimensional map that reflects 
how individual cells are similar to or different from each other when every measured cellular target is 
simultaneously taken into account. Cell density and expression of individual markers are displayed for a 
wide range of features using the same t-SNE axes. Data collected from the same patients as shown in 
biaxial analyses in Figure A-3 were analyzed by viSNE and are shown in Figure A-4 (tonsil, Figure A-4A; 
glioma, Figure A-4B; and melanoma, Figure A-4C). For each sample, a separate pair of t-SNE axes was 
created (i.e., each sample was analyzed separately in viSNE to create sample-specific viSNE plots, each 
of which has its own, sample-specific t-SNE axes). All computational analysis was performed using 
Cytobank software (http://www.cytobank.org; (301)). 
 
Time considerations 
The protocols in this unit were experimentally tested on human gliomas, human melanomas, and SCLC 
PDXs that were transported to the laboratory within 1 hr after surgical resection. Human tonsils were transported 
within 4 hr after resection. After tissue is transported to the laboratory, this dissociation protocol can be completed 
in 2 to 3 hr, depending on the size of the tissue sample. The size of the tissue sample determines the time that 
is needed for mechanical dissociation (larger tissue samples take more time to be properly minced, whereas 
smaller tissue samples take less time). The time for enzymatic dissociation is not affected by tissue size. The 
approximate timing of the protocol is: 10 to 30 min for mechanical dissociation, 1 hr for enzymatic dissociation, 
15 to 30 min for cell straining, 10 to 30 min for red blood cell lysis and counting, and 10 to 30 min for diluting 
cells for cryopreservation, if needed (see Basic Protocol 1). Once viable single cells are obtained (either from 
immediate dissociation or from cryopreservation), live surface immunostaining can be completed in 1 hr, followed 
by 10 to 15 min of cell fixation. Duration of intracellular staining varies depending on whether permeabilization 
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and staining with saponin (1 hr) is required for the panel of interest. Permeabilization with methanol is usually 
performed overnight, but can be performed for as little as 10 min (278). Once all cells are permeabilized by ice-
cold methanol, an additional 1 hr is required for intracellular immunostaining with isotope-labeled antibodies. 
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APPENDIX B 
Fluorescence Cell Barcoding 
 
Author: Nalin Leelatian 
 
Introduction 
 High-content fluorescence flow cytometry enables quantification of multiple cellular targets in millions of 
individual cells (276, 364, 399). This technology has been extensively incorporated in both research and clinical 
settings for characterizing cellular phenotype, identifying novel cell subsets, monitoring therapy responsiveness, 
as well as dissecting mechanisms by which cells resist therapy (14, 15, 80). Practically, 5-10 parameters can be 
simultaneously quantified in every cell. This limit can be further extended to 15-25 parameters, depending on 
the settings of a specific flow cytometer, antibody panel design, and the capability for pre-analytical signal 
compensation (283). 
 Due to its quantitative capacity at the single cell level, fluorescence flow cytometry is an appealing 
platform for high-throughput drug screening assays as well as for the dissection of mechanistic responses of 
cells to external stimuli and inhibition (12, 15, 83, 300). The increasing scale of screening assays creates new 
challenges for flow cytometry approaches, especially the need to precisely capture the subtle differences in 
signal across multiple samples (14, 15, 80, 84). The time and cost of large-scale flow cytometry platforms also 
increase exponentially. Therefore, there is an urgent need to minimize these technical challenges, while 
maintaining the accuracy of data interpretation. 
 Fluorescence cell barcoding (FCB) increases the throughput of flow cytometry, minimizes inter-sample 
signal variation, and significantly reduces reagent cost (344, 400). In short, multiple samples (such as cells 
treated with different inhibitors or signaling stimuli) are labeled with different combinations of fluorophores, which 
have different excitation and/or emission wavelengths, at different concentrations. Thus, each sample would 
have a unique fluorescence “barcode”. After barcoding, all the samples are than physically combined for 
simultaneous antibody staining and data acquisition, according to a traditional flow cytometry workflow. Unique 
barcodes enable computational separation of the samples during subsequent analysis. 
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A previously published protocol effectively combined 96 samples using three different fluorophores, 
namely Pacific Blue, Alexa 488, and Alexa 700 (344). Notably, these fluorophores have different excitation 
wavelengths (i.e. they are maximally excited by three different lasers on the cytometer). One of the key 
challenges in FCB assays is that, when designing a fluorescence panel, some of the channels must be dedicated 
for FCB, leaving fewer channels for biological measurements. For example, if a 10-color panel is to be used, 
three channels would be dedicated for FCB, leaving seven additional channels for feature quantification. To 
maximize the capacity of flow cytometry, an immediate objective should be to optimize the FCB protocol so that 
fewer fluorophores can be used to barcode at least the same number of samples. 
Additionally, the use of FCB fluorophores that have different excitation wavelengths can place a challenge 
on subsequent data analysis. Specifically, if the antibody that detects a cellular target of interested is conjugated 
to a fluorophore that has the same excitation wavelengths and a nearby emission spectra as one of the FCB 
dyes, there is potential for signal spillover between the FCB channels and the channel dedicated for quantifying 
biological features (401). Therefore, the excitation and emission spectra of the FCB dye combinations must also 
be taken in to consideration when designing and optimizing a FCB workflow. 
Here, an FCB protocol that utilizes only two fluorophores, Pacific Blue and Pacific Orange, is described. 
These fluorophores have different emission spectra but are maximally excited at the same excitation wavelength 
(~405 nm). The advantage of this protocol is that one laser is fully dedicated for FCB, leaving 2-4 lasers, and up 
to 15-20 channels, for quantification of biological features. Another advantage is that if the FCB scale is to be 
expanded, additional dyes that can be maximally excited by the same laser can easily be incorporated. The 
protocol described here includes details on how to optimize the dye concentrations to combine 12 to 96 samples 
for simultaneous analysis. The approaches to address signal compensation for accurate data interpretation are 
also discussed.  
 
Fluorescence cell barcoding protocol 
 Here, a step-by-step 48-plex (8X Pacific Blue and 6X Pacific Orange) FCB protocol is described. 
Specifically, this protocol is to be used for barcoding cells that have been fixed and permeabilized with 100% 
ice-cold methanol for at least 20 minutes (278, 312). Fluorophore concentrations for 48-plex FCB are specified 
172 
  
in Table SB-1 (see Table SB-2 for 96-plax FCB). Other FCB conditions, such as live or post-saponin barcoding, 
should be optimized separately and are not detailed in this protocol, but are discussed briefly later in this chapter.  
 
Reagents 
1. Pacific Blue succinimidyl ester. 
2. Pacific Orange succinimidyl ester. 
3. V-bottom 96-well plate with lid. 
4. 12-channel pipet. 
5. 200 μL pipet tips. 
6. Dimethyl sulfoxide (DMSO). 
7. 16% paraformaldehyde (PFA) aqueous solution. 
8. Absolute methanol stored at -20°C or lower. 
9. 1X phosphate buffered saline (PBS). 
10. Staining medium: 1% bovine serum albumin (BSA) in PBS. 
11. 12 x 75 mm round-bottom polystyrene cytometry tubes. 
12. Parafilm. 
13. Aluminum foil 
 
Preparing a 48-plex cell barcoding plate 
1. Prepare different concentrations of Pacific Blue and Pacific Orange dyes according to Table SB-1. Dilute 
dyes in DMSO. 
2. Transfer 10 μL of Pacific Blue and 10 μL of Pacific Orange to each well, based on the layout depicted in 
Figure B-1. For example, for well B4 (row B, column 4), mix 10 μL of Pacific Blue level 2 with 10 μL of 
Pacific Orange level 4. 
3. Cover plate with a lid and wrap the side of the plate with parafilm. 
4. Use aluminum foil to cover plate to project the fluorophores from light. 
5. Transfer plate to -80C for long-term storage, if needed. 
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Figure B-1 Plate layout for 48-plex fluorescence cell barcoding  
Eight levels of Pacific Blue (PB) and six levels of Pacific Orange (PO) can be combined to generate a 48-plex FCB 
platform (see Table SB-1). A 96-well plate can hold two sets of 48-plx FCB (FCB1 and FCB2). 
 
Cell fixation and permeabilization 
6. Perform the biological experiment, if needed, in a 96-well plate. At this point, cells can be in either PBS 
or the original experimental solution. 
a. For each barcode set, there should be 48 conditions in total (half of the plate). If there are more 
than 48 conditions, the total set of barcodes should be increased accordingly. 
b. At least one of the 48 conditions should be an untreated/unstimulated condition. This would serve 
as a biological internal negative control. 
c. If the experiment was not performed in a 96-well plate, cells must be resuspended in the 
appropriate volume indicated in Step 7. 
7. Transfer 200 μL of cells from each condition of the original 96-well plate to a new, V-bottom 96-well plate, 
using a multi-channel pipet.  
a. See previously established protocol for cell viability staining, if desired (Ax700 viability stain, (81)). 
8. Add 20 μL of 16% PFA to each well. Mix cells with PFA by pipetting using a multi-channel pipet. 
9. Leave the cells for 10 minutes at room temperature. 
174 
  
10. Centrifuge the 96-well plate at 800 x g for 5 min at room temperature. 
11. Decant the plate to remove supernatant. 
a. Flip the plate in one, swift motion. Only invert the plate once. Do not re-invert the plate since it 
would cause the cell pellets to detach from the bottom of the plate. 
12. With the lid on, briefly vortex the plate to mix the cell pellets with the void volume. 
13. Use a multi-channel pipet to add 200 μL of 100% ice-cold methanol to each well. Pipet to mix. 
14. Put the lid back on and wrap the plate with parafilm.  
15. Store the plate at -20˚C for at least 20 min or overnight. 
a. If the cells are to be stored more than a week, transfer cells to -80˚C for long-term storage. 
 
Fluorescence cell barcoding 
16. Transfer barcode plate to room temperature, if previously kept at -80˚C. Keep the plate in the dark and 
wait for dye to completely thaw (about 10-15 minutes). 
17. Transfer cell plate to room temperature. 
18. Centrifuge cell plate at 800 x g for 5 min at room temperature. 
19. Decant the plate to remove supernatant (see Step 11 Note). 
20. With the lid on, briefly vortex the plate to mix the cell pellets with the void volume. 
21. Use a multi-channel pipet to add 200 μL of room temperature PBS to each well. Pipet to mix. 
22. Repeat Steps 18-21 once. 
23. Transfer 180 μL of cells from each well to the barcode plate. Pipet to mix. 
a. Carefully document the sample that goes into each barcode well. 
b. Be careful not to expose cells to any reagents that contain FBS or BSA prior to the barcode step 
since the excess amine groups from these reagents can impact the incorporation of dyes into 
cells (see Discussion). 
c. The remaining cells in the original cell plate can be combined and set aside as “Unstained” control. 
Keep the cells in a 5 mL FACS tube at 4˚C. 
24. Leave cells in the dark at room temperature for 30 minutes 
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25. Use a multi-channel pipet to add 20 μL of 1% BSA in PBS (staining media) to each well. Pipet to mix. 
26. Centrifuge cell plate at 800 x g for 5 min at room temperature. 
27. Decant the plate to remove supernatant (see Step 11 Note). 
28. With the lid on, briefly vortex the plate to mix the cell pellets with the void volume. 
29. Use a multi-channel pipet to add 200 μL of staining media to each well. Pipet to mix. 
30. Repeat Steps 26-28 once. 
 
Creating Pacific Blue and Pacific Orange control tubes 
31. Add 200 μL of staining media to the following wells: PB1PO1 (A1), PB8PO1 (H1), and PB1PO6 (A6) (see 
Figure B-1). Pipet to mix. 
32. Label 2 FACS tubes as “Pacific Blue compensation” and “Pacific Orange compensation” 
33. Transfer 10 μL of cell suspension from A1 and H1 to “Pacific Blue compensation” tube. Add 200 μL of 
PBS to the tube. Keep the tube at 4˚C. 
34. Transfer 10 μL of cell suspension from A1 and A6 to “Pacific Orange compensation” tube. Add 200 μL of 
PBS to the tube. Keep the tube at 4˚C. 
 
Combining cells for barcode-only control and for subsequent immunostains 
35. Use the remaining volume in the plate to combine all the cells from 48 wells into a new FACS tube labeled 
“Barcode-only”. 
36. Add 200 μL of staining media to a few more wells. Repeat Step 35 twice to completely remove cells from 
the barcode plate. 
37. Centrifuge cell FACS tube at 800 x g for 5 min at room temperature. 
38. Decant the tube to remove supernatant (see Step 11 Note). 
39. Briefly vortex the plate to mix the cell pellet with the void volume. 
40. Add 1 mL of staining media. Briefly vortex to mix. 
41. Repeat Steps 37-40 twice. 
42. Centrifuge cell FACS tube at 800 x g for 5 min at room temperature. 
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43. Decant the tube to remove supernatant (see Step 11 Note). 
44. Add the appropriate amount of staining volume for subsequent immunostaining, if needed (see (81) for 
a detailed immunostaining protocol). If no immunostaining is needed, skip to Step 46. 
45. Transfer cell suspension into a new FACS tube for immunostaining.  
46. Add 1mL of PBS to the remaining cells in the “Barcode-only” tube.  
47. Centrifuge cell FACS tube at 800 x g for 5 min at room temperature. 
48. Decant the tube to remove supernatant (see Step 11 Note). 
49. Briefly vortex the plate to mix the cell pellet with the void volume. 
50. Repeat Steps 46-49 once. 
51. Add 200 μL of PBS to the “Barcode-only” tube and keep the tube at 4˚C until ready for flow cytometry. 
d. If a viability stain, such as Ax700, was used in Step 7, only the Ax700- live cells should be included 
for signal compensation (see “De-barcoding and signal compensation” under Discussion). This is 
accomplished by computationally gating for Ax700- cells after sample collection, prior to data 
analysis. 
 
Discussion 
Cell permeabilization reagents can impact fluorescence cell barcoding 
Since the multi-dimensionality nature of fluorescence flow cytometry enables quantification of multiple 
parameters in single cells, this technology is often used for simultaneous characterization of both surface and 
intracellular features (14, 15, 312, 345, 402). This usually requires a multi-step staining protocol, which include 
a surface staining step (usually performed on live cells), followed by one or more intracellular staining steps 
(312). The optimization of FCB for a given experiment depends largely on the step by which sample combination 
is needed (Figure B-2). Any immunostaining prior to FCB must be performed on each sample separately. 
Generally, there are two types of FCB; live FCB, and post-permeabilization FCB (400).  
The succinimidyl esters of the fluorophores used in this FCB protocol react to amine sources (i.e. 
proteins) in the cells (403). The available binding sites per cell, therefore, directly influence the level of 
fluorophore that would be incorporated. Therefore, more dyes are more likely to be incorporated into larger cells, 
and less dyes into smaller cells. This factor needs to be taken into consideration during experiment design and 
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data analysis, especially during the de-barcoding steps (see De-barcoding and signal compensation).  
Importantly, it is necessary to separately test the individual fluorophores to optimize the concentrations needed 
for different barcoding protocols, since different cell barcoding conditions (pre- vs post-permeabilization) would 
directly impact the degree of dye incorporation per cell. In general, live FCB requires a higher concentration of 
fluorophore to yield the same fluorescence intensity compared to post-permeabilization FCB, due to fewer 
available proteins and amine groups on the cell surfaces. 
 
 
 
Figure B-2 Fluorescence cell barcoding immediately precedes sample pooling  
Samples can be properly combined for simultaneous immunostaining and analysis only after FCB. (Left) If the protocol is 
optimized for live FCB, samples can be combined after FCB for live, surface immunostaining. (Middle and Right) If post-
permeabilization FCB is to be used, samples must undergo surface immunostaining separately (if needed) prior to FCB and 
sample pooling. 
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Figure B-3 Permeabilization reagents impact bindings of FCB dye to cells  
(A, top) Four levels of Pacific blue were used to barcode cells that were permeabilized with 100% ice-cold methanol (blue), 
0.1% saponin (orange), 0.05% saponin (gray), and 0.02% saponin (yellow). Y-axis represents raw fluorescence intensity (x 
104). (A, bottom) histogram of cells that were permeabilized with different reagents (rows) and barcoded with different 
concentrations of Pacific Blue (columns), are shown. Values adjacent to histograms indicate transformed ratios of values 
by table’s minimum. (B) Similar analysis was performed using three levels of Pacific Orange. 
 
The type of cell permeabilization reagent also impacts FCB. For example, when the same concentrations 
of Pacific Blue and Pacific Orange were used to barcode cells that were permeabilized with either 100% ice-cold 
methanol (see FCB protocol) or different concentrations of saponin, cells that were permeabilized with methanol 
showed higher fluorescence signals, whereas saponin permeabilization resulted in lower fluorescence signals 
regardless of its concentration (Figure B-3).  
 
Correlations between concentrations of fluorophores and signal intensity  
Precise titration of fluorophore is key to a successful FCB experiment. Specifically, when a new dye is to 
be used, it is essential to characterize the relationship between dye concentrations and fluorescence intensity. 
As mentioned previously, the method for cell barcoding directly impacts the dye incorporation and would alter 
the relationship between dye concentrations and fluorescence intensity. The example detailed here utilized cells 
that were permeabilized with 100% ice-cold methanol for at least 20 minutes (278). 
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Figure B-4 Pac Blue and Pac Orange titrations and equations 
(A) Raji cells stained with 24 levels of Pacific blue (PB) ranging from 0.21 to 7.28 μg/mL were analyzed and histograms are 
illustrated. (B) Similar titration was performed with Pacific orange (PO) using SKO cells, ranging from 0.06 to 6.14 μg/mL. 
Unstained cells were included as controls (top rows) (C-D) Relationship between dye concentration and raw fluorescence 
intensity are shown, and the linear equations are specified for each fluorophore. X-axis represents concentration of 
fluorophore (μg/mL), and y-axis represents raw fluorescence intensity (x 104). 
 
As the concentration of fluorophores increases, the raw fluorescence intensity also increases (Figure B-
4). Notably, Pacific Blue was used at a lower concentration than Pacific Orange to achieve similar fluorescence 
intensity (Figure B-4C and Figure B-4D). The relationships between dye concentrations and fluorescence 
intensity (FI) could be illustrated as linear correlations that passed closely to the (0,0) coordinated (Figures B-
4C and Figure B-4D), as reflected in the dye-intensity equations (1) and (2): 
(1) Raw FI   =   68,673(PB conc) +   0.00118  
(2) Raw FI   =   6,550(PO conc) +   0.0008    
Note: FI, fluorescence intensity; conc, concentration (μg/mL), PB, Pacific Blue; PO, Pacific Orange 
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Figure B-5 Higher concentrations of fluorophores lead to significant spillover and spreading error 
(A) Assessment of signal spill-over from 24 levels of Pacific blue into other channels after compensation is illustrated. X-
axis represents an increasing concentration of Pacific blue from left to right, and y-axis represents recipient channels (Pacific 
Orange, Ax488, PE, PerCP-Cy5.5, PE-Cy7, Ax647, and Ax700). Sample that contained Raji cells stained 24 levels of Pacific 
blue is shown in the top row. Individual Pacific Blue levels (levels 1, 20, and 24) are also shown separately. (B) Similar 
assessment was performed in SKO cells stained with 24 levels of Pacific orange. X-axis represents an increasing 
concentration of Pacific orange from left to right, and y-axis represents recipient channels. Individual levels that are shown 
included levels 1, 19, and 24. Arrows demonstrate signal spill-over and spreading errors. Also refer to Figure B-3. 
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Once the dye-intensity equations are computed, the number of samples for a given FCB experiment can 
be tailored as needed (see Table SB-1 and Table SB-2). The lower limit of the FCB range is usually the lowest 
concentration that can be easily distinguished from unstained, non-barcoded samples (L1; Figures B-4A and 
Figure B-4B). This concentration can be slightly adjusted for ease of subsequent de-barcoding (i.e. to easily 
separate barcoded samples from cells that were not properly barcoded). The major concern for determining the 
upper limit of each dye is its potential spill-over into other channels, especially those with similar emission 
spectra. It is critical that the spill-over from the highest concentration must be easily compensated and have no 
spreading error in other channels, since these can lead to false positive or false negative signals (Figure B-5). 
After the upper and lower limits are determined, the concentrations of fluorophores for individual FCB level are 
then calculated from the equations. FIs that are in between the upper and lower limits are pre-determined, with 
the goal to equally separate each level on a log or asinh scale. Each FI would be the desired median FI for a 
given FCB level. Note that log or asinh scales are standard for flow cytometry data visualization, which equally 
emphasize the fold-change differences at lower and higher FIs. The fewer the number of samples to be 
barcoded, the easier the FCB optimization and subsequent computational de-barcoding (sample gating and 
isolation) since there would be more separation between each sample (Figure B-6). 
 
De-barcoding and signal compensation 
The purpose of sample de-barcoding is to computationally separate pooled data into individual samples 
for subsequent analysis. Since each sample is stained with both Pacific Blue and Pacific Orange at specific 
concentrations, this step requires proper signal compensation between the two FCB channels (Figure B-7A). 
The practical strategy of FCB compensation is to align the median signal of same level of each dye (e.g. all PB1 
or all PO1) in a straight line, on either the y-axis (here, Pacific Orange) or the x-axis (here, Pacific Blue), 
depending on the data display. As seen in the “before compensation” plot, for a given level of Pacific orange 
(row, y-axis)), as the signal of Pacific Blue increases (column, x-axis), the signal of Pacific Orange also increases. 
However, based on the FCB scheme, Pacific Orange signals on any given row should remain constant. 
Therefore, Pacific Blue is the “source” of the false positive signal seen in Pacific Orange, which is the “detector” 
or “signal recipient”. Similar spill-over from Pacific Orange into Pacific Blue is also seen, but now the source and 
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recipient are now switched. Notably, the degree of PO-into-PB spill-over is of a lesser degree than the PB-into-
PO spill-over. This is expected as signal spill-over is usually more prominent if the detecting channel has a longer 
emission wavelength. 
 
Figure B-6 Complexity of FCB can be augmented to increase experimental throughput 
(A) A 12-plex FCB is shown on a biaxial single-cell plot. The scheme of the FCB includes 4 levels of Pacific Blue and 3 
levels of Pacific Orange. (B) Augmented 48-plex (8 levels of Pacific Blue and 6 levels of Pacific Orange), and (C) 96-plex 
(12 levels of Pacific Blue and 8 levels of Pacific Orange) are also shown. 
 
After the FCB channels are properly compensated, individual samples can be isolated by sequential 
biaxial gating. (Figure B-7B). It is important to computationally separate the sample in a stepwise manner, rather 
than gating directly on the PB-PO biaxial plot. As mentioned previously, larger cells usually have more proteins 
and amine groups to react with barcoding dyes. Even in seemingly homogenous samples such as cell lines, the 
size of individual cells can vary. And therefore, per-cell FI of the barcoding dyes would vary based on cell size 
(forward-scatter, FSC-A, x-axis; Figure B-7B, top). This variation can be seen on the PB-PO biaxial plot. For 
example, in the 12-plex FCB, the larger cells within each of the 12 populations would be on the top right part of 
the population, whereas smaller cells would be on the bottom left (Figure B-6A). These “tails” can significantly 
overlap with other nearby populations as the number of barcoded samples increases (Figures B-6B and B-6C), 
making direct gating on the PB-PO biaxial plots challenging. A sequential gating scheme starting with 1) a biaxial 
plot of cell size (FSC-A) vs one of the barcoding dyes (here, Pacific Orange; Figure B-7B, top), followed by 2) a 
secondary PB-PO biaxial plot, is performed to avoid incorrect assignment of cells to the wrong sample. 
183 
  
 
Figure B-7 De-barcoding and signal compensation are crucial for data analysis 
(A) A 96-plex FCB of single SKO cells before (top) and after (bottom) signal compensation is illustrated. (B) After Pacific 
Blue and Pacific Orange compensation, pooled data are computationally separated into individual samples by biaxial gating. 
The first step is to separate one of the FCB channels (in this case, Pacific Orange), into different levels. And within each 
level (Pacific Orange L4 is shown as an example), the second FCB dye (Pacific Blue) is used to identify individual samples. 
(C) Spill-over signals from Pacific Blue, and (D) Pacific Orange, into other recipient channels (y-axes) before (left) and after 
(right) appropriate compensation are illustrated. Appropriate de-barcoding and compensation resulted in sample separation 
(E and F), and lack of signal spill-over into recipient channels (G) are shown. 
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After FCB channels are decompensated and individual samples are isolated, any signal spill-over from 
FBC channels into other detectors should be corrected (Figure B-7C and B-7D). This can happen even with an 
ideal antibody panel design, due to the nature of fluorophore excitation and emission spectra. The practical 
approach of this step is the same as FCB signal compensation; for any given concentration of Pacific Blue and 
Pacific Orange, there should be no signal spill-over into any other recipient channels. For example, before 
compensation, as the signal of Pacific Orange increased, the signal detected as Ax488 also increased (Figure 
B-7D, top left). But since neither Ax488 dye nor Ax488-conjugated antibody was used, there should be no Ax488 
signal in any of the samples. A compensation value must, therefore, be added to remove the false positive Ax488 
signal that resulted from Pacific Orange spill-over (Figures B-7D, top right, and Figure B-8). After appropriate 
signal compensation, there were no change in signal in any of the other recipient channels, even at the highest 
levels of Pacific Blue and Pacific Orange (Figure B-7E, Figure B-7F, and Figure B-7G). This ensures that in an 
actual experiment with additional fluorescence-tagged antibodies, any signal detected in those recipient 
channels would be a reflection of true biological changes. 
 
Figure B-8 Matrix depicting compensation values in an example FCB panel 
Compensation matrix of 96-plax FCB data shown in Figure B-6. Numbers represent compensation values, ranging from 0% 
to 100%. For the corresponding source (row) and detector (column), the compensation values are always 100%. Other 
numbers reflect the percent of false positive signal from other given channels. For example, there is a 21% false positive 
signal that was detected as Pacific Orange that was in fact a spill-over from Pacific Blue. PB = Pacific Blue, PO = Pacific 
Orange, PC5 = PerCP-Cy5.5, and PC7 = PE-Cy7. 
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During FCB optimization, it is critical to compare an unstained sample with samples that are fully 
barcoded without additional antibodies (barcode-only sample). This ensures that the observed signals are due 
to FCB alone. However, it is important to assess the signal spill-over form the FCB channels into other channels 
that might be used for biological quantification in subsequent experiments. And most importantly, both unstained 
and barcode-only samples should always be collected as controls (see FCB protocol), even while performing 
actual biological experiments, to ensure appropriate signal compensation for accurate data interpretation. 
 
Conclusions 
 Fluorescence cell barcoding is a technical approach that significantly enhances the throughput of 
conventional fluorescence flow cytometry. FCB increases the accuracy of data analysis, especially for inter-
sample comparison, and reduces reagent costs. Notably, FCB is especially suitable for experimentation that 
requires accurate comparisons between multiple samples or conditions. The FCB protocol discussed here can 
be readily coupled with a liquid handling system to enable high-throughput assay automation. The high flexibility 
of the FCB protocol allows users to easily tailor the dye combinations to accommodate different experiment 
purposes. Even though 12-, 48-, and 96-plex FCB schemes were discussed here, additional fluorophores can 
be titrated and added to the protocol if needed. As mentioned previously, fewer biological readouts would fit into 
a panel that uses more fluorophores for FCB. Thus, a 384-plex or even a 1536-plex FCB format might be more 
suitable for experimentations where fewer biological readouts are required (e.g. a drug screening assay where 
only apoptosis or cell death are the end-points of interest). A challenge in FCB analysis is the signal 
compensation and sample de-barcoding. A step-wise analysis approach described here enables accurate 
assignment of cells to a given barcoded sample. This can be easily developed into a computational de-barcode 
algorithm that, when coupled with robotic liquid handling, would result in a fully automated experimental and 
analytical pipeline. 
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Table SB-1 Concentrations of Pacific Blue and Pacific Orange for 48-plex barcoding 
 
Pacific Orange 
Concentrations for 
1:20 dilution (μg/mL)* 
L1 0.218 
L2 0.542 
L3 1.352 
L4 3.371 
L5 8.404 
L6 20.95 
  
Pacific Blue 
Concentrations for 
1:20 dilution (μg/mL)* 
L1 0.038 
L2 0.080 
L3 0.172 
L4 0.367 
L5 0.785 
L6 1.679 
L7 3.589 
L8 7.672 
 
* Add 10 μL of the dyes to each well, according to the outline 
in Figure B-1. The total volume of dye per well will be 20 μL. 
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Table SB-2 Concentrations of Pacific Blue and Pacific Orange for 96-plex barcoding 
 
Pacific Orange 
Concentrations for 
1:20 dilution (μg/mL) 
L1 0.370 
L2 0.659 
L3 1.172 
L4 2.087 
L5 3.715 
L6 6.612 
L7 11.770 
L8 20.95 
  
Pacific Blue 
Concentrations for 
1:20 dilution (μg/mL) 
L1 0.031 
L2 0.051 
L3 0.085 
L4 0.140 
L5 0.230 
L6 0.380 
L7 0.627 
L8 1.035 
L9 1.708 
L10 2.818 
L11 4.650 
L12 7.672 
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APPENDIX C 
Using Fluorescence Flow Cytometry to Quantify Cellular Uptake of Compounds 
and Track Signaling Responses  
 
Authors: Katherine M. Chong, Nalin Leelatian, Sean M. DeGuire, Asa A. Brockman, David C. Earl, Rebecca A. 
Ihrie, Jonathan M. Irish, Brian O. Bachmann, and Gary A. Sulikowski 
 
Data presented in this chapter was published in Journal of Antibiotics (Tokyo) 2016 (Chong, Leelatian et al. 
2017), titled “The use of fluorescently-tagged apoptolidins in cellular uptake and response studies”. 
 
Preface 
 The study described here presents another application of fluorescence flow cytometry to track cellular 
drug uptake. Here, two forms of apoptolidin, a drug that was shown to preferentially induce cell death in 
transformed glial cells compared to non-transformed cells, were conjugated to fluorescent cyanine-3 (Cy3). This 
allows direct tracking of their differential uptake in a panel of human cells in conjunction with the quantification 
of signaling alterations and functional changes secondary to drug treatments. This approach has significant 
implications in the identification of novel therapeutic compounds that specifically target cancer cells, or cancer 
cell subsets, compared to normal cells. Additionally, the high-dimensionality nature of flow cytometry enables 
simultaneous dissection of the mechanistic alterations, such as decreased phosphorylation of a specific signaling 
effector, in cancer cells that were targeted by the drugs. This is especially valuable for pre-clinical studies that 
aim to characterize drug specificity and cytotoxicity mechanisms. Additionally, the drug conjugation reaction can 
potentially be adapted to enable labeling with metal isotopes for a high-dimensional single-cell characterization 
by mass cytometry.  
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Abstract 
The apoptolidins are glycomacrolide microbial metabolites reported to be selectively cytotoxic against 
tumor cells. Using fluorescently tagged active derivatives we demonstrate selective uptake of these four tagged 
glycomacrolides in cancer cells over healthy human blood cells. We also demonstrate the utility of these five 
fluorescently tagged glycomacrolides in fluorescent flow cytometry to monitor cellular uptake of the six 
glycomacrolides and cellular response. 
 
Introduction 
Apoptolidin A, isolated from an actinomycete (FU 40), was reported to selectively induce cell death in 
E1A and E1A/E1B19K transformed rat glia cells, while normal rat glia and 3Y1 fibroblast cells were found to be 
non-responsive to apoptolidin A (404). The pathway of cell death was proposed to be apoptosis based on 
observed cell morphology and DNA laddering. Khosla and Salomon later demonstrated apoptolidin A induced 
apoptosis in LYas mouse lymphoma cells via mitochondrial pathway (405, 406). In early 2015, Ishmael and co-
workers demonstrated apoptolidin A treatment to several tumor cell lines in culture, caused a shift in cellular 
metabolism and status of AMP-activated protein kinase (AMPK) stress pathway leading to autophagy as 
characterized by increased phosphorylation of AMPK (Thr 172), acetyl-CoA carboxylase (ACC), and Unc-51 like 
autophagy activating kinase (ULK) (407). The observed effects were consistent with ATP synthase 
(mitochondrial respiration) inhibition as a mode of action (405, 406). 
 
Figure C-1 Apoptolidins and fluorescent derivatives 
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Since the original isolation of apoptolidin A, over eight congeners have been produced by fermentation 
(408-413) mutasynthesis, precursor directed biosynthesis (414, 415), and chemical synthesis (Figure C-1) (416-
418). Accompanying cell cytotoxicity studies have demonstrated the need for deoxy sugars to observe cellular 
activity, as the aglycone (apoptolidinone) has shown no activity (EC50 >10 μm) in a variety of tumor cell lines 
(for example, H292, breast, and HCT 116) (417, 418). 
 Dye labeled small molecules enable visualization of cellular uptake, localization and selective response 
studies using confocal microscopy. We had prepared cyanine-3 (Cy3) conjugates of apoptolidin A and H enabling 
cellular localization studies that demonstrated localization in the mitochondria using H292 cells (419). Recently, 
Hecht and co-workers demonstrated using dye-labeled conjugates of bleomycin and its corresponding aglycone 
(deglycobleomycin), the selective uptake of the former by cancer cells in cell culture (420-423). We reasoned 
similar studies could be conducted using Cy3 apoptolidins A/H in cell culture leading to a possible explanation 
of the observed cell selectivity as described in the original isolation paper. Furthermore, we employed fluorescent 
flow cytometry to monitor cellular uptake of fluorescent apoptolidin probes in a high-throughput, single-cell 
format. 
 
Materials and methods 
Production and chemical synthesis of apoptolidins and fluorescent derivatives 
Apoptolidins A and H were produced by fermentation of the apoptolidin producer FU 40 and a mutant 
strain (ApoGT2 knockout) at Vanderbilt University. Cyanine-3 derivatives of apoptolidin A and H were prepared 
by semi synthesis as described earlier. 
Uptake of apoptolidins A and H in various cell types 
Human cancer cell lines and peripheral blood mononuclear cells (PBMCs) were used to characterize 
uptake of apoptolidin A and apoptolidin H. The following cell lines were included: SW620 (colon cancer), U87-
MG (glioblastoma), LN229 (glioblastoma), and A549 (lung adenocarcinoma). Cell lines were cultured under 
ATCC recommended protocols. Cells were detached using Trypsin and resuspended in recommended culture 
media at 1 × 106 cells ml−1 prior to drug treatment. Human PBMCs were collected from a healthy donor, following 
the protocols approved by Vanderbilt University Medical Center Institutional Review Board, processed by 
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standard Ficoll preparation protocol, and cryopreserved in liquid nitrogen. PBMCs were thawed and resuspended 
in warm RPMI 1640 media containing 10% FBS at 1 × 106 cells ml−1 prior to drug treatment. Cells were treated 
with either vehicle dimethyl sulfoxide (DMSO), 1 μm of Cy3 apoplolidin A, or 1 μm of Cy3 apoptolidin H for 1 h at 
37 °C. Cells were washed twice in PBS and fixed with 1.6% paraformaldehyde for 10 min at room temperature, 
and were permeabilized with ice-cold methanol for 30 min. 
 
Fluorescence flow cytometry 
After methanol permeabilization, cells were stained with 1:250 anti p-ACC antibody (cell signaling) for 
30 min in the dark at room temperature. Cells were then stained with 1:1000 Donkey anti-Rabbit Ax647 (Life 
Technologies, Carlsbad, CA, USA) for 30 min in the dark at room temperature and were washed and 
resuspended in PBS for analysis on 5-laser BD LSRII (BD Biosciences, San Jose, CA, USA) at the Vanderbilt 
Flow Cytometry Shared Resource and evaluated using the Cytobank software (Mountain View, CA, USA). 
Untreated cells were stained with only the secondary antibody and used as negative control. 
 
Confocal microscopy 
The stained cell suspensions described above were incubated with diaminophenylindole at 1 μg ml−1 for 
10 min at room temperature and placed on glass slides for imaging on an LSM 710 META inverted microscope 
(Zeiss, Oberkdochen, Germany) at the Vanderbilt Cell Imaging Shared Resource. Data were analyzed using 
Zen 2011 software.  
 
Results and Discussion 
In earlier work, we determined (using Cy3) that apoptolidin A and H localized in the mitochondria of 
human lung (H292) tumor cells using confocal microscopy.16 This observation is in complete agreement with 
earlier reports describing apoptolidin A as a potential ATP synthase (oxidative phosphorylation) inhibitor (405, 
406).  
 In the original isolation paper and later when evaluated against the National Cancer Institute 60 (NCI-60) 
human cancer cell line panel, apoptolidin A was described as a selective inhibitor of cell growth (404-406). Cell 
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selectivity can be imparted by either selective cell uptake and/or targeting of cell phenotype (for example, 
metabolic state of a tumor cell). Hecht and co-workers have demonstrated cyanine tagged bleomycin is 
selectively taken up in most cancer cell lines in comparison with ‘normal’ cell counterparts in cell culture (422, 
423). However, these studies determined the activity of compounds, including apoptolidin, after long-term 
treatment (2–6 days) of cells in vitro. Here, we aimed to characterize the immediate uptake of apoptolidin A and 
H by different human cell types, as well as their signaling responses to the treatment.  
We used confocal fluorescent microscopy to characterize the uptake of Cy3 apoptolidin A and H in 
healthy PBMCs and human lung adenocarcinoma (A549) and human glioblastoma (U87) tumor cells after 1-
hour treatment (Figure C-2). The confocal images revealed minimal uptake of Cy3 apoptolidins by healthy 
PBMCs, but higher uptake of Cy3 apoptolidins by A549 and U87 tumor cells.  
 
 
Figure C-2 Differential uptake of Cy3 apoptolidins by tumor cells relative to healthy blood cells 
Confocal images of different human cell types showing minimal Cy3 apoptolidins uptake (green) by healthy PBMCs and 
higher uptake in A549 and U87 cells. Nuclei were stained with diaminophenylindole (pink). Scale bars=50 μm. DIC, 
differential interference contrast.  
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Figure C-3 Fluorescent flow cytometry used to monitor cellular uptake of Cy3 apoptolidins and phosphorylation 
of ACC (Ser79) 
Biaxial contour plots are shown to represent cell density (heat).  
 
Fluorescent phospho-specific flow cytometry (phospho-flow) employs fluorescently tagged antibodies to 
dissect activation of cell signaling pathways in single cells in response to treatment with small molecules including 
natural products (402). As fluorophores with different emission wavelengths can be monitored in different 
channels the uptake of fluorescent small molecules can be monitored as well as cell response. For example, the 
cellular uptake of fluorescent anticancer agents such as daunomycin as well as fluorescent nanoparticles has 
been monitored by traditional flow cytometry (424, 425). Phospho-flow allows quantitative measurement of 
activated signaling responses of individual cells to external stimuli, such as drug treatment. Often patient-derived 
tumor cells contain a heterogeneous mix of different cell subsets, which can harbor distinct sensitivity to 
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exogenous agents. Apoptolidin A and C sensitive cell lines including glioblastoma (U87), were reported to 
undergo autophagy by way of AMPK activation, as indicated by increased phosphorylation of AMPK (Thr 172), 
ACC (Ser79), and ULK1 (Ser555).4 In earlier publications colon cancer SW620 cells were reported as 
apoptolidin A sensitive, while A549 cells appeared apoptolidin A insensitive when evaluated in the NCI-60 cell 
line.2 Using phospho-flow, we monitored cell uptake of Cy3 apoptolidins and phosphorylation of ACC after short-
term (1 h) treatment with vehicle (DMSO) or apoptolidins (Figure C-3). We examined the response of healthy 
PBMCs, glioblastoma (U87 and LN-229), lung adenocarcinoma (A549), and colorectal (SW620) tumor cell lines 
to Cy3 apoptolidins A and H.  
After 1 h of treatment, healthy PBMCs and all four cancer cell lines showed almost complete (>98%) 
uptake of Cy3 apoptolidins A and H (x-axis). Cancer cells showed higher Cy3 signal compared with healthy 
PBMCs, suggesting greater uptake of Cy3 apoptolidin A and H, corresponding to imaging data in Figure C-2.  
We also measured phosphorylation-specific ACC (p-ACC; y-axis), a marker indicative of autophagy 
(406). In all cancer cell lines, we observed a proportion of cell subset that showed high p-ACC signal at baseline 
(DMSO treatment). LN229 glioblastoma cells showed the highest increase in the abundance of this subset, from 
2.74% (DMSO) to 12.39% and 15.28% after Cy3 apoptolidin A and H treatments, respectively. The majority 
(>99%) of p-ACC expressing LN229 cells after apoptolidin treatments were among the Cy3-positive cells, or cells 
that had Cy3 apoptolidin-A and H uptake. In contrast, healthy human PBMCs did not show an increase in p-ACC 
expression in response to apoptolidin treatments.  
A549 and SW620 cells showed only a minimal increase in abundance of cells expressing p-ACC after 
treatment with Cy3 apoptolidin-A and H, suggesting that A549 and SW620 cells were relatively insensitive to 
apoptolidins than LN229 cells at 1 h. However, U87 cells showed no increase in p-ACC activity after short-term 
treatment with apoptolidins A/H.  
In summary, we have shown the utility of fluorescently labeled glycomacrolides (apoptolidins) in 
monitoring cellular uptake and response, using confocal microscopy and fluorescent flow cytometry. All human 
cell types tested showed more than 98% uptake of apoptolidins after 1 h of treatment. LN229 cells responded 
with a markedly increase in p-ACC expressing cells, suggesting their sensitivity to apoptolidins. Even though the 
responses were not as striking, A549 and SW620 cells also showed minimal increase in p-ACC after 1-hour of 
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apoptolidin treatment, whereas healthy human PBMCs and U87 cells did not. Additional kinetics studies would 
be required for in-depth characterization of the effects of apoptolidins in other cell types. While the current work 
was conducted using cell lines, we anticipate this approach will be very useful in the study of heterogeneous cell 
populations using single cell proteomics as this will provide quantitative data on healthy versus tumor cell small 
molecule uptake and response.  
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APPENDIX D 
Discovery of Human Cell Selective Effector Molecules Using 
Single Cell Multiplexed Activity Metabolomics 
 
Authors: David C. Earl, P. Brent Ferrell, Jr., Nalin Leelatian, Jordan T. Froese, Benjamin J. Reisman, Jonathan 
M. Irish, and Brian O. Bachmann 
 
Data presented in this chapter was published in Nature Communications 2018 (Earl, Ferrell, Leelatian et al. 
2018, open access). 
 
Preface 
 This work presents an application of fluorescence cell barcoding (FCB) for high-throughput drug 
screening. Acute myeloid leukemia (AML) patient samples were subjected to ex vivo treatments with crude 
biological extracts from bacteria that were separated using reverse-phase liquid chromatography. This platform 
was coupled with a 48-plex FCB format that is described in detail in Appendix B. This array led to a rapid, high-
throughput, discovery of novel compounds that differentially targeted leukemic blasts and non-malignant blood 
cells.  
 Fluorescence flow cytometry-based high-throughput drug screening can be tailored based on the highly 
flexible layout of FCB. This work is an excellent example of how coupling phosphorylation-specific flow cytometry 
with FCB can effectively and accurately characterize the cell subset-specific mechanisms that occurred as a 
result of treatments with biological extracts, now identified as potential novel therapeutics. Additionally, the liquid 
chromatography was shown here to be an excellent approach for first-pass cytotoxic screening of crude 
biological extracts, bypassing the need for laborious compound isolations. This technique pairs exceptionally 
well with FCB and could be the ideal initial screening platform for future drug discoveries. 
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Abstract 
Discovering bioactive metabolites within a metabolome is challenging because there is generally little 
foreknowledge of metabolite molecular and cell-targeting activities. Here, single-cell response profiles and 
primary human tissue comprise a response platform used to discover novel microbial metabolites with cell-type-
selective effector properties in untargeted metabolomic inventories. Metabolites display diverse effector 
mechanisms, including targeting protein synthesis, cell cycle status, DNA damage repair, necrosis, apoptosis, 
or phosphoprotein signaling. Arrayed metabolites are tested against acute myeloid leukemia patient bone 
marrow and molecules that specifically targeted blast cells or nonleukemic immune cell subsets within the same 
tissue biopsy are revealed. Cell-targeting polyketides are identified in extracts from biosynthetically prolific 
bacteria, including a previously unreported leukemia blast-targeting anthracycline and a polyene macrolactam 
that alternates between targeting blasts or nonmalignant cells by way of light-triggered photochemical 
isomerization. High-resolution cell profiling with mass cytometry confirms response mechanisms and is used to 
validate initial observations. 
 
Introduction 
A metabolome is the sum of primary and secondary metabolites produced by an organism in its 
environment. Constitutive metabolites are capable of interacting intra and extracellularly with receptors and 
active sites within DNA (426-428), RNA (429, 430), and proteins (431, 432), and metabolites are therefore close 
partners in growth, homeostasis, and signaling in heterogeneous environments (433-437). Chemical 
communication mediated via the inventory of an organism’s cellular metabolites therefore defines an important 
molecular axis of interaction within and between organisms (438). Tapping into this communication system has 
become a central empirical activity in chemical biology and has repeatedly illuminated molecular solutions to 
problems with significant clinical relevance, such as the discovery of new bioeffector antibiotics and 
chemotherapeutics (439, 440). Tools to map novel bioeffector molecules to functional roles in responding cells 
—i.e., to identify bioeffector mechanism class—have been adapted into single-cell assays (10, 11) that stratify 
clinical outcomes and predict treatment responses (12, 13, 15, 80, 375, 376). Together with cellular barcoding 
(344, 346) and single-cell chemical biology assays (345), the recent advances in cytomics have raised the 
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exciting possibility of undertaking personalized metabolomic response profiling and bioeffector mechanism class 
identification in primary human tissue biopsies obtained for clinical research (11, 284, 441). 
 Despite the centrality of metabolite functional analysis, the development of a generalizable omics-scale 
solution for uncovering the functional roles of secondary metabolites within disease-relevant cellular contexts 
remains a substantial challenge (442). It is now possible to convert biological extracts (e.g., of microbial culture, 
plant/tissue origin) into highly characterized chromatographic microtiter arrays by split flow liquid 
chromatographic mass spectrometry (443). The biological characterization of such untargeted metabolomic 
arrays results in the generation of “bioactivity chromatograms”, and correlation analysis to matched extracted 
ion current (EIC) mass chromatograms identifies candidate metabolites linked to measured bioassay targets. 
However, per-well single-assay modalities greatly limit the efficiency of this approach, and targeted biochemical 
assays or phenotypic assays against cell lines reveal only a fraction of significant roles of metabolites in arrays. 
 Signaling profiles of primary cancer cells measured using phospho-specific flow cytometry (phospho-
flow) have been shown to stratify the outcome of acute myeloid leukemia (AML) (12, 80) and B cell non-Hodgkin’s 
lymphoma (13, 15) based on signaling network responses to environmental cues, such as cytokines. Single-cell 
chemical biology assays have also been developed for fluorescence cytometry (345) and mass cytometry (300) 
to characterize pathway and cell-type-specific responses to small molecules. Fluorescence cytometry has the 
advantage of cellular throughput and more robust barcoding potential (359), whereas mass cytometry has the 
power to track more than 35 key markers of AML cell phenotype and function simultaneously (12, 290, 374). 
These assays rely on cellular barcoding to multiplex a large number of variables representing stimulation 
conditions, compounds, dosages, or timepoints (344, 346, 400). Such cytomic approaches are further 
strengthened by recently developed computational tools to reveal and characterize changes in cell subsets (290, 
314, 321). 
 Here, a combination of 1) phospho-flow, 2) single-cell chemical biology, and 3) cellular barcoding was 
matched with 4) metabolomic arrays to identify natural product secondary metabolites that specifically target 
primary human leukemia cells and spare adjacent nonmalignant immune cells. This activity metabolomics 
platform is termed multiplexed activity metabolomics (MAM) and comprises a system for single-cell metabolome-
scale analysis of bioactivity using human cells from primary tissue biopsies in a high-throughput screening-
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compatible microtiter format. This untargeted assay modality samples a cross section of biological responses in 
a heterogeneous mixture of cells representing an in vivo human tissue environment and has the potential to 
identify disease-relevant bioactive metabolites within metabolomic arrays. 
 
Results 
Cytometry-enabled MAM platform 
The MAM workflow (Figure D-1) first generates a metabolomic array in microtiter plate format via 
reversed-phase liquid chromatographic separation of a crude biological extract produced by a “stimulus” 
organism. A portion of the effluent is diverted to a polarity-switching electrospray mass spectrometric analyzer 
(ESI-MS) and the remainder of the effluent to a microtiter plate fraction collector after passing through a UV/Vis 
diode array detector. Following evaporation and resuspension of collected fractions, cell preparations from a 
“response” organism (e.g., humans, represented by tissue cells) are added to the microtiter wells for incubation 
with the metabolomic fractions to induce cellular responses (Figure D-1a). Cells within wells are then stained for 
viability, fixed, and permeabilized, and fluorescent cell barcoding (FCB, Figure D-1b) is used to label the well 
contents via differential staining of cells with N-hydroxysuccinimide (NHS) ester-functionalized fluorescent dyes. 
Thus, “barcoded” cells in the microtiter wells are then pooled and stained with multiple fluorescent antibodies to 
quantitate cell status and targeted cell-type-specific responses to metabolites. Critically, flow cytometric gating 
based on the barcoding fluorophores facilitates the assignment of cells to their original coordinates on the 
microtiter plate metabolite array (i.e., “deconvolutes” treatment conditions for each cell), yielding simultaneous 
bioassay marker quantitation per well for each targeted antibody–fluorophore conjugate. Barcoding enables 
high-throughput antibody assays by using a fraction of antibody reagents compared to a microtiter format, and 
pooling also ensures the uniformity of antibody staining of cells across all wells, decreasing experimental 
variation. The result is a multiplexed series of well coordinate-linked immunoassay profiles running through the 
metabolomic fraction array. Metabolomic features (positive and negative m/z, UV, and retention time), which are 
generated via EIC analysis of all significant detected metabolites, are then manually or automatically correlated 
with bioactivity features, which are peaks generated from bioassay profiles across wells. 
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Figure D-1 Metabolome functional analysis by multiplexed activity metabolomics (MAM). a High-data-content 
metabolomic arrays are generated in replicate from a “stimulus” organism via split-flow polarity switching chromatography 
mass spectrometry. A suspension of disaggregated tissue cells from a “response” organism (human) is added to the 
metabolomic array. b Flow cytometric cell barcoding and multiplexed immunoassays are used to identify multiple cell 
type/subtype-specific biological responses to metabolites in the array. Correlation analysis of the resulting bioactivity and 
UV/ESI/MS(±) data generate putative functional activities for metabolites. An example of MAM with a natural product 
producing actinomycete and a cell preparation derived from an AML patient including, but not limited to lymphocytes, 
monocytes, and leukemia blasts, as well as their subtypes is illustrated here. 
  
To maximize available fluorescence channels for multiparameter flow cytometry, FCB was adapted to 
barcode 48 wells with two fluorescent NHS ester-activated dye gradients of NHS-Pacific Orange and NHS-
Pacific Blue. After two-dimensional barcoding, wells were pooled into a single tube and stained with fluorescently 
tagged antibodies. To test the robustness of the FCB assay, Kasumi-1 cells were incubated in 48 wells in a 
checkerboard fashion with vehicle dimethylsulfoxide (DMSO) or one of two benchmark natural products: the 
podophyllotoxin derivative etoposide (444), a potent topoisomerase inhibitor and inducer of double-strand DNA 
breaks, or the bisindole alkaloid staurosporine (445), a classical inducer of apoptosis. After treatment, cells were 
stained with a permeability/viability indicator, Alexafluor 700 (Ax700) (446), barcoded, combined into a single 
tube, and then stained with fluorescently labeled antibodies specific to either cleaved caspase-3 (cCasp3), a 
protein activated in apoptosis (447), or γH2AX, a histone phosphorylated during genomic damage (448, 449). A 
representative workflow and data for etoposide are shown in Figure D-2. Analysis of single-cell events revealed 
two populations for each readout, and biaxial plots of Pacific Orange vs. Pacific Blue yielded 48 distinct 
populations (Figure D-2a). Recovery of the well coordinates and determination of antibody binding in debarcoded 
populations was accomplished using Cytobank, a cloud-based cytometric analysis platform, to confirm 
compound-specific effects (Supplementary Figure D-1a, b). In the case of etoposide, gating for γH2AX and then 
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debarcoding illustrated the bifurcated response within the checkerboard (Figure D-2b), and biaxially gated 
percent changes reflect bioassay results (Figure D-2c). Comparable results were obtained for staurosporine 
(Supplementary Figure D-1c), and these results were used to calculate the standard deviation of each assay 
plate, which conformed to levels in standard practice in high-throughput screening analysis (Z factor>0.77) 
(Figure D-2b and Supplementary Figure D-1c). As an additional evaluation of barcoding, cCasp3 and γH2AX 
expression induced by staurosporine and etoposide, respectively, was demonstrated to be dose dependent 
within assay conditions by separate cytometric barcoding of concentration response curves and quantitating 
antibody binding (Supplementary Figure D-1d). 
 
 
Figure D-2 Validation of a 48-well single-cell chemical biology assay for DNA damage response mechanism class. 
Design of a checkerboard validation experiment using Kasumi cells and a DNA-active natural product. a Overview of 48-
well fluorescent cell barcoding and debarcoding validation. Compounds and vehicle are added in a checkerboard pattern to 
48 wells, and cells are added and incubated prior to being barcoded using dye gradients of N-hydroxysuccinimide functional 
Pacific Orange (PO) and Pacific Blue (PB). Cells are stained with Ax700, fixed, permeabilized, and pooled prior to 
immunoassay with antibodies tagged with nonoverlapping fluorescent dyes. Cells are analyzed by flow cytometry and gated 
selecting (i) intact, single cells, (ii) PO to reveal columns, and (iii) PB to reveal rows and generate populations for each well. 
PO* and PB* denote dye intensity after correcting for cell morphology using a protocol from ref. 67. A data set using Kasumi 
cells for an etoposide checkerboard assayed with γH2AX binding, which is a marker for DNA damage-associated activity is 
shown here. b Graphical representation of well coordinates generated from pooled cells by gating on forward scatter and 
γH2AX and then debarcoding as above to reveal the checkerboard pattern. c Biaxial plots of individual wells representing 
a condition, as in Figure D-1a. d Percent γH2AX positive for each well was calculated using a cutoff of 103.2 to determine 
statistical effect size (Z′). A similar demonstration with etoposide vs. cCasp3 is shown in Supplementary Figure D-1. 
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The integrated analysis of a high-performance liquid chromatography (HPLC)/MS-generated 
chromatographic array in conjunction with FCB and cellular response data (MAM) was validated using a 
chemically defined mixture of bioactive compounds. A mixture of six structurally and mechanistically diverse 
cytotoxic small molecules was chromatographically arrayed and assayed against a human myeloid leukemia-
derived cell line (KG1) using the MAM platform. EIC chromatograms for the six compounds can be readily 
compared to bioactivity chromatograms and demonstrated specific and mechanistically expected responses to 
multiplexed immunoassays (Supplementary Figure D-2a). For instance, the EIC peak for the known apoptosis-
inducing secondary metabolite staurosporine (m/z = 467.5), was the highest correlating peak in the well 25 
bioactivity bin for cCasp3. Similarly, the largest response for γH2AX occurred in well 20, matching the retention 
time of the potent topoisomerase inhibitor etoposide (m/z = 606.5). Of note, in this experiment of modest 
complexity, a single cytometric flow run generates an aggregate of 240 individual raw immunoassays, which 
may be further combined into additional function assays that can be compared to arrayed compound elution 
profiles. Importantly, MAM successfully identified and differentiated compounds in a mixture based on their 
elution profile and differential response to a multiplexed antibody panel. 
 
MAM finds bioactive metabolites within complex extracts 
 The identification of bioactive molecules within complex cellular (e.g., microbial) metabolomes using 
MAM requires that barcoding and bioassay cytometric measurements be stable to potential interferences present 
under typical secondary metabolite-producing conditions, such as soluble extractable cellular metabolites, cell 
wall components, and spent growth medium species. The robustness of MAM was therefore tested by 
fractionating and analyzing a concentrated methanolic microbial extract generated from a Streptomyces strain 
grown in complex media and spiked with etoposide and staurosporine prior to chromatography. Prior to spiking, 
the extract possessed no measurable bioactivity. After fractionation, wells were evaporated, and KG1 cells were 
added to the plate and incubated for 16 h. Subsequent to fixation and permeabilization, cells were barcoded, 
pooled, and assayed using antibodies against γH2AX and cCasp3. Bioactivity chromatograms for these markers 
were generated from the debarcoded data set and formatted for correlation analysis. Cells were effectively 
assigned as distinct populations to the 48 wells according to the dye-gradient selection, demonstrating no 
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cytometric interference with FCB from extract components. Moreover, as shown in Supplementary Figure D-2b, 
lots of median fluorescence intensity for cCasp3, and γH2AX expression per debarcoded population generated 
bioactivity chromatograms for correlation analysis. Importantly, although the EIC abundance of staurosporine 
and etoposide was below the threshold of the average intensity of the TIC (Supplementary Figure D-2c), both 
were the highest Pearson-correlating components in the bioactive fractions. Despite the presence of high-
abundance products of cellular metabolism and media components, no additional potent cCasp3 or 
γH2AXmodulating activities were observed in the test metabolome. 
 
Finding metabolites with anticancer activity in human tissue 
 In addition to quantitating intracellular events and cell status immunomarkers, single-cell characterization 
via cytometry facilitates the differentiation of cell types within heterogeneous mixtures based on cell size, shape, 
complexity (via differential light scattering), and the detection of cell-type-selective surface markers (399, 450). 
This enables characterization of the ways in which the components of metabolomic arrays affect molecular 
phenotypic changes in mixtures of cells, including primary cell preparations that more closely approximate a 
native cancerous microenvironment than pure immortalized cell lines. Acute myeloid leukemia patient bone 
marrow samples were selected as an advantageous system for MAM due to their beneficial cytometric properties 
and clinical significance. AML remains a deadly adult cancer, and treatments have not greatly improved the 5-
year overall survival rate, which is 21.3% overall and remains under 5% for patients who are 65 and older (451). 
Bone marrow biopsies that are routinely obtained from patients being treated for AML contain a complex mixture 
of multiple cancer and normal cell types. These tissues are fully “suspended”, require minimal processing (e.g., 
disaggregation) for cytometric analysis, and contain a mixture of cell types representative of in vivo therapeutic 
contexts. Cytometric characterization of AML via immunophenotyping is widespread in the diagnosis and 
management of this disease, providing a strong basis for biomarker selection and analysis. 
 To test the ability of MAM to assess the effects of a bioactive metabolomic array against a heterogeneous 
cell mixture, microbial metabolomic arrays were incubated with cell preparations derived from AML biopsy 
samples from two separate patients. The patient samples used in this experiment represent two common 
underlying genetic mutational profiles occurring in AML. Patient 001 was a 23-year-old female with a gene 
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translocation (MLL-MLLT3) correlated to intermediate prognosis but without other tested common molecular 
mutations. Patient 015 was a 68-year-old male with the FMS-like tyrosine kinase 3 internal tandem duplication 
(FLT3-ITD) strongly associated with poor prognosis (374), but with otherwise normal cytogenetics. Subsequent 
to aspiration from bone marrow, red blood cells and platelets were removed from the patient samples via density 
gradient separation, resulting in bone marrow mononuclear cells (BMMCs) containing a mixture of 
heterogeneous AML blasts and nonmalignant myeloid and lymphoid cells and their progenitors (452). These 
heterogeneous mixtures served as the response organism system for multiplexed cellular and biochemical 
analysis. For the microbial metabolomic array source organism, we selected an actinomycete strain designated 
Streptomyces specus that we had isolated from Blue Springs cave in Sparta, Tennessee. S. specus was of 
particular relevance, as it had been observed via depreplication analysis of HPLC/MS data to produce a family 
of anthracycline natural products related to the clinically employed AML drug daunorubicin, including baumycins, 
unusual natural acetal functionalized congeners (436), and related anthracycline functional metabolites with 
apparent masses not previously reported. 
 In the case of the S. specus metabolomic array interacting with AML biopsy samples, and gating for the 
three major cell types, the strongest bioactivity was observed in the viable (Ax700−) and γH2AX+ and cCasp3+ 
subsets in both patients (Figure D-3, Supplementary Figure D-3). The sample derived from Patient 015 contained 
the three readily discernable subpopulations of leukemia blasts, myeloid cells, and lymphocytes, which could be 
separately debarcoded to yield defined cell-type response profiles in each well (Supplementary Figure D-3a). 
Patient 001’s sample was comprised of predominantly leukemia blasts and lymphocytes. Individual biaxial plots 
(Supplementary Figs. 4–5) were used to generate well bioactivity profiles based on set positivity thresholds. A 
subset of these bioactivity chromatograms is shown in Figure D-3d and indicates the presence of bioactive 
molecules in the S. specus extract, which can be preliminarily identified via comparison of EIC to bioactivity 
profiles. Bioactivity profiles represent averages of thousands of single-cell measurements and are highly 
reproducible between biological replicates (Supplementary Figure D-3b). Two observations result from this data 
set. First, apparent cell-type selectivity was demonstrated for several features in the metabolomics array. For 
instance, a 2.5- and 47-fold increase in selective blast-targeting bioactivity vs. leukocytes was observed eluting 
in wells 17 and 24, respectively. Second, patient-specific activities were evident in bioactivity profiles. 
205 
  
Examination of HPLC/MS and bioactivity profiles of well 17, containing the most abundant m/z = 442, revealed 
a 30-fold increase in apoptosis and fivefold increase in DNA damage in patient 001 vs. patient 015. A similar 
trend was observed in later eluting wells containing anthracycline chromophores. Notably, patient 015 possessed 
the FLT3-ITD phenotype, which is an internal tandem deletion in kinaseencoding gene FLT3 demonstrated to 
confer resistance to anthracyclines (374). Therefore, these observations are consistent with substantially 
enhanced resistance to anthracyclines in patient 015. 
 To validate bioactive features putatively identified using MAM, most abundant correlating mass features 
were isolated. The most potent bioactivity peak was observed in well 21 and correlated to the most abundant 
eluting anthracycline (m/z = 674), termed specumycin A1. Specumycin A1 was isolated in scale-up fermentations 
and its structure was determined by multidimensional nuclear magnetic resonance experiments (Supplementary 
Table D-2). The planar structure of specumycin A1 is identical to the structures of baumycin A1/2, which contain 
an unusual acetal appending the 3′-O-methyl on the daunosamine sugar (415). The next most abundant feature, 
and the primary feature in well 20, was specumycin B1 (Supplementary Table D-3), a previously unreported 11-
deoxy congener. Specumycin B1 was observed to be as active to A1 under assay conditions but threefold less 
abundant, suggesting a potentially more potent congener. Comprehensive isolation of low-abundance bioactive 
species is beyond the scope of this study. However, cell-type and patient-specific responses identified by MAM, 
such as bioactive metabolites demonstrating enhanced activity against a FLT3-ITD AML sample and selective 
activity for leukemia cells (e.g., well 24, m/z = 1054, Figure D-3), demonstrate the potential of this platform for 
performing preliminary analysis and prioritization of activity differences within a natural product family for 
common AML subclasses. 
The cell-targeting potential of secondary metabolites within metabolomic arrays in the anthracycline-
resistant phenotype sample (015), was further explored employing the soil actinobacterium Nocardiopsis sp. 
FU40 as a source organism. This strain produces a family of bioactive compounds called apoptolidins (A–H) 
(453), which are cytotoxic glycosylated macrolides, and a pair of cytotoxic glycosylated polyene macrolactams, 
ciromicins A and B (454). Thus, a metabolome array was generated from Nocardiopsis sp. FU40, AML Patient 
015-derived anthracycline-resistant cell preparations were incubated with the array and subjected the samples 
to MAM analysis. In Figure D-4 a selection of bioactivity profiles generated from this single data set is shown, 
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indicating how the arrayed metabolome is obtained from Nocardiopsis sp. FU40 can be mined for bioeffectors 
that have selective activity against different cell types present in an AML patient. For instance, apoptolidins 
selectively induced caspase-dependent apoptosis in lymphocytes, whereas ciromicins induced apoptosis most 
prominently in leukemic cells. Similarly, apoptolidin A induced γH2AX, apoptosis, and decreased p-Histone H3 
signaling selectively in lymphocytes, and ciromicins induced more DNA damage in monocytes and blast cells. 
Taken together, these data demonstrate the identification of differential cell targeting of secondary metabolites 
against primary cell mixtures in the background of an extracted microbial metabolome. In contrast to the 
specumycins, ciromicins demonstrate potent selectivity for blasts in comparison to lymphocytes in the 
anthracycline-resistant phenotype. 
 
Light-modulated secondary metabolite cell-type targeting 
 Expansion of the bioactivity chromatogram in the region of ciromicin elution revealed that the isobaric 
metabolites ciromicin A and ciromicin B were resolved into separate wells with strikingly distinct biological 
phenotypes. Specifically, ciromicin A displayed maximal apoptosis markers in leukemia blast cells, whereas its 
photoisomerization product ciromicin B stimulated monocyte apoptosis. We recently reported the discovery of 
ciromicins in an apoptolidin polyketide synthase knockout strain of Nocardopsis sp. FU40, and demonstrated 
that ciromicin B is the product of an unexpected visible light-initiated 12-π electron photoisomerization of 
ciromicin A58. The identification of ciromicins here in the wild-type monoculture of Nocardopsis sp. FU40 was 
surprising because it is produced in low levels in the wild-type strain. Thus, the sensitivity of the MAM platform 
using primary cells was capable of effectively identifying the bioactivity of this low abundant secondary metabolite 
family, and the modest resolution of 48-well binning of fractions was sufficient to resolve bioactivities of closely 
eluting species. 
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Figure D-3 A structurally novel acetal-functional anthracycline selectively targets leukemic blast cells and not 
nonmalignant lymphocytes within a human bone marrow biopsy. a Chromatographic arraying of Streptomyces specus 
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was performed using split flow HPLC/UV/MS with polarity-switching mass scanning resulting in an array of highly 
characterized fractions from a crude extract of the baumycin producer S. specus. Primary cell preparations were prepared 
from AML patient biopsy. The metabolite array was incubated with heterogeneous cell samples, and the cells were then 
viability stained, fixed, barcoded, and stained with antibodies for biomarker and surface marker expression. Standard gating 
was performed using biaxial plots of CD45 expression vs. SSC was used to determine cell-type subsets (blue gate: 
lymphocytes, red gate: blasts) that were each individually analyzed for γH2AX and cCasp3 expression. b Structures of 
specumycin A1 and B1. c Biaxial plots of selected wells gated for lymphocytes and leukemia blasts. d Total ion current and 
selected extracted ion currents of metabolites within the metabolome of S. specus correlating to bioactive wells from assays 
against two patient samples. Bar graphs of percent of cells in the upper left quadrant of marker/viability gate (marker positive 
and viable cells). The solid red line is the arcsinh transformed median of the marker. For patient 015, the average cells 
collected per well were 3996 blasts (minimum 240) and 764 lymphocytes (minimum 66). For patient 001, the average 
collected per well was 1655 blasts (minimum 189) and 53 lymphocytes (minimum 17). 
 
 
 
Figure D-4 An optochemical cell selectivity switching natural product in Nocardiopsis revealed by primary cell 
MAM. The top metabolome row (orange) shows total ion current and extracted ions for ciromicins A and B (m/z = 515, 15, 
and 16 min) and apoptolidin (m/z = 1129.5, 23.4 min) with their elution times shown in dotted lines. The next four rows show 
selected bioactivity chromatograms from a single flow experiment, which were generated by adding an aspirated preparation 
of bone marrow mononuclear cells from an AML patient, barcoding, immunostaining, and debarcoding. The immunostaining 
panel contained CD45 (leukocyte-common antigen), cCasp3 (cleaved caspase), γH2AX (DNA damage), p-Histone H3 (cell 
cycle marker upregulated during mitosis), and p-S6 (marker for active translation). The average collected per well was 5400 
blasts (minimum 209), 750 monocytes (minimum 19), and 291 lymphocytes (minimum 20). Histograms for each marker for 
highlighted wells are shown in Supplementary Figure D-6 
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 The discovery of putative cell-type-specific cellular responses to ciromicin isomers using MAM may be 
considered as a primary screening “hit”, describing a multidimensional response of a metabolomics fraction with 
associated correlation coefficientranked metabolite features. To validate the unusual photochemically triggered 
modulation of primary cell selectivity, pure ciromicins A and B were isolated from scaled-up cultures and assayed 
against the same biopsy sample using an enhanced panel of 29 cell surface markers that classifies all myeloid 
cell populations when paired with unsupervised machine-learning tools. The viSNE algorithm, which allows 
robust identification of both nonmalignant and leukemia cell subsets (452), was applied to data sets collected by 
mass cytometry after a 48-h treatment of patient-derived BMMC with ciromicin A, ciromicin B, or DMSO. In Figure 
D-5a viSNE maps showing the overall changes in the cellular landscape of the primary BMMC after this treatment 
are shown. Proximity in viSNE space corresponds to similarity in cell-type identity, while differences in 
immunophenotype drive separation of cells (dots) on a viSNE map. To quantify the overall shifts in cellular 
subsets, gates were drawn on the viSNE map corresponding to prominent populations based on abundance 
(Figure D-5a). The relative abundance of phenotypically distinct cell subsets present in different treatment 
conditions and the enriched features of these populations were characterized (Figure D-5a). Per cell marker 
expression and median values allowed assignment of cellular identity to populations (Supplementary Figure D-
7). Changes in the relative abundance of each population demonstrated that photoisomerization polarizes overall 
cellular immunophenotype within leukemia cells. Based on subset gating within viSNE, ciromicin B reduced the 
relative abundance of leukemia stem cells and hematopoietic stem cells and smaller blast subsets, while 
ciromicin A reduced the largest blast subset (subset 9, Figure D-5a). Both isomers had comparatively little impact 
on lymphoid cells, which were comprised largely of CD4+ and CD8+ T cells (subsets 2 and 4, Figure D-5a and 
Supplementary Table D-1). Next, marker enrichment modeling (MEM) was used to characterize feature 
enrichment in comparison to a population of CD34+CD38−Lin− cells within the leukemia sample. MEM identified 
changes in populations between ciromicin A and ciromicin B, including greater enrichment for CD13, a marker 
of myeloid differentiation, and CD43, or sialophorin, which is commonly expressed on more mature myeloid cells 
such as granulocytes and monocytes, after treatment with ciromicin A within a major leukemia population (subset 
9, Figure D-5b). Overall, the pattern of cell-type selectivity expanded the depth of the initial screen, validating 
MAM’s ability to identify selectively bioactive compounds. 
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Figure D-5 Photochemical isomers ciromicins A and B selectively target different cell subsets within the 
heterogeneous mixture of patient biopsy cells. Mass cytometry uses DOTA-chelated metals detected by inductively 
coupled plasma mass spectrometry (ICP-MS) to eliminate spectral overlap, expanding the feature range to 29 antibody-
quantified features per cell. a viSNE maps of 20,000 individual cells from each condition are organized according to 
differences in their surface marker profiles for each treatment condition. b MEM labels for three blasts subsets and plots of 
population prevalence with observed prevalence in white and 95% binomial confidence interval represented by a box. c 
Marker enrichment modeling (MEM) was used to characterize major populations within the samples and highlight 
differences in marker expression relative to a gated population of phenotypic hematopoietic stem cells (gate 11). Heat maps 
of hierarchical clustered MEM labels reveal subsets specific differences and cellular identification. Heat maps of median 
marker expression are shown in Supplementary Figure D-7. Dose–response data against PMBCs from a healthy donor and 
patient sample 015 are shown in Supplementary Figure D-8. 
 
Discussion 
 Cancer is challenging to study and to therapeutically manipulate, due in part to the complexity of cell 
signaling processes affected by pharmacological interactions, and system heterogeneity as seen in the 
polyclonal nature of cancer cells, the complexity of the supporting stroma, and the infiltrating immune cells (11, 
80). MAM as implemented here provides a generalizable system to link metabolomic feature data from one 
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organism or system to functional targets or their causally related networks within another heterogeneous cellular 
environment. A key feature of the cytometric strategy underpinning MAM is its ability to analyze heterogeneous 
mixtures of cells, which more closely approximate a native cellular milieu than immortalized cell lines, using 
multiplexed markers of cell status and type. Specifically, MAM was employed here to study the interkingdom 
interactions of metabolomes of two secondary metabolite-producing soil bacteria with primary cell preparations 
from two phenotypically distinct patient-derived AML cell samples. The combination of metabolomics, single-cell 
biology, and cheminformatics used here identified biologically active secondary metabolites produced at low 
levels that mediate apoptosis, DNA damage, and cell signaling in a cohort of cells present in AML patient’s bone 
marrow samples. In this primary cytological screen, differential activities were identified for secondary 
metabolites present within complex and concentrated microbial extracts. 
 The cave-derived bacterium S. specus is a producer of multiple compounds that share the anthracycline 
core of daunorubicin, which is used in combination therapy with nucleoside analog cytarabine as the standard 
of care in the treatment of AML, but differ in decorating glycosides (455). Specumycins described here are 
daunorubicin variants similar to baumycins, appended with an unusual acid-labile acetal moiety on the 3′-
hydroxyl of daunosamine (456), and are reported to demonstrate broad cytotoxicity comparable to that of 
daunorubicin (405). Despite its clinical significance, daunorubicin is actually a low-abundance biosynthetic 
intermediate en route to baumycin in most daunorubicin producers, and is typically isolated by acid-catalyzed 
degradation of baumycin glycosides (456). However, though being the major product of most daunorubicin 
biosynthetic pathways, the potential role of the baumycin acetal moiety in cytotoxicity and cell targeting has 
remained untested prior to this study. Applying MAM to the metabolomic array of S. specus revealed activities 
of a spectrum of specumycin polyketides and related metabolites against divergent primary cell phenotypes. 
Along with the discovery of the previously unreported and more potent compound specumycin B1, these data 
suggest previously unnoticed potential for the 3′-acetal functional in AML anthracycline therapy. Validating the 
observed bioactivity trends, the two most abundant features demonstrated potent activity against leukemia blasts 
and leukocyte cells and were isolated and structurally elucidated. Numerous less abundant species displayed 
remarkable differential cell-type targeting between patients, suggesting an untapped potential for discovery of 
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more selective pharmacological agents within the anthracycline family in biosynthetically competent 
actinomycete strains. 
 Nocardiopsis sp. FU40 was selected as a subject for the MAM platform as its metabolomic array is 
complex, both in terms of the sheer number of apoptolidin analogs it produces (denoted A–H), and in its capacity 
to simultaneously produce polyene macrolactams and aromatic polyketides that were previously reported to 
possess moderate-to-potent cytotoxicity against cell lines. Applying MAM to test Nocardiopsis arrays against 
AML primary cell preparations successfully deconvoluted apoptolidins from ciromicins and revealed distinct cell-
targeting phenotypes. Apoptolidin A and its isobaric analogs present in the extract (isoapoptolidins A and G) 
correlated to the most potent lymphocyte-targeting activity across all markers. The induction of cCasp3 in 
lymphocytes is consistent to prior studies of this compound performed in cell lines, which also present evidence 
in support of mitochondrial FoF1-ATPase targeting within this family (457). Other apoptolidin congeners are 
generally chromatographically dispersed from apoptolidin A, but did not display this degree of activity. Notably, 
the apoptolidins only nominally affected marker expression in leukemia blasts and monocytes, demonstrating 
how MAM readily identifies first-pass cell-targeting activity in primary tissue samples. The distinctive 
blast/myeloid cell-type targeting observed for ciromicins A and B was notable, and careful examination of their 
elution region revealed a remarkable switch of cell specificity between blast and nonblast myeloid lineages for 
the two compounds. 
 As a follow-up to using MAM as a primary assay for lead discovery, mass cytometry was used as a 
secondary validation and deep cell-profiling assay. A 29-marker mass cytometry panel was used to classify the 
cellular effects of purified ciromicins A and B on subsets in primary cell preparations. Mass cytometry revealed 
changes in differentiated immunophenotypic subsets and demonstrated that visible light-induced 
photoisomerization of ciromicin A to B induces wholesale shifts in cell-type targeting and indicating the 
importance of aglycone structure and geometry to the mechanism of action of this family of macrolactams. For 
instance, bicyclic Michael acceptor containing ciromicin A exerted its greatest influence on the largest subset of 
AML cells, whereas tetracyclic potentially less electrophillic ciromicin B targeted stem-like myeloid progenitors, 
a subset that may be beneficial to address in therapy (458, 459). Mass cytometry also revealed that ciromicins 
target leukemia blasts in a patient with an anthracycline-resistant leukemia phenotype and, unlike anthracyclines 
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in the previous study, have little negative effect on lymphoid cells. Finally, mass cytometric findings, performed 
in concert with MAM using patient samples, validated and provided a deeper profiling of bioactive compounds 
discovered. Overall, the multiplexed single-cell approaches used here represent a paradigm shift in comparison 
to typical discovery efforts using monoclonal immortalized cell lines or other research models that do not 
accurately reflect the cell diversity and composition of primary human tumors and leukemic tissues. That 
ciromicins A and B represent photoswitching natural products with distinct cell subtype-targeting phenotypes 
provides potential tools for investigating the pharmacology of this family and the effects of targeting subtypes. 
Notably, molecular photopharmacological switches currently find broad application toward understanding cellular 
function by leveraging the spatiotemporal control afforded by such compounds (460). 
 In summary, a general method is demonstrated for searching preliminary structure–activity relationships 
in secondary metabolite families in producing organisms, without the need for compound isolation, and provides 
insight into how bioactive lead compounds affect diseased and normal cell types in major patient phenotypes 
using clinical samples. Given that there are a limited number of distinct clinical subsets, automated cytometric 
analysis of untargeted metabolomic inventories against sets of relevant patient phenotypes provides a process 
for “personalized” natural product discovery. This is a proof-of-principle study of a viable drug discovery platform. 
In a full-scale implementation, cells derived from multiple patients, including cells derived from healthy 
individuals, would be necessary to realize the full scope of lead-compound preclinical assessment. While applied 
here for the case of identifying bioactive secondary metabolites within metabolomes, the MAM platform enables 
the discovery of cellular responses to molecular inventories, regardless of sources. Given the importance of all 
chemical communications in mediating life processes within and between organisms, a generalizable method 
for identifying functional roles for metabolites has significant potential in applications spanning a broad range of 
applications in cellular chemical biology. 
 
Methods 
Preparation of microbial crude extracts  
Streptomyces strains were maintained on ISP2 agar (yeast extract 4 g/L, malt extract 10 g/L, glucose 4 
g/L, and agar 20 g/L, pH 7.2). Loops of mycelia were used to inoculate 5-mL seed cultures in ISP2 medium 
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(yeast extract 4 g/L, malt extract 10 g/L, and glucose 4 g/L, pH 7.2) for Streptomyces strains, incubating them 
for 3 days at 30 °C. Seed cultures were then transferred to 250-mL Erlenmeyer flasks containing 25 mL of BA 
medium (soybean powder 15 g/L, glucose 10 g/L, soluble starch 10 g/L, NaCl 3 g/L, MgSO4 1 g/L, K2HPO4 1 
g/L, and trace elemental solution 1 mL/L, pH 7.2) and grown for 7 days at 30 °C with shaking. Aqueous 
fermentation broth was extracted by shaking with Diaion HP20 synthetic absorbent resin (Alfa Aesar) (125 mL 
of HP20 bead/H2O slurry per 500 mL of aqueous broth) for 2 h. Fermentation broth was then centrifuged (3700 
× g, 30 min) and the supernatant was decanted. Metabolites were eluted from absorbent resin and cells with 
methanol (250 mL of methanol/125 mL of HP20 bead/H2O slurry) by shaking for 1.5 h, followed by centrifugation 
(3700 × g, 30 min) and decanting of the methanol extract. Further extraction was performed with acetone (250 
mL of acetone/125 mL of HP20 bead/H2O slurry) by shaking for 1.5 h, followed by centrifugation (3700 × g, 30 
min) and decanting of the acetone extract. Nocardiopsis strains were cultured and extracted as previously 
described (453). Purified ciromicins A and B were isolated from co-cultures as previously described (454). 
Kasumi-1 and KG-1 cell lines were obtained from ATCC and identified using mass cytometry analysis of 35 
myeloid proteins as reported previously (374). 
 
Specumycin A1 and B1 isolation  
Crude acetone extract was concentrated and fractionated with Sephadex LH-20 resin (GE Healthcare 
Bio-Sciences) with methanol as the eluent. Fractions were analyzed by analytical HPLC/MS, and fractions 
containing the compound(s) of interest were pooled and further purified by preparative HPLC (Waters, XBridge 
C18 Prep, 5 μM) (10 mL/min, 0–1 min: 100% solution A, 5 min: 85% solution A; 15% solution B, 65 min: 15% 
solution A; 85% solution B, and 70 min: 100% solution B) (Solution A = 95:5, H2O:MeCN, 10mM NH4OAc; 
Solution B: 5:95 H2O:MeCN, 10mM NH4OAc). In order to obtain analytical purity, fractions containing the 
compound of interest (34–35 min) were pooled and purified by flash column chromatography (98:2 
CH2Cl2:MeOH to 95:5 CH2Cl2:MeOH). The structure of specumycins A1 and B1 was elucidated using a 
combination of mass spectrometry and two-dimensional nuclear magnetic resonsance spectroscopy data. Mass 
spectrometry data produced with electrospray ionization and collected in both positive and negative modes 
provided the molecular weight of specumycins A1 and B1. Correlated nuclear magnetic spectroscopy (COSY) 
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allowed for the assignment of the spin systems present in the aglycone, amino sugar, and acetal moieties of 
specumycins A1 and B1. Multiplicity-edited heteronuclear single-quantum coherence spectroscopy allowed for 
assigned 1H shifts to be correlated to their corresponding 13C shifts, as well as for the assignment of shifts as 
corresponding to methylenes or methines. Full structure elucidation was completed with heteronuclear multiple-
bond correlation spectroscopy, which allowed for the assignment of remaining shifts based upon their proximity 
to assigned shifts. 
 
Generation of metabolomic arrays 
Mass spectrometry was performed by using a TSQ Triple Quantum mass spectrometer equipped with an 
electrospray ionization source and Surveyor PDA Plus detector. For positive ion mode, the following settings 
were used: capillary temperature was 270 °C; spray voltage 4.2 kV; spray current 30 mA; capillary voltage 35 V; 
tube lens 119 V; and skimmer offset 15 V. For negative ion mode, capillary temperature 270 °C; spray voltage 
30 kV; spray current 20 mA; capillary voltage 35 V; tube lens 119 V; and skimmer offset 15 V. Fraction plates 
were prepared by injecting 20 μL of purified compounds in methanol or concentrated extract via a Thermo PAL 
auto injector onto a phenomenex luna 5 μm C18(2) reverse-phase HPLC column. The sample was fractionated 
using a gradient of 100% Buffer A (95% H2O, 5% acetonitrile) to 100% Buffer B (5% acetonitrile, 95% H2O) over 
48 min at a flow rate of 1 mL/min and a fixed splitter with a 3:1 ratio with three parts going to the photodiode 
array detector and fraction collector and one part going to the MS. Fractions were collected in 1-min intervals in 
a 96 deep well plate. A volume of 150 μL of eluent from each well was transferred to four replica plates and dried 
in vacuo using a Genevac HT-2 system at 30 °C. 
 
Fluorescent cell barcoding of cell-seeded metabolomic arrays  
Eight serial 1:2.14 dilutions of Pacific Blue were prepared, covering a concentration range from 0.038 to 
7.67 μg/mL. Six serial 1:2.5 dilutions of Pacific Orange were prepared, covering a concentration range from 0.22 
to 21 μg/mL. Each dilution of Pacific Blue was added to all wells in a single row of a 96-well plate (10 μL/well), 
so that the dye concentration in each row decreased from the top to the bottom of the plate. Similarly, each 
dilution of Pacific Orange was added to all wells in a column of the same 96-well plate (10 μL/well), so that the 
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concentration in each column decreased from columns 1 to 6 and from columns 7 to 12. This procedure yielded 
two sets of 48 barcoded wells per plate. Approximately 200,000 cells (180 μL suspended in phosphate-buffered 
saline (PBS)) were added to each well and incubated in the dark at room temperature for 30 min. Staining was 
then quenched by addition of 75 μL of 1% BSA (Sigma) in PBS. 
 
Antibody staining  
Cells were stained with antibodies in 100-μL staining medium for 30 min in the dark, unless otherwise 
noted. Individual antibodies were added in accordance with the manufacturer’s instructions. Staining was 
quenched with 1% BSA in PBS, and stained cells were washed with PBS prior to analysis. 
 
Validation checkerboard 
Kasumi-1 cells were incubated with either 20 μM etoposide or 1 μM staurosporine and/or DMSO in a 
checkerboard pattern overnight. After treatment, cells were stained with Alexa 700, fixed, permeabilized, 
barcoded, pooled, and then stained with anti-γH2AX-PerCP-Cy5.5 (clone N1-431, BD) or anti-cleaved caspase-
3-PE (clone C92-605, BD). Subsequent to staining, samples were run on a five-laser BD Fortessa flow cytometer. 
Upon gating single-cell events, wells were debarcoded, and the percent of positive cells for each respective 
marker was determined for each of the 48 populations. Z scores were calculated according to the formula Z = 1 
– 3(σp + σn)/|μp – μn|. 
 
Dose–response curves 
Serial dilutions of etoposide and staurosporine were prepared from DMSO stocks (10 mM) covering a 
range from 100 μM to 100 nM. A volume of 1 μL of each dilution point was added to a well. Each compound 
titration was handled individually on a separate plate. KG1 cells [150,000 in 199 μL of culture medium (RPMI1640 
+ 20% FBS + 1% penicillin/streptomycin)] were added to each well and mixed by pipetting. After incubation for 
16 h, cells were stained with Alexa 700, fixed with 1.6% paraformaldehyde, and permeabilized in methanol for 
20 min at –20 °C. Wells were then barcoded as described above, combined, and then stained with antibodies 
specific for anti-cleaved caspase-3-PE (clone C92-605, BD), or anti-γH2AX-PerCP-Cy5.5 (clone N1-431, BD). 
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MAM protocol with six pure compounds 
DMSO stocks (10mM) of etoposide, staurosporine, CL994, PF04708671, PCI34051, mevastatin, and 
NU7441 were added (1 μL each) to 43 μL of methanol and fractionated as described above. Before addition of 
cells, compounds in the wells were suspended by addition of 1 μL of DMSO and mixing by Vortex. KG1 cells 
[150,000 in 199 μL of culture medium (RPMI1640 + 20% fetal bovine serum (FBS) + 1% penicillin/streptomycin)] 
were added to each well and mixed by pipetting. After incubation for 16 h, cells were stained with Alexa 700, 
fixed with 1.6% paraformaldehyde, and permeabilized in methanol for 20min at −20 °C. Wells were then 
barcoded as described above, combined, and then stained with the following antibodies: anti-cleaved caspase-
3-PE (clone C92-605, BD), anti-p-Histone H3-PE-Cy7 (clone HTA28, BioLegend), anti-γH2AX-PerCP-Cy5.5 
(clone N1-431, BD), and anti-p-S6-Ax647 (clone D57.22E, CST). 
 
MAM using crude extract with internal standards 
DMSO stocks (10 mM) of etoposide and staurosporine were added (1 μL each) to 48 μL of a crude extract 
(200 mg/mL in 50% methanol/water) and fractionated as described above. The extract was generated from a 
Streptomyces cave strain grown in BA medium, and extracted with 50% methanol prior to evaporation in vacuo. 
Before treatment, compounds in the wells were suspended by addition of 1 μL of DMSO and mixing by vortexing. 
KG1 cells [150,000 in 199 μL of culture medium (RPMI1640 + 20% fetal bovine serum (FBS) + 1% 
penicillin/streptomycin)] were added to each well and mixed. After incubation for 16 h, cells were stained with 
Ax700, fixed with 1.6% paraformaldehyde, and permeabilized in methanol for 20 min at −20 °C. Wells were then 
barcoded as described above, combined, and then stained with anti-cleaved caspase-3-PE (clone C92-605, BD) 
and anti-γH2AX-PerCP-Cy5.5 (clone N1-431, BD). 
 
AML patient samples 
All specimens were obtained in accordance with the Declaration of Helsinki following protocols approved 
by the Vanderbilt University Medical Center Institutional Review Board. Details of patients and sample acquisition 
were previously published49. Briefly, consent was obtained via an approved written consent form, and eligibility 
criteria included ≥18 years of age with suspected AML undergoing clinical evaluation at Vanderbilt. Samples 
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analyzed here were collected from bone marrow prior to any treatment. Once obtained, samples underwent 
immediate (within <30 min) density gradient separation of mononuclear cells using a BD Vacutainer CPT Cell 
Preparation Tube with Sodium Heparin (BD Biosciences, Franklin Lakes, NJ). The separated mononuclear cells 
were then pelleted with low-speed centrifugation (200 × g) and aliquoted into multiple cryotubes in an 88% FBS 
+ 12% DMSO solution. Samples were stored at −80 °C for 24–72 h prior to long-term storage in liquid nitrogen. 
Patient 1,305,001 (001) was found to have the MLL-MLLT3 t(9;11)(p22;q23) translocation in all cells by 
karyotype analysis and was without other tested common molecular mutations (which included FLT3-ITD, NPM1, 
CEPBA, and c-KIT)66. Patient 1305015 (015) had a normal karyotype, but was found to have both a FLT3-ITD 
and an NPM1 mutation. 
 
MAM of bacterial extracts against primary cell preparations 
Primary cell preparations were thawed, and 200,000 cells were added to each well of a fraction plate 
containing a metabolite array that was generated from a crude extract from S. specus or Nocardiopsis sp. FU40. 
After a 16-h incubation, cells were stained for viability, fixed, permeabilized, barcoded, and stained with the 
following antibodies: anti-Human CD45-Ax488 (clone HI30, BioLegend), anti-cleaved caspase-3-PE (clone C92-
605, BD), anti-p-Histone H3-PE-Cy7 (clone HTA28, BioLegend), anti-γH2AX-PerCP-Cy5.5 (clone N1-431, BD), 
and anti-p-S6-Ax647 (clone D57.22E, CST). SSC and CD45 expression were used to define lymphocyte, 
monocyte, and blast populations. Each population was then debarcoded, and readouts were determined for 48 
wells per cell type. 
 
Deep profiling of ciromicins A and B against primary cell preparations 
Ciromicins were purified by separation on a Water 600 HPLC system with a reverse-phase column using 
a linear gradient of water/acetonitrile containing 0.1% formic acid. Fractions with UV absorbance indicative of 
ciromicins were then combined and applied on a size exclusion Sephadex LH-20 column for a gravity elution in 
methanol. Ciromicin A and B were then separated by a secondary HPLC purification. Approximately 6 million 
cells (2 million per condition) from a thawed primary AML sample were incubated in culture medium [80% RPMI 
1640 (Mediatech, Inc., Manassas, VA) + 20% FBS (Gibco standard FBS, Life Technologies, Grand Island, NY) 
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with 10 μM ciromicin A, ciromicin B, or DMSO] for 48 h. Mass cytometry experiments were performed as 
previously described17. Briefly, after incubation with ciromicin A, B, or vehicle, samples were pelleted by 
centrifugation at 200 × g, resuspended and washed with PBS (HyClone, HyClone Laboratories, Logan, UT), 
pelleted, and resuspended in PBS. They were then stained with Cell-ID Cisplatin (Fluidigm, South San Francisco, 
CA) as per the manufacturer’s recommended protocol. The cells were washed and resuspended in staining 
medium [CSM: PBS + 1% BSA (Fisher Scientific, Fair Lawn, NJ)]. Cells were then stained with a mass cytometry 
antibody panel of 29 extracellular antibodies designed to characterize AML blasts and most non-AML peripheral 
blood mononuclear cells consisting of anti-human CD235a-141 (clone HIR2, Fluidigm), anti-human CD117-143 
(clone 104D2, Fluidigm), anti-human CD11b-144 (clone ICRF44, Fluidigm), anti-human CD4-145 (clone RPAT4, 
Fluidigm), anti-human CD64-146 (clone 10.1, Fluidigm), anti-human CD36-147 (clone 5-271, BioLegend), anti-
human CD34-148 (clone 581, Fluidigm), anti-human CCR2-149 (clone K036C2, BioLegend), anti-human CD43-
150 (clone 84-3C1, Fluidigm), antihuman CD123-151 (clone 6H6, Fluidigm), anti-human CD13-152 (clone 
WM15, Fluidigm), anti-human CD45RA-153 (clone HI100, Fluidigm), anti-human CD45-154 (clone HI30, 
Fluidigm), anti-human CD86-156 (clone IT2.2, Fluidigm), antihuman CD33-158 (clone WM53, Fluidigm), anti-
human CD11c-159 (clone BU15, Fluidigm), anti-human CD14-160 (clone M5E2, Fluidigm), anti-human CD32-
161 (clone FUN-2, BioLegend), anti-human CDHLA-DR-163 (clone L243, BioLegend), anti-human CD15-164 
(clone W6D3, Fluidigm), anti-human CD16-165 (clone 3G8, Fluidigm), anti-human CD38-167 (clone HIT2, 
Fluidigm), anti-human CD8-168 (clone SK1, Fluidigm), anti-human CD25-169 (clone 2A3, Fluidigm), antihuman 
CD3-170 (clone UCHT1, Fluidigm), anti-human CD184-173 (clone 12G5, Fluidigm), anti-human PD1-174 (clone 
EH12.2H7, Fluidigm), anti-human PD-L1-175 (clone 29E.2A3, Fluidigm), and anti-human CD56-176 (clone 
CMSSB, Fluidigm) 50. A master mix of these antibodies was added to each sample to give a final staining volume 
of 50 μL and incubated at room temperature for 30 min. Cells were then washed twice, first with CSM and then 
with PBS and then permeabilized in –20 °C 100% methanol for 20 min. Following permeabilization, cells were 
washed, stained with 250 nM iridium intercalator (Fluidigm, South San Francisco, CA) for 30 min at 4 °C, washed 
twice in PBS, and then resuspended in 500 μL of ddH2O for CyTOF analysis. Samples were analyzed using a 
CyTOF 1.0 cytometer (Fluidigm, South San Francisco, CA) (452). 
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Data availability 
Kasumi validation data (Figure D-2) and AML patient sample responses to S. specus (Figure D-3) and 
Nocardiopsis (Figure D-4) were generated by fluorescence cytometry as described by Irish et al (15, 80). and 
Krutzik et al (344, 345, 400). and are available as FCS files in FlowRepository 
(https://flowrepository.org/experiments/1476, https://flowrepository.org/experiments/1477, 
https://flowrepository.org/experiments/1478, and https://flowrepository.org/experiments/1479). AML patient 
sample responses to ciromicin A and ciromicin B (Figure D-5) were generated by mass cytometry as described 
by Leelatian et al (81). and Ferrell et al (374). and are available as FCS files in FlowRepository 
(https://flowrepository.org/experiments/1480). MEM enrichment scores (Figure D-5b) were generated as in 
Diggins et al (321). using stem-like population 11 as a reference. 
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Supplemental information 
 
Figure SD-1. Gating strategy for assay validation and demonstration of dose dependent behavior in FCB array 
assays. a) All collected events from etoposide checkerboard experiment were gated for intact cells (FSC vs SSC), then 
single cells (FSC vs FSC-W) and finally for maker expression. Biaxial plots of single cells (PO vs PB) colored by γH2AX 
expression visually reflect the checkboard pattern. Plots of only γH2AX- cells or γH2AX+ cells show populations whose FCB 
coordinates match assay wells with vehicle or compound respectively. b) Same as (a) for staurosporine checkerboard 
experiment with cCasp3 used as the marker readout. c) Determination of z score from staurosporine checkerboard. d) A 
titration series of etoposide and staurosporine was prepared on a microtiter plate, incubated with KG1 cells, barcoded and 
stained. EC50 values were calculated using the median fluorescent intensity of cell populations from each well. The average 
collected cells per well used to calculate z score was 1016 events (minimum 79). The average collected cells per well used 
to calculate EC50 values was 3122 events (minimum 794). 
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Figure SD-2. Integration and validation of chromatographic arrays and FCB. Chromatographic arraying is performed 
using split flow HPLC/UV/MS with polarity switching mass scanning resulting in an array of highly characterized fractions. 
a) A mixture six bioactive small molecules was arrayed onto a microtiter plate via split flow HPLC/MS fractionation and 
solvent was evaporated. Subsequently KG1 cells were added to the wells of the plate for incubation with the various 
toxicants. Cells were stained with Alexa-700 dye to indicate cell viability, fixed, permeabilized, barcoded, pooled and then 
immuno-stained with antibody-dye conjugates for DNA damage and apoptosis using anti-γH2AX and anti-cCasp3, 
respectively, and additional conjugates directed against phosphorylated Histone H3 (p-HH3), and phosphorylated ribosomal 
protein S6K (p-S6). The sample was analyzed via flow cytometry, and reconstructed bioactivity chromatograms were 
generated by gating on viable and marker positive (γH2AX and cCasp3) or marker negative (p-Histone H3 and p-S6) cells. 
Selective ion traces are aligned with bioactivity chromatograms. b) crude extract spiked with etoposide and staurosporine 
prior to fractionation. Bioactivity chromatograms were constructed using the arcsinh transformed median of all cells per well. 
c. expansion of TIC, and EIC for etoposide and staurosporine. Red line denotes threshold for signal greater than 3 standard 
deviations of the readout from 4 blank control wells. The average collected cells per well in a was 656 events (minimum 89) 
and in b was 1277 (minimum 102). 
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Figure SD-3. Comparison of replicates of MAM with primary patient samples. a) Samples from patient 015 were 
incubated with two replicate plates of the fractionated S. specus extract. b) Bar graphs show the average of the arcsin 
transformed medians for each marker for the two experiments. Error bars are standard deviations. For each of the 48 
lymphocyte populations from each well, an average of 1360 events were recorded in each replicate experiment. For myeloid 
populations the average collected cells per well was 595 and for blast populations was 5755. 
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Figure SD-4. Biaxial plots of cCasp3 vs Ax700 from fraction wells containing specumycins. The predominant analogs 
of the specumycins elute from 20 to 21 minutes with well 21 containing the highest amount of specumycin A. Also shown 
are the biaxial plots from well 48 which contained only elution buffer and well 24 containing the m/z 1054. 
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Figure SD-5. Biaxial plots of γH2AX vs Ax700 from fraction wells containing specumycins. Same as Supplementary 
Figure D-4. except corresponding plots for γH2AX are shown instead. 
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Figure SD-6. Histogram plots of each marker in control wells and highlighted wells in Figure D-4. a) Marker 
distribution in wells 23 and 24 which had the maximal response in lymphocytes and contained the apoptolidins. b) and c) 
Marker distribution in wells 15 and 16 which contained the ciromicins which induced the largest response in monocytes and 
blasts. 
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Figure SD-7. Median marker expression of gated viSNE populations. a) 12 major populations were identified after 
viSNE analysis and gated. b) Median marker expression for each gated population after treatment with vehicle, ciromicin A 
or B. c) MEM text labels for gated populations with population 11 (LSC/HSCs) used as reference. 
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Figure SD-8. 24 hour titration of ciromicins assayed against a PBMCs from a healthy donor and b a AML patient 
sample. Points represent the average of two replicate experiments. 
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Table SD-1. Changes in Population (Percent of Cells) in Response to Ciromicins 
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Table SD-2. NMR Shift Assignments for specumycin A1 
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Table SD-3. NMR Shift Assignments for specumycin B1 
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APPENDIX E 
Characterizing Cell Subsets Using Marker Enrichment Modeling 
 
Authors: Kirsten E. Diggins, Allison R. Greenplate, Nalin Leelatian, Cara E. Wogsland, and Jonathan M. Irish 
 
Data presented in this chapter was published in Nature Methods 2017 (Diggins, Greenplate Leelatian et al. 2017) 
 
Preface 
 The most differentially or most highly expressed cellular features are often the presumed significant 
characteristics of a given cell population. However, these features can show certain variability even within a 
seemingly uniform cell type. The work presented here introduces a new quantitative measure of cellular features, 
Marker Enrichment Modeling (MEM), which emphasizes not only the magnitude of feature expression but also 
feature variability. MEM determines, quantitatively, how specific a feature is to a given cell subset, compared to 
a reference point. This was proven to be powerful for cell subset identification compared to the qualitative 
description of canonical lineage markers, even in the context of a well-described human tissue type. Specifically, 
MEM effectively distinguished glioblastoma cells from tumor-infiltrating immune cells even without the 
information of canonical identity proteins. 
 This work is incorporated as a component of the automated risk-stratification workflow that led to the 
discovery of novel stratifying glioblastoma cell subsets, described in Chapter 6. Importantly, MEM was key to 
revealing the enriched features that specifically and critically defined the clinically significant glioblastoma cells. 
This led to the development of a clinically applicable manual analysis workflow and suggested the essential 
features of clinically unfavorable cells that should be tested as targets for innovative therapy in glioblastoma. 
 
Abstract 
 Learning cell identity from high-content single-cell data presently relies on human experts. We present 
Marker Enrichment Modeling (MEM), an algorithm that objectively describes cells by quantifying contextual 
feature enrichment and reporting a human and machine-readable text label. MEM outperforms traditional metrics 
in describing immune and cancer cell subsets from fluorescence and mass cytometry.  MEM provides a 
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quantitative language to communicate characteristics of new and established cytotypes observed in complex 
tissues. 
 
Main Text 
Quantitative cytometry workflows have developed diverse approaches to grouping cells into populations 
and visualizing results in graphs that arrange populations based on phenotype (314, 394). Important features of 
populations are typically assumed to be those most highly or differentially expressed. This approach works well 
when feature variability is low and cells match established types, but computational analysis of single cell data 
routinely reveals novel cells with non-canonical phenotypes (5, 294, 441).  This is especially common in diseases 
where abnormal expression profiles and signaling responses distinguish clinically significant cell subsets (12, 
15, 80, 360, 375).  Existing statistical approaches can be used to characterize a population’s degree of difference 
from a reference, but may be limited to a normal distribution or may not account for intra- and inter-population 
variability in a single metric.   
 The MEM equation (equation (1)) produces a signed value for each population feature by quantifying 
positive and negative, population-specific, contextual feature enrichment relative to a reference cell population 
(Supplementary Note 1).  
MEM score = ,    (MAGPOP-MAGREF) <0  MEM = -MEM       (Eq. 1) 
In Eq. 1, POP denotes the population of interest, REF denotes the reference population to which POP 
will be compared, MAG is feature magnitude (here, median protein expression detected by mass or fluorescence 
flow cytometry), and IQR indicates the interquartile range.  A reference population (REF) is chosen based on a 
biological comparison of interest (Supplementary Note 1, Supplementary Table 1, Supplementary Figure E1).  
MEM was designed to quantify enrichment, whereas other metrics used in cytometry, such as Kolmogorov-
Smirnov (K-S) (461), area under the ROC curve (AUC) (462), and Earth Mover’s Distance (EMD) (463), capture 
other differences between frequency distributions (Supplementary Note 1).  In datasets including healthy human 
blood, bone marrow, and tonsil, murine tissues, and human tumors, MEM identified key proteins used by experts 
to distinguish rare and novel cell subsets.  
1|| 


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 Four cytometry studies, Dataset A (81), Dataset B (83), Dataset C (294), and Dataset D, collected as 
described by Leelatian and Doxie, et al. (284), were used to evaluate the ability of MEM to identify biological 
features of expert and machine identified cell subsets.  For datasets A, B, and C, populations had been previously 
identified by experts and by computational tools including viSNE (290) and SPADE (282), which are used in 
mass cytometry for dimensionality reduction and cell clustering (314), respectively.   
Dataset A was mass cytometry data quantifying expression of 25 proteins on healthy human peripheral 
blood mononuclear cells (PBMC) (81).  This dataset was chosen for two reasons: 1) the 7 cell subsets present 
are well-established, phenotypically distinct populations that served as a gold standard of biological ‘truth’ and 
2) the cells in each of the 7 subsets were characterized for 25 proteins that displayed varying homogeneous and 
heterogeneous expression patterns.  Populations were expert gated following viSNE analysis and each 
population was compared to the other cells in the sample (Figure E1, Supplementary Table 2).  MEM returned 
labels that matched prior expert analysis (81) and correctly assigned high positive enrichment values to canonical 
protein features of each subset (Figure E1b), including CD4 on CD4+ T cells (▲CD4+6 CD3+5 ▼CD8a-4 CD16-3), 
IgM on IgM+ B cells (▲MHC II+8 IgM+6 CD19+5 ▼CD4-6 CD3-5), CD11c and MHC II on monocytes (▲CD11c+8 
CD33+7 CD14+6 CD61+6 MHC II+4 CD44+3 ▼CD3-5 CD4-4), and CD16 on NK cells (▲CD16+9 CD56+2 CD11c+2 
▼CD4-7 CD3-4 CD44-3).  Proteins that were not significantly enriched on any of the 7 subsets of mature human 
blood mononuclear cells were correctly assigned near-zero MEM scores (e.g. CD34 and CD117 proteins 
expressed on hematopoietic stem cells, Figure E1b).  Similarly, proteins with little variability across cell subsets 
were assigned low, near-zero MEM scores, even for highly expressed proteins (e.g. CD45 on all subsets, 
CD45RA on non-T cells, Figure E1b).  Incorporating information about feature variability allowed MEM to capture 
negative enrichment that was not reflected in magnitude difference (MAGDIFF, Supplementary Note 2). Highly 
enriched proteins were more important to accurate population identification than proteins characterized by high 
median expression alone (Figure E1c; Supplementary Figure E2; Supplementary Figure E3).   
To test the hypothesis that features with high MEM scores would be important for computational cluster 
formation, the 25 proteins measured in Dataset A (Figure 1b) were sorted in six ways: 1) high to low MEM score, 
2) high to low median value, 3) high to low MAGDIFF, 4) high to low z-score, 5) high to low K-S statistic, and 6) 
randomly (Supplementary Table 3). Z-score and K-S statistic values are shown in Supplementary Table 4. The 
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proteins were then sequentially, cumulatively excluded from use in k-means clustering and f-measure was 
calculated to measure clustering accuracy (Figure E1c and Supplementary Figure E2). The order in which 
markers were excluded is shown in Supplementary Table 3. Random exclusion was performed 15 times and the 
average result is shown (Figure E1c). Clustering accuracy was most impacted by excluding proteins based on 
MEM score.  F-measure dropped to 0.75 after removing the proteins with the top 6 MEM scores, whereas a 
comparable F-measure decrease was only observed after removing the 14 highest markers based on MAGDIFF, 
the 13 highest markers based on z-score, and the 12 highest markers based on K-S statistic values 
(Supplementary Figure E2). Removing markers based on median was not significantly different from removing 
markers randomly until the 15 markers with the highest median signal intensity were excluded (Supplementary 
Figure E2).   The same analysis was performed with viSNE in place of k-means clustering to visualize loss of 
population resolution (Supplementary Figure E3c). In this case, loss of accuracy was reflected in the viSNE map 
as a loss of separation between “islands” of cells. These results indicated that MEM enrichment scores captured 
markers that were important to cell identity better than traditional comparisons based solely on median protein 
expression.   
Dataset B was mass cytometry data quantifying expression of 31 proteins on healthy human bone marrow 
(83). Computational and expert analysis had previously identified 23 populations of cells that were analyzed here 
by MEM (Supplementary Note 3).  For example, the cell subset labeled as HSCs was highly enriched for CD34 
(CD34+6) and negatively enriched for CD45 (CD45-5). Dataset B also illustrated the general rule that MEM scores 
will approach median values as feature variability within populations decreases (Supplementary Figure E4).  
MEM captured feature enrichment and heterogeneity better than median in diverse populations, as in Figure 
E1c. 
Dataset C was mass cytometry data quantifying expression of 38 proteins on murine cells from eight 
tissues4 (Supplementary Note 4).  In this dataset, “cluster 28” was a novel population identified as CD11bint NK 
cells.  The MEM label for cluster 28 within ILCs was ▲CD11b+5 CD62L+3 ▼CD4-7 CD103-4 Terr119-3 
(Supplementary Note 4 and Supplementary Figure E5).  This MEM label captured the key feature of this novel 
innate lymphoid cell subset (CD11bint) and highlighted additional features that can be used to match this subset 
to cells identified by others (i.e., to cytotype the population).  These results indicate that MEM labels complement 
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unbiased population discovery and effectively characterize cyto incognito (296) by providing unbiased 
descriptions that correctly capture key features of novel cell types. 
 
Figure E-1 Marker enrichment modeling (MEM) automatically labels human blood cell populations in Dataset A. a) 
Cells from normal human blood grouped into 7 canonical populations using viSNE analysis and expert review of 25D mass 
cytometry data.  b)  MEM labels computationally generated for each canonical cell subset. Heatmaps show protein 
enrichment values used to generate MEM labels and the median protein expression values for each protein on each cell 
subset.  Variability in protein expression across the 7 canonical cell populations is shown below to highlight proteins that 
were expressed homogeneously (low variability, e.g. CD45) and those that were expressed heterogeneously (high 
variability, e.g. CD8a, CD4). c) Graphs show decreasing f-measure (clustering accuracy) as markers were excluded from 
k-means cluster analysis based on high to low absolute MEM or median values, compared to random exclusion. 
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Figure E-2 Hierarchical clustering based solely on MEM label groups T cells and B cells measured in diverse studies 
using different cytometry platforms. A) MEM label values were compared for each of 80 populations (CD4+ T cells and 
B cells) from 3 human tissues representing 6 mass cytometry studies and 1 fluorescence flow cytometry study.  Populations 
are shown clustered according to MEM label percent similarity.  Tissue type, source study (numbered 1-7 and referenced 
in online methods), and individual sample IDs are indicated to the right. *indicates samples stimulated by bacterial 
superantigen Staphlococcus enterotoxin B (SEB). B) Representative MEM labels for CD4+ T cells (top) and B cells (bottom) 
from SEB-stimulated normal human blood (1.4, top, mass cytometry), normal human bone marrow (5, mass cytometry), 
normal human tonsil (2.5, mass cytometry), SEB-stimulated normal human blood (1.4, bottom, fluorescence flow cytometry), 
and normal human blood (6.1, mass cytometry). 
 
 An important aspect of MEM is generation of machine-readable quantitative labels that can be used to 
register population identities across samples and studies.  A MEM label for a newly discovered population can 
be compared quantitatively against a reference set of established MEM labels or a MEM label reported in a 
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paper.  To illustrate this idea, the pairwise, normalized root-mean-squared distance (RMSD) of MEM scores was 
calculated as a measure of similarity between 80 populations of cells from 7 different studies including healthy 
CD4+ T cell and B cell (Figure E2).  Cells had highly similar MEM scores within each major cell type, regardless 
of platform (mass or fluorescence flow cytometry), study, or tissue source.  For example, T cells run on mass 
cytometry from different blood donors were 97% ± 1.3 similar to each other, 85% ± 1.9 similar to T cells from 
blood run on fluorescence flow cytometry, and 87% ± 2.1 similar to T cells from tonsil run on mass cytometry 
(Figure E2, Supplementary Table 5).  However, these cells were 66.9% ± 13 similar to any B cell population. 
This indicates that MEM scores provide a way to communicate cell identity and to quantify similarities of cell 
types from the text label alone.   
 
Figure E-3 MEM correctly grouped immune and cancer cell populations from glioma tumors using nine proteins 
expressed on cancer cells in Dataset D. (A) A heatmap of MEM enrichment scores is shown for 52 populations of cells 
identified in tumors from 4 glioblastoma patients (G-08, G-10, G-11, G22) in an unsupervised manner using viSNE.  (B) 
Each population was annotated for a cell type based on review of the MEM label and classified as tumor infiltrating APCs 
(blue), tumor infiltrating T cells (green), or non-immune tumor cells (red).  (C) A heatmap of median intensity values is shown 
for the 13 measured proteins from each of the 52 tumor cell populations.   
 
 Dataset D included 52 populations of tumor infiltrating APCs, tumor infiltrating T cells, and non-immune 
malignant tumor cells identified in human glioma tumors (284).  To obtain these populations, each tumor was 
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analyzed by viSNE and cell subsets were expert gated solely on t-SNE cluster density (Supplementary Figure 
E6).  To determine whether MEM could distinguish immune cell subsets from other tumor cell types with limited 
information, MEM scores were calculated using only 9 markers that were expected to be expressed on cancer 
cells (S100B, TUJ1, GFAP, Nestin, MET, PDGFRα, EGFR, HLA-DR, and CD44, Figure E3a).  The 52 
populations were grouped into 13 major cell types based on MEM enrichment of 9 analyzed proteins, and these 
groups were interpreted as tumor infiltrating APCs (Figure E3b, blue), tumor infiltrating T cells (Figure E3b, 
green), or non-immune tumor cells (Figure E3b, red).  To confirm cell identity, four protein features that had been 
excluded from MEM analysis were assessed (Figure E3c, CD45, CD3, CD45RO, and CD64). CD45 and CD3 
were used to confirm T cell identity and CD45 and CD64 were used to confirm APC identity. MEM correctly 
identified both immune cell subsets from all tumor types without using key immune lineage markers and without 
using healthy populations (e.g. APCs from blood or tonsil) to guide the clustering.  Thus, MEM labels 
distinguished populations of cells based on non-traditional features and in a disease context.  
MEM labels provided a quantitative language to objectively communicate characteristics of new and 
established cell types observed in complex tissue microenvironments.  Algorithmic comparison of MEM labels 
correctly identified 80 cell populations from 7 studies of 3 human tissues measured using different 
instrumentation and distinguished tumor-infiltrating immune cell subsets and malignant cell populations from 
human glioma tumors.  Following additional validation in other cell types, tissues, and instrumentation platforms, 
it may be possible for machines and humans to use MEM labels to learn and clearly communicate cell identity 
(cytotype).  Given widespread adoption and reporting, MEM labels could be used to communicate cytotypes in 
a manner analogous to cluster of differentiation (CD) naming of antigen targets of antibodies (396).  MEM can 
compare populations against a common reference (Supplementary Note 5) and guide feature selection for 
computational and experimental analysis.  MEM can also be used to monitor changes in tissues over time during 
treatment.  Deviation from a stable MEM score for peripheral blood cell subsets would be expected in the case 
of emerging malignant cells (360), and lack of change towards a healthy set of MEM scores for blood or bone 
marrow cell subsets might indicate a lack of response to chemotherapy for a leukemia patient.  MEM is expected 
to assist in machine learning applications by providing quantitative text descriptions of cytotype that can be 
algorithmically parsed and used to classify newly identified cell subpopulations.   
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Methods 
Code availability 
Software for generating MEM scores is available as Supplementary Software. 
 
CyTOF data preprocessing and analysis 
Data analysis was performed using the online analysis platform Cytobank (301) and the statistical 
programming environment R. Raw median intensity (MI) values were transformed to a hyperbolic arcsine scale. 
A cofactor of 15 was used for the PBMC data set (Figure E1), and a cofactor of 5 was used for the normal human 
bone marrow data set and for the murine myeloid data set. Single, intact cells were gated based on event length 
and nucleic acid intercalator (iridium). Major PBMC subsets were gated based on CD45 expression (leukocytes) 
and on canonical lineage marker expression to identify major blood cell subsets. 
FCS files were exported from Cytobank as FCS or tab-delimited text files that were parsed for expression 
intensity information using the R package flowCore (464). MEM was calculated using the arcsinh-transformed 
MI values, as described above. Heatmaps were generated using the heatmap.2 function in the gplots R package 
(465). 
 
Fluorescence Phospho-Flow AML data analysis 
Data were downloaded from Cytobank as FCS files and processed in R as described above. MFI values 
were transformed to a log-normal scale. For each AML patient, a median value and an IQR value was calculated 
for each marker in the unstimulated condition and for the stimulated conditions. The unstimulated median values 
were subtracted from the stimulated median values, and likewise for the IQR values. MEM was then calculated 
by comparing each patient's subtracted median and IQR values to those of the other patients. This enabled a 
comparison of fold-change signaling values rather than raw values. 
 
Marker enrichment modeling 
Marker enrichment modeling (MEM) analysis begins after populations have been identified and is 
designed to provide a simple way to compare findings from experts working with different platforms or performing 
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analysis using different computational tools for population discovery (282, 295, 466-468) and graphical 
visualization (12, 80, 83, 288, 469). These tools have differing strengths that depend greatly on the structure of 
the data sets and controls, the biological goals of the study, and the quality of the existing knowledge in the field 
(314, 359, 394). 
MEM equation. The MEM equation is implemented as an R package (Supplementary Software). 
Currently, MEM uses medians as the magnitude value; however, depending on the data type, mean may be a 
more appropriate magnitude statistic, and mean could be substituted for median in the equation. Similarly, other 
statistics, such as variance, might be substituted for IQR. The MEM equation was developed with the intention 
of capturing and quantifying population-specific feature enrichment in a simple equation that avoids overfitting 
or unnecessary computation. The primary goal of this equation is to scale magnitude differences depending on 
distribution spread. While other distribution features such as skew or shape could be informative, incorporating 
only two pieces of information—magnitude and spread—into the equation captured enough information to be 
useful in quantifying both positive and negative population-specific feature enrichment. 
MEM output and score scaling. The MEM R script outputs a heatmap of MEM values with a text label 
summary of feature enrichment as the population (row) names. The + or − value provided along with the marker 
name is converted to a −10 to +10 scale and rounded to the nearest integer. As implemented here, the maximum 
of the scale was set using the highest absolute value MEM score observed across all markers and populations. 
All values in the matrix are divided by this maximum value and multiplied by 10 to achieve the −10 to +10 scaling. 
After scaling, the original sign value is reapplied to each MEM score. Scaling the output this way is intended to 
generate MEM values and labels that are intuitive to human readers and to facilitate comparison of feature 
enrichment across experiments, samples, batches, timepoints, and data types. 
IQR threshold. Because MEM uses a ratio of IQR values, near-zero values in the denominator, IQRPOP, 
will greatly increase MEM scores. For each measurement type, it is important to identify a minimum significant 
IQR value so that small IQR values below the platform's ability to distinguish signal from noise do not 
inappropriately increase MEM scores. To automatically determine a minimum threshold for IQRPOP, the 
algorithm here calculated the average of the IQR values that were associated with the lowest quartile of 
population and reference medians. For the mass and fluorescence cytometry data sets used, the automatically 
246 
  
calculated IQR threshold was on average 0.5 ± X, and so the IQR threshold for all studies here was set to 0.5. 
The default IQR threshold in the algorithm is also set to 0.5. To have the IQR threshold recalculated, investigators 
should specify the 'auto' option for the IQR.thresh argument in the MEM function. It is recommended that 
investigators applying MEM to data sets from different instruments or who are testing MEM for the first time 
determine whether a change in the IQR threshold is needed. 
Reference population selection. MEM scores are contextual; a population's MEM score depends on the 
reference population(s) to which it is compared. Selection of a reference population should be made deliberately 
depending on the biological question being addressed. When populations in a MEM analysis arise from different 
experimental sources, it may be necessary in some cases to normalize measurements before MEM analysis to 
avoid artifacts from experimental variation. 
 
PBMC processing and mass cytometry 
PBMC were isolated and cryopreserved as described by Greenplate et al. (360). PBMC were stained 
with metal-conjugated antibodies and prepared for the mass cytometry as previously described (360). The 
following antibodies were used in the staining panel at a 1:2,000 dilution: CD19-142, CCR5-144, CD4-145, 
CD64-146, CD20-147, CCR4-149, CD43-150, CD14-151, TCRγδ-152, CD45RA-153, CD45-154, CXCR3-156, 
CD33-158, CCR7-159, CD28-169, CD29-162, CD45RO-164, CD16-165, CD44-166, CD27-167, CD8-168, 
CD25-169, CD3-170, CD57-172, PD-L1-175, and CD56-176 (Fluidigm Sciences). In addition, the following 
purified antibodies from Biolegend were labeled using MaxPar DN3 kits (Fludigm Sciences), stored at 4 °C in 
antibody stabilization buffer (Candor Bioscience GmbH) and used in the same panel at a 1:100 dilution: ICOS-
141, TIM-143, CD38-148, CD32-161, HLA-DR-163, CXCR5-171, and PD-1-174. 
 
Cell subpopulation MEM score similarity calculations 
Comparison of CD4+T cells to B cells in Figure E2. In order to assess the robustness of MEM across 
tissue sample types, donors, experimental runs, and flow cytometry platforms (fluorescence and mass 
cytometry), MEM scores were calculated for cell subsets from seven different experiments that included three 
healthy human bone marrow samples (83, 290, 374), nine healthy human PBMC samples (81, 470), and six 
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healthy human tonsil samples (82). MEM scores were calculated for each population using as the reference 
population a combination of hematopoietic stem cells gated as CD34+ CD38lo/− from two studies of healthy human 
bone marrow (83, 374). Population similarity was calculated using root mean squared distance (r.m.s. deviation) 
calculated on all population MEM scores in a pairwise fashion. MEM scores were calculated using all markers 
in common between each data set and the HSC reference (Supplementary Table 5). 
r.m.s. deviation was calculated here as the square root of the average in squared distance between all 
MEM values in common for each pair of populations (Supplementary Table 5) and then converted into percent 
maximum possible r.m.s. deviation. Given the −10 to +10 MEM scale, an r.m.s. deviation of 20 was the maximum 
possible difference and corresponded to 0% similarity, whereas an r.m.s. deviation of 0 between MEM labels 
indicated 100% similarity. This approach emphasized differences in marker expression when comparing 
populations. Calculated statistics for CD4+ T cell comparisons included average MEM value +/− s.d. and P value 
calculated using an unpaired, two-tailed Student's t-test. 
Human glioma and normal immune cell MEM analysis. Glioblastoma data (G-08, G-10, G-11, and G-22) 
were collected following a published protocol16. Cells were stained with isotope-tagged antibodies to detect 
surface and intracellular targets following established protocols (81, 284). MEM analysis of glioblastoma patient 
samples was performed with nine markers (S100B, TUJ1, GFAP, Nestin, MET, PDGFRα, EGFR, HLA-DR, and 
CD44), using arcsinh transformation of original median intensity values with a cofactor of 5. Each cell subset 
was the POP, and the remaining cell subsets were the REF in the analysis. 
 
Z-score and K–S statistic calculations 
Z-score was calculated between POP and REF as (MEANpop-MEANref)/STDEVref for each marker. 
The K–S statistic (461, 471) was calculated comparing the distribution for each marker on POP and REF 
using the function ks.test() in R. 
 
F-measure analysis 
PBMC populations were defined by expert human gating on canonical markers. For F-measure analysis 
(Figure E1c and Supplementary Figure E2), the 25 measured markers from the CyTOF analysis of healthy PBMC 
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were sorted based on absolute MEM scores, median values, median difference, Z-score, and K–S statistic 
(shown in Supplementary Figure E2), or randomly across all PBMC populations and the 25 measured proteins. 
The 5 × 25 matrix was converted into an ordered vector (length 25 × 5) and then sorted by absolute value. The 
first occurrence of each marker in the list was kept, and subsequent occurrences of that marker in the list (i.e., 
that marker's scores on other populations) were discarded. The order of markers excluded by MEM, median, 
median difference, Z-score, and K–S statistic are shown in Supplementary Table 3. Markers were then 
sequentially, cumulatively excluded from k-means clustering of cells from high to low absolute for each statistic 
or score. F-measure was calculated as: 
 
 
 
An F-measure was calculated for each round of clustering, where truth was the cell cluster ID resulting 
from clustering on all 25 markers. The moving average of F-measure with an interval of 3 was calculated in 
Microsoft Excel. The F-measures for random marker exclusion are the average at each point of 15 different 
rounds of random marker exclusion from clustering. 
 
Data Availability Statement 
The normal human PBMC dataset (Figure E1) were generated by CyTOF analysis as described by 
Leelatian, et al. (81) and is available as an FCS file in Flow Repository 
(https://flowrepository.org/experiments/1043).  
The normal human bone marrow data set from Bendall and Simonds, et al15 (Dataset B, Supplementary 
Note 3) was downloaded from Cytobank (466) as FCS files that included the cell population IDs defined by 
Bendall and Simonds, et al. (83) (https://reports.cytobank.org/1/v1).  MEM enrichment scores from Dataset B 
were compared to the authors’ analysis and prior studies of proteins marking stem cells, progenitor cells, and 
mature cells (467, 468). 
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The murine myeloid CyTOF dataset from Becher, et al (294) (Dataset C, Supplementary Note 4) was 
downloaded from Cytobank as FCS files that contained gated cell events and cluster IDs as designated by 
automated analysis conducted by Becher et al (294). MEM enrichment scores from Dataset C were compared 
to the authors’ analysis and prior studies of neutrophils (288, 295). 
Datasets for Figure E2 were generated in 7 separate fluorescence and mass cytometry studies by 1) 
Nicholas et al. (470), 2) Polikowsky et al. (82), 3) Ferrell et al. (374), 4) Amir et al. (290), 5) Bendall and Simonds 
et al. (83), 6) Greenplate et al., previously unpublished data, and 7) Leelatian et al (81). 
The phospho-flow AML data set generated by Irish et al.6 (Supplementary Note 5-Fig.2) was downloaded 
from Cytobank as FCS files. 
The human GBM mass cytometry dataset (Figure E3) was generated and analyzed as described by 
Leelatian and Doxie et al. (284) and are available on Flow Repository as text files 
(https://flowrepository.org/experiments/1044/). 
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Supplemental Data 
 
 
Figure SE-1 Examples of MEM reference population selection to capture different contexts 
Alternative reference populations (REF) can be used to capture how features of the test population (POP) are enriched in 
different contexts. Reference comparisons include a) all non-population cells in the sample or experiment (default), b) a 
population from another sample in the same study, c) a population from the same sample, d) multiple subsets of non-
population cells from the same sample, e) a standard control population, and f) pairwise comparison between all populations 
in a sample. 
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Figure SE-2 MEM highly scores markers that are important to clustering accuracy 
Markers were sequentially and cumulatively excluded from k-means cluster analysis of Dataset A, from high to low, sorted 
based on 5 different statistics or scores (marker order shown in Supplementary Table 3): MEM, median, median difference 
(MAGDIFF), z-score, and Kolmogorov-Smirnov (K-S) statistic. Clustering accuracy was quantified as the f-measure where 
true cluster identity was assumed to be the clusters formed by clustering on all 25 markers in the dataset. The moving 
average of the f-measure is shown. Error bars represent the standard error. The vertical red line indicates the number of 
excluded features at which the f-measure reached 0.75. 
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Figure SE-3 MEM highly scores markers that are important to viSNE mapping 
a) viSNE map for healthy human blood, built using 25 surface protein markers. Populations were identified by expert analysis 
and color coded. 
b). Top to bottom, left to right: viSNE maps generated as markers were iteratively, cumulatively excluded based on their 
MEM scores (high to low absolute value). Heat intensity for each cell indicates CD8 expression. 
c) Top to bottom, left to right: viSNE maps generated as markers were iteratively, cumulatively excluded based on their 
median scores (high to low absolute value). Heat intensity for each cell indicates CD8 expression. 
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Figure SE-4 MEM scores largely reflect median expression values for relatively homogenous populations 
Heatmaps show median intensity of protein expression (left) and protein enrichment by MEM (right) for measured proteins 
in 28 populations characterized as relatively homogeneous for established cell types by expert analysis (rows). Each 
population was compared to the other 27 subsets for the MEM analysis. MEM scores approach median expression values 
in homogeneous populations because the contribution of variance approaches zero. 
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Figure SE-5 Focused MEM analysis quantifies feature enrichment within phenotypically similar groups of cells 
a-f) Focused MEM analysis on murine myeloid cell subsets. A MEM label for one population within each group is shown as 
an example. Groups were defined as the 6 major murine subgroups identified by t-SNE and DensVM by Becher et al. (294). 
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Figure SE-6 Unsupervised clustering and gating of 52 populations of malignant and immune cells in glioma 
Live nucleated immune and malignant cells were gated from glioma tumors as described in Leelatian and Doxie et al., 
Cytometry B 20164. Patient-specific t-SNE axes were created in separate viSNE analyses of each tumor (e.g. t-SNE1-G-
08 for glioma tumor G-08). Shown here is density of cells on t-SNE1 vs. t-SNE2 from each tumor-specific viSNE analysis. 
Expert analysis of density was then used to identify 52 cell clusters from the 4 glioma tumors. These 52 populations were 
subsequently grouped by MEM in Figure E5a using 9 proteins expressed on malignant cells. 
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